<pmc-articleset xmlns:ns0="http://www.niso.org/schemas/ali/1.0/" xmlns:ns1="http://www.w3.org/1999/xlink">
<article article-type="review-article" xml:lang="en" dtd-version="1.4">
<front>
<journal-meta>
<journal-id journal-id-type="nlm-ta">Cancer Metastasis Rev</journal-id>
<journal-id journal-id-type="iso-abbrev">Cancer Metastasis Rev</journal-id>
<journal-id journal-id-type="pmc-domain-id">365</journal-id>
<journal-id journal-id-type="pmc-domain">springeropen</journal-id>
<journal-title-group>
<journal-title>Cancer Metastasis Reviews</journal-title>
</journal-title-group>
<issn pub-type="ppub">0167-7659</issn>
<issn pub-type="epub">1573-7233</issn>
<custom-meta-group>
<custom-meta>
<meta-name>pmc-is-collection-domain</meta-name>
<meta-value>yes</meta-value>
</custom-meta>
<custom-meta>
<meta-name>pmc-collection-title</meta-name>
<meta-value>Springer</meta-value>
</custom-meta>
</custom-meta-group>
</journal-meta>
<article-meta>
<article-id pub-id-type="pmcid">PMC7497309</article-id>
<article-id pub-id-type="pmcid-ver">PMC7497309.1</article-id>
<article-id pub-id-type="pmcaid">7497309</article-id>
<article-id pub-id-type="pmcaiid">7497309</article-id>
<article-id pub-id-type="pmid">32372224</article-id>
<article-id pub-id-type="doi">10.1007/s10555-020-09883-w</article-id>
<article-id pub-id-type="publisher-id">9883</article-id>
<article-version article-version-type="pmc-version">1</article-version>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Article</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>FOXO transcription factor family in cancer and metastasis</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name name-style="western">
<surname>Jiramongkol</surname>
<given-names initials="Y">Yannasittha</given-names>
</name>
<xref ref-type="aff" rid="Aff1" />
</contrib>
<contrib contrib-type="author" corresp="yes">
<name name-style="western">
<surname>Lam</surname>
<given-names initials="EWF">Eric W.-F.</given-names>
</name>
<address>
<email>eric.lam@imperial.ac.uk</email>
</address>
<xref ref-type="aff" rid="Aff1" />
</contrib>
<aff id="Aff1">
<institution-wrap>
<institution-id institution-id-type="GRID">grid.7445.2</institution-id>
<institution-id institution-id-type="ISNI">0000 0001 2113 8111</institution-id>
<institution>Department of Surgery and Cancer, </institution>
<institution>Imperial College London, Hammersmith Hospital Campus, </institution>
</institution-wrap>London, W12 0NN UK </aff>
</contrib-group>
<pub-date pub-type="epub">
<day>5</day>
<month>5</month>
<year>2020</year>
</pub-date>
<pub-date pub-type="ppub">
<year>2020</year>
</pub-date>
<volume>39</volume>
<issue>3</issue>
<issue-id pub-id-type="pmc-issue-id">365321</issue-id>
<fpage>681</fpage>
<lpage>709</lpage>
<pub-history>
<event event-type="pmc-release">
<date>
<day>05</day>
<month>05</month>
<year>2020</year>
</date>
</event>
<event event-type="pmc-live">
<date>
<day>29</day>
<month>09</month>
<year>2020</year>
</date>
</event>
<event event-type="pmc-last-change">
<date iso-8601-date="2024-08-01 01:25:25.390">
<day>01</day>
<month>08</month>
<year>2024</year>
</date>
</event>
</pub-history>
<permissions>
<copyright-statement>© The Author(s) 2020</copyright-statement>
<license license-type="OpenAccess">
<ns0:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ns0:license_ref>
<license-p>
<bold>Open Access</bold> This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <ext-link ext-link-type="uri" ns1:href="http://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>.</license-p>
</license>
</permissions>
<self-uri content-type="pmc-pdf" ns1:href="10555_2020_Article_9883.pdf" />
<abstract id="Abs1">
<p id="Par1">Forkhead box O (FOXO) transcription factors regulate diverse biological processes, affecting development, metabolism, stem cell maintenance and longevity. They have also been increasingly recognised as tumour suppressors through their ability to regulate genes essential for cell proliferation, cell death, senescence, angiogenesis, cell migration and metastasis. Mechanistically, FOXO proteins serve as key connection points to allow diverse proliferative, nutrient and stress signals to converge and integrate with distinct gene networks to control cell fate, metabolism and cancer development. In consequence, deregulation of FOXO expression and function can promote genetic disorders, metabolic diseases, deregulated ageing and cancer. Metastasis is the process by which cancer cells spread from the primary tumour often <italic toggle="yes">via</italic> the bloodstream or the lymphatic system and is the major cause of cancer death. The regulation and deregulation of FOXO transcription factors occur predominantly at the post-transcriptional and post-translational levels mediated by regulatory non-coding RNAs, their interactions with other protein partners and co-factors and a combination of post-translational modifications (PTMs), including phosphorylation, acetylation, methylation and ubiquitination. This review discusses the role and regulation of FOXO proteins in tumour initiation and progression, with a particular emphasis on cancer metastasis. An understanding of how signalling networks integrate with the FOXO transcription factors to modulate their developmental, metabolic and tumour-suppressive functions in normal tissues and in cancer will offer a new perspective on tumorigenesis and metastasis, and open up therapeutic opportunities for malignant diseases.</p>
</abstract>
<kwd-group xml:lang="en">
<title>Keywords</title>
<kwd>Forkhead</kwd>
<kwd>Transcription factor</kwd>
<kwd>Cancer metastasis</kwd>
<kwd>Tumour suppressor</kwd>
<kwd>Post-translational regulation</kwd>
<kwd>Protein interactions</kwd>
</kwd-group>
<funding-group>
<award-group>
<funding-source>
<institution>Imperial College London</institution>
</funding-source>
</award-group>
</funding-group>
<custom-meta-group>
<custom-meta>
<meta-name>pmc-status-qastatus</meta-name>
<meta-value>0</meta-value>
</custom-meta>
<custom-meta>
<meta-name>pmc-status-live</meta-name>
<meta-value>yes</meta-value>
</custom-meta>
<custom-meta>
<meta-name>pmc-status-embargo</meta-name>
<meta-value>no</meta-value>
</custom-meta>
<custom-meta>
<meta-name>pmc-status-released</meta-name>
<meta-value>yes</meta-value>
</custom-meta>
<custom-meta>
<meta-name>pmc-prop-open-access</meta-name>
<meta-value>yes</meta-value>
</custom-meta>
<custom-meta>
<meta-name>pmc-prop-olf</meta-name>
<meta-value>no</meta-value>
</custom-meta>
<custom-meta>
<meta-name>pmc-prop-manuscript</meta-name>
<meta-value>no</meta-value>
</custom-meta>
<custom-meta>
<meta-name>pmc-prop-legally-suppressed</meta-name>
<meta-value>no</meta-value>
</custom-meta>
<custom-meta>
<meta-name>pmc-prop-has-pdf</meta-name>
<meta-value>yes</meta-value>
</custom-meta>
<custom-meta>
<meta-name>pmc-prop-has-supplement</meta-name>
<meta-value>no</meta-value>
</custom-meta>
<custom-meta>
<meta-name>pmc-prop-pdf-only</meta-name>
<meta-value>no</meta-value>
</custom-meta>
<custom-meta>
<meta-name>pmc-prop-suppress-copyright</meta-name>
<meta-value>no</meta-value>
</custom-meta>
<custom-meta>
<meta-name>pmc-prop-is-real-version</meta-name>
<meta-value>no</meta-value>
</custom-meta>
<custom-meta>
<meta-name>pmc-prop-is-scanned-article</meta-name>
<meta-value>no</meta-value>
</custom-meta>
<custom-meta>
<meta-name>pmc-prop-preprint</meta-name>
<meta-value>no</meta-value>
</custom-meta>
<custom-meta>
<meta-name>pmc-prop-in-epmc</meta-name>
<meta-value>yes</meta-value>
</custom-meta>
<custom-meta>
<meta-name>pmc-license-ref</meta-name>
<meta-value>CC BY</meta-value>
</custom-meta>
<custom-meta>
<meta-name>issue-copyright-statement</meta-name>
<meta-value>© Springer Science+Business Media, LLC, part of Springer Nature 2020</meta-value>
</custom-meta>
</custom-meta-group>
</article-meta>
</front>
<body>
<sec id="Sec1">
<title>Introduction</title>
<p id="Par2">Cancer is a leading cause of death worldwide. It is a group of diseases that can initiate in any tissue or organ when abnormal cells grow uncontrollably and migrate from their original sites to invade other parts of the body. Metastasis is the process by which cancer cells spread from their origins to secondary sites of the body, often <italic toggle="yes">via</italic> the bloodstream or the lymphatic system. In most cases, metastatic cancer cannot be cured by treatment. Because of this, metastasis is the major cause of cancer mortality and is responsible for over 90% of cancer deaths [<xref ref-type="bibr" rid="CR1">1</xref>]. Forkhead box (FOX) proteins are a vast group of transcription factors united by an evolutionarily conserved winged-helix DNA binding domain. FOXOs (forkhead box proteins of class O subgroup) are considered to be tumour suppressors by virtue of their established functions in cell cycle arrest, apoptosis, senescence, differentiation, DNA damage repair and scavenging of reactive oxygen species [<xref ref-type="bibr" rid="CR2">2</xref>]. Besides these cellular processes essential for cancer initiation (tumorigenesis), FOXOs have also emerged as key modulators of metastasis and angiogenesis, two key factors critical for cancer progression and establishment at secondary sites.</p>
<p id="Par3">The FOX winged-helix structure, reminiscent of a butterfly, consists of three N-terminal α-helices, three β-strands and two loops [<xref ref-type="bibr" rid="CR3">3</xref>]. Through this unique structural feature, the FOX proteins recognise the <italic toggle="yes">cis</italic>-regulatory sequences in their target genes to direct gene expression [<xref ref-type="bibr" rid="CR4">4</xref>]. To date, 19 (A–S) subfamilies and 50 mammalian FOX proteins have been identified and are classified according to their sequence homology within the winged-helix and other functional domains. Despite the FOX proteins possessing highly analogous DNA binding domains, their distinct tissue-specific expression patterns and regulatory mechanisms provide them their dedicated functions [<xref ref-type="bibr" rid="CR5">5</xref>]. However, in addition to their specific roles, evidence suggests that FOX proteins also possess a certain degree of functional redundancy to safeguard organisms against a broad spectrum of developmental and metabolic diseases due to the loss of function of a single-core FOX protein or gene in haploid insufficiency. In consequence, the misregulation, misexpression and/or mutation of FOX genes can lead to human genetic and metabolic diseases, deregulated ageing and cancer.</p>
</sec>
<sec id="Sec2">
<title>Normal FOXO function</title>
<p id="Par4">In mammals, the FOXO subfamily consists of four members (FOXO1, FOXO3, FOXO4 and FOXO6). These four FOXO transcription factors bind to their target genes as monomers or heterodimers to control cell fate under distinct conditions [<xref ref-type="bibr" rid="CR5">5</xref>]. They also interact with co-activator, co-repressors and other protein partners to modulate and to fine-tune their activity. All FOXO proteins have 4 different core functional domains, namely the winged-helix DNA binding domain, the nuclear localisation sequence, the nuclear export sequence and the transactivation domain [<xref ref-type="bibr" rid="CR6">6</xref>]. The FOXO-DNA binding domain recognises and binds to the consensus sequences (5′-GTAAA(C/T)A-3′) in the genome [<xref ref-type="bibr" rid="CR7">7</xref>]. Furthermore, the consensus flanking sequences also play a critical part in determining the interaction specificity between the target gene and FOX protein [<xref ref-type="bibr" rid="CR6">6</xref>]. Each of the FOXO proteins is differentially expressed in distinct tissues. For instance, FOXO1 and FOXO4 are highly expressed in adipose tissue and skeletal muscle, respectively [<xref ref-type="bibr" rid="CR8">8</xref>]. FOXO3 is ubiquitously expressed in multiple tissues, including the brain, kidney and heart, whilst FOXO6 is predominantly expressed during the development and in nervous tissue [<xref ref-type="bibr" rid="CR8">8</xref>, <xref ref-type="bibr" rid="CR9">9</xref>]. Despite their distinct tissue-specific expression patterns, regulatory overlap and functional redundancy among FOXO proteins have been observed [<xref ref-type="bibr" rid="CR10">10</xref>]. This may impact the role and regulation of FOXOs in multiple FOXO protein–expressing cells [<xref ref-type="bibr" rid="CR10">10</xref>].</p>
<p id="Par5">FOXO genes are conserved throughout evolution from lower organisms to mammals but exist only as a single gene in invertebrates. FOXO is known as dFOXO in the fruit fly <italic toggle="yes">Drosophila melanogaster</italic>, Daf-16 in the nematode <italic toggle="yes">Caenorhabditis elegans</italic> and FoxO in <italic toggle="yes">Hydra vulgaris</italic> [<xref ref-type="bibr" rid="CR11">11</xref>, <xref ref-type="bibr" rid="CR12">12</xref>]. In fact, the first forkhead (FOX) gene was initially identified in fruit flies as a genetic mutation to a homeotic gene, leading to the development of an abnormal forked head structure [<xref ref-type="bibr" rid="CR13">13</xref>]. A later study showed that dFOXO controls <italic toggle="yes">Drosophila</italic> lifespan and mediates insulin signalling in flies [<xref ref-type="bibr" rid="CR14">14</xref>]. In <italic toggle="yes">C. elegans</italic>, Daf-16 is characterised as a downstream target of insulin/insulin-like growth factor 1 (IGF-1) pathway and the expression of Daf-16 is associated with <italic toggle="yes">C. elegans</italic> ageing and longevity [<xref ref-type="bibr" rid="CR15">15</xref>]. In <italic toggle="yes">Hydra</italic>, FoxO is a critical regulator for unlimited lifespan [<xref ref-type="bibr" rid="CR16">16</xref>]. Whilst direct experimental evidence for a role for FOXO in longevity has not been demonstrated in mammals, studies from these evolutionarily conserved model organisms suggest that FOXO proteins are important for the regulation of development and senescence/ageing. Collectively, these FOXO transcription factors are involved in the regulation of the cell cycle, apoptosis and metabolism. In the experimental model organisms, FOXOs have also been found to control stem cell maintenance and lifespan as well as age-related diseases, such as cancer, ageing and diabetes. Multiple upstream pathways regulate FOXO activity through post-translational modifications and co-factor interactions. The diversity of this upstream regulation and the downstream effects of FOXOs suggest that they function as regulators of tissue homeostasis over time and coordinators of responses to environmental changes, including growth factor deprivation, metabolic stress (e.g. metabolite starvation) and oxidative stress [<xref ref-type="bibr" rid="CR17">17</xref>].</p>
<p id="Par6">As transcription factors, the predominant mode of action of FOXO proteins is through binding to FHRE elements located at proximal gene promoter regions and recruiting other components of the transcription apparatus, including other transcription factors, transcriptional co-factors and chromatin regulators to modulate target gene transcription [<xref ref-type="bibr" rid="CR2">2</xref>]. Compacted chromatin constitutes a barrier to transcription activators accessing promoters, and studies using a recombinant FOXO1 protein have shown that FOXO proteins can operate as ‘pioneer’ factors, by recognising their cognate sites within the promoter on a nucleosome, opening up chromatin and conferring an active chromatin state for transcription to proceed [<xref ref-type="bibr" rid="CR18">18</xref>, <xref ref-type="bibr" rid="CR19">19</xref>]. This role of FOXO proteins as pioneer factors is further confirmed by later studies showing that FOXO1, like other forkhead proteins, can open and remodel chromatin and recruit additional regulatory factors to promote transcription <italic toggle="yes">via</italic> its winged-helix motif [<xref ref-type="bibr" rid="CR20">20</xref>, <xref ref-type="bibr" rid="CR21">21</xref>]. Moreover, recent epigenetic studies have shown that FOXO3 is also recruited to the more distal gene regulatory elements called enhancers. In these cases, FOXO3 and, probably, other FOXOs function by binding to already active enhancers to further promote their ability to drive cell type–specific gene expression [<xref ref-type="bibr" rid="CR22">22</xref>].</p>
</sec>
<sec id="Sec3">
<title>Tumour-suppressive roles of FOXOs</title>
<sec id="Sec4">
<title>FOXOs and tumorigenesis</title>
<p id="Par7">FOXOs are considered to be tumour suppressors by virtue of their established functions in cell cycle arrest, senescence, apoptosis, differentiation, DNA damage repair and scavenging of reactive oxygen species [<xref ref-type="bibr" rid="CR2">2</xref>]. Studies using FOXO gene knockout mice have helped to confirm FOXO proteins as genuine tumour suppressors [<xref ref-type="bibr" rid="CR23">23</xref>]. FOXO (<italic toggle="yes">foxo1/3/4</italic>
<sup>
<italic toggle="yes">−/−</italic>
</sup>) triple-knockout mice develop thymic lymphomas and haemangiomas. These triple FOXO1/3/4-deficient animals have been shown to be predisposed to lymphomagenesis through the loss of restriction on cellular proliferation and survival. At the same time, these triple-FOXO1/3/4-deficient animal studies also reveal that the FOXO isoforms have overlapping functions in distinct biological functions in specific tissues, and that FOXO proteins are associated with cancer progression, metastasis and angiogenesis. FOXO proteins have been proposed as tumour suppressors primarily because of their established functions in promoting cell cycle arrest and apoptosis as well as preventing the accumulation of damages induced by genotoxic agents and oxidative stress [<xref ref-type="bibr" rid="CR2">2</xref>, <xref ref-type="bibr" rid="CR3">3</xref>, <xref ref-type="bibr" rid="CR24">24</xref>].</p>
</sec>
<sec id="Sec5">
<title>FOXOs and senescence</title>
<p id="Par8">Senescence is an irreversible state of cell cycle arrest and a critical tumour-suppressive barrier to obstruct neoplastic transformation of stem cells. It limits the renewal capacity of stem cells and cancer cells. A role for FOXO protein in cellular senescence is confirmed by an <italic toggle="yes">in vivo</italic> study showing that oncogene-induced senescence also involves the repression of the phosphoinositide 3-kinase (PI3K)-Akt oncogenic signalling pathway and the consequent induction of FOXO activity [<xref ref-type="bibr" rid="CR25">25</xref>]. In support of this, FOXO3 overexpression or inhibition of the PI3K-Akt signalling axis can induce cells to enter senescence through promoting the expression of p27<sup>Kip1</sup> [<xref ref-type="bibr" rid="CR26">26</xref>]. In addition, FOXO3 promotes the expression of the retinoblastoma family protein p130 (RB2) to induce senescence in proliferating cells [<xref ref-type="bibr" rid="CR26">26</xref>, <xref ref-type="bibr" rid="CR27">27</xref>]. FOXO3 can also repress the expression of the potent oncogene FOXM1 to limit stem cell renewal to trigger senescence [<xref ref-type="bibr" rid="CR28">28</xref>–<xref ref-type="bibr" rid="CR31">31</xref>]. FOXM1 can counteract oxidative stress–induced senescence through enhancing the transcription of the cell self-renewal Bmi-1 gene [<xref ref-type="bibr" rid="CR32">32</xref>]. Moreover, inhibition of FOXM1 in cancer cells, such as those of breast, gastric, gallbladder and liver cancer, leads to cellular senescence [<xref ref-type="bibr" rid="CR33">33</xref>–<xref ref-type="bibr" rid="CR36">36</xref>]. In agreement, overexpression of the cyclin-dependent kinase (CDK)4/6-targeting microRNA miR-506 can induce senescence in ovarian cancer cells through repressing FOXM1 [<xref ref-type="bibr" rid="CR37">37</xref>]. Likewise, the CDK4/6 inhibitor LEE011 can also induce senescence in neuroblastoma cells through restricting the induction of FOXM1 [<xref ref-type="bibr" rid="CR38">38</xref>]. Collectively, these findings propose a key tumour-suppressive role for FOXO proteins and downstream targets in cellular senescence in both normal and cancer cells.</p>
</sec>
<sec id="Sec6">
<title>FOXOs and autophagy</title>
<p id="Par9">As tumour suppressors, FOXOs play multiple roles in restricting cancer development and progression. FOXO proteins are involved in the regulation of autophagy which functions to destroy and recycle the cytoplasmic organelles and macromolecules. Autophagy is a tumour-suppressive mechanism in that it can prevent cellular transformation by preventing the accumulation of carcinogenic defective lipids, proteins and organelles. Moreover, it is also a mediator of anticancer chemotherapy–induced cell death [<xref ref-type="bibr" rid="CR39">39</xref>]. Conversely, autophagy also enables cancer cells to survive under stress conditions, such as nutrient starvation, oxidative stress and chemotherapy. For example, haploinsufficiency of the autophagy genes, such as LC3, BECN1 and Bif-1, has been shown to drive chromosome instability, increase migration and promote early tumorigenesis [<xref ref-type="bibr" rid="CR40">40</xref>–<xref ref-type="bibr" rid="CR43">43</xref>]. One of the first reports of FOXO3 having a role in autophagy comes from a mouse muscle atrophy study showing that FOXO3 activates protein degradation by inducing autophagy in skeletal muscle cells [<xref ref-type="bibr" rid="CR44">44</xref>]. FOXO proteins are also involved in the regulation of autophagy in order to recycle essential amino acids during nutrient starvation [<xref ref-type="bibr" rid="CR45">45</xref>]. FOXO3 has been shown to induce autophagy in a FOXO1-dependent fashion by activating PIK3CA to enhance the PI3K-Akt activity [<xref ref-type="bibr" rid="CR46">46</xref>]. Specifically, FOXO1 depletion has been found to attenuate FOXO3-induced autophagy in a number of cell lines [<xref ref-type="bibr" rid="CR46">46</xref>]. Autophagic cell death is enhanced when the acetylated FOXO1 binds to an E1-like autophagy-related protein 7 (Atg7), an essential initiator of autophagy [<xref ref-type="bibr" rid="CR47">47</xref>]. Despite these findings showing that FOXOs have a tumour-suppressive role in the context of autophagy, other reports indicate they have an oncogenic role. For example, studies from neuronal cells reveal that c-Jun N-terminal kinase (JNK) deficiency causes increased autophagy by promoting cell survival through the FOXO1-BNIP3-Beclin-1 pathway [<xref ref-type="bibr" rid="CR48">48</xref>]. In these JNK-deficient neurons, FOXO1 is activated to promote the expression of BNIP3 which displaces the autophagic effector Beclin-1 from inactive Bcl-XL complexes to induce autophagy and cell survival [<xref ref-type="bibr" rid="CR48">48</xref>]. However, under energy stress conditions, p38 mitogen-activated protein kinase (MAPK) has also been shown to induce this FOXO-BNIP3 axis to repress mTORC1 and cell survival [<xref ref-type="bibr" rid="CR49">49</xref>]. Similarly, the deacetylase SIRT1 has been shown to repress the ability of acetylated FOXO3 to induce BNIP3 expression to promote apoptosis and attenuate autophagy [<xref ref-type="bibr" rid="CR50">50</xref>]. On the evidence of these findings, the role of FOXO proteins in autophagy is likely to be context-dependent and can be a double-edged sword in terms of tumour suppression and malignant transformation.</p>
</sec>
<sec id="Sec7">
<title>FOXOs and metastasis</title>
<p id="Par10">Numerous histopathological studies have demonstrated a connection between low FOXO expression and increased cancer metastasis [<xref ref-type="bibr" rid="CR51">51</xref>–<xref ref-type="bibr" rid="CR53">53</xref>]. A critical event that plays multiple roles in metastasis is the epithelial-mesenchymal transition (EMT), which is a biological process by which epithelial cells undergo changes that allow the development of a more aggressive mesenchymal cellular phenotype with the properties of stem cells [<xref ref-type="bibr" rid="CR54">54</xref>]. EMT has, in fact, been suggested to be engaged in multiple steps of the metastasis process. A recent study shows that FOXO1 silencing using small interfering ribonucleic acid (siRNA) in hepatocellular carcinoma enhances mesenchymal and reduces epithelial marker expression, as in EMT [<xref ref-type="bibr" rid="CR55">55</xref>]. The study also reveals that EMT induced by zinc finger E-box-binding homeobox 2 (ZEB2) can be suppressed by FOXO1 overexpression [<xref ref-type="bibr" rid="CR55">55</xref>]. The metastasis suppressor gene nm23-H1 is involved in restricting the progression of a number of human cancers, including non-small cell lung cancer (NSCLC), and has also been shown to be positively regulated by FOXO1 in lung cancer [<xref ref-type="bibr" rid="CR56">56</xref>]. In addition to FOXO1, FOXO3 is also strongly associated with the metastasis of multiple malignancies, including breast, pancreatic and kidney cancers [<xref ref-type="bibr" rid="CR57">57</xref>–<xref ref-type="bibr" rid="CR59">59</xref>]. Although overwhelming evidence has pinpointed FOXOs as suppressors of cell migration and metastasis, some literature suggests that FOXOs have an otherwise oncogenic role. Some correlation studies have linked high FOXO expression with poor cancer patient prognosis and enhanced metastasis [<xref ref-type="bibr" rid="CR60">60</xref>–<xref ref-type="bibr" rid="CR67">67</xref>]. Specifically, high FOXO1 and FOXO3 expression has been correlated with matrix metalloproteinase (MMP) upregulation and enhanced cancer metastasis [<xref ref-type="bibr" rid="CR68">68</xref>, <xref ref-type="bibr" rid="CR69">69</xref>]. Overexpression of FOXO1 can also promote the podocyte EMT induced by high glucose conditions [<xref ref-type="bibr" rid="CR70">70</xref>]. Equally, FOXO3 has been demonstrated in many studies to promote cell invasion and migration through inducing the expression of MMPs, including MMP-2, MMP-3, MMP-9 and MMP-13 [<xref ref-type="bibr" rid="CR69">69</xref>, <xref ref-type="bibr" rid="CR71">71</xref>–<xref ref-type="bibr" rid="CR73">73</xref>]. However, it is also notable that these studies have been centred upon normal endothelial cells. Although FOXO4 has been shown to activate the expression of MMP-9 essential for vascular smooth muscle cell migration, it also inhibits gastric cancer cell proliferation and migration [<xref ref-type="bibr" rid="CR74">74</xref>, <xref ref-type="bibr" rid="CR75">75</xref>]. The fact that FOXOs are involved in regulating cell migration is further supported by the observation that FOXO6 regulates Plxna4-mediated neuronal migration during development [<xref ref-type="bibr" rid="CR76">76</xref>]. However, when overexpressed, FOXO6 has also been shown to inhibit breast cancer cell migration and invasion [<xref ref-type="bibr" rid="CR77">77</xref>]. These conflicting findings may reflect the cell type–specific roles of FOXOs in cell migration and metastasis. It is possible that FOXOs have a pro-metastatic function in normal endothelial cells but switch to a tumour-suppressive anti-metastatic role in cancer cells. On the whole, these findings support the hypothesis that FOXO proteins are genuine tumour suppressors but the underlying mechanisms involved in this switch from normal to cancer cells need further elucidation.</p>
</sec>
<sec id="Sec8">
<title>FOXOs and angiogenesis</title>
<p id="Par11">Angiogenesis is the process whereby new blood vessels are formed. This process facilitates the delivery of oxygen and nutrients to the target tissues and cells. These functions also make angiogenesis essential for the spreading and establishment of tumour metastases. Essentially, angiogenesis facilitates the escape of tumour cells into the bloodstream and the establishment of metastatic colonies at secondary sites. In a manner similar to angiogenesis, lymphangiogenesis also helps to disseminate lymphatic metastases. Insights from human endothelial cell studies and gene knockout mouse models have revealed a clear role for FOXO proteins in regulating the angiogenic activity of endothelial cells and blood vessel formation [<xref ref-type="bibr" rid="CR23">23</xref>, <xref ref-type="bibr" rid="CR78">78</xref>]. Indeed, overexpression of constitutively active FOXO1 or FOXO3, but surprisingly not FOXO4, significantly inhibits endothelial tube formation and migration. Appropriately, FOXO1 and FOXO3 are, in fact, the most abundant FOXO proteins in mature endothelial cells. Consistent with this, silencing of either FOXO1 or FOXO3 also leads to a significant increase in the migratory and sprout-forming capacity of endothelial cells [<xref ref-type="bibr" rid="CR78">78</xref>]. In concordance with a key role for FOXOs in angiogenesis, further gene expression profiling analysis also reveals that endogenous FOXO1 and FOXO3 negatively regulate a set of angiogenesis-related and vascular remodelling genes, including angiopoietin 2 (Ang2) and eNOS, to repress blood vessel formation and maturation [<xref ref-type="bibr" rid="CR78">78</xref>]. The role of FOXOs in angiogenesis is further supported by studies in FOXO1/3/4 triple-knockout mice showing that FOXO depletion potentiates angiogenesis in mouse liver in response to simulation by pro-angiogenic growth factors, such as vascular endothelial growth factor (VEGF) and basic fibroblast growth factor (bFGF) [<xref ref-type="bibr" rid="CR23">23</xref>]. Further work using the FOXO1/3/4 knockout mouse system confirms that FOXOs directly regulate the expression of endothelial cell morphogenic and vascular homeostatic mediators, including Sprouty2 and PBX1, which control the process of angiogenesis [<xref ref-type="bibr" rid="CR23">23</xref>]. FOXO3 has also been reported to repress the expression of the potent angiogenic growth factor VEGF at the promoter level in breast cancer [<xref ref-type="bibr" rid="CR31">31</xref>]. Similarly, FOXO1 has also been found to regulate VEGFA expression and promote angiogenesis [<xref ref-type="bibr" rid="CR79">79</xref>].</p>
</sec>
</sec>
<sec id="Sec9">
<title>Deregulation of FOXOs in cancer and metastasis</title>
<sec id="Sec10">
<title>FOXO mutation in cancer</title>
<p id="Par12">The human FOXO1 (also known as FKHR; forkhead in rhabdomyosarcoma) was first identified as the fusion partner of paired box protein (PAX) 3/7 in alveolar rhabdomyosarcoma, a paediatric tumour of skeletal muscle. The majority of highly metastatic and aggressive alveolar rhabdomyosarcomas harbour the FOXO1-PAX3/7 protein, resulting from t(2;13)(q35;q14) and t(1;13)(p36;q14) chromosomal translocation, respectively [<xref ref-type="bibr" rid="CR80">80</xref>, <xref ref-type="bibr" rid="CR81">81</xref>]. Both PAX3 and PAX7 are important regulators of myogenesis [<xref ref-type="bibr" rid="CR82">82</xref>], and their fusion proteins with FOXO1 carry the FOXO1 transactivation domain which confers a gain-of-function oncogenic PAX3/7 phenotype. These genetic changes are somatic and not inherited in the family. A G protein–coupled receptor (GPCR) Cnr1 has previously been shown to induce PAX3-FOXO1 expression to augment cell invasive capacity in alveolar rhabdomyosarcoma. From the study, the use of Cnr1 antagonist or genetic deletion attenuates migration of alveolar rhabdomyosarcoma to the lungs [<xref ref-type="bibr" rid="CR83">83</xref>]. In a similar manner to the FOXO1 chromosomal translocation in alveolar rhabdomyosarcoma, FOXO3 (also known as FKHRL1) and FOXO4 (also known as AFX) are translocated to the MLL gene in mixed lineage leukaemia (MLL), an aggressive paediatric blood cancer [<xref ref-type="bibr" rid="CR11">11</xref>]. MLL is characterised by the presence of a MLL-FOXO3/4 fusion protein, resulting from the t(6;11)(q21;q23) and t(X;11)(q13.1;q23) chromosomal translocation, respectively [<xref ref-type="bibr" rid="CR84">84</xref>, <xref ref-type="bibr" rid="CR85">85</xref>]. Importantly, these genetic rearrangements in alveolar rhabdomyosarcoma and MLLs not only create new oncogenic fusion proteins but also cause the loss of FOXO allele from the original chromosome, resulting in FOXO locus haploinsufficiency [<xref ref-type="bibr" rid="CR86">86</xref>]. Unlike the other FOXOs, FOXO6 has not been shown to be involved in chromosomal translocation. It has also been reported that the FOXO3 is a tumour suppressor gene commonly deleted during early-stage lung adenocarcinoma carcinogenesis [<xref ref-type="bibr" rid="CR87">87</xref>, <xref ref-type="bibr" rid="CR88">88</xref>]. Characterisation of a common chromosomal 6q21 deletion in mature B cell lymphomas and childhood acute lymphoblastic leukaemia has also uncovered FOXO3 as being one of the three tumour suppressor genes frequently deleted in these rare blood cancers [<xref ref-type="bibr" rid="CR89">89</xref>]. A loss of FOXO1 in a chromosomal deletion at 13q14 is associated with tumorigenesis of the benign mammary and vaginal myofibroblastomas [<xref ref-type="bibr" rid="CR90">90</xref>]. Similarly, deletion of FOXO3 at 6q21 is shown to be linked with a rare highly aggressive lymphoid malignancy, natural killer cell neoplasms [<xref ref-type="bibr" rid="CR91">91</xref>]. However, despite these examples of translocation and deletion of FOXO genes in alveolar rhabdomyosarcoma, mixed lineage leukaemia, lung adenocarcinoma and natural killer cell neoplasms, FOXO genes are generally rarely mutated in human cancers, suggesting deregulated FOXO expression and function as the predominant mechanism for cancer development and progression. The reason for the lack of FOXO mutations in cancer is unclear. However, it has been shown that a monoallelic 13q14 deletion in mammalian cells can result in a reduction in FOXO1 expression levels and cellular proliferation stress, which can, in turn, cause oxidative stress to activate the p38 MAPK to induce cellular senescence <italic toggle="yes">via</italic> the oestrogen receptor (ER) stress-activating transcription factor 6 (ATF6) axis [<xref ref-type="bibr" rid="CR92">92</xref>]. This might represent a tumour suppressor loss–induced senescence mechanism to prevent the loss of FOXO genes [<xref ref-type="bibr" rid="CR93">93</xref>].</p>
</sec>
<sec id="Sec11">
<title>Regulation of FOXOs by post-translational modifications</title>
<p id="Par13">As mentioned, FOXOs are predominantly deregulated at the post-translational level in most cancers. In response to external stimuli, FOXO proteins are rapidly reversible-regulated by multiple layers of post-translational and post-transcriptional modifications including phosphorylation, acetylation, ubiquitination, glycosylation and methylation (Fig. <xref rid="Fig1" ref-type="fig">1</xref>). These modifications control FOXO functions through adjusting their turnover (stability), altering their subcellular localisation, changing their DNA binding affinity, controlling their transcriptional activity and regulating their interaction with co-factors. For example, these post-translational modifications can induce FOXO conformational changes and introduce new binding motifs for FOXO-binding proteins, which, in turn, regulate the expression, subcellular localisation, DNA binding and transcriptional activity of FOXOs [<xref ref-type="bibr" rid="CR86">86</xref>]. FOXO proteins are best studied for their regulation <italic toggle="yes">via</italic> phosphorylation at different conserved serine and threonine amino acid residues predominantly by the insulin and cellular stress pathways [<xref ref-type="bibr" rid="CR30">30</xref>].<fig id="Fig1" position="float" orientation="portrait">
<label>Fig. 1</label>
<caption>
<p>Compilation of post-translational modifications and post-transcriptional controls of FOXO proteins. At the protein level, multiple signalling pathways from different sources converge to regulate FOXO subcellular localisation, activity and stability. At the post-transcriptional level, microRNA regulates FOXO proteins to modulate cell proliferation, invasion and metastasis. Regulation: red, negative; green, positive; and grey, not known. Amino acids: threonine (Thr), lysine (Lys), serine (Ser) and arginine (Arg)</p>
</caption>
<graphic id="MO1" position="float" orientation="portrait" ns1:href="10555_2020_9883_Fig1_HTML.jpg" />
</fig>
</p>
</sec>
<sec id="Sec12">
<title>FOXOs and Akt-mediated phosphorylation</title>
<p id="Par14">The growth factor–regulated PI3K-Akt (also known as PKB) signalling cascade is one of the most frequently dysregulated pathways in cancer, resulting commonly in an upregulation of Akt and thereby an attenuation of FOXO activity [<xref ref-type="bibr" rid="CR94">94</xref>]. Consumption of glucose-containing diets increases glucose levels in the blood serum which supplies different organs as a primary source of energy. In response to high serum glucose levels, pancreatic β-cells synthesise and secrete insulin to lower the elevated blood glucose level by promoting the cellular glucose uptake using insulin-regulated glucose transporter GLUT4 through the PI3K-Akt signalling pathway [<xref ref-type="bibr" rid="CR95">95</xref>, <xref ref-type="bibr" rid="CR96">96</xref>]. Indeed, cancer cells utilise glucose for proliferation and metastasis [<xref ref-type="bibr" rid="CR97">97</xref>]. Upon induction of the insulin receptors, the activated Akt suppresses the function and alter the subcellular localisation of FOXO proteins. Specifically, the high nutrient availability triggers insulin signalling pathway to promote Akt-mediated FOXO1 (Thr24, Ser256 and Ser319), FOXO3 (Thr32, Ser253 and Ser315), FOXO4 (Thr28, Ser193 and Ser258) and FOXO6 (Thr26 and Ser184) phosphorylations [<xref ref-type="bibr" rid="CR86">86</xref>]. Notably, FOXO6 is only phosphorylated at two sites and it is not regulated by nucleo-cytoplasmic shuttling [<xref ref-type="bibr" rid="CR98">98</xref>]. FOXO1 (Thr24 and Ser256) and FOXO3 (Thr32 and Ser253) phosphorylations serve as docking sites for chaperone protein 14-3-3 on the N-terminus and the DNA binding domain of the FOXO protein [<xref ref-type="bibr" rid="CR11">11</xref>]. The binding of the 14-3-3 protein is believed to expose the FOXO nuclear export sequence to promote nuclear exclusion. Similarly, the binding of the 14-3-3 to FOXO proteins reduces the access of nuclear importing machinery to nuclear localisation sequence (NLS), suggesting that the 14-3-3 interaction prevents FOXO from nuclear translocation [<xref ref-type="bibr" rid="CR99">99</xref>]. Another study has shown that simultaneous binding of 14-3-3 on these phosphorylated sites also disrupts and affects FOXO DNA binding capability [<xref ref-type="bibr" rid="CR100">100</xref>]. For FOXO1, the cytoplasmic sequestration is shown to be promoted by the phosphorylation at Ser256 which introduces a negative charge to the basic nuclear localisation signal sequence [<xref ref-type="bibr" rid="CR101">101</xref>]. In response to growth factor, phosphorylation of FOXO1 by Akt at Ser319 also primes the casein kinase 1 (CK1) to phosphorylate FOXO1 further at Ser322 and Ser325 [<xref ref-type="bibr" rid="CR102">102</xref>]. These CK1 phosphorylation sites directly promote the interaction between FOXO1 and the nuclear export machinery Ran-CRM1 complex [<xref ref-type="bibr" rid="CR102">102</xref>]. Conversely, the Akt-mediated phosphorylated FOXO1 and FOXO3 nuclear exclusion can be rescued by dephosphorylation mediated by protein phosphatase 2A (PP2A) (Fig. <xref rid="Fig2" ref-type="fig">2</xref>) [<xref ref-type="bibr" rid="CR103">103</xref>, <xref ref-type="bibr" rid="CR104">104</xref>].<fig id="Fig2" position="float" orientation="portrait">
<label>Fig. 2</label>
<caption>
<p>FOXO regulation by phosphorylation. Signals from various sources induce signalling pathways to regulate FOXO activity. Insulin signalling pathway induces Akt-mediated FOXO inhibition and facilitates 14-3-3 protein binding and nuclear exclusion. Subsequently, the cytoplasmic FOXO is ubiquitinated by SKP2 for protein degradation. This 14-3-3-bound FOXO can be rescued by JNK phosphorylation and PP2A dephosphorylation. Stress-activated p38, JNK and PERK promote FOXO transcriptional activity. In parallel, AMP sensor detects low intracellular energy and promotes FOXO <italic toggle="yes">via</italic> AMPK phosphorylation. However, stress-activated ERK inhibits FOXO activity by promoting MDM2-mediated polyubiquitination</p>
</caption>
<graphic id="MO2" position="float" orientation="portrait" ns1:href="10555_2020_9883_Fig2_HTML.jpg" />
</fig>
</p>
<p id="Par15">High levels of Akt-phosphorylated FOXO proteins are correlated with poor patient overall disease-free survival rate in many cancers [<xref ref-type="bibr" rid="CR105">105</xref>]. At the molecular level, a study shows that the Akt signalling pathway suppresses cell migration and invasion through FOXO1 to inhibit runt-related transcription factor 2 (RUNX2) transcriptional activity in prostate cancer [<xref ref-type="bibr" rid="CR106">106</xref>]. FOXO4 has also been identified by a genome-wide RNAi screen to be a suppressor of metastasis through antagonising PI3K/AKT signal pathway and RUNX2-dependent transcription in prostate cancer [<xref ref-type="bibr" rid="CR53">53</xref>]. Besides RUNX2, its closed relatives RUNX1 and RUNX3 are also linked to FOXO proteins in restricting cancer survival [<xref ref-type="bibr" rid="CR107">107</xref>, <xref ref-type="bibr" rid="CR108">108</xref>]. However, in these cases, RUNX1 and RUNX3 bind to and cooperate with FOXO proteins to promote cell death in breast and gastric cancers. Moreover, Akt-regulated FOXO4 has been shown to promote anti-metastatic protein ANXA8 in the bile duct cancer, cholangiocarcinoma [<xref ref-type="bibr" rid="CR109">109</xref>]. FOXO3 can also modulate cell invasion by regulating the expression of MMP-9 in glioblastoma [<xref ref-type="bibr" rid="CR110">110</xref>]. Through FOXO6, EGFR signalling controls SRY-related HMG-box 2 (SOX2) expression in lung cancer [<xref ref-type="bibr" rid="CR111">111</xref>]. Recently, a SOX2 knockdown experiment shows that basal cell carcinoma migration is regulated by Akt signalling pathway [<xref ref-type="bibr" rid="CR58">58</xref>]. In agreement, another recent study shows that hypoxia-induced breast cancer cell migration is regulated by SOX2 transcription factor [<xref ref-type="bibr" rid="CR112">112</xref>].</p>
</sec>
<sec id="Sec13">
<title>Stress signals in FOXO regulation</title>
<p id="Par16">Unlike the nutrient and growth factor–mediated PI3K-Akt signalling cascade, FOXO activity can be enhanced by the stress-activated signalling pathway. In cancer cells, stress can promote or restrict cancer growth and progression. Reactive oxygen species (ROS) levels are often elevated in cancers by various factors, including enhanced oncogenic activity and increased metabolic function [<xref ref-type="bibr" rid="CR113">113</xref>]. In mitochondria, ROS is a by-product of oxidative phosphorylation where a large amount of energy is generated [<xref ref-type="bibr" rid="CR114">114</xref>]. During the process, electron transport chain complex–produced superoxide is reduced into hydrogen peroxide by Sirtuin-stimulated manganese-dependent superoxide dismutase (MnSOD, also called SOD2) [<xref ref-type="bibr" rid="CR115">115</xref>]. This FOXO-regulated SOD2 modulates cellular antioxidant capacity. A loss of FOXO function increases intracellular ROS, pushing cancer cells to rely on Warburg effect to prevent further cellular damages [<xref ref-type="bibr" rid="CR11">11</xref>, <xref ref-type="bibr" rid="CR116">116</xref>]. However, lower SOD2 expression allows cancer cells to acquire beneficial DNA damages for enhanced proliferation and to obtain drug resistance mutations [<xref ref-type="bibr" rid="CR11">11</xref>]. Similarly, chemically induced stresses from multiple chemotherapeutic treatments have also been shown to integrate with FOXO activity [<xref ref-type="bibr" rid="CR30">30</xref>, <xref ref-type="bibr" rid="CR117">117</xref>]. Cancer cells control these stresses by inducing JNK to activate FOXO-mediated oxidative stress resistance [<xref ref-type="bibr" rid="CR118">118</xref>]. Notably, the responses of FOXOs to stress are dependent on the stress intensity in different conditions and contexts.</p>
<p id="Par17">Oxidative stress–activated JNK can also phosphorylate the 14-3-3 protein (Ser184) to enhance FOXO activity. The phosphorylation releases FOXO proteins from 14-3-3, exposing the nuclear localisation signals to promote nuclear translocation [<xref ref-type="bibr" rid="CR119">119</xref>]. In parallel, JNK also antagonises Akt activity by phosphorylating FOXO3 at Ser574 for activation [<xref ref-type="bibr" rid="CR120">120</xref>]. Under oxidative stress, JNK phosphorylates FOXO4 directly at Thr447 and Thr451 to promote FOXO4 nuclear localisation [<xref ref-type="bibr" rid="CR118">118</xref>]. Similarly, oxidative stress induces mammalian Ste20-like kinase 1 (Mst1) kinase activation in Hippo signalling pathway to promote FOXO1-mediated apoptosis [<xref ref-type="bibr" rid="CR121">121</xref>]. During oxidative stress, Mst1 phosphorylates FOXO1 (Ser212) and FOXO3 (Ser207) directly to disrupt the binding of 14-3-3 protein to promote FOXO activity [<xref ref-type="bibr" rid="CR122">122</xref>, <xref ref-type="bibr" rid="CR123">123</xref>]. Recently, FOXO protein activity has been inversely linked to epidermal growth factor receptor 2 (EGFR2, also known as HER2) overexpression. A study shows that HER2 negatively regulates FOXO1 at the transcriptional level [<xref ref-type="bibr" rid="CR124">124</xref>]. Like the insulin signalling pathway, this HER2 regulation of FOXO activity is mediated <italic toggle="yes">via</italic> the PI3K/Akt signalling pathway [<xref ref-type="bibr" rid="CR125">125</xref>].</p>
<p id="Par18">Consistently, treatment of cancer cells with EGFR/HER2-tyrosine kinase inhibitors (EGFR/HER2-TKI; e.g. gefitinib and lapatinib) or anti-ErbB-2 monoclonal antibodies (e.g. trastuzumab) induces cell proliferative arrest and/or cell death, and this has been shown to be mediated through the PI3K/Akt/FOXO3 signalling axis [<xref ref-type="bibr" rid="CR31">31</xref>, <xref ref-type="bibr" rid="CR126">126</xref>–<xref ref-type="bibr" rid="CR132">132</xref>]. Appropriately, an HER2 upregulation induces both Akt and JNK to promote gastric cancer growth and metastasis [<xref ref-type="bibr" rid="CR133">133</xref>]. These findings suggest that multiple stress signals converge and integrate to regulate FOXO activity and that FOXO proteins are important factors in a pivot balance to determine cell fates (Fig. <xref rid="Fig3" ref-type="fig">3</xref>). It is also plausible that an intermediate degree of stress promotes cell metastasis to evade from the source of stress whilst a high level of stress induces cell death.<fig id="Fig3" position="float" orientation="portrait">
<label>Fig. 3</label>
<caption>
<p>The balance of signal regulation. FOXO proteins are the point of signal integration from various sources. The intensity of these signals critically determines cell fate. Activated kinases in different pathways can either inhibit or activate FOXO transcriptional activity. A shift in signal intensity towards the inhibition of FOXO proteins allows cancer development and progression</p>
</caption>
<graphic id="MO3" position="float" orientation="portrait" ns1:href="10555_2020_9883_Fig3_HTML.jpg" />
</fig>
</p>
<p id="Par19">Beside the stress-induced JNK, FOXO is also regulated by two other major MAPKs: extracellular signal–regulated kinases (ERKs) and the p38 family of stress-activated MAPKs [<xref ref-type="bibr" rid="CR134">134</xref>]. These signalling pathways (JNK, ERK and p38) modulate the FOXO-regulated intracellular ROS cooperatively [<xref ref-type="bibr" rid="CR135">135</xref>]. In fact, the outcome of the FOXO activity regulation is predominantly controlled by the duration and magnitude of the multiple MAPK signal integration [<xref ref-type="bibr" rid="CR136">136</xref>]. Each of the MAPKs (JNK, ERK and p38) is regulated by mitogen-activated protein kinase phosphatases (MKPs) to control its activity and subcellular localisation, increasing the complexity of FOXO regulation [<xref ref-type="bibr" rid="CR136">136</xref>]. Indeed, increased MKP expression elevates cancer progression and drug resistance, linking MKPs to FOXO function [<xref ref-type="bibr" rid="CR137">137</xref>]. Although there is no evidence of a direct link between MKP and FOXO activities in human cancer, a study has demonstrated that insulin-induced MKP3 (also known as dual-specificity phosphatase 6; DUSP7) interacts and dephosphorylates FOXO1 on Ser256 in a mouse model to promote its nuclear import for gluconeogenic gene transcription [<xref ref-type="bibr" rid="CR138">138</xref>]. Noteworthy, gluconeogenetic enzymes play a crucial part in the regulation of cancer EMT [<xref ref-type="bibr" rid="CR139">139</xref>]. A study also shows that ERK directly phosphorylates FOXO1 at Ser246, Ser284, Ser295, Ser326, Ser413, Ser415, Ser429, Ser467 and Ser475 to alter the transcriptional activity of Ets1, a regulator of angiogenesis-related genes [<xref ref-type="bibr" rid="CR134">134</xref>]. However, the functional consequence of the ERK/FOXO1-regulated Ets1 on the induction of angiogenesis and metastasis has yet to be confirmed in cancer cells.</p>
<p id="Par20">In cancer, the ERK and p38 MAPK pathways cooperate to control anoikis, a form of cell death triggered by a loss of extracellular matrix (ECM) attachment [<xref ref-type="bibr" rid="CR140">140</xref>]. Anoikis resistance, the insensitivity to anoikis-induced cell death, is a prerequisite for EMT and cancer metastasis [<xref ref-type="bibr" rid="CR141">141</xref>]. Indeed, anoikis has been shown to be regulated by FOXO3 activity during breast cancer metastasis [<xref ref-type="bibr" rid="CR142">142</xref>]. It has also been shown that both ERK and p38 MAPK can activate FOXO1 by phosphorylation [<xref ref-type="bibr" rid="CR134">134</xref>]. Nine serine residues in FOXO1 are phosphorylated by ERK, whilst five of them (i.e. Ser284, Ser295, Ser326, Ser467 and Ser475) are also phosphorylated by p38 MAPK [<xref ref-type="bibr" rid="CR134">134</xref>]. Whilst the physiological consequence of the ERK and p38 MAPK-dependent FOXO1 phosphorylation is unclear, p38 MAPK induction promotes fibroblast cell invasion and anchorage-independent cell growth [<xref ref-type="bibr" rid="CR143">143</xref>]. In agreement, inhibition of p38 MAPK reduces glioma invasiveness [<xref ref-type="bibr" rid="CR144">144</xref>]. MKK4 also mediates suppression of metastasis in ovarian cancer <italic toggle="yes">via</italic> activation of p38 MAPK [<xref ref-type="bibr" rid="CR145">145</xref>]. Moreover, the upstream regulator of ERK MEK1/2 can directly induce Akt for FOXO1 phosphorylation to promote cell migration [<xref ref-type="bibr" rid="CR146">146</xref>]. Another study shows that inhibition of both Akt and ERK signalling pathways synergistically induces FOXO transcriptional activity to inhibit angiogenesis [<xref ref-type="bibr" rid="CR147">147</xref>]. Moreover, UV irradiation induces stress-mediated JNK to suppress both ERK and Akt activities and promotes FOXO3 nuclear translocation, probably for DNA damage repair [<xref ref-type="bibr" rid="CR148">148</xref>]. Conversely, ERK2 can also promote cell migration and invasion through the Rac1/Cdc42 guanine nucleotide exchange factor (GEF) DOCK10, which induces JNK to activate FOXO1 and promote EMT [<xref ref-type="bibr" rid="CR149">149</xref>]. Paradoxically, the loss of FOXO1 which is followed by an upregulation of p38 initiates a compensatory mechanism to promote other FOXO protein activities. p38 MAPK has been shown to phosphorylate FOXO3 on Ser7 to mediate nuclear localisation and senescence in response to doxorubicin-induced DNA damages in breast cancer [<xref ref-type="bibr" rid="CR150">150</xref>]. In a similar manner, the p38 MAPK is also activated by cetuximab to induce cell death and inhibit cell proliferation <italic toggle="yes">via</italic> FOXO3 in colorectal cancer [<xref ref-type="bibr" rid="CR151">151</xref>]. During ER stress, unfolded protein response (UPR) activates inositol-requiring enzyme 1 (IRE1), protein kinase R (PKR)-like ER kinase (PERK) and ATF6 to promote ER folding capacity and maintain cellular proteostasis for cell survival [<xref ref-type="bibr" rid="CR152">152</xref>, <xref ref-type="bibr" rid="CR153">153</xref>]. Furthermore, PERK has previously been shown to promote FOXO1 activity by direct phosphorylation at Ser298, Ser301 and Ser303, representing another layer of FOXO regulation in cancer [<xref ref-type="bibr" rid="CR154">154</xref>]. Nevertheless, a recent study has shown that PERK, instead of promoting FOXO activity, can inhibit FOXO activity through enhancing Akt activity [<xref ref-type="bibr" rid="CR155">155</xref>]. Together, these findings suggest that cancer cell metastasis is regulated by FOXO proteins, whose activity is, in turn, modulated by stress-activated signals, including the JNK, ERK and p38 MAPKs.</p>
</sec>
<sec id="Sec14">
<title>FOXO ubiquitination</title>
<p id="Par21">The Akt-phosphorylated FOXOs (e.g. FOXO1 at Ser256) are recognised by the activated F-box protein S-phase kinase-associated protein 2 (SKP2) in the SCF<sup>SKP2</sup> E3 ligase complex, which targets FOXO proteins for polyubiquitination and degradation [<xref ref-type="bibr" rid="CR156">156</xref>]. Interestingly, FOXO3 has also been shown to be a negative regulator of SKP2 expression, and this could represent a positive feed-forward loop in the regulation of FOXO expression and activity [<xref ref-type="bibr" rid="CR157">157</xref>]. Collectively, the Akt-phosphorylated FOXOs are sequestered in the cytoplasm, transcriptionally inactive and targeted by the ubiquitin-proteasome system for degradation. At the molecular level, ERK phosphorylates FOXO1 and FOXO3 (Ser294, Ser344 and Ser425) to recruit the MDM2 E3 ubiquitin ligase for FOXO poly-ubiquitination and proteasomal degradation [<xref ref-type="bibr" rid="CR158">158</xref>, <xref ref-type="bibr" rid="CR159">159</xref>]. Besides poly-ubiquitination, a study suggests that FOXO4 can be mono-ubiquitinated at Lys199 and Lys211 by MDM2 in response to oxidative stress for nuclear translocation. The mono-ubiquitinated FOXO4 can be reversed by ubiquitin-specific protease 7 (USP7; also known as HAUSP)–mediated de-ubiquitination [<xref ref-type="bibr" rid="CR160">160</xref>, <xref ref-type="bibr" rid="CR161">161</xref>]. However, the mono-ubiquitination on other FOXO proteins has not been demonstrated and the exact mechanism of this modification is still unclear (Fig. <xref rid="Fig2" ref-type="fig">2</xref>). As glucose is a source of energy, Akt-mediated FOXO1 ubiquitination is also interconnected with an energy homeostasis regulator, the 5′ adenosine monophosphate–activated protein kinase (AMPK). AMPK is an intracellular energy sensor which senses the ADP/ATP ratio and regulates cell growth, autophagy and metabolism [<xref ref-type="bibr" rid="CR162">162</xref>]. A study shows that AMPK-mediated FOXO1 phosphorylation at Ser383 and Thr649 promotes FOXO protein stability, nuclear translocation and transcriptional activity [<xref ref-type="bibr" rid="CR163">163</xref>]. A recent study also demonstrates that AMPK can phosphorylate FOXO1 at Ser22 to activate FOXO1 by blocking Akt-mediated FOXO sequestration by the 14-3-3 protein in the cytoplasm [<xref ref-type="bibr" rid="CR164">164</xref>]. Indeed, the hypoxia-induced AMPK has been shown to promote FOXO1 activity [<xref ref-type="bibr" rid="CR165">165</xref>]. Likewise, FOXO3 is also phosphorylated by AMPK at Thr179, Ser399, Ser413, Ser555, Ser588 and Ser626 for transcriptional activation, but this AMPK-mediated phosphorylation enhances the activity of FOXO3, without altering its subcellular localisation and DNA binding affinity [<xref ref-type="bibr" rid="CR166">166</xref>]. Indeed, AMPK-induced FOXO3 phosphorylation has been shown to suppress pancreatic cancer growth and metastasis [<xref ref-type="bibr" rid="CR167">167</xref>]. Of note, in response to growth factor stimulation, IκB kinase (IKK) also exclusively phosphorylates FOXO3 (Ser644) for ubiquitination and degradation as the other FOXO proteins do not have similar amino acid residues [<xref ref-type="bibr" rid="CR168">168</xref>].</p>
</sec>
<sec id="Sec15">
<title>FOXO regulation by other kinases and factors</title>
<p id="Par22">Besides the PI3K-Akt and stress-activated MAPK signalling pathways, many other kinases and dependent cascades also contribute to FOXO regulation. For instance, the p21-activated kinase (PAK1, a downstream target of PI3K) can bind and phosphorylate FOXO1 directly to prevent its nuclear translocation in breast cancer [<xref ref-type="bibr" rid="CR169">169</xref>]. Similarly, the transforming growth factor β–activated kinase (TAK1)-Nemo-like kinase (NLK) pathway also mediates FOXO1 phosphorylation in the transactivation domain to drive its nuclear exclusion [<xref ref-type="bibr" rid="CR170">170</xref>]. The dual-specificity tyrosine-phosphorylated and regulated kinase 1 (DYRK1) phosphorylates FOXO1 (Ser329) to promote its activity in unstimulated quiescent mammalian cells [<xref ref-type="bibr" rid="CR171">171</xref>, <xref ref-type="bibr" rid="CR172">172</xref>]. Recently, a study shows that the glucagon-activated PKA also phosphorylates FOXO1 at Ser276 to promote its nuclear relocalisation and stability in liver cancer and limit insulin-induced FOXO nuclear export and their ubiquitination-degradation [<xref ref-type="bibr" rid="CR173">173</xref>].</p>
<p id="Par23">During normal cell divisions, CDK/cyclin complexes are the main regulators of the cell cycle checkpoints which can influence cell fates. However, in cancer, these CDK/cyclin complexes are commonly deregulated, resulting in deregulated and highly proliferative cells [<xref ref-type="bibr" rid="CR174">174</xref>]. Indeed, CDK1 (also called CDC2) and CDK2 have shown to phosphorylate FOXO1 at Ser249 to alter its subcellular localisation. Paradoxically, FOXO1 has also been found to be activated by CDK1 to induce apoptosis gene activation in post-mitotic neurons but FOXO1 phosphorylation by CDK1 promotes its inhibition in human prostate adenocarcinoma cells [<xref ref-type="bibr" rid="CR175">175</xref>, <xref ref-type="bibr" rid="CR176">176</xref>]. These contrasting findings may reflect the deregulation of normal FOXO1 control and function in cancer cells. On the other hand, CDK2 has been confirmed to inhibit FOXO1 by promoting its nuclear exclusion to suppress FOXO1 transcriptional activity [<xref ref-type="bibr" rid="CR177">177</xref>]. With respect to cell migration, an activator of CDK1 and CDK2, Cdc25A phosphatase can enhance FOXO1 stability to promote MMP-1-mediated metastasis in breast cancer [<xref ref-type="bibr" rid="CR68">68</xref>]. Consistent with this finding, the FOXO1-derived small peptide FO1-6nl inhibits CDK1/2-mediated FOXO1 phosphorylation and prevents prostate cancer proliferation [<xref ref-type="bibr" rid="CR178">178</xref>]. In addition, FOXO3 circular RNA (circ-FOXO3) has been reported to form an inhibitory complex with CDK2 and p21<sup>Cip1</sup> to restrict cell cycle progression [<xref ref-type="bibr" rid="CR179">179</xref>]. During cell division, genotoxic stress, induced by cytotoxic chemotherapeutic agents, can revert the FOXO phosphorylation state and induce a senescent and/or apoptotic response in cancer cells [<xref ref-type="bibr" rid="CR64">64</xref>, <xref ref-type="bibr" rid="CR126">126</xref>, <xref ref-type="bibr" rid="CR127">127</xref>, <xref ref-type="bibr" rid="CR129">129</xref>, <xref ref-type="bibr" rid="CR151">151</xref>, <xref ref-type="bibr" rid="CR155">155</xref>, <xref ref-type="bibr" rid="CR177">177</xref>, <xref ref-type="bibr" rid="CR180">180</xref>–<xref ref-type="bibr" rid="CR184">184</xref>]. On the other hand, FOXO3 can also upregulate the expression of DNA damage–inducible 45 (GADD45) of the DNA repair mechanism and has a role in ATM-mediated DNA damage response to prevent cancer from acquiring further mutations [<xref ref-type="bibr" rid="CR185">185</xref>, <xref ref-type="bibr" rid="CR186">186</xref>]. These findings further emphasise the importance of FOXO3 in the prevention of cancer propagation and progression.</p>
</sec>
<sec id="Sec16">
<title>FOXO acetylation</title>
<p id="Par24">Although mammalian cells have protein kinases in place to regulate FOXO activity, another post-translational modification (PTM) acetylation applies extra layers of control to fine-tune their cellular functions. In general, depending on the sites of modification, acetylation of nuclear proteins usually alters their DNA binding affinity and, hence, their activity [<xref ref-type="bibr" rid="CR187">187</xref>]. For FOXO proteins, acetylation occurs predominantly at the Wing2 region of the forkhead DNA binding domain, where FOXO proteins were used for recognising their DNA consensus sequences on target genes [<xref ref-type="bibr" rid="CR188">188</xref>]; however, the functional consequence of FOXO acetylation is not clear-cut. An earlier report suggests that acetylation of sites Lys242, Lys245 and Lys262 located within the DNA binding domain of FOXO1 attenuates its transcriptional activity [<xref ref-type="bibr" rid="CR189">189</xref>]. In support of this, it has been demonstrated that oxidative stress–induced CREB-binding protein (CBP)/p300 acetylates FOXO1 at Lys245, Lys248 and Lys262 to restrict its DNA binding in cancer [<xref ref-type="bibr" rid="CR190">190</xref>]. However, another subsequent crystallographic structural analysis suggests that acetylation at equivalent sites (Lys242 and Lys245) in FOXO3 enhances its DNA binding and, therefore, its transcriptional activity [<xref ref-type="bibr" rid="CR191">191</xref>]. For FOXO1, there is also a controversial link between phosphorylation and acetylation. One study shows that FOXO1 acetylation requires insulin-induced Akt phosphorylation to prime the modification [<xref ref-type="bibr" rid="CR192">192</xref>]. Yet, another suggests that p300-mediated acetylation can increase sensitivity for the inhibitory FOXO1 phosphorylation at Ser253 [<xref ref-type="bibr" rid="CR189">189</xref>]. Despite the controversy over the exact order in which these modifications occur, these data suggest that acetylation and Akt-mediated phosphorylation cooperate to inhibit FOXO1 activity. Upon acetylation, FOXO1 has also been shown to have a reduced affinity for the genomic compacting protein nucleosomes, affecting multiple gene accessibility for other transcription factors [<xref ref-type="bibr" rid="CR193">193</xref>].</p>
<p id="Par25">FOXO acetylation is primarily mediated by CBP/p300 and reversed by Sirtuins (SIRTs), which are a group of highly conserved NAD-dependent deacetylases which have many roles in epigenetics and human diseases, including cancer [<xref ref-type="bibr" rid="CR194">194</xref>]. An earlier study suggests that SIRT2-mediated deacetylation promotes FOXO3 transactivation activity to reduce cellular ROS and induce cell death in cancer cells [<xref ref-type="bibr" rid="CR195">195</xref>]. However, a later study by the same research group has shown that SIRT1 and SIRT2 mediate deacetylation of FOXO3 to promote FOXO3 ubiquitination and degradation in Skp2-dependent manner, implying that acetylation increases FOXO stability and enhances its tumour-suppressive function [<xref ref-type="bibr" rid="CR196">196</xref>]. The discrepancy between the two studies is likely due to the overlapping and compensatory roles played by SIRT1 and SIRT2 in cancer, whilst inhibition of one leads to the induction of the other [<xref ref-type="bibr" rid="CR197">197</xref>]. In support of a tumour-suppressive role for FOXO acetylation, a report shows that the acetylation recruits FOXO1 to promyelocytic leukaemia (PML) protein in the nucleus to protect FOXO1 against ubiquitination and to promote its activity in pancreatic beta cells [<xref ref-type="bibr" rid="CR198">198</xref>]. In agreement, the interaction between FOXO3 and PML has also been observed in breast cancer [<xref ref-type="bibr" rid="CR199">199</xref>]. In addition, another study shows that four-and-a-half LIM 2 (FHL2) interacts with FOXO1 to facilitate SIRT1-mediated deacetylation to reduce FOXO1 activity in prostate cancer [<xref ref-type="bibr" rid="CR188">188</xref>]. SIRT6 also represses FOXO3 acetylation to promote clonal renewal and survival in breast cancer [<xref ref-type="bibr" rid="CR200">200</xref>]. Similarly, FOXO4 acetylation induces apoptosis of podocytes in diabetes through activating the pro-apoptotic gene Bim (Bcl-2l11) [<xref ref-type="bibr" rid="CR201">201</xref>]. Studies on mitochondrial reprogramming have produced further evidence that SIRTs repress FOXO acetylation to promote cancer progression and metastasis. Elevated ROS in cancer has been shown to lead to mitochondrial reprogramming <italic toggle="yes">via</italic> the evolutionarily conserved SIRT-FOXO-SOD2 axis to neutralise oxidative stress and promote cancer survival and metastasis [<xref ref-type="bibr" rid="CR202">202</xref>, <xref ref-type="bibr" rid="CR203">203</xref>]. Besides SIRTs, the histone deacetylase HDAC3 has been shown to be specifically recruited by geminin to FOXO3 to facilitate FOXO3 deacetylation and breast cancer metastasis [<xref ref-type="bibr" rid="CR57">57</xref>]. In spite of this tumour-suppressive protective role, geminin is also frequently overexpressed in human cancers. Collectively, the evidence accumulated to date suggests that FOXO acetylation is mediated by EP300/CBP and is reversed by SIRTs in general, promoting the tumour-suppressive function of FOXOs by increasing the transcription of genes important for cell proliferative arrest, senescence and cell death.</p>
<p id="Par26">Besides its tumour-suppressive function, recent evidence also reveals that FOXO acetylation is also targeted by anticancer chemotherapeutics to mediate their cytotoxic and cytostatic function. For example, it has been reported that capsaicin treatment induces CBP and represses SIRT1 expression, resulting in an increase in FOXO1 acetylation to limit pancreatic tumour growth [<xref ref-type="bibr" rid="CR204">204</xref>]. Moreover, SIRT6 can promote paclitaxel and epirubicin resistance in breast cancer [<xref ref-type="bibr" rid="CR200">200</xref>]. EP300 and SIRT1/6 also co-regulate the cytotoxic function of the EGFR/HER2 inhibitor lapatinib through modulating FOXO3 acetylation and activity in breast cancer [<xref ref-type="bibr" rid="CR129">129</xref>]. Similarly, SIRT2-mediated FOXO3 deacetylation has also been implicated in lapatinib response and sensitivity, and that SIRT2 can specifically antagonise the cytotoxicity of lapatinib through mediating FOXO3 deacetylation in both sensitive and resistant nasopharyngeal carcinoma (NPC) cells. The synthetic glucocorticoid dexamethasone also targets FOXO3 phosphorylation on Ser7 and acetylation on Lys242/Lys245 to mediate its cytotoxic function in B acute lymphoblastic leukaemia (B-ALL) [<xref ref-type="bibr" rid="CR180">180</xref>]. These findings also propose that SIRTs can be important biomarkers for metastatic and drug-resistant clones and that targeting the SIRT-FOXO3 axis may provide novel strategies for treating cancer and for overcoming chemoresistance. Indeed, specific as well as pan-SIRT inhibitors have proved to be effective in tackling cancer and in overcoming cancer drug resistance [<xref ref-type="bibr" rid="CR129">129</xref>, <xref ref-type="bibr" rid="CR197">197</xref>, <xref ref-type="bibr" rid="CR205">205</xref>, <xref ref-type="bibr" rid="CR206">206</xref>].</p>
</sec>
<sec id="Sec17">
<title>Other FOXO PTMs</title>
<p id="Par27">Methylation is a post-translational modification which introduces a methyl group to proteins. Protein methylation is predominantly associated with histone methylation which modulates gene expression [<xref ref-type="bibr" rid="CR207">207</xref>]. However, FOXO proteins are also direct targets of methylation. For instance, the ubiquitously expressed and tissue-specific protein arginine <italic toggle="yes">N</italic>-methyltransferase 1 (PRMT1) has been reported to methylate FOXO1 at Arg248 and Arg250 to block the Akt-mediated Ser253 phosphorylation and inhibition [<xref ref-type="bibr" rid="CR208">208</xref>]. The lysine methyltransferase Set9 has also been demonstrated to methylate FOXO3. This Set9-mediated FOXO3 methylation at Lys270 leads to attenuation of its DNA binding activity and downregulation of transactivation without affecting the Akt-mediated phosphorylation, its protein stability and subcellular localisation [<xref ref-type="bibr" rid="CR209">209</xref>]. On the evidence of these studies, FOXO methylation appears to promote the activity of FOXO proteins. In fact, protein methylation has been shown to have a role in protein-protein interaction, DNA binding affinity, protein stability and subcellular localisation [<xref ref-type="bibr" rid="CR210">210</xref>].</p>
<p id="Par28">It is also unclear whether like methylation, other less common post-translational modifications (i.e. glutathionylation, glycosylation, SUMOylation, hydroxylation, neddylation, citrullination, prenylation, palmitoylation, myristoylation and <italic toggle="yes">s</italic>-nitrosylation) also directly modify FOXO proteins and if they are involved in modulating FOXO activity in cancer [<xref ref-type="bibr" rid="CR211">211</xref>]. For example, neddylation inactivation by the specific inhibitor MLN4924 can prevent FOXO3 nuclear export, decrease its binding to the ESR1 (oestrogen receptor) gene promoter and improve fulvestrant sensitivity in breast cancer. Nevertheless, in this case, it is still unknown whether FOXO3 is directly modified by neddylation and if FOXO3 neddylation has a role in modulating its activity [<xref ref-type="bibr" rid="CR212">212</xref>].</p>
</sec>
<sec id="Sec18">
<title>Protein-protein interactions in FOXO regulation</title>
<p id="Par29">Apart from the post-translational modifications, protein-protein interactions also modulate FOXO function and activity. Peroxisome proliferator–activated receptors (PPARs) are a family of ligand-activated nuclear receptor transcription factors that function downstream of ERK to regulate cell metabolism and adipocyte differentiation [<xref ref-type="bibr" rid="CR213">213</xref>]. In this respect, FOXO1 and PPAR can compete for ERK signals and thereby antagonise the transcriptional activity of one another [<xref ref-type="bibr" rid="CR214">214</xref>]. In liver carcinoma cells, PPAR can also interfere with the binding of apolipoprotein C III (ApoC-III) to FOXO1, affecting the lipid metabolism and serum triglyceride levels [<xref ref-type="bibr" rid="CR215">215</xref>, <xref ref-type="bibr" rid="CR216">216</xref>]. ApoC-III plays a key role in the regulation of triglyceride metabolism and has been suggested to be a predictive marker for NSCLC [<xref ref-type="bibr" rid="CR217">217</xref>]. Nonetheless, lipid metabolism and lipid-mediated signalling are a key to cancer metastasis [<xref ref-type="bibr" rid="CR218">218</xref>], and dysregulated lipid metabolic enzymes are known to be associated with cancer cell invasion and metastasis [<xref ref-type="bibr" rid="CR219">219</xref>].</p>
<p id="Par30">In the nucleus, androgen receptor (AR) has been reported to interact with FOXO1. The nuclear receptor AR, which is expressed in a vast range of tissue, responds to the male sex hormone androgen for activation [<xref ref-type="bibr" rid="CR220">220</xref>]. Indeed, the development of prostate cancer is intimately associated with androgen. In prostate cancer, elevated AR expression promotes EMT [<xref ref-type="bibr" rid="CR221">221</xref>]. Likewise, AR promotes haematogenous metastasis and angiogenesis of clear cell renal cell carcinoma (CCRCC) [<xref ref-type="bibr" rid="CR222">222</xref>]. In prostate cancer, an activated nuclear AR binds to and reduces the DNA binding capacity of FOXO1 in an Akt-independent manner, affecting the expression of the proapoptotic genes, such as Fas [<xref ref-type="bibr" rid="CR223">223</xref>]. Thus, AR binding generally reduces the tumour-suppressive function of FOXO proteins. ER is another hormone-regulated receptor that has a strong link with cancer metastasis. ER is overexpressed in multiple cancers, including breast and ovarian cancers [<xref ref-type="bibr" rid="CR224">224</xref>]. In breast cancer, ER, encoded by oestrogen receptor alpha gene (ESR1), is commonly deregulated by gene amplification, point mutations and genetic fusion, leading to enhanced cancer invasion and metastasis [<xref ref-type="bibr" rid="CR225">225</xref>]. The oestrogen-activated ER has been shown to interact with FOXO1 to repress its activity, and it is speculated that this interaction may play a part in the regulation of cancer metastasis [<xref ref-type="bibr" rid="CR226">226</xref>].</p>
<p id="Par31">Poly(ADP-ribose) polymerase 1 (PARP1) is a nuclear protein important for the regulation of DNA damage repair, chromatin remodelling, cell death and gene transcription [<xref ref-type="bibr" rid="CR227">227</xref>, <xref ref-type="bibr" rid="CR228">228</xref>]. PARP1 has been shown to promote cell metastasis in melanoma and in prostate and lung cancers [<xref ref-type="bibr" rid="CR229">229</xref>–<xref ref-type="bibr" rid="CR231">231</xref>]. FOXO1 interacts with PARP1and gets poly(ADP-ribosyl)ated in an Akt-independent manner, resulting in suppression of FOXO1 transcriptional activity and cell proliferation [<xref ref-type="bibr" rid="CR232">232</xref>]. In cancer cells, PPARγ co-activator 1α (PGC-1α) interacts with FOXO1 and acts as a co-activator in hepatocytes for activation of gluconeogenic genes. The study shows that the interaction is involved in the cellular oxidative stress protection and can be interrupted by insulin-mediated Akt phosphorylation [<xref ref-type="bibr" rid="CR233">233</xref>, <xref ref-type="bibr" rid="CR234">234</xref>]. Moreover, FOXO1 has been shown to regulate PGC-1α at the transcript level, suggesting a feedback mechanism for oxidative stress regulation [<xref ref-type="bibr" rid="CR235">235</xref>]. Like PGC-1α, FOXO1 also interacts with C/EBPα to promote the expression of gluconeogenic genes, including phosphoenolpyruvate carboxykinase (PEPCK) [<xref ref-type="bibr" rid="CR236">236</xref>]. The gluconeogenic enzymes are known to affect cancer growth [<xref ref-type="bibr" rid="CR237">237</xref>, <xref ref-type="bibr" rid="CR238">238</xref>]. Recently, gluconeogenesis has also been shown to be upregulated in brain metastatic breast cancer cells, suggesting that an increase in energy production can promote cancer metastasis <italic toggle="yes">via</italic> FOXOs [<xref ref-type="bibr" rid="CR239">239</xref>].</p>
<p id="Par32">Fanconi anaemia, complementation group D2 (FANCD2) is an important DNA damage response protein, which is activated during DNA replication as well as DNA damage repair [<xref ref-type="bibr" rid="CR240">240</xref>]. In the rare genetic disease Fanconi anaemia (FA), the loss of FANCD2 activity has been shown to contribute to an accumulation of genetic mutations and therefore promote leukaemogenesis or tumorigenesis [<xref ref-type="bibr" rid="CR240">240</xref>]. In cancer cells, FANCD2 also interacts with FOXO3 to regulate antioxidant gene expression in response to oxidative stress [<xref ref-type="bibr" rid="CR241">241</xref>]. Whilst the interaction between FANCD2 and FOXO3 has not been directly linked to cancer metastasis, FANCD2 overexpression on its own has been shown to be correlated with lymph node metastasis of colon cancer [<xref ref-type="bibr" rid="CR242">242</xref>]. Elevated FANCD2 expression also increases cancer therapy tolerance and is associated with an increased risk of metastasis [<xref ref-type="bibr" rid="CR243">243</xref>]. Indeed, induction of antioxidant gene expression by FANCD2 and FOXO3 can also impact on cancer therapy resistance as radiotherapy and chemotherapeutic drugs can influence cancer treatment outcome through their modulation of ROS [<xref ref-type="bibr" rid="CR244">244</xref>, <xref ref-type="bibr" rid="CR245">245</xref>]. Notably, in parallel to FOXO protein regulation, MYC, which controls at least 15% of the entire genome, is also regulated by the PI3K-Akt pathway [<xref ref-type="bibr" rid="CR246">246</xref>]. With similar upstream regulation, the oncogenic MYC also competes with FOXO3 for the binding of promoter regions of genes, including p27<sup>Kip1</sup> [<xref ref-type="bibr" rid="CR247">247</xref>]. The p27<sup>Kip1</sup> is a CDK inhibitor which regulates cell cycle progression, and it is often downregulated in cancer [<xref ref-type="bibr" rid="CR248">248</xref>]. FOXO proteins also cooperate with other FOX proteins to bind to and drive the transcription of target genes. For example, FOXO1 and FOXA1/A2 have been shown to facilitate one another’s binding and collaborate to open chromatin at insulin-regulated genes [<xref ref-type="bibr" rid="CR20">20</xref>, <xref ref-type="bibr" rid="CR21">21</xref>]. Furthermore, FOXO1 also cooperates with FOXA1 to function as pioneer factors to facilitate AR binding in prostate cancer [<xref ref-type="bibr" rid="CR249">249</xref>]. In other words, FOXOs also work together with other FOX proteins to facilitate the recruitment of other transcriptional elements to promote the transcription of target genes.</p>
</sec>
<sec id="Sec19">
<title>FOXO post-transcriptional regulation by microRNAs</title>
<p id="Par33">MicroRNAs (miRs) are small non-coding RNAs (about 22 nucleotides) that participate in RNA silencing, and these small RNAs also participate in the regulation of FOXO expression post-transcriptionally through inducing FOXO messenger RNA (mRNA) degradation, translation inhibition and gene silencing (Fig. <xref rid="Fig1" ref-type="fig">1</xref>) [<xref ref-type="bibr" rid="CR250">250</xref>, <xref ref-type="bibr" rid="CR251">251</xref>]. MicroRNAs, such as miR-107, miR-132, miR-223 and miR-1269, have been shown to negatively regulate FOXO1 expression to promote cell proliferation in a number of cancer cells [<xref ref-type="bibr" rid="CR252">252</xref>–<xref ref-type="bibr" rid="CR255">255</xref>]. Likewise, miR-21 promotes the proliferation of pancreatic ductal adenocarcinoma (PDAC) through repressing FOXO1 expression [<xref ref-type="bibr" rid="CR256">256</xref>, <xref ref-type="bibr" rid="CR257">257</xref>]. Notably, the miR-21 has also been shown to regulate cancer metastasis [<xref ref-type="bibr" rid="CR251">251</xref>]. Interestingly, miR-21 can also promote growth, metastasis and drug resistance in cancer cells by targeting phosphatase and tensin (PTEN) homologue, an upstream repressor of Akt-PI3K activity and, therefore, an indirect activator of FOXOs [<xref ref-type="bibr" rid="CR258">258</xref>]. Thus, miRs, like miR-21, regulate not only FOXO expression but also their activity at the same time [<xref ref-type="bibr" rid="CR259">259</xref>]. Wnt/beta-catenin activates miR-183/miR-96/miR-182 expression in hepatocellular carcinoma to promote cancer cell invasion. Meanwhile, a similar group of microRNAs, miR-193, miR-96 and miR-182, also suppress FOXO1 expression in hepatocellular carcinoma, resulting in enhanced cell invasion and metastasis [<xref ref-type="bibr" rid="CR260">260</xref>]. A similar outcome is also observed with FOXO1, when targeted by miR-135a and miR-544 [<xref ref-type="bibr" rid="CR261">261</xref>, <xref ref-type="bibr" rid="CR262">262</xref>]. In endometrial cancer, miR-9, miR-27a, miR-96, miR-128, miR-153, miR-183 and miR-186 also function cooperatively to suppress FOXO1-regulated cell cycle arrest and cell death [<xref ref-type="bibr" rid="CR263">263</xref>]. The concerted effort of this group of miRNAs to suppress FOXO1 renders depletion of one miR species having no effects on FOXO1 expression or endometrial cancer cell proliferation and survival [<xref ref-type="bibr" rid="CR263">263</xref>]. The microRNA miR-29c also represses FOXO1 expression to facilitate breast cancer cell growth, migration and invasion [<xref ref-type="bibr" rid="CR264">264</xref>], whilst miR-135b inhibits FOXO1 expression to promote cell proliferation and invasion in osteosarcoma [<xref ref-type="bibr" rid="CR265">265</xref>]. In contrast, miR-124 and miR-145 can enhance FOXO1 activity to promote cell cycle arrest and delay cell proliferation, respectively [<xref ref-type="bibr" rid="CR266">266</xref>, <xref ref-type="bibr" rid="CR267">267</xref>].</p>
<p id="Par34">Interestingly, miR-96 is found to promote colorectal cancer proliferation through targeting both FOXO1 and FOXO3, suggesting that there are common complementary sequences in FOXOs for miR binding [<xref ref-type="bibr" rid="CR268">268</xref>]. Similarly, miR-182 suppresses both FOXO1 and FOXO3 expression levels in prostate and skin cancer, respectively, to promote cancer cell migration and invasion [<xref ref-type="bibr" rid="CR269">269</xref>, <xref ref-type="bibr" rid="CR270">270</xref>]. In agreement, a study with anti-miR-182 mimetics in the xenograft mouse model has shown that miR-182 inhibition can restrict ovarian cancer cell invasion and metastasis <italic toggle="yes">in vivo</italic> [<xref ref-type="bibr" rid="CR271">271</xref>]. Furthermore, miR-132, miR-223 and miR-27a can induce proliferative arrest and cancer cell death through FOXO1 and FOXO3 [<xref ref-type="bibr" rid="CR272">272</xref>]. In Alzheimer disease, miR-132 and miR-212 also control FOXO3-mediated neuronal apoptosis [<xref ref-type="bibr" rid="CR273">273</xref>]. FOXO3 is also targeted by miR-592 and miR-1307 to promote colorectal cancer metastasis and prostate cancer proliferation, respectively [<xref ref-type="bibr" rid="CR274">274</xref>, <xref ref-type="bibr" rid="CR275">275</xref>]. FOXO4 is targeted by miR-499-5p and miR-1274a for enhanced cell metastasis in colon and gastric cancers, respectively [<xref ref-type="bibr" rid="CR276">276</xref>, <xref ref-type="bibr" rid="CR277">277</xref>]. Similarly, miR-150 restricts the expression of FOXO4 to promote cervical cancer proliferation and lung cancer cell metastasis [<xref ref-type="bibr" rid="CR278">278</xref>, <xref ref-type="bibr" rid="CR279">279</xref>]. Not only FOXO expression and activity are regulated by miRs; evidence also exists that miRs are also regulated by FOXO proteins. In fact, cross-talks between miR-155-5p and FOXO3 have been shown to modulate cell growth in lung cancer [<xref ref-type="bibr" rid="CR280">280</xref>]. The miR-155 has also been associated with circular RNA FOXO3 (circ-FOXO3) and FOXO3 in lung cancer migration and invasion [<xref ref-type="bibr" rid="CR281">281</xref>]. The circ-FOXO3 shares identical sequences with FOXO3 mRNA and can buffer several miRs from interacting with FOXO3 mRNA. Thus, circ-FOXO3 can upregulate FOXO3 expression by preventing the binding of miR to the FOXO3 mRNA [<xref ref-type="bibr" rid="CR282">282</xref>]. Furthermore, FOXO3 upregulates miR-622 to suppress hypoxia-inducible factor 1 alpha (HIF-1α) to induce cell invasion and migration in lung cancer [<xref ref-type="bibr" rid="CR283">283</xref>]. FOXO3 has also been shown to bind and activate miR-34 for β-catenin inhibition which subsequently suppresses cell migration in prostate cancer [<xref ref-type="bibr" rid="CR284">284</xref>]. Whilst many reports have documented the direct relationships between miR and FOXO expression levels, another microRNA (miR-205) has been shown to antagonise Akt signalling in lung cancer, providing an indirect route to activate FOXO activity [<xref ref-type="bibr" rid="CR285">285</xref>]. Although miRs have been established to play a key part in regulating FOXO expression and cancer metastasis, how these miRs are regulated themselves remains to be explored. Nonetheless, these findings suggest that post-transcriptional regulation of FOXO expression is important for the regulation of FOXO activity in the modulation tumorigenesis and metastasis.</p>
</sec>
<sec id="Sec20">
<title>Cross-communication between FOXOs and other FOX proteins</title>
<p id="Par35">In mammals, there are 50 known FOX proteins. Together, they regulate a wide range of biological processes encompassing cell proliferation, survival, differentiation, migration and stress response. These FOX proteins share highly homologous DNA binding domains and recognise overlapping gene targets. In consequence, tissue-specific misregulation or misexpression of these FOX genes can lead to a gain of function and result in cancer initiation and progression. Recent evidence also suggests these FOX proteins share several attributes, and intriguingly, one of them common to the majority of FOX proteins is their regulation of cancer metastasis. Apart from having overlapping functions, the expression and activity of FOXOs are also influenced directly and indirectly by their close cousins, such as FOXM1, FOXC1, FOXC2, FOXF1, FOXS1, FOXG1 and FOXK2 (Fig. <xref rid="Fig4" ref-type="fig">4</xref>) [<xref ref-type="bibr" rid="CR286">286</xref>]. FOXM1 (also known as HFH-11B, Trident, Win and MPP2) is an oncogenic transcription factor which is known to be overexpressed during early cancer development [<xref ref-type="bibr" rid="CR287">287</xref>]. It is also a potent regulator of metastasis [<xref ref-type="bibr" rid="CR288">288</xref>]. To date, many studies have documented that FOXM1 is a key regulator of cancer cell proliferation, DNA damage repair, cancer drug resistance, metastasis and invasion [<xref ref-type="bibr" rid="CR289">289</xref>, <xref ref-type="bibr" rid="CR290">290</xref>]. The tumour suppressor FOXO3 can antagonise the oncogenic activity of FOXM1 in a number of ways. Apart from FOXO3 and FOXM1 having opposite effects on chromatin remodelling of common target genes, FOXO3 also competes with FOXM1 for DNA binding at target genes and directly represses FOXM1 expression at the promoter level [<xref ref-type="bibr" rid="CR2">2</xref>]. These multiple levels of control of FOXM1 by FOXO3 emphasise the significance of FOXO3 as a tumour suppressor. FOXO3 and FOXM1 are also intimately associated with chemotherapeutic drug resistance and cancer stem cell properties [<xref ref-type="bibr" rid="CR30">30</xref>, <xref ref-type="bibr" rid="CR289">289</xref>–<xref ref-type="bibr" rid="CR291">291</xref>]. Furthermore, the FOXO3-FOXM1 axis has been shown to regulate VEGF, an important factor for angiogenesis and metastasis [<xref ref-type="bibr" rid="CR31">31</xref>]. Indeed, targeting FOXM1 has been shown to significantly inhibit cancer growth and metastasis [<xref ref-type="bibr" rid="CR292">292</xref>]. Interestingly, FOXM1 and Aurora kinase A (AURKA) promote the activity and expression of each other in a positive feedback loop [<xref ref-type="bibr" rid="CR293">293</xref>]. AURKA has also been shown to negatively regulate FOXO1 at the transcriptional level, indicating that FOXM1 can indirectly regulate FOXO expression <italic toggle="yes">via</italic> AURKA to sustain its expression and activity in cancer cells [<xref ref-type="bibr" rid="CR294">294</xref>]. Likewise, Akt and FOXM1, both upstream inhibitors of FOXO3, also positively regulate cell migration in a positive feedback loop manner to promote tongue squamous cell carcinoma cell migration [<xref ref-type="bibr" rid="CR295">295</xref>]. FOXC1 (also known as FKHL7) is another forkhead protein closely related to metastasis and FOXO function. High FOXC1 expression has been found to be associated with highly metastatic colon, breast and liver cancers [<xref ref-type="bibr" rid="CR296">296</xref>–<xref ref-type="bibr" rid="CR299">299</xref>]. FOXC1 has also been shown to induce MMP-7 expression to promote breast cancer metastasis [<xref ref-type="bibr" rid="CR299">299</xref>]. Furthermore, overexpression of FOXC1 promotes tumour metastasis and predicts poor prognosis in liver cancer [<xref ref-type="bibr" rid="CR296">296</xref>]. Conversely, knockdown of FOXC1 reduces the expression of mesenchymal genes, such as vimentin, fibronectin and N-cadherin [<xref ref-type="bibr" rid="CR300">300</xref>]. Furthermore, FOXC1 knockdown displays lower expression levels of MMP-1, MMP-2, MMP-7 and MMP-9 with reduced mesenchymal characteristics and metastatic capability [<xref ref-type="bibr" rid="CR301">301</xref>]. In melanoma, FOXC1 has been shown to promote tumorigenesis by activating the MST1R/PI3K/Akt pathway and is associated with poor prognosis [<xref ref-type="bibr" rid="CR302">302</xref>]. Thus, FOXC1 can repress FOXO activity through enhancing the PI3K/Akt signalling. Similarly, FOXC2 (also known as MGH1 and FKHL14) has been linked to metastasis in breast cancer, colorectal cancer (CRC) and osteosarcoma [<xref ref-type="bibr" rid="CR303">303</xref>–<xref ref-type="bibr" rid="CR306">306</xref>]. FOXC2 has been demonstrated to also upregulate ERK and Akt activities to mediate FOXO3 inhibition [<xref ref-type="bibr" rid="CR307">307</xref>]. Anoikis can also induce FOXC2 expression to facilitate cancer migration in osteosarcoma [<xref ref-type="bibr" rid="CR303">303</xref>]. This anoikis-induced osteosarcoma cell invasiveness and metastasis to the lung are dependent on the ability of FOXC2 to induce CXCR4, a chemokine receptor responsible for tumour growth, invasion, angiogenesis, metastasis, relapse and therapeutic resistance [<xref ref-type="bibr" rid="CR308">308</xref>]. High FOXC2 expression is strongly correlated with invasion and metastasis of CRC [<xref ref-type="bibr" rid="CR304">304</xref>], whereas downregulation of FOXC2 reduces colon cancer invasiveness and their metastatic potential [<xref ref-type="bibr" rid="CR304">304</xref>]. In concordance, FOXC2 has been found to be required for EMT and the display of mesenchymal-like properties in breast cancer [<xref ref-type="bibr" rid="CR305">305</xref>, <xref ref-type="bibr" rid="CR306">306</xref>]. FOXF1 (also known as FKHL5) is essential for mesenchymal cell migration [<xref ref-type="bibr" rid="CR309">309</xref>]. Previously, FOXF1 has been shown to induce p38 MAPK activity, one of the upstream activators of FOXO1 and FOXO3 [<xref ref-type="bibr" rid="CR310">310</xref>]. Similarly, FOXF1 suppresses osteosarcoma cell invasion and migration by decreasing MMP-2 and MMP-9 expression levels [<xref ref-type="bibr" rid="CR311">311</xref>]. In agreement, FOXF1 can be promoted by the tumour suppressor p53 to induce the expression of E-cadherin (the epithelial cadherin), an epithelial cell marker [<xref ref-type="bibr" rid="CR312">312</xref>]. Although FOXF1 has not been directly associated with FOXOs, it is plausible that FOXF1 can induce p38 MAPK to activate FOXO activity. On the contrary, FOXF1 has also been found to induce EMT and angiogenesis by activating SNAI1 and VEGFA, respectively, to promote cancer metastasis and angiogenesis in colon cancer [<xref ref-type="bibr" rid="CR313">313</xref>, <xref ref-type="bibr" rid="CR314">314</xref>]. In the tumour microenvironment, FOXF1 also stimulates cancer-associated fibroblasts to facilitate lung cancer tumorigenesis and migration [<xref ref-type="bibr" rid="CR315">315</xref>]. Based on this evidence, it is likely that FOXF1 has different metastatic and angiogenic roles in epithelial and mesenchymal cells. FOXS1 (also known as FKHL18) has been shown to suppress the transcriptional activity of FOXO3 and FOXO4 [<xref ref-type="bibr" rid="CR316">316</xref>]. Although FOXS1 is predominately expressed in the nervous system, overexpression of FOXS1 can inhibit gastric cancer proliferation and metastasis [<xref ref-type="bibr" rid="CR317">317</xref>]. Microarray analysis of metastasis-associated mRNA also shows that FOXS1 is downregulated in high metastatic lung cancer [<xref ref-type="bibr" rid="CR318">318</xref>]. The forkhead protein FOXG1 (previously known as BF1) forms a complex with FOXO and SMAD proteins to promote neuronal differentiation [<xref ref-type="bibr" rid="CR319">319</xref>]. Notably, SMAD3 and SMAD4 also interact with FOXO1 to promote the transcription of p21Cip1, an important negative cell cycle regulator [<xref ref-type="bibr" rid="CR320">320</xref>]. Whilst the FOXG1-FOXO1 complex has not been proved to be directly linked to cell metastasis, suppression of FOXG1 by miR-200b can promote cell proliferation and metastasis in cervical cancer [<xref ref-type="bibr" rid="CR321">321</xref>]. Furthermore, miR-422a also negatively regulates FOXG1 expression to modulate liver cancer metastasis [<xref ref-type="bibr" rid="CR322">322</xref>]. FOXK2 has also been found to regulate FOXO3 expression at the transcriptional level to mediate the cytotoxic effects of epirubicin and paclitaxel in breast cancer [<xref ref-type="bibr" rid="CR323">323</xref>]. Interestingly, like FOXO3, FOXK2 has been shown to be able to repress breast cancer carcinogenesis [<xref ref-type="bibr" rid="CR324">324</xref>].<fig id="Fig4" position="float" orientation="portrait">
<label>Fig. 4</label>
<caption>
<p>Relationships between FOX proteins. Apart from the conventional signalling pathways, FOXO proteins are also regulated by other FOX proteins which modulate FOXO activity. FOXO proteins are the central axis of many signalling pathways which determine cell fates. Downregulation of FOXO proteins enhances cell proliferation, invasion, metastasis and angiogenesis</p>
</caption>
<graphic id="MO4" position="float" orientation="portrait" ns1:href="10555_2020_9883_Fig4_HTML.jpg" />
</fig>
</p>
<p id="Par36">Although a direct relationship between FOXOs and some of the other FOX proteins has yet to be established, these FOX proteins have already been shown to have a key role in cancer cell metastasis. For instance, FOXQ1 has been shown to modulate EMT in breast, gastric, bladder and cervical cancers [<xref ref-type="bibr" rid="CR325">325</xref>–<xref ref-type="bibr" rid="CR328">328</xref>]. FOXQ1 also promotes metastasis by transactivating ZEB2 and VersicanV1 expression in liver cancer [<xref ref-type="bibr" rid="CR329">329</xref>]. Likewise, FOXQ1 also negatively regulates CDH1, which encodes epithelial cadherin or E-cadherin, to promote oesophageal squamous cell carcinoma metastasis [<xref ref-type="bibr" rid="CR330">330</xref>]. In colon cancer, FOXQ1 transactivates Twist1 to suppress E-cadherin expression [<xref ref-type="bibr" rid="CR331">331</xref>]. Notably, loss of FOXF2 expression promotes EMT in breast and liver cancers [<xref ref-type="bibr" rid="CR332">332</xref>, <xref ref-type="bibr" rid="CR333">333</xref>]. In agreement, FOXF2 has shown to negatively regulate FOXC2-mediated cancer and EMT phenotypes [<xref ref-type="bibr" rid="CR334">334</xref>]. This occurrence of closely linked downstream genes between FOXOs and other forkheads also highlights the involvement of tissue-specific misregulation or misexpression of FOX proteins, including FOXOs, during tumorigenesis, in particular in cancer metastasis.</p>
</sec>
</sec>
<sec id="Sec21">
<title>Targeting FOXO in cancer therapy</title>
<p id="Par37">To date, many naturally derived and chemically synthesised compounds have been appraised for their potentials in cancer treatment. Remarkably, many compounds studied with demonstrated therapeutic capacities have been found to modulate FOXO expression and/or activity. This is due to the involvement of FOXO proteins in the regulation of genes linked to crucial drug action–related cellular processes, including stem cell renewal, DNA repair, cell death, metabolism, cell migration, angiogenesis, cell cycle control and cell division, as mentioned earlier. Therefore, not surprising, the mechanisms of resistance to conventional cytotoxic chemotherapeutics and to molecularly targeted therapies are also linked directly to deregulated signalling mediated through the FOXO transcription factors. Many currently used and proven cancer therapeutics, including paclitaxel, doxorubicin, epirubicin, lapatinib, gefitinib, imatinib and cisplatin, have been confirmed to mediate their cytotoxic and cytostatic functions through FOXO. For example, the anti-EGFR/HER small molecule inhibitors lapatinib and gefitinib have been shown to mediate their cytostatic and cytotoxic functions though activating FOXO3 <italic toggle="yes">via</italic> modulating the PI3K-Akt and p38/JNK/ERK pathways [<xref ref-type="bibr" rid="CR31">31</xref>, <xref ref-type="bibr" rid="CR126">126</xref>, <xref ref-type="bibr" rid="CR127">127</xref>, <xref ref-type="bibr" rid="CR129">129</xref>, <xref ref-type="bibr" rid="CR131">131</xref>, <xref ref-type="bibr" rid="CR132">132</xref>]. Similarly, the therapeutic monoclonal antibody trastuzumab (Herceptin) directed against the extracellular domain of mutated HER2 also mediates its antiproliferative effects through FOXO3 and its downstream target survivin (BRC5) [<xref ref-type="bibr" rid="CR335">335</xref>]. Genotoxic agents, including doxorubicin, epirubicin, cisplatin and 5-fluorouracil (5-FU), can also cause DNA damage and oxidative stress <italic toggle="yes">via</italic> FOXO3 [<xref ref-type="bibr" rid="CR30">30</xref>]. The anthracycline doxorubicin induces FOXO3 activation and nuclear translocation by phosphorylating FOXO3 on Ser7 residue <italic toggle="yes">via</italic> p38 MAPK [<xref ref-type="bibr" rid="CR336">336</xref>]. FOXO3 also induces doxorubicin-induced apoptosis through its transcriptional repression of miR-21 which, in turn, modulates the expression of pro-apoptotic factors, Fas-L, Bim and survivin [<xref ref-type="bibr" rid="CR183">183</xref>, <xref ref-type="bibr" rid="CR337">337</xref>]. Another study shows that FOXO3 activation increases expression of TRAIL and cell death in response to doxorubicin in hepatocellular carcinoma (HCC), suggesting that FOXO3 is required for doxorubicin sensitivity. Conversely, FOXO3 inactivation and sequestration in the cytoplasm are closely associated with doxorubicin resistance [<xref ref-type="bibr" rid="CR338">338</xref>]. Furthermore, SIRT1 has been shown to deacetylate p53 and FOXO3 which contributes to doxorubicin resistance [<xref ref-type="bibr" rid="CR339">339</xref>]. In a similar manner, another anthracycline epirubicin, which is an epimer of doxorubicin, also mediates its anticancer activity through FOXO3 [<xref ref-type="bibr" rid="CR200">200</xref>]. Other studies have verified FOXO3 as a key mediator of cisplatin action [<xref ref-type="bibr" rid="CR182">182</xref>, <xref ref-type="bibr" rid="CR340">340</xref>]. Accordingly, it has been shown that cisplatin treatment causes a decrease in Akt-mediated FOXO3 phosphorylation in colon cancer cells, resulting in its nuclear translocation and activation [<xref ref-type="bibr" rid="CR182">182</xref>]. Conversely, impaired FOXO3 nuclear accumulation and the consequent failure to induce apoptosis have been associated with the development of cisplatin resistance. Interestingly, increased FOXO3 activation in cisplatin-resistant colon cancer cells with the small molecule Akt inhibitor, tricirbine/API-2, can override cisplatin resistance by blocking Akt-mediated FOXO3 phosphorylation [<xref ref-type="bibr" rid="CR182">182</xref>]. Paclitaxel functions by inducing microtubule dysfunction and, eventually, cell death by mitotic catastrophe [<xref ref-type="bibr" rid="CR183">183</xref>, <xref ref-type="bibr" rid="CR184">184</xref>, <xref ref-type="bibr" rid="CR341">341</xref>, <xref ref-type="bibr" rid="CR342">342</xref>]. Paclitaxel has been shown to induce JNK-MAPK to phosphorylate and activate FOXO3 directly, as well as derepressing the inhibition of Akt on FOXO3 to induce apoptosis <italic toggle="yes">via</italic> Bim and other pro-apoptotic molecules [<xref ref-type="bibr" rid="CR183">183</xref>, <xref ref-type="bibr" rid="CR184">184</xref>, <xref ref-type="bibr" rid="CR343">343</xref>]. Indeed, FOXO3 phosphorylation by p38/JNK MAPK on Ser7 can promote its nuclear localisation and activation as well as its acetylation by CBP/p300 on Lys-242/245 [<xref ref-type="bibr" rid="CR180">180</xref>]. Compounds such as β-lapachone and 5-fluorouracil have been shown to induce cancer apoptosis through the activation of FOXOs and its target FOXM1 [<xref ref-type="bibr" rid="CR344">344</xref>, <xref ref-type="bibr" rid="CR345">345</xref>].</p>
<p id="Par38">Some naturally derived compounds including benzyl isothiocyanate, resveratrol, quercetin, arsenic trioxide and caffeic acid phenethyl ester (CAPE) have been shown to restrain cancer growth through FOXO activation [<xref ref-type="bibr" rid="CR346">346</xref>]. Naturally derived compounds which can be found in daily diets also have a great potential in preventing cancer progression. Recently, studies with the extracted compounds are intensified to promote the concern for healthier diets. For instance, resveratrol in grapes promotes the transcriptional activity of FOXOs through AMPK to reduce ROS in a number of cancers [<xref ref-type="bibr" rid="CR163">163</xref>]. Benzyl isothiocyanate (BITC) promotes the expression of FOXO-regulated Bim, p27<sup>Kip1</sup> and p21<sup>Cip1</sup> by reducing the Akt-mediated FOXO phosphorylation in pancreatic tumour [<xref ref-type="bibr" rid="CR347">347</xref>]. Similarly, pterostilbene in blueberries activates FOXO1 by the suppression of Akt and ERK activity and increases 5-FU chemosensitivity in colon cancer [<xref ref-type="bibr" rid="CR348">348</xref>]. A glutamate receptor antagonist, dizocilpine (also known as MK-801), has been shown to enhance FOXO1 nuclear localisation and promote its tumour suppressor function [<xref ref-type="bibr" rid="CR349">349</xref>]. The chilli pepper extract capsaicin activates JNK to induce FOXO1 acetylation for Bim-induced apoptosis in pancreatic cancer [<xref ref-type="bibr" rid="CR204">204</xref>]. Polydatin, a natural precursor of resveratrol, also upregulates FOXO1 through inhibition of Akt and STAT3 signalling pathway to suppress hepatocellular carcinoma cell migration and invasion [<xref ref-type="bibr" rid="CR350">350</xref>]. Isorhapontigenin, another analogue of resveratrol, also inhibits STAT1 to enhance FOXO1 activity and limits bladder cancer cell invasion [<xref ref-type="bibr" rid="CR351">351</xref>]. Polyphenol epigallocatechin-3-gallate in green tea can upregulate FOXO3 and suppress breast cancer metastasis [<xref ref-type="bibr" rid="CR352">352</xref>]. Ergosterol from the mushroom <italic toggle="yes">Amauroderma rude</italic> also increases FOXO3 expression to inhibit cell migration and invasion [<xref ref-type="bibr" rid="CR353">353</xref>]. Although some studies have exposed the underlying mechanisms of action of some of these compounds, the exact mechanisms for the rest of these naturally derived compounds are not fully understood. Thus far, none of these naturally derived compounds is officially used in the clinic for cancer treatment in consequence. Nevertheless, these findings further support the hypothesis that FOXOs serve as the sensor as well as the mediator of anticancer agents.</p>
<p id="Par39">As FOXO expression and activity are often adaptively downregulated in malignancies and are further attenuated in drug-resistant cancer, the expression of some of their important downstream transcriptional targets is also diminished as a result. Thus, it is rational to propose that interventions aimed at the downstream targets of FOXO proteins could induce cancer and drug-resistant cell-specific elimination and form the basis for novel anticancer therapies [<xref ref-type="bibr" rid="CR30">30</xref>]. Indeed, recent research has shown that PERK (PKR-like endoplasmic reticulum kinase, also called eukaryotic translation initiation factor 2-alpha kinase 3 (EIF2A3K)) is regulated by FOXO3 and thus exposed a transformed cell and chemotherapeutic drug–resistant cancer cell vulnerability in PERK [<xref ref-type="bibr" rid="CR155">155</xref>]. In this case, small molecule PERK inhibitors, which have been generated and tested for neurodegenerative diseases, can be repositioned to target cancer cells.</p>
</sec>
<sec id="Sec22">
<title>Conclusion</title>
<p id="Par40">Collectively, research studies to date have pointed to a key tumour-suppressive role for FOXO transcription factors. This is mediated through the ability of FOXOs to regulate genes essential for cell proliferative arrest, cell death, autophagy, senescence, angiogenesis, cell migration and metastasis. FOXO proteins also integrate diverse proliferative, nutrient and stress signals with distinct gene networks to control cell fate, metabolism and cancer development. Notably, evidence also exists that FOXO proteins can sometimes support cancer progression, angiogenesis, metastasis and drug resistance in a cell type and context–dependent manner. Intriguingly, the mechanisms of action of conventional cytotoxic chemotherapeutics and novel molecularly targeted therapies are also invariably linked to FOXO transcription factors (Fig. <xref rid="Fig5" ref-type="fig">5</xref>). Thus, FOXO proteins have been firmly established as not only important markers for cancer diagnosis and prognosis but also targets for cancer intervention. Whilst the mechanisms underlying their roles and regulations are still being uncovered, accumulated research has also shown that FOXO expression and activity are predominantly regulated at the post-transcriptional and post-translational levels and are adaptively downregulated in cancer cells. Thus, targeting the upstream regulators of FOXOs may provide novel strategies of cancer treatment and for overcoming drug resistance. Equally, the FOXO downstream targets, which are adaptively downregulated with FOXOs in cancer, may represent vulnerabilities for cancer intervention strategies.<fig id="Fig5" position="float" orientation="portrait">
<label>Fig. 5</label>
<caption>
<p>Role of the FOXO transcription factors. FOXOs exhibit tumour-suppressive roles in inhibiting tumorigenesis by promoting cell apoptosis and senescence. However, depending on the cell type and context–dependent manner, FOXOs may drive cell autophagy, metastasis and angiogenesis for the cell survival. Notably, FOXOs play a very important role in stress modulation and drug resistance</p>
</caption>
<graphic id="MO5" position="float" orientation="portrait" ns1:href="10555_2020_9883_Fig5_HTML.jpg" />
</fig>
</p>
</sec>
</body>
<back>
<fn-group>
<fn>
<p>
<bold>Publisher’s note</bold>
</p>
<p>Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p>
</fn>
</fn-group>
<ref-list id="Bib1">
<title>References</title>
<ref id="CR1">
<label>1.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western">
<surname>Guan</surname>
<given-names>X</given-names>
</name>
</person-group>
<article-title>Cancer metastases: challenges and opportunities</article-title>
<source>Acta Pharmaceutica Sinica B</source>
<year>2015</year>
<volume>5</volume>
<issue>5</issue>
<fpage>402</fpage>
<lpage>418</lpage>
<pub-id pub-id-type="doi">10.1016/j.apsb.2015.07.005</pub-id>
<pub-id pub-id-type="pmid">26579471</pub-id>
<pub-id pub-id-type="pmcid">PMC4629446</pub-id>
</element-citation>
</ref>
<ref id="CR2">
<label>2.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western">
<surname>Lam</surname>
<given-names>EW</given-names>
</name>
<name name-style="western">
<surname>Brosens</surname>
<given-names>JJ</given-names>
</name>
<name name-style="western">
<surname>Gomes</surname>
<given-names>AR</given-names>
</name>
<name name-style="western">
<surname>Koo</surname>
<given-names>CY</given-names>
</name>
</person-group>
<article-title>Forkhead box proteins: tuning forks for transcriptional harmony</article-title>
<source>Nature Reviews Cancer</source>
<year>2013</year>
<volume>13</volume>
<issue>7</issue>
<fpage>482</fpage>
<lpage>495</lpage>
<pub-id pub-id-type="doi">10.1038/nrc3539</pub-id>
<pub-id pub-id-type="pmid">23792361</pub-id>
</element-citation>
</ref>
<ref id="CR3">
<label>3.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western">
<surname>Myatt</surname>
<given-names>SS</given-names>
</name>
<name name-style="western">
<surname>Lam</surname>
<given-names>EW</given-names>
</name>
</person-group>
<article-title>The emerging roles of forkhead box (Fox) proteins in cancer</article-title>
<source>Nature Reviews Cancer</source>
<year>2007</year>
<volume>7</volume>
<issue>11</issue>
<fpage>847</fpage>
<lpage>859</lpage>
<pub-id pub-id-type="doi">10.1038/nrc2223</pub-id>
<pub-id pub-id-type="pmid">17943136</pub-id>
</element-citation>
</ref>
<ref id="CR4">
<label>4.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western">
<surname>Nakagawa</surname>
<given-names>S</given-names>
</name>
<name name-style="western">
<surname>Gisselbrecht</surname>
<given-names>SS</given-names>
</name>
<name name-style="western">
<surname>Rogers</surname>
<given-names>JM</given-names>
</name>
<name name-style="western">
<surname>Hartl</surname>
<given-names>DL</given-names>
</name>
<name name-style="western">
<surname>Bulyk</surname>
<given-names>ML</given-names>
</name>
</person-group>
<article-title>DNA-binding specificity changes in the evolution of forkhead transcription factors</article-title>
<source>Proceedings of the National Academy of Sciences of the United States of America</source>
<year>2013</year>
<volume>110</volume>
<issue>30</issue>
<fpage>12349</fpage>
<lpage>12354</lpage>
<pub-id pub-id-type="doi">10.1073/pnas.1310430110</pub-id>
<pub-id pub-id-type="pmid">23836653</pub-id>
<pub-id pub-id-type="pmcid">PMC3725104</pub-id>
</element-citation>
</ref>
<ref id="CR5">
<label>5.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western">
<surname>Benayoun</surname>
<given-names>BA</given-names>
</name>
<name name-style="western">
<surname>Caburet</surname>
<given-names>S</given-names>
</name>
<name name-style="western">
<surname>Veitia</surname>
<given-names>RA</given-names>
</name>
</person-group>
<article-title>Forkhead transcription factors: key players in health and disease</article-title>
<source>Trends in Genetics</source>
<year>2011</year>
<volume>27</volume>
<issue>6</issue>
<fpage>224</fpage>
<lpage>232</lpage>
<pub-id pub-id-type="doi">10.1016/j.tig.2011.03.003</pub-id>
<pub-id pub-id-type="pmid">21507500</pub-id>
</element-citation>
</ref>
<ref id="CR6">
<label>6.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western">
<surname>Kim</surname>
<given-names>CG</given-names>
</name>
<name name-style="western">
<surname>Lee</surname>
<given-names>H</given-names>
</name>
<name name-style="western">
<surname>Gupta</surname>
<given-names>N</given-names>
</name>
<name name-style="western">
<surname>Ramachandran</surname>
<given-names>S</given-names>
</name>
<name name-style="western">
<surname>Kaushik</surname>
<given-names>I</given-names>
</name>
<name name-style="western">
<surname>Srivastava</surname>
<given-names>S</given-names>
</name>
<etal />
</person-group>
<article-title>Role of forkhead box class O proteins in cancer progression and metastasis</article-title>
<source>Seminars in Cancer Biology</source>
<year>2018</year>
<volume>50</volume>
<fpage>142</fpage>
<lpage>151</lpage>
<pub-id pub-id-type="doi">10.1016/j.semcancer.2017.07.007</pub-id>
<pub-id pub-id-type="pmid">28774834</pub-id>
<pub-id pub-id-type="pmcid">PMC5794649</pub-id>
</element-citation>
</ref>
<ref id="CR7">
<label>7.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western">
<surname>Yusuf</surname>
<given-names>D</given-names>
</name>
<name name-style="western">
<surname>Butland</surname>
<given-names>SL</given-names>
</name>
<name name-style="western">
<surname>Swanson</surname>
<given-names>MI</given-names>
</name>
<name name-style="western">
<surname>Bolotin</surname>
<given-names>E</given-names>
</name>
<name name-style="western">
<surname>Ticoll</surname>
<given-names>A</given-names>
</name>
<name name-style="western">
<surname>Cheung</surname>
<given-names>WA</given-names>
</name>
<etal />
</person-group>
<article-title>The transcription factor encyclopedia</article-title>
<source>Genome Biology</source>
<year>2012</year>
<volume>13</volume>
<issue>3</issue>
<fpage>R24</fpage>
<pub-id pub-id-type="doi">10.1186/gb-2012-13-3-r24</pub-id>
<pub-id pub-id-type="pmid">22458515</pub-id>
<pub-id pub-id-type="pmcid">PMC3439975</pub-id>
</element-citation>
</ref>
<ref id="CR8">
<label>8.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western">
<surname>Furuyama</surname>
<given-names>T</given-names>
</name>
<name name-style="western">
<surname>Nakazawa</surname>
<given-names>T</given-names>
</name>
<name name-style="western">
<surname>Nakano</surname>
<given-names>I</given-names>
</name>
<name name-style="western">
<surname>Mori</surname>
<given-names>N</given-names>
</name>
</person-group>
<article-title>Identification of the differential distribution patterns of mRNAs and consensus binding sequences for mouse DAF-16 homologues</article-title>
<source>The Biochemical Journal</source>
<year>2000</year>
<volume>349</volume>
<issue>Pt 2</issue>
<fpage>629</fpage>
<lpage>634</lpage>
<pub-id pub-id-type="doi">10.1042/0264-6021:3490629</pub-id>
<pub-id pub-id-type="pmid">10880363</pub-id>
<pub-id pub-id-type="pmcid">PMC1221187</pub-id>
</element-citation>
</ref>
<ref id="CR9">
<label>9.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western">
<surname>Fu</surname>
<given-names>Z</given-names>
</name>
<name name-style="western">
<surname>Tindall</surname>
<given-names>DJ</given-names>
</name>
</person-group>
<article-title>FOXOs, cancer and regulation of apoptosis</article-title>
<source>Oncogene</source>
<year>2008</year>
<volume>27</volume>
<issue>16</issue>
<fpage>2312</fpage>
<lpage>2319</lpage>
<pub-id pub-id-type="doi">10.1038/onc.2008.24</pub-id>
<pub-id pub-id-type="pmid">18391973</pub-id>
<pub-id pub-id-type="pmcid">PMC2819403</pub-id>
</element-citation>
</ref>
<ref id="CR10">
<label>10.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western">
<surname>Bullock</surname>
<given-names>M</given-names>
</name>
</person-group>
<article-title>FOXO factors and breast cancer: outfoxing endocrine resistance</article-title>
<source>Endocrine-Related Cancer</source>
<year>2016</year>
<volume>23</volume>
<issue>2</issue>
<fpage>R113</fpage>
<lpage>R130</lpage>
<pub-id pub-id-type="doi">10.1530/ERC-15-0461</pub-id>
<pub-id pub-id-type="pmid">26612860</pub-id>
</element-citation>
</ref>
<ref id="CR11">
<label>11.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western">
<surname>Dansen</surname>
<given-names>TB</given-names>
</name>
<name name-style="western">
<surname>Burgering</surname>
<given-names>BM</given-names>
</name>
</person-group>
<article-title>Unravelling the tumor-suppressive functions of FOXO proteins</article-title>
<source>Trends in Cell Biology</source>
<year>2008</year>
<volume>18</volume>
<issue>9</issue>
<fpage>421</fpage>
<lpage>429</lpage>
<pub-id pub-id-type="doi">10.1016/j.tcb.2008.07.004</pub-id>
<pub-id pub-id-type="pmid">18715783</pub-id>
</element-citation>
</ref>
<ref id="CR12">
<label>12.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western">
<surname>Martins</surname>
<given-names>R</given-names>
</name>
<name name-style="western">
<surname>Lithgow</surname>
<given-names>GJ</given-names>
</name>
<name name-style="western">
<surname>Link</surname>
<given-names>W</given-names>
</name>
</person-group>
<article-title>Long live FOXO: unraveling the role of FOXO proteins in aging and longevity</article-title>
<source>Aging Cell</source>
<year>2016</year>
<volume>15</volume>
<issue>2</issue>
<fpage>196</fpage>
<lpage>207</lpage>
<pub-id pub-id-type="doi">10.1111/acel.12427</pub-id>
<pub-id pub-id-type="pmid">26643314</pub-id>
<pub-id pub-id-type="pmcid">PMC4783344</pub-id>
</element-citation>
</ref>
<ref id="CR13">
<label>13.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western">
<surname>Hacker</surname>
<given-names>U</given-names>
</name>
<name name-style="western">
<surname>Grossniklaus</surname>
<given-names>U</given-names>
</name>
<name name-style="western">
<surname>Gehring</surname>
<given-names>WJ</given-names>
</name>
<name name-style="western">
<surname>Jackle</surname>
<given-names>H</given-names>
</name>
</person-group>
<article-title>Developmentally regulated Drosophila gene family encoding the fork head domain</article-title>
<source>Proceedings of the National Academy of Sciences of the United States of America</source>
<year>1992</year>
<volume>89</volume>
<issue>18</issue>
<fpage>8754</fpage>
<lpage>8758</lpage>
<pub-id pub-id-type="doi">10.1073/pnas.89.18.8754</pub-id>
<pub-id pub-id-type="pmid">1356269</pub-id>
<pub-id pub-id-type="pmcid">PMC49999</pub-id>
</element-citation>
</ref>
<ref id="CR14">
<label>14.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western">
<surname>Hwangbo</surname>
<given-names>DS</given-names>
</name>
<name name-style="western">
<surname>Gershman</surname>
<given-names>B</given-names>
</name>
<name name-style="western">
<surname>Tu</surname>
<given-names>MP</given-names>
</name>
<name name-style="western">
<surname>Palmer</surname>
<given-names>M</given-names>
</name>
<name name-style="western">
<surname>Tatar</surname>
<given-names>M</given-names>
</name>
</person-group>
<article-title>Drosophila dFOXO controls lifespan and regulates insulin signalling in brain and fat body</article-title>
<source>Nature</source>
<year>2004</year>
<volume>429</volume>
<issue>6991</issue>
<fpage>562</fpage>
<lpage>566</lpage>
<pub-id pub-id-type="doi">10.1038/nature02549</pub-id>
<pub-id pub-id-type="pmid">15175753</pub-id>
</element-citation>
</ref>
<ref id="CR15">
<label>15.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western">
<surname>Kenyon</surname>
<given-names>C</given-names>
</name>
<name name-style="western">
<surname>Chang</surname>
<given-names>J</given-names>
</name>
<name name-style="western">
<surname>Gensch</surname>
<given-names>E</given-names>
</name>
<name name-style="western">
<surname>Rudner</surname>
<given-names>A</given-names>
</name>
<name name-style="western">
<surname>Tabtiang</surname>
<given-names>R</given-names>
</name>
</person-group>
<article-title>A C. elegans mutant that lives twice as long as wild type</article-title>
<source>Nature</source>
<year>1993</year>
<volume>366</volume>
<issue>6454</issue>
<fpage>461</fpage>
<lpage>464</lpage>
<pub-id pub-id-type="doi">10.1038/366461a0</pub-id>
<pub-id pub-id-type="pmid">8247153</pub-id>
</element-citation>
</ref>
<ref id="CR16">
<label>16.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western">
<surname>Boehm</surname>
<given-names>AM</given-names>
</name>
<name name-style="western">
<surname>Khalturin</surname>
<given-names>K</given-names>
</name>
<name name-style="western">
<surname>Anton-Erxleben</surname>
<given-names>F</given-names>
</name>
<name name-style="western">
<surname>Hemmrich</surname>
<given-names>G</given-names>
</name>
<name name-style="western">
<surname>Klostermeier</surname>
<given-names>UC</given-names>
</name>
<name name-style="western">
<surname>Lopez-Quintero</surname>
<given-names>JA</given-names>
</name>
<etal />
</person-group>
<article-title>FoxO is a critical regulator of stem cell maintenance in immortal Hydra</article-title>
<source>Proceedings of the National Academy of Sciences of the United States of America</source>
<year>2012</year>
<volume>109</volume>
<issue>48</issue>
<fpage>19697</fpage>
<lpage>19702</lpage>
<pub-id pub-id-type="doi">10.1073/pnas.1209714109</pub-id>
<pub-id pub-id-type="pmid">23150562</pub-id>
<pub-id pub-id-type="pmcid">PMC3511741</pub-id>
</element-citation>
</ref>
<ref id="CR17">
<label>17.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western">
<surname>Eijkelenboom</surname>
<given-names>A</given-names>
</name>
<name name-style="western">
<surname>Burgering</surname>
<given-names>BM</given-names>
</name>
</person-group>
<article-title>FOXOs: signalling integrators for homeostasis maintenance</article-title>
<source>Nature Reviews Molecular Cell Biology</source>
<year>2013</year>
<volume>14</volume>
<issue>2</issue>
<fpage>83</fpage>
<lpage>97</lpage>
<pub-id pub-id-type="doi">10.1038/nrm3507</pub-id>
<pub-id pub-id-type="pmid">23325358</pub-id>
</element-citation>
</ref>
<ref id="CR18">
<label>18.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western">
<surname>Zaret</surname>
<given-names>KS</given-names>
</name>
<name name-style="western">
<surname>Carroll</surname>
<given-names>JS</given-names>
</name>
</person-group>
<article-title>Pioneer transcription factors: establishing competence for gene expression</article-title>
<source>Genes &amp; Development</source>
<year>2011</year>
<volume>25</volume>
<issue>21</issue>
<fpage>2227</fpage>
<lpage>2241</lpage>
<pub-id pub-id-type="doi">10.1101/gad.176826.111</pub-id>
<pub-id pub-id-type="pmid">22056668</pub-id>
<pub-id pub-id-type="pmcid">PMC3219227</pub-id>
</element-citation>
</ref>
<ref id="CR19">
<label>19.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western">
<surname>Hatta</surname>
<given-names>M</given-names>
</name>
<name name-style="western">
<surname>Cirillo</surname>
<given-names>LA</given-names>
</name>
</person-group>
<article-title>Chromatin opening and stable perturbation of core histone:DNA contacts by FoxO1</article-title>
<source>The Journal of Biological Chemistry</source>
<year>2007</year>
<volume>282</volume>
<issue>49</issue>
<fpage>35583</fpage>
<lpage>35593</lpage>
<pub-id pub-id-type="doi">10.1074/jbc.M704735200</pub-id>
<pub-id pub-id-type="pmid">17923482</pub-id>
</element-citation>
</ref>
<ref id="CR20">
<label>20.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western">
<surname>Yalley</surname>
<given-names>A</given-names>
</name>
<name name-style="western">
<surname>Schill</surname>
<given-names>D</given-names>
</name>
<name name-style="western">
<surname>Hatta</surname>
<given-names>M</given-names>
</name>
<name name-style="western">
<surname>Johnson</surname>
<given-names>N</given-names>
</name>
<name name-style="western">
<surname>Cirillo</surname>
<given-names>LA</given-names>
</name>
</person-group>
<article-title>Loss of interdependent binding by the FoxO1 and FoxA1/A2 forkhead transcription factors culminates in perturbation of active chromatin marks and binding of transcriptional regulators at insulin-sensitive genes</article-title>
<source>The Journal of Biological Chemistry</source>
<year>2016</year>
<volume>291</volume>
<issue>16</issue>
<fpage>8848</fpage>
<lpage>8861</lpage>
<pub-id pub-id-type="doi">10.1074/jbc.M115.677583</pub-id>
<pub-id pub-id-type="pmid">26929406</pub-id>
<pub-id pub-id-type="pmcid">PMC4861452</pub-id>
</element-citation>
</ref>
<ref id="CR21">
<label>21.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western">
<surname>Schill</surname>
<given-names>D</given-names>
</name>
<name name-style="western">
<surname>Nord</surname>
<given-names>J</given-names>
</name>
<name name-style="western">
<surname>Cirillo</surname>
<given-names>LA</given-names>
</name>
</person-group>
<article-title>FoxO1 and FoxA1/2 form a complex on DNA and cooperate to open chromatin at insulin-regulated genes</article-title>
<source>Biochemistry and Cell Biology</source>
<year>2019</year>
<volume>97</volume>
<issue>2</issue>
<fpage>118</fpage>
<lpage>129</lpage>
<pub-id pub-id-type="doi">10.1139/bcb-2018-0104</pub-id>
<pub-id pub-id-type="pmid">30142277</pub-id>
</element-citation>
</ref>
<ref id="CR22">
<label>22.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western">
<surname>Eijkelenboom</surname>
<given-names>A</given-names>
</name>
<name name-style="western">
<surname>Mokry</surname>
<given-names>M</given-names>
</name>
<name name-style="western">
<surname>Smits</surname>
<given-names>LM</given-names>
</name>
<name name-style="western">
<surname>Nieuwenhuis</surname>
<given-names>EE</given-names>
</name>
<name name-style="western">
<surname>Burgering</surname>
<given-names>BM</given-names>
</name>
</person-group>
<article-title>FOXO3 selectively amplifies enhancer activity to establish target gene regulation</article-title>
<source>Cell Reports</source>
<year>2013</year>
<volume>5</volume>
<issue>6</issue>
<fpage>1664</fpage>
<lpage>1678</lpage>
<pub-id pub-id-type="doi">10.1016/j.celrep.2013.11.031</pub-id>
<pub-id pub-id-type="pmid">24360957</pub-id>
</element-citation>
</ref>
<ref id="CR23">
<label>23.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western">
<surname>Paik</surname>
<given-names>JH</given-names>
</name>
<name name-style="western">
<surname>Kollipara</surname>
<given-names>R</given-names>
</name>
<name name-style="western">
<surname>Chu</surname>
<given-names>G</given-names>
</name>
<name name-style="western">
<surname>Ji</surname>
<given-names>H</given-names>
</name>
<name name-style="western">
<surname>Xiao</surname>
<given-names>Y</given-names>
</name>
<name name-style="western">
<surname>Ding</surname>
<given-names>Z</given-names>
</name>
<etal />
</person-group>
<article-title>FoxOs are lineage-restricted redundant tumor suppressors and regulate endothelial cell homeostasis</article-title>
<source>Cell</source>
<year>2007</year>
<volume>128</volume>
<issue>2</issue>
<fpage>309</fpage>
<lpage>323</lpage>
<pub-id pub-id-type="doi">10.1016/j.cell.2006.12.029</pub-id>
<pub-id pub-id-type="pmid">17254969</pub-id>
<pub-id pub-id-type="pmcid">PMC1855089</pub-id>
</element-citation>
</ref>
<ref id="CR24">
<label>24.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western">
<surname>Nestal de Moraes</surname>
<given-names>G</given-names>
</name>
<name name-style="western">
<surname>Bella</surname>
<given-names>L</given-names>
</name>
<name name-style="western">
<surname>Zona</surname>
<given-names>S</given-names>
</name>
<name name-style="western">
<surname>Burton</surname>
<given-names>MJ</given-names>
</name>
<name name-style="western">
<surname>Lam</surname>
<given-names>EW</given-names>
</name>
</person-group>
<article-title>Insights into a critical role of the FOXO3a-FOXM1 axis in DNA damage response and genotoxic drug resistance</article-title>
<source>Current Drug Targets</source>
<year>2016</year>
<volume>17</volume>
<issue>2</issue>
<fpage>164</fpage>
<lpage>177</lpage>
<pub-id pub-id-type="doi">10.2174/1389450115666141122211549</pub-id>
<pub-id pub-id-type="pmid">25418858</pub-id>
<pub-id pub-id-type="pmcid">PMC5403963</pub-id>
</element-citation>
</ref>
<ref id="CR25">
<label>25.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western">
<surname>Courtois-Cox</surname>
<given-names>S</given-names>
</name>
<name name-style="western">
<surname>Genther Williams</surname>
<given-names>SM</given-names>
</name>
<name name-style="western">
<surname>Reczek</surname>
<given-names>EE</given-names>
</name>
<name name-style="western">
<surname>Johnson</surname>
<given-names>BW</given-names>
</name>
<name name-style="western">
<surname>McGillicuddy</surname>
<given-names>LT</given-names>
</name>
<name name-style="western">
<surname>Johannessen</surname>
<given-names>CM</given-names>
</name>
<etal />
</person-group>
<article-title>A negative feedback signaling network underlies oncogene-induced senescence</article-title>
<source>Cancer Cell</source>
<year>2006</year>
<volume>10</volume>
<issue>6</issue>
<fpage>459</fpage>
<lpage>472</lpage>
<pub-id pub-id-type="doi">10.1016/j.ccr.2006.10.003</pub-id>
<pub-id pub-id-type="pmid">17157787</pub-id>
<pub-id pub-id-type="pmcid">PMC2692661</pub-id>
</element-citation>
</ref>
<ref id="CR26">
<label>26.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western">
<surname>Collado</surname>
<given-names>M</given-names>
</name>
<name name-style="western">
<surname>Medema</surname>
<given-names>RH</given-names>
</name>
<name name-style="western">
<surname>Garcia-Cao</surname>
<given-names>I</given-names>
</name>
<name name-style="western">
<surname>Dubuisson</surname>
<given-names>ML</given-names>
</name>
<name name-style="western">
<surname>Barradas</surname>
<given-names>M</given-names>
</name>
<name name-style="western">
<surname>Glassford</surname>
<given-names>J</given-names>
</name>
<etal />
</person-group>
<article-title>Inhibition of the phosphoinositide 3-kinase pathway induces a senescence-like arrest mediated by p27Kip1</article-title>
<source>The Journal of Biological Chemistry</source>
<year>2000</year>
<volume>275</volume>
<issue>29</issue>
<fpage>21960</fpage>
<lpage>21968</lpage>
<pub-id pub-id-type="doi">10.1074/jbc.M000759200</pub-id>
<pub-id pub-id-type="pmid">10791951</pub-id>
</element-citation>
</ref>
<ref id="CR27">
<label>27.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western">
<surname>Zheng</surname>
<given-names>T</given-names>
</name>
<name name-style="western">
<surname>Lu</surname>
<given-names>Y</given-names>
</name>
</person-group>
<article-title>Changes in SIRT1 expression and its downstream pathways in age-related cataract in humans</article-title>
<source>Current Eye Research</source>
<year>2011</year>
<volume>36</volume>
<issue>5</issue>
<fpage>449</fpage>
<lpage>455</lpage>
<pub-id pub-id-type="doi">10.3109/02713683.2011.559301</pub-id>
<pub-id pub-id-type="pmid">21501079</pub-id>
</element-citation>
</ref>
<ref id="CR28">
<label>28.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western">
<surname>Zhao</surname>
<given-names>F</given-names>
</name>
<name name-style="western">
<surname>Lam</surname>
<given-names>EW</given-names>
</name>
</person-group>
<article-title>Role of the forkhead transcription factor FOXO-FOXM1 axis in cancer and drug resistance</article-title>
<source>Frontiers in Medicine</source>
<year>2012</year>
<volume>6</volume>
<issue>4</issue>
<fpage>376</fpage>
<lpage>380</lpage>
<pub-id pub-id-type="doi">10.1007/s11684-012-0228-0</pub-id>
<pub-id pub-id-type="pmid">23124885</pub-id>
</element-citation>
</ref>
<ref id="CR29">
<label>29.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western">
<surname>Wilson</surname>
<given-names>MS</given-names>
</name>
<name name-style="western">
<surname>Brosens</surname>
<given-names>JJ</given-names>
</name>
<name name-style="western">
<surname>Schwenen</surname>
<given-names>HD</given-names>
</name>
<name name-style="western">
<surname>Lam</surname>
<given-names>EW</given-names>
</name>
</person-group>
<article-title>FOXO and FOXM1 in cancer: the FOXO-FOXM1 axis shapes the outcome of cancer chemotherapy</article-title>
<source>Current Drug Targets</source>
<year>2011</year>
<volume>12</volume>
<issue>9</issue>
<fpage>1256</fpage>
<lpage>1266</lpage>
<pub-id pub-id-type="doi">10.2174/138945011796150244</pub-id>
<pub-id pub-id-type="pmid">21443467</pub-id>
</element-citation>
</ref>
<ref id="CR30">
<label>30.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western">
<surname>Yao</surname>
<given-names>S</given-names>
</name>
<name name-style="western">
<surname>Fan</surname>
<given-names>LY</given-names>
</name>
<name name-style="western">
<surname>Lam</surname>
<given-names>EW</given-names>
</name>
</person-group>
<article-title>The FOXO3-FOXM1 axis: a key cancer drug target and a modulator of cancer drug resistance</article-title>
<source>Seminars in Cancer Biology</source>
<year>2018</year>
<volume>50</volume>
<fpage>77</fpage>
<lpage>89</lpage>
<pub-id pub-id-type="doi">10.1016/j.semcancer.2017.11.018</pub-id>
<pub-id pub-id-type="pmid">29180117</pub-id>
<pub-id pub-id-type="pmcid">PMC6565931</pub-id>
</element-citation>
</ref>
<ref id="CR31">
<label>31.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western">
<surname>Karadedou</surname>
<given-names>CT</given-names>
</name>
<name name-style="western">
<surname>Gomes</surname>
<given-names>AR</given-names>
</name>
<name name-style="western">
<surname>Chen</surname>
<given-names>J</given-names>
</name>
<name name-style="western">
<surname>Petkovic</surname>
<given-names>M</given-names>
</name>
<name name-style="western">
<surname>Ho</surname>
<given-names>KK</given-names>
</name>
<name name-style="western">
<surname>Zwolinska</surname>
<given-names>AK</given-names>
</name>
<etal />
</person-group>
<article-title>FOXO3a represses VEGF expression through FOXM1-dependent and -independent mechanisms in breast cancer</article-title>
<source>Oncogene</source>
<year>2012</year>
<volume>31</volume>
<issue>14</issue>
<fpage>1845</fpage>
<lpage>1858</lpage>
<pub-id pub-id-type="doi">10.1038/onc.2011.368</pub-id>
<pub-id pub-id-type="pmid">21860419</pub-id>
<pub-id pub-id-type="pmcid">PMC3232453</pub-id>
</element-citation>
</ref>
<ref id="CR32">
<label>32.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western">
<surname>Li</surname>
<given-names>SK</given-names>
</name>
<name name-style="western">
<surname>Smith</surname>
<given-names>DK</given-names>
</name>
<name name-style="western">
<surname>Leung</surname>
<given-names>WY</given-names>
</name>
<name name-style="western">
<surname>Cheung</surname>
<given-names>AM</given-names>
</name>
<name name-style="western">
<surname>Lam</surname>
<given-names>EW</given-names>
</name>
<name name-style="western">
<surname>Dimri</surname>
<given-names>GP</given-names>
</name>
<etal />
</person-group>
<article-title>FoxM1c counteracts oxidative stress-induced senescence and stimulates Bmi-1 expression</article-title>
<source>The Journal of Biological Chemistry</source>
<year>2008</year>
<volume>283</volume>
<issue>24</issue>
<fpage>16545</fpage>
<lpage>16553</lpage>
<pub-id pub-id-type="doi">10.1074/jbc.M709604200</pub-id>
<pub-id pub-id-type="pmid">18408007</pub-id>
<pub-id pub-id-type="pmcid">PMC2423239</pub-id>
</element-citation>
</ref>
<ref id="CR33">
<label>33.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western">
<surname>Kongsema</surname>
<given-names>M</given-names>
</name>
<name name-style="western">
<surname>Wongkhieo</surname>
<given-names>S</given-names>
</name>
<name name-style="western">
<surname>Khongkow</surname>
<given-names>M</given-names>
</name>
<name name-style="western">
<surname>Lam</surname>
<given-names>EW</given-names>
</name>
<name name-style="western">
<surname>Boonnoy</surname>
<given-names>P</given-names>
</name>
<name name-style="western">
<surname>Vongsangnak</surname>
<given-names>W</given-names>
</name>
<etal />
</person-group>
<article-title>Molecular mechanism of forkhead box M1 inhibition by thiostrepton in breast cancer cells</article-title>
<source>Oncology Reports</source>
<year>2019</year>
<volume>42</volume>
<issue>3</issue>
<fpage>953</fpage>
<lpage>962</lpage>
<pub-id pub-id-type="doi">10.3892/or.2019.7225</pub-id>
<pub-id pub-id-type="pmid">31322278</pub-id>
<pub-id pub-id-type="pmcid">PMC6667886</pub-id>
</element-citation>
</ref>
<ref id="CR34">
<label>34.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western">
<surname>Zeng</surname>
<given-names>J</given-names>
</name>
<name name-style="western">
<surname>Wang</surname>
<given-names>L</given-names>
</name>
<name name-style="western">
<surname>Li</surname>
<given-names>Q</given-names>
</name>
<name name-style="western">
<surname>Li</surname>
<given-names>W</given-names>
</name>
<name name-style="western">
<surname>Bjorkholm</surname>
<given-names>M</given-names>
</name>
<name name-style="western">
<surname>Jia</surname>
<given-names>J</given-names>
</name>
<etal />
</person-group>
<article-title>FoxM1 is up-regulated in gastric cancer and its inhibition leads to cellular senescence, partially dependent on p27 kip1</article-title>
<source>The Journal of Pathology</source>
<year>2009</year>
<volume>218</volume>
<issue>4</issue>
<fpage>419</fpage>
<lpage>427</lpage>
<pub-id pub-id-type="doi">10.1002/path.2530</pub-id>
<pub-id pub-id-type="pmid">19235838</pub-id>
</element-citation>
</ref>
<ref id="CR35">
<label>35.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western">
<surname>Tao</surname>
<given-names>J</given-names>
</name>
<name name-style="western">
<surname>Xu</surname>
<given-names>XS</given-names>
</name>
<name name-style="western">
<surname>Song</surname>
<given-names>YZ</given-names>
</name>
<name name-style="western">
<surname>Qu</surname>
<given-names>K</given-names>
</name>
<name name-style="western">
<surname>Wu</surname>
<given-names>QF</given-names>
</name>
<name name-style="western">
<surname>Wang</surname>
<given-names>RT</given-names>
</name>
<etal />
</person-group>
<article-title>Down-regulation of FoxM1 inhibits viability and invasion of gallbladder carcinoma cells, partially dependent on inducement of cellular senescence</article-title>
<source>World Journal of Gastroenterology</source>
<year>2014</year>
<volume>20</volume>
<issue>28</issue>
<fpage>9497</fpage>
<lpage>9505</lpage>
<pub-id pub-id-type="doi">10.3748/wjg.v20.i28.9497</pub-id>
<pub-id pub-id-type="pmid">25071344</pub-id>
<pub-id pub-id-type="pmcid">PMC4110581</pub-id>
</element-citation>
</ref>
<ref id="CR36">
<label>36.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western">
<surname>Yang</surname>
<given-names>X</given-names>
</name>
<name name-style="western">
<surname>Qu</surname>
<given-names>K</given-names>
</name>
<name name-style="western">
<surname>Tao</surname>
<given-names>J</given-names>
</name>
<name name-style="western">
<surname>Yin</surname>
<given-names>G</given-names>
</name>
<name name-style="western">
<surname>Han</surname>
<given-names>S</given-names>
</name>
<name name-style="western">
<surname>Liu</surname>
<given-names>Q</given-names>
</name>
<etal />
</person-group>
<article-title>Inhibition of CIP2A attenuates tumor progression by inducing cell cycle arrest and promoting cellular senescence in hepatocellular carcinoma</article-title>
<source>Biochemical and Biophysical Research Communications</source>
<year>2018</year>
<volume>495</volume>
<issue>2</issue>
<fpage>1807</fpage>
<lpage>1814</lpage>
<pub-id pub-id-type="doi">10.1016/j.bbrc.2017.11.124</pub-id>
<pub-id pub-id-type="pmid">29175329</pub-id>
</element-citation>
</ref>
<ref id="CR37">
<label>37.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western">
<surname>Liu</surname>
<given-names>G</given-names>
</name>
<name name-style="western">
<surname>Sun</surname>
<given-names>Y</given-names>
</name>
<name name-style="western">
<surname>Ji</surname>
<given-names>P</given-names>
</name>
<name name-style="western">
<surname>Li</surname>
<given-names>X</given-names>
</name>
<name name-style="western">
<surname>Cogdell</surname>
<given-names>D</given-names>
</name>
<name name-style="western">
<surname>Yang</surname>
<given-names>D</given-names>
</name>
<etal />
</person-group>
<article-title>MiR-506 suppresses proliferation and induces senescence by directly targeting the CDK4/6-FOXM1 axis in ovarian cancer</article-title>
<source>The Journal of Pathology</source>
<year>2014</year>
<volume>233</volume>
<issue>3</issue>
<fpage>308</fpage>
<lpage>318</lpage>
<pub-id pub-id-type="doi">10.1002/path.4348</pub-id>
<pub-id pub-id-type="pmid">24604117</pub-id>
<pub-id pub-id-type="pmcid">PMC4144705</pub-id>
</element-citation>
</ref>
<ref id="CR38">
<label>38.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western">
<surname>Rader</surname>
<given-names>J</given-names>
</name>
<name name-style="western">
<surname>Russell</surname>
<given-names>MR</given-names>
</name>
<name name-style="western">
<surname>Hart</surname>
<given-names>LS</given-names>
</name>
<name name-style="western">
<surname>Nakazawa</surname>
<given-names>MS</given-names>
</name>
<name name-style="western">
<surname>Belcastro</surname>
<given-names>LT</given-names>
</name>
<name name-style="western">
<surname>Martinez</surname>
<given-names>D</given-names>
</name>
<etal />
</person-group>
<article-title>Dual CDK4/CDK6 inhibition induces cell-cycle arrest and senescence in neuroblastoma</article-title>
<source>Clinical Cancer Research</source>
<year>2013</year>
<volume>19</volume>
<issue>22</issue>
<fpage>6173</fpage>
<lpage>6182</lpage>
<pub-id pub-id-type="doi">10.1158/1078-0432.CCR-13-1675</pub-id>
<pub-id pub-id-type="pmid">24045179</pub-id>
<pub-id pub-id-type="pmcid">PMC3844928</pub-id>
</element-citation>
</ref>
<ref id="CR39">
<label>39.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western">
<surname>Notte</surname>
<given-names>A</given-names>
</name>
<name name-style="western">
<surname>Leclere</surname>
<given-names>L</given-names>
</name>
<name name-style="western">
<surname>Michiels</surname>
<given-names>C</given-names>
</name>
</person-group>
<article-title>Autophagy as a mediator of chemotherapy-induced cell death in cancer</article-title>
<source>Biochemical Pharmacology</source>
<year>2011</year>
<volume>82</volume>
<issue>5</issue>
<fpage>427</fpage>
<lpage>434</lpage>
<pub-id pub-id-type="doi">10.1016/j.bcp.2011.06.015</pub-id>
<pub-id pub-id-type="pmid">21704023</pub-id>
</element-citation>
</ref>
<ref id="CR40">
<label>40.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western">
<surname>Delaney</surname>
<given-names>JR</given-names>
</name>
<name name-style="western">
<surname>Patel</surname>
<given-names>CB</given-names>
</name>
<name name-style="western">
<surname>Willis</surname>
<given-names>KM</given-names>
</name>
<name name-style="western">
<surname>Haghighiabyaneh</surname>
<given-names>M</given-names>
</name>
<name name-style="western">
<surname>Axelrod</surname>
<given-names>J</given-names>
</name>
<name name-style="western">
<surname>Tancioni</surname>
<given-names>I</given-names>
</name>
<etal />
</person-group>
<article-title>Haploinsufficiency networks identify targetable patterns of allelic deficiency in low mutation ovarian cancer</article-title>
<source>Nature Communications</source>
<year>2017</year>
<volume>8</volume>
<fpage>14423</fpage>
<pub-id pub-id-type="doi">10.1038/ncomms14423</pub-id>
<pub-id pub-id-type="pmid">28198375</pub-id>
<pub-id pub-id-type="pmcid">PMC5316854</pub-id>
</element-citation>
</ref>
<ref id="CR41">
<label>41.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western">
<surname>Takahashi</surname>
<given-names>Y</given-names>
</name>
<name name-style="western">
<surname>Hori</surname>
<given-names>T</given-names>
</name>
<name name-style="western">
<surname>Cooper</surname>
<given-names>TK</given-names>
</name>
<name name-style="western">
<surname>Liao</surname>
<given-names>J</given-names>
</name>
<name name-style="western">
<surname>Desai</surname>
<given-names>N</given-names>
</name>
<name name-style="western">
<surname>Serfass</surname>
<given-names>JM</given-names>
</name>
<etal />
</person-group>
<article-title>Bif-1 haploinsufficiency promotes chromosomal instability and accelerates Myc-driven lymphomagenesis via suppression of mitophagy</article-title>
<source>Blood</source>
<year>2013</year>
<volume>121</volume>
<issue>9</issue>
<fpage>1622</fpage>
<lpage>1632</lpage>
<pub-id pub-id-type="doi">10.1182/blood-2012-10-459826</pub-id>
<pub-id pub-id-type="pmid">23287860</pub-id>
<pub-id pub-id-type="pmcid">PMC3587325</pub-id>
</element-citation>
</ref>
<ref id="CR42">
<label>42.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western">
<surname>Julian</surname>
<given-names>LM</given-names>
</name>
<name name-style="western">
<surname>Delaney</surname>
<given-names>SP</given-names>
</name>
<name name-style="western">
<surname>Wang</surname>
<given-names>Y</given-names>
</name>
<name name-style="western">
<surname>Goldberg</surname>
<given-names>AA</given-names>
</name>
<name name-style="western">
<surname>Dore</surname>
<given-names>C</given-names>
</name>
<name name-style="western">
<surname>Yockell-Lelievre</surname>
<given-names>J</given-names>
</name>
<etal />
</person-group>
<article-title>Human pluripotent stem cell-derived TSC2-haploinsufficient smooth muscle cells recapitulate features of lymphangioleiomyomatosis</article-title>
<source>Cancer Research</source>
<year>2017</year>
<volume>77</volume>
<issue>20</issue>
<fpage>5491</fpage>
<lpage>5502</lpage>
<pub-id pub-id-type="doi">10.1158/0008-5472.CAN-17-0925</pub-id>
<pub-id pub-id-type="pmid">28830860</pub-id>
<pub-id pub-id-type="pmcid">PMC5645248</pub-id>
</element-citation>
</ref>
<ref id="CR43">
<label>43.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western">
<surname>Delaney</surname>
<given-names>JR</given-names>
</name>
<name name-style="western">
<surname>Patel</surname>
<given-names>CB</given-names>
</name>
<name name-style="western">
<surname>Bapat</surname>
<given-names>J</given-names>
</name>
<name name-style="western">
<surname>Jones</surname>
<given-names>CM</given-names>
</name>
<name name-style="western">
<surname>Ramos-Zapatero</surname>
<given-names>M</given-names>
</name>
<name name-style="western">
<surname>Ortell</surname>
<given-names>KK</given-names>
</name>
<etal />
</person-group>
<article-title>Autophagy gene haploinsufficiency drives chromosome instability, increases migration, and promotes early ovarian tumors</article-title>
<source>PLoS Genetics</source>
<year>2020</year>
<volume>16</volume>
<issue>1</issue>
<fpage>e1008558</fpage>
<pub-id pub-id-type="doi">10.1371/journal.pgen.1008558</pub-id>
<pub-id pub-id-type="pmid">31923184</pub-id>
<pub-id pub-id-type="pmcid">PMC6953790</pub-id>
</element-citation>
</ref>
<ref id="CR44">
<label>44.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western">
<surname>Sanchez</surname>
<given-names>AM</given-names>
</name>
<name name-style="western">
<surname>Candau</surname>
<given-names>RB</given-names>
</name>
<name name-style="western">
<surname>Bernardi</surname>
<given-names>H</given-names>
</name>
</person-group>
<article-title>FoxO transcription factors: their roles in the maintenance of skeletal muscle homeostasis</article-title>
<source>Cellular and Molecular Life Sciences</source>
<year>2014</year>
<volume>71</volume>
<issue>9</issue>
<fpage>1657</fpage>
<lpage>1671</lpage>
<pub-id pub-id-type="doi">10.1007/s00018-013-1513-z</pub-id>
<pub-id pub-id-type="pmid">24232446</pub-id>
<pub-id pub-id-type="pmcid">PMC11113648</pub-id>
</element-citation>
</ref>
<ref id="CR45">
<label>45.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western">
<surname>Galluzzi</surname>
<given-names>L</given-names>
</name>
<name name-style="western">
<surname>Pietrocola</surname>
<given-names>F</given-names>
</name>
<name name-style="western">
<surname>Bravo-San Pedro</surname>
<given-names>JM</given-names>
</name>
<name name-style="western">
<surname>Amaravadi</surname>
<given-names>RK</given-names>
</name>
<name name-style="western">
<surname>Baehrecke</surname>
<given-names>EH</given-names>
</name>
<name name-style="western">
<surname>Cecconi</surname>
<given-names>F</given-names>
</name>
<etal />
</person-group>
<article-title>Autophagy in malignant transformation and cancer progression</article-title>
<source>The EMBO Journal</source>
<year>2015</year>
<volume>34</volume>
<issue>7</issue>
<fpage>856</fpage>
<lpage>880</lpage>
<pub-id pub-id-type="doi">10.15252/embj.201490784</pub-id>
<pub-id pub-id-type="pmid">25712477</pub-id>
<pub-id pub-id-type="pmcid">PMC4388596</pub-id>
</element-citation>
</ref>
<ref id="CR46">
<label>46.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western">
<surname>Zhou</surname>
<given-names>J</given-names>
</name>
<name name-style="western">
<surname>Liao</surname>
<given-names>W</given-names>
</name>
<name name-style="western">
<surname>Yang</surname>
<given-names>J</given-names>
</name>
<name name-style="western">
<surname>Ma</surname>
<given-names>K</given-names>
</name>
<name name-style="western">
<surname>Li</surname>
<given-names>X</given-names>
</name>
<name name-style="western">
<surname>Wang</surname>
<given-names>Y</given-names>
</name>
<etal />
</person-group>
<article-title>FOXO3 induces FOXO1-dependent autophagy by activating the AKT1 signaling pathway</article-title>
<source>Autophagy</source>
<year>2012</year>
<volume>8</volume>
<issue>12</issue>
<fpage>1712</fpage>
<lpage>1723</lpage>
<pub-id pub-id-type="doi">10.4161/auto.21830</pub-id>
<pub-id pub-id-type="pmid">22931788</pub-id>
<pub-id pub-id-type="pmcid">PMC3541283</pub-id>
</element-citation>
</ref>
<ref id="CR47">
<label>47.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western">
<surname>Zhao</surname>
<given-names>Y</given-names>
</name>
<name name-style="western">
<surname>Yang</surname>
<given-names>J</given-names>
</name>
<name name-style="western">
<surname>Liao</surname>
<given-names>W</given-names>
</name>
<name name-style="western">
<surname>Liu</surname>
<given-names>X</given-names>
</name>
<name name-style="western">
<surname>Zhang</surname>
<given-names>H</given-names>
</name>
<name name-style="western">
<surname>Wang</surname>
<given-names>S</given-names>
</name>
<etal />
</person-group>
<article-title>Cytosolic FoxO1 is essential for the induction of autophagy and tumour suppressor activity</article-title>
<source>Nature Cell Biology</source>
<year>2010</year>
<volume>12</volume>
<issue>7</issue>
<fpage>665</fpage>
<lpage>675</lpage>
<pub-id pub-id-type="doi">10.1038/ncb2069</pub-id>
<pub-id pub-id-type="pmid">20543840</pub-id>
</element-citation>
</ref>
<ref id="CR48">
<label>48.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western">
<surname>Xu</surname>
<given-names>P</given-names>
</name>
<name name-style="western">
<surname>Das</surname>
<given-names>M</given-names>
</name>
<name name-style="western">
<surname>Reilly</surname>
<given-names>J</given-names>
</name>
<name name-style="western">
<surname>Davis</surname>
<given-names>RJ</given-names>
</name>
</person-group>
<article-title>JNK regulates FoxO-dependent autophagy in neurons</article-title>
<source>Genes &amp; Development</source>
<year>2011</year>
<volume>25</volume>
<issue>4</issue>
<fpage>310</fpage>
<lpage>322</lpage>
<pub-id pub-id-type="doi">10.1101/gad.1984311</pub-id>
<pub-id pub-id-type="pmid">21325132</pub-id>
<pub-id pub-id-type="pmcid">PMC3042155</pub-id>
</element-citation>
</ref>
<ref id="CR49">
<label>49.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western">
<surname>Lin</surname>
<given-names>A</given-names>
</name>
<name name-style="western">
<surname>Yao</surname>
<given-names>J</given-names>
</name>
<name name-style="western">
<surname>Zhuang</surname>
<given-names>L</given-names>
</name>
<name name-style="western">
<surname>Wang</surname>
<given-names>D</given-names>
</name>
<name name-style="western">
<surname>Han</surname>
<given-names>J</given-names>
</name>
<name name-style="western">
<surname>Lam</surname>
<given-names>EW</given-names>
</name>
<etal />
</person-group>
<article-title>The FoxO-BNIP3 axis exerts a unique regulation of mTORC1 and cell survival under energy stress</article-title>
<source>Oncogene</source>
<year>2014</year>
<volume>33</volume>
<issue>24</issue>
<fpage>3183</fpage>
<lpage>3194</lpage>
<pub-id pub-id-type="doi">10.1038/onc.2013.273</pub-id>
<pub-id pub-id-type="pmid">23851496</pub-id>
<pub-id pub-id-type="pmcid">PMC4365448</pub-id>
</element-citation>
</ref>
<ref id="CR50">
<label>50.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western">
<surname>Gu</surname>
<given-names>X</given-names>
</name>
<name name-style="western">
<surname>Han</surname>
<given-names>D</given-names>
</name>
<name name-style="western">
<surname>Chen</surname>
<given-names>W</given-names>
</name>
<name name-style="western">
<surname>Zhang</surname>
<given-names>L</given-names>
</name>
<name name-style="western">
<surname>Lin</surname>
<given-names>Q</given-names>
</name>
<name name-style="western">
<surname>Gao</surname>
<given-names>J</given-names>
</name>
<etal />
</person-group>
<article-title>SIRT1-mediated FoxOs pathways protect against apoptosis by promoting autophagy in osteoblast-like MC3T3-E1 cells exposed to sodium fluoride</article-title>
<source>Oncotarget</source>
<year>2016</year>
<volume>7</volume>
<issue>40</issue>
<fpage>65218</fpage>
<lpage>65230</lpage>
<pub-id pub-id-type="doi">10.18632/oncotarget.11573</pub-id>
<pub-id pub-id-type="pmid">27564107</pub-id>
<pub-id pub-id-type="pmcid">PMC5323150</pub-id>
</element-citation>
</ref>
<ref id="CR51">
<label>51.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western">
<surname>Habashy</surname>
<given-names>HO</given-names>
</name>
<name name-style="western">
<surname>Rakha</surname>
<given-names>EA</given-names>
</name>
<name name-style="western">
<surname>Aleskandarany</surname>
<given-names>M</given-names>
</name>
<name name-style="western">
<surname>Ahmed</surname>
<given-names>MA</given-names>
</name>
<name name-style="western">
<surname>Green</surname>
<given-names>AR</given-names>
</name>
<name name-style="western">
<surname>Ellis</surname>
<given-names>IO</given-names>
</name>
<etal />
</person-group>
<article-title>FOXO3a nuclear localisation is associated with good prognosis in luminal-like breast cancer</article-title>
<source>Breast Cancer Research and Treatment</source>
<year>2011</year>
<volume>129</volume>
<issue>1</issue>
<fpage>11</fpage>
<lpage>21</lpage>
<pub-id pub-id-type="doi">10.1007/s10549-010-1161-z</pub-id>
<pub-id pub-id-type="pmid">21336599</pub-id>
</element-citation>
</ref>
<ref id="CR52">
<label>52.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western">
<surname>Bullock</surname>
<given-names>MD</given-names>
</name>
<name name-style="western">
<surname>Bruce</surname>
<given-names>A</given-names>
</name>
<name name-style="western">
<surname>Sreekumar</surname>
<given-names>R</given-names>
</name>
<name name-style="western">
<surname>Curtis</surname>
<given-names>N</given-names>
</name>
<name name-style="western">
<surname>Cheung</surname>
<given-names>T</given-names>
</name>
<name name-style="western">
<surname>Reading</surname>
<given-names>I</given-names>
</name>
<etal />
</person-group>
<article-title>FOXO3 expression during colorectal cancer progression: biomarker potential reflects a tumour suppressor role</article-title>
<source>British Journal of Cancer</source>
<year>2013</year>
<volume>109</volume>
<issue>2</issue>
<fpage>387</fpage>
<lpage>394</lpage>
<pub-id pub-id-type="doi">10.1038/bjc.2013.355</pub-id>
<pub-id pub-id-type="pmid">23828518</pub-id>
<pub-id pub-id-type="pmcid">PMC3721407</pub-id>
</element-citation>
</ref>
<ref id="CR53">
<label>53.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western">
<surname>Su</surname>
<given-names>B</given-names>
</name>
<name name-style="western">
<surname>Gao</surname>
<given-names>L</given-names>
</name>
<name name-style="western">
<surname>Baranowski</surname>
<given-names>C</given-names>
</name>
<name name-style="western">
<surname>Gillard</surname>
<given-names>B</given-names>
</name>
<name name-style="western">
<surname>Wang</surname>
<given-names>J</given-names>
</name>
<name name-style="western">
<surname>Ransom</surname>
<given-names>R</given-names>
</name>
<etal />
</person-group>
<article-title>A genome-wide RNAi screen identifies FOXO4 as a metastasis-suppressor through counteracting PI3K/AKT signal pathway in prostate cancer</article-title>
<source>PLoS One</source>
<year>2014</year>
<volume>9</volume>
<issue>7</issue>
<fpage>e101411</fpage>
<pub-id pub-id-type="doi">10.1371/journal.pone.0101411</pub-id>
<pub-id pub-id-type="pmid">24983969</pub-id>
<pub-id pub-id-type="pmcid">PMC4077825</pub-id>
</element-citation>
</ref>
<ref id="CR54">
<label>54.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western">
<surname>Mani</surname>
<given-names>SA</given-names>
</name>
<name name-style="western">
<surname>Guo</surname>
<given-names>W</given-names>
</name>
<name name-style="western">
<surname>Liao</surname>
<given-names>MJ</given-names>
</name>
<name name-style="western">
<surname>Eaton</surname>
<given-names>EN</given-names>
</name>
<name name-style="western">
<surname>Ayyanan</surname>
<given-names>A</given-names>
</name>
<name name-style="western">
<surname>Zhou</surname>
<given-names>AY</given-names>
</name>
<etal />
</person-group>
<article-title>The epithelial-mesenchymal transition generates cells with properties of stem cells</article-title>
<source>Cell</source>
<year>2008</year>
<volume>133</volume>
<issue>4</issue>
<fpage>704</fpage>
<lpage>715</lpage>
<pub-id pub-id-type="doi">10.1016/j.cell.2008.03.027</pub-id>
<pub-id pub-id-type="pmid">18485877</pub-id>
<pub-id pub-id-type="pmcid">PMC2728032</pub-id>
</element-citation>
</ref>
<ref id="CR55">
<label>55.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western">
<surname>Dong</surname>
<given-names>T</given-names>
</name>
<name name-style="western">
<surname>Zhang</surname>
<given-names>Y</given-names>
</name>
<name name-style="western">
<surname>Chen</surname>
<given-names>Y</given-names>
</name>
<name name-style="western">
<surname>Liu</surname>
<given-names>P</given-names>
</name>
<name name-style="western">
<surname>An</surname>
<given-names>T</given-names>
</name>
<name name-style="western">
<surname>Zhang</surname>
<given-names>J</given-names>
</name>
<etal />
</person-group>
<article-title>FOXO1 inhibits the invasion and metastasis of hepatocellular carcinoma by reversing ZEB2-induced epithelial-mesenchymal transition</article-title>
<source>Oncotarget</source>
<year>2017</year>
<volume>8</volume>
<issue>1</issue>
<fpage>1703</fpage>
<lpage>1713</lpage>
<pub-id pub-id-type="doi">10.18632/oncotarget.13786</pub-id>
<pub-id pub-id-type="pmid">27924058</pub-id>
<pub-id pub-id-type="pmcid">PMC5352090</pub-id>
</element-citation>
</ref>
<ref id="CR56">
<label>56.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western">
<surname>Zhang</surname>
<given-names>L</given-names>
</name>
<name name-style="western">
<surname>Li</surname>
<given-names>L</given-names>
</name>
<name name-style="western">
<surname>Wei</surname>
<given-names>H</given-names>
</name>
<name name-style="western">
<surname>Guo</surname>
<given-names>L</given-names>
</name>
<name name-style="western">
<surname>Ai</surname>
<given-names>C</given-names>
</name>
<name name-style="western">
<surname>Xu</surname>
<given-names>H</given-names>
</name>
<etal />
</person-group>
<article-title>Transcriptional factor FOXO3 negatively regulates the expression of nm23-H1 in non-small cell lung cancer</article-title>
<source>Thoracic Cancer</source>
<year>2016</year>
<volume>7</volume>
<issue>1</issue>
<fpage>9</fpage>
<lpage>16</lpage>
<pub-id pub-id-type="doi">10.1111/1759-7714.12260</pub-id>
<pub-id pub-id-type="pmid">26816534</pub-id>
<pub-id pub-id-type="pmcid">PMC4718119</pub-id>
</element-citation>
</ref>
<ref id="CR57">
<label>57.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western">
<surname>Zhang</surname>
<given-names>L</given-names>
</name>
<name name-style="western">
<surname>Cai</surname>
<given-names>M</given-names>
</name>
<name name-style="western">
<surname>Gong</surname>
<given-names>Z</given-names>
</name>
<name name-style="western">
<surname>Zhang</surname>
<given-names>B</given-names>
</name>
<name name-style="western">
<surname>Li</surname>
<given-names>Y</given-names>
</name>
<name name-style="western">
<surname>Guan</surname>
<given-names>L</given-names>
</name>
<etal />
</person-group>
<article-title>Geminin facilitates FoxO3 deacetylation to promote breast cancer cell metastasis</article-title>
<source>The Journal of Clinical Investigation</source>
<year>2017</year>
<volume>127</volume>
<issue>6</issue>
<fpage>2159</fpage>
<lpage>2175</lpage>
<pub-id pub-id-type="doi">10.1172/JCI90077</pub-id>
<pub-id pub-id-type="pmid">28436938</pub-id>
<pub-id pub-id-type="pmcid">PMC5451250</pub-id>
</element-citation>
</ref>
<ref id="CR58">
<label>58.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western">
<surname>Li</surname>
<given-names>J</given-names>
</name>
<name name-style="western">
<surname>Yang</surname>
<given-names>R</given-names>
</name>
<name name-style="western">
<surname>Dong</surname>
<given-names>Y</given-names>
</name>
<name name-style="western">
<surname>Chen</surname>
<given-names>M</given-names>
</name>
<name name-style="western">
<surname>Wang</surname>
<given-names>Y</given-names>
</name>
<name name-style="western">
<surname>Wang</surname>
<given-names>G</given-names>
</name>
</person-group>
<article-title>Knockdown of FOXO3a induces epithelial-mesenchymal transition and promotes metastasis of pancreatic ductal adenocarcinoma by activation of the beta-catenin/TCF4 pathway through SPRY2</article-title>
<source>Journal of Experimental &amp; Clinical Cancer Research</source>
<year>2019</year>
<volume>38</volume>
<issue>1</issue>
<fpage>38</fpage>
<pub-id pub-id-type="doi">10.1186/s13046-019-1046-x</pub-id>
<pub-id pub-id-type="pmid">30691517</pub-id>
<pub-id pub-id-type="pmcid">PMC6350320</pub-id>
<related-article related-article-type="retraction-forward" ext-link-type="pmc" ns1:href="PMC9204885" />
</element-citation>
</ref>
<ref id="CR59">
<label>59.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western">
<surname>Ni</surname>
<given-names>D</given-names>
</name>
<name name-style="western">
<surname>Ma</surname>
<given-names>X</given-names>
</name>
<name name-style="western">
<surname>Li</surname>
<given-names>HZ</given-names>
</name>
<name name-style="western">
<surname>Gao</surname>
<given-names>Y</given-names>
</name>
<name name-style="western">
<surname>Li</surname>
<given-names>XT</given-names>
</name>
<name name-style="western">
<surname>Zhang</surname>
<given-names>Y</given-names>
</name>
<etal />
</person-group>
<article-title>Downregulation of FOXO3a promotes tumor metastasis and is associated with metastasis-free survival of patients with clear cell renal cell carcinoma</article-title>
<source>Clinical Cancer Research</source>
<year>2014</year>
<volume>20</volume>
<issue>7</issue>
<fpage>1779</fpage>
<lpage>1790</lpage>
<pub-id pub-id-type="doi">10.1158/1078-0432.CCR-13-1687</pub-id>
<pub-id pub-id-type="pmid">24486593</pub-id>
</element-citation>
</ref>
<ref id="CR60">
<label>60.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western">
<surname>Kim</surname>
<given-names>SY</given-names>
</name>
<name name-style="western">
<surname>Yoon</surname>
<given-names>J</given-names>
</name>
<name name-style="western">
<surname>Ko</surname>
<given-names>YS</given-names>
</name>
<name name-style="western">
<surname>Chang</surname>
<given-names>MS</given-names>
</name>
<name name-style="western">
<surname>Park</surname>
<given-names>JW</given-names>
</name>
<name name-style="western">
<surname>Lee</surname>
<given-names>HE</given-names>
</name>
<etal />
</person-group>
<article-title>Constitutive phosphorylation of the FOXO1 transcription factor in gastric cancer cells correlates with microvessel area and the expressions of angiogenesis-related molecules</article-title>
<source>BMC Cancer</source>
<year>2011</year>
<volume>11</volume>
<fpage>264</fpage>
<pub-id pub-id-type="doi">10.1186/1471-2407-11-264</pub-id>
<pub-id pub-id-type="pmid">21696576</pub-id>
<pub-id pub-id-type="pmcid">PMC3135570</pub-id>
</element-citation>
</ref>
<ref id="CR61">
<label>61.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western">
<surname>Kim</surname>
<given-names>JH</given-names>
</name>
<name name-style="western">
<surname>Kim</surname>
<given-names>MK</given-names>
</name>
<name name-style="western">
<surname>Lee</surname>
<given-names>HE</given-names>
</name>
<name name-style="western">
<surname>Cho</surname>
<given-names>SJ</given-names>
</name>
<name name-style="western">
<surname>Cho</surname>
<given-names>YJ</given-names>
</name>
<name name-style="western">
<surname>Lee</surname>
<given-names>BL</given-names>
</name>
<etal />
</person-group>
<article-title>Constitutive phosphorylation of the FOXO1A transcription factor as a prognostic variable in gastric cancer</article-title>
<source>Modern Pathology</source>
<year>2007</year>
<volume>20</volume>
<issue>8</issue>
<fpage>835</fpage>
<lpage>842</lpage>
<pub-id pub-id-type="doi">10.1038/modpathol.3800789</pub-id>
<pub-id pub-id-type="pmid">17491598</pub-id>
</element-citation>
</ref>
<ref id="CR62">
<label>62.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western">
<surname>Santamaria</surname>
<given-names>CM</given-names>
</name>
<name name-style="western">
<surname>Chillon</surname>
<given-names>MC</given-names>
</name>
<name name-style="western">
<surname>Garcia-Sanz</surname>
<given-names>R</given-names>
</name>
<name name-style="western">
<surname>Perez</surname>
<given-names>C</given-names>
</name>
<name name-style="western">
<surname>Caballero</surname>
<given-names>MD</given-names>
</name>
<name name-style="western">
<surname>Ramos</surname>
<given-names>F</given-names>
</name>
<etal />
</person-group>
<article-title>High FOXO3a expression is associated with a poorer prognosis in AML with normal cytogenetics</article-title>
<source>Leukemia Research</source>
<year>2009</year>
<volume>33</volume>
<issue>12</issue>
<fpage>1706</fpage>
<lpage>1709</lpage>
<pub-id pub-id-type="doi">10.1016/j.leukres.2009.04.024</pub-id>
<pub-id pub-id-type="pmid">19457552</pub-id>
</element-citation>
</ref>
<ref id="CR63">
<label>63.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western">
<surname>Qian</surname>
<given-names>Z</given-names>
</name>
<name name-style="western">
<surname>Ren</surname>
<given-names>L</given-names>
</name>
<name name-style="western">
<surname>Wu</surname>
<given-names>D</given-names>
</name>
<name name-style="western">
<surname>Yang</surname>
<given-names>X</given-names>
</name>
<name name-style="western">
<surname>Zhou</surname>
<given-names>Z</given-names>
</name>
<name name-style="western">
<surname>Nie</surname>
<given-names>Q</given-names>
</name>
<etal />
</person-group>
<article-title>Overexpression of FoxO3a is associated with glioblastoma progression and predicts poor patient prognosis</article-title>
<source>International Journal of Cancer</source>
<year>2017</year>
<volume>140</volume>
<issue>12</issue>
<fpage>2792</fpage>
<lpage>2804</lpage>
<pub-id pub-id-type="doi">10.1002/ijc.30690</pub-id>
<pub-id pub-id-type="pmid">28295288</pub-id>
</element-citation>
</ref>
<ref id="CR64">
<label>64.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western">
<surname>Chen</surname>
<given-names>J</given-names>
</name>
<name name-style="western">
<surname>Gomes</surname>
<given-names>AR</given-names>
</name>
<name name-style="western">
<surname>Monteiro</surname>
<given-names>LJ</given-names>
</name>
<name name-style="western">
<surname>Wong</surname>
<given-names>SY</given-names>
</name>
<name name-style="western">
<surname>Wu</surname>
<given-names>LH</given-names>
</name>
<name name-style="western">
<surname>Ng</surname>
<given-names>TT</given-names>
</name>
<etal />
</person-group>
<article-title>Constitutively nuclear FOXO3a localization predicts poor survival and promotes Akt phosphorylation in breast cancer</article-title>
<source>PLoS One</source>
<year>2010</year>
<volume>5</volume>
<issue>8</issue>
<fpage>e12293</fpage>
<pub-id pub-id-type="doi">10.1371/journal.pone.0012293</pub-id>
<pub-id pub-id-type="pmid">20808831</pub-id>
<pub-id pub-id-type="pmcid">PMC2924889</pub-id>
</element-citation>
</ref>
<ref id="CR65">
<label>65.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western">
<surname>Tenbaum</surname>
<given-names>SP</given-names>
</name>
<name name-style="western">
<surname>Ordonez-Moran</surname>
<given-names>P</given-names>
</name>
<name name-style="western">
<surname>Puig</surname>
<given-names>I</given-names>
</name>
<name name-style="western">
<surname>Chicote</surname>
<given-names>I</given-names>
</name>
<name name-style="western">
<surname>Arques</surname>
<given-names>O</given-names>
</name>
<name name-style="western">
<surname>Landolfi</surname>
<given-names>S</given-names>
</name>
<etal />
</person-group>
<article-title>Beta-catenin confers resistance to PI3K and AKT inhibitors and subverts FOXO3a to promote metastasis in colon cancer</article-title>
<source>Nature Medicine</source>
<year>2012</year>
<volume>18</volume>
<issue>6</issue>
<fpage>892</fpage>
<lpage>901</lpage>
<pub-id pub-id-type="doi">10.1038/nm.2772</pub-id>
<pub-id pub-id-type="pmid">22610277</pub-id>
</element-citation>
</ref>
<ref id="CR66">
<label>66.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western">
<surname>Wang</surname>
<given-names>JH</given-names>
</name>
<name name-style="western">
<surname>Tang</surname>
<given-names>HS</given-names>
</name>
<name name-style="western">
<surname>Li</surname>
<given-names>XS</given-names>
</name>
<name name-style="western">
<surname>Zhang</surname>
<given-names>XL</given-names>
</name>
<name name-style="western">
<surname>Yang</surname>
<given-names>XZ</given-names>
</name>
<name name-style="western">
<surname>Zeng</surname>
<given-names>LS</given-names>
</name>
<etal />
</person-group>
<article-title>Elevated FOXO6 expression correlates with progression and prognosis in gastric cancer</article-title>
<source>Oncotarget</source>
<year>2017</year>
<volume>8</volume>
<issue>19</issue>
<fpage>31682</fpage>
<lpage>31691</lpage>
<pub-id pub-id-type="doi">10.18632/oncotarget.15920</pub-id>
<pub-id pub-id-type="pmid">28404958</pub-id>
<pub-id pub-id-type="pmcid">PMC5458239</pub-id>
</element-citation>
</ref>
<ref id="CR67">
<label>67.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western">
<surname>Ryu</surname>
<given-names>KJ</given-names>
</name>
<name name-style="western">
<surname>Park</surname>
<given-names>C</given-names>
</name>
<name name-style="western">
<surname>Hong</surname>
<given-names>M</given-names>
</name>
<name name-style="western">
<surname>Ko</surname>
<given-names>YH</given-names>
</name>
<name name-style="western">
<surname>Kim</surname>
<given-names>WS</given-names>
</name>
<name name-style="western">
<surname>Kim</surname>
<given-names>SJ</given-names>
</name>
</person-group>
<article-title>FOXO4 expression is related to stem cell-like properties and resistance to treatment in diffuse large B-cell lymphoma</article-title>
<source>Oncotarget</source>
<year>2017</year>
<volume>8</volume>
<issue>2</issue>
<fpage>2466</fpage>
<lpage>2476</lpage>
<pub-id pub-id-type="doi">10.18632/oncotarget.13690</pub-id>
<pub-id pub-id-type="pmid">27911272</pub-id>
<pub-id pub-id-type="pmcid">PMC5356816</pub-id>
</element-citation>
</ref>
<ref id="CR68">
<label>68.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western">
<surname>Feng</surname>
<given-names>X</given-names>
</name>
<name name-style="western">
<surname>Wu</surname>
<given-names>Z</given-names>
</name>
<name name-style="western">
<surname>Wu</surname>
<given-names>Y</given-names>
</name>
<name name-style="western">
<surname>Hankey</surname>
<given-names>W</given-names>
</name>
<name name-style="western">
<surname>Prior</surname>
<given-names>TW</given-names>
</name>
<name name-style="western">
<surname>Li</surname>
<given-names>L</given-names>
</name>
<etal />
</person-group>
<article-title>Cdc25A regulates matrix metalloprotease 1 through Foxo1 and mediates metastasis of breast cancer cells</article-title>
<source>Molecular and Cellular Biology</source>
<year>2011</year>
<volume>31</volume>
<issue>16</issue>
<fpage>3457</fpage>
<lpage>3471</lpage>
<pub-id pub-id-type="doi">10.1128/MCB.05523-11</pub-id>
<pub-id pub-id-type="pmid">21670150</pub-id>
<pub-id pub-id-type="pmcid">PMC3147788</pub-id>
</element-citation>
</ref>
<ref id="CR69">
<label>69.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western">
<surname>Storz</surname>
<given-names>P</given-names>
</name>
<name name-style="western">
<surname>Doppler</surname>
<given-names>H</given-names>
</name>
<name name-style="western">
<surname>Copland</surname>
<given-names>JA</given-names>
</name>
<name name-style="western">
<surname>Simpson</surname>
<given-names>KJ</given-names>
</name>
<name name-style="western">
<surname>Toker</surname>
<given-names>A</given-names>
</name>
</person-group>
<article-title>FOXO3a promotes tumor cell invasion through the induction of matrix metalloproteinases</article-title>
<source>Molecular and Cellular Biology</source>
<year>2009</year>
<volume>29</volume>
<issue>18</issue>
<fpage>4906</fpage>
<lpage>4917</lpage>
<pub-id pub-id-type="doi">10.1128/MCB.00077-09</pub-id>
<pub-id pub-id-type="pmid">19564415</pub-id>
<pub-id pub-id-type="pmcid">PMC2738298</pub-id>
</element-citation>
</ref>
<ref id="CR70">
<label>70.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western">
<surname>Du</surname>
<given-names>M</given-names>
</name>
<name name-style="western">
<surname>Wang</surname>
<given-names>Q</given-names>
</name>
<name name-style="western">
<surname>Li</surname>
<given-names>W</given-names>
</name>
<name name-style="western">
<surname>Ma</surname>
<given-names>X</given-names>
</name>
<name name-style="western">
<surname>Wu</surname>
<given-names>L</given-names>
</name>
<name name-style="western">
<surname>Guo</surname>
<given-names>F</given-names>
</name>
<etal />
</person-group>
<article-title>Overexpression of FOXO1 ameliorates the podocyte epithelial-mesenchymal transition induced by high glucose in vitro and in vivo</article-title>
<source>Biochemical and Biophysical Research Communications</source>
<year>2016</year>
<volume>471</volume>
<issue>4</issue>
<fpage>416</fpage>
<lpage>422</lpage>
<pub-id pub-id-type="doi">10.1016/j.bbrc.2016.02.066</pub-id>
<pub-id pub-id-type="pmid">26902117</pub-id>
</element-citation>
</ref>
<ref id="CR71">
<label>71.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western">
<surname>Lee</surname>
<given-names>SJ</given-names>
</name>
<name name-style="western">
<surname>Park</surname>
<given-names>SS</given-names>
</name>
<name name-style="western">
<surname>Lee</surname>
<given-names>US</given-names>
</name>
<name name-style="western">
<surname>Kim</surname>
<given-names>WJ</given-names>
</name>
<name name-style="western">
<surname>Moon</surname>
<given-names>SK</given-names>
</name>
</person-group>
<article-title>Signaling pathway for TNF-alpha-induced MMP-9 expression: Mediation through p38 MAP kinase, and inhibition by anti-cancer molecule magnolol in human urinary bladder cancer 5637 cells</article-title>
<source>International Immunopharmacology</source>
<year>2008</year>
<volume>8</volume>
<issue>13–14</issue>
<fpage>1821</fpage>
<lpage>1826</lpage>
<pub-id pub-id-type="doi">10.1016/j.intimp.2008.08.018</pub-id>
<pub-id pub-id-type="pmid">18801463</pub-id>
</element-citation>
</ref>
<ref id="CR72">
<label>72.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western">
<surname>Diebold</surname>
<given-names>I</given-names>
</name>
<name name-style="western">
<surname>Petry</surname>
<given-names>A</given-names>
</name>
<name name-style="western">
<surname>Burger</surname>
<given-names>M</given-names>
</name>
<name name-style="western">
<surname>Hess</surname>
<given-names>J</given-names>
</name>
<name name-style="western">
<surname>Gorlach</surname>
<given-names>A</given-names>
</name>
</person-group>
<article-title>NOX4 mediates activation of FoxO3a and matrix metalloproteinase-2 expression by urotensin-II</article-title>
<source>Molecular Biology of the Cell</source>
<year>2011</year>
<volume>22</volume>
<issue>22</issue>
<fpage>4424</fpage>
<lpage>4434</lpage>
<pub-id pub-id-type="doi">10.1091/mbc.E10-12-0971</pub-id>
<pub-id pub-id-type="pmid">21965295</pub-id>
<pub-id pub-id-type="pmcid">PMC3216667</pub-id>
</element-citation>
</ref>
<ref id="CR73">
<label>73.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western">
<surname>Yu</surname>
<given-names>H</given-names>
</name>
<name name-style="western">
<surname>Fellows</surname>
<given-names>A</given-names>
</name>
<name name-style="western">
<surname>Foote</surname>
<given-names>K</given-names>
</name>
<name name-style="western">
<surname>Yang</surname>
<given-names>Z</given-names>
</name>
<name name-style="western">
<surname>Figg</surname>
<given-names>N</given-names>
</name>
<name name-style="western">
<surname>Littlewood</surname>
<given-names>T</given-names>
</name>
<etal />
</person-group>
<article-title>FOXO3a (forkhead transcription factor O subfamily member 3a) links vascular smooth muscle cell apoptosis, matrix breakdown, atherosclerosis, and vascular remodeling through a novel pathway involving MMP13 (matrix metalloproteinase 13)</article-title>
<source>Arteriosclerosis, Thrombosis, and Vascular Biology</source>
<year>2018</year>
<volume>38</volume>
<issue>3</issue>
<fpage>555</fpage>
<lpage>565</lpage>
<pub-id pub-id-type="doi">10.1161/ATVBAHA.117.310502</pub-id>
<pub-id pub-id-type="pmid">29326312</pub-id>
<pub-id pub-id-type="pmcid">PMC5828387</pub-id>
</element-citation>
</ref>
<ref id="CR74">
<label>74.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western">
<surname>Su</surname>
<given-names>L</given-names>
</name>
<name name-style="western">
<surname>Liu</surname>
<given-names>X</given-names>
</name>
<name name-style="western">
<surname>Chai</surname>
<given-names>N</given-names>
</name>
<name name-style="western">
<surname>Lv</surname>
<given-names>L</given-names>
</name>
<name name-style="western">
<surname>Wang</surname>
<given-names>R</given-names>
</name>
<name name-style="western">
<surname>Li</surname>
<given-names>X</given-names>
</name>
<etal />
</person-group>
<article-title>The transcription factor FOXO4 is down-regulated and inhibits tumor proliferation and metastasis in gastric cancer</article-title>
<source>BMC Cancer</source>
<year>2014</year>
<volume>14</volume>
<fpage>378</fpage>
<pub-id pub-id-type="doi">10.1186/1471-2407-14-378</pub-id>
<pub-id pub-id-type="pmid">24886657</pub-id>
<pub-id pub-id-type="pmcid">PMC4063225</pub-id>
</element-citation>
</ref>
<ref id="CR75">
<label>75.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western">
<surname>Li</surname>
<given-names>H</given-names>
</name>
<name name-style="western">
<surname>Liang</surname>
<given-names>HP</given-names>
</name>
<name name-style="western">
<surname>Castrillon</surname>
<given-names>DH</given-names>
</name>
<name name-style="western">
<surname>DePinho</surname>
<given-names>RA</given-names>
</name>
<name name-style="western">
<surname>Olson</surname>
<given-names>EN</given-names>
</name>
<name name-style="western">
<surname>Liu</surname>
<given-names>ZP</given-names>
</name>
</person-group>
<article-title>FoxO4 regulates tumor necrosis factor alpha-directed smooth muscle cell migration by activating matrix metalloproteinase 9 gene transcription</article-title>
<source>Molecular and Cellular Biology</source>
<year>2007</year>
<volume>27</volume>
<issue>7</issue>
<fpage>2676</fpage>
<lpage>2686</lpage>
<pub-id pub-id-type="doi">10.1128/Mcb.01748-06</pub-id>
<pub-id pub-id-type="pmid">17242183</pub-id>
<pub-id pub-id-type="pmcid">PMC1899894</pub-id>
</element-citation>
</ref>
<ref id="CR76">
<label>76.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western">
<surname>Paap</surname>
<given-names>RH</given-names>
</name>
<name name-style="western">
<surname>Oosterbroek</surname>
<given-names>S</given-names>
</name>
<name name-style="western">
<surname>Wagemans</surname>
<given-names>C</given-names>
</name>
<name name-style="western">
<surname>von Oerthel</surname>
<given-names>L</given-names>
</name>
<name name-style="western">
<surname>Schellevis</surname>
<given-names>RD</given-names>
</name>
<name name-style="western">
<surname>Vastenhouw-van der Linden</surname>
<given-names>AJA</given-names>
</name>
<etal />
</person-group>
<article-title>FoxO6 affects Plxna4-mediated neuronal migration during mouse cortical development</article-title>
<source>Proceedings of the National Academy of Sciences of the United States of America</source>
<year>2016</year>
<volume>113</volume>
<issue>45</issue>
<fpage>E7087</fpage>
<lpage>E7096</lpage>
<pub-id pub-id-type="doi">10.1073/pnas.1609111113</pub-id>
<pub-id pub-id-type="pmid">27791111</pub-id>
<pub-id pub-id-type="pmcid">PMC5111667</pub-id>
</element-citation>
</ref>
<ref id="CR77">
<label>77.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western">
<surname>Ye</surname>
<given-names>H</given-names>
</name>
<name name-style="western">
<surname>Duan</surname>
<given-names>M</given-names>
</name>
</person-group>
<article-title>Downregulation of FOXO6 in breast cancer promotes epithelial-mesenchymal transition and facilitates migration and proliferation of cancer cells</article-title>
<source>Cancer Management and Research</source>
<year>2018</year>
<volume>10</volume>
<fpage>5145</fpage>
<lpage>5156</lpage>
<pub-id pub-id-type="doi">10.2147/CMAR.S157661</pub-id>
<pub-id pub-id-type="pmid">30464613</pub-id>
<pub-id pub-id-type="pmcid">PMC6215919</pub-id>
</element-citation>
</ref>
<ref id="CR78">
<label>78.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western">
<surname>Potente</surname>
<given-names>M</given-names>
</name>
<name name-style="western">
<surname>Urbich</surname>
<given-names>C</given-names>
</name>
<name name-style="western">
<surname>Sasaki</surname>
<given-names>K</given-names>
</name>
<name name-style="western">
<surname>Hofmann</surname>
<given-names>WK</given-names>
</name>
<name name-style="western">
<surname>Heeschen</surname>
<given-names>C</given-names>
</name>
<name name-style="western">
<surname>Aicher</surname>
<given-names>A</given-names>
</name>
<etal />
</person-group>
<article-title>Involvement of Foxo transcription factors in angiogenesis and postnatal neovascularization</article-title>
<source>The Journal of Clinical Investigation</source>
<year>2005</year>
<volume>115</volume>
<issue>9</issue>
<fpage>2382</fpage>
<lpage>2392</lpage>
<pub-id pub-id-type="doi">10.1172/JCI23126</pub-id>
<pub-id pub-id-type="pmid">16100571</pub-id>
<pub-id pub-id-type="pmcid">PMC1184037</pub-id>
</element-citation>
</ref>
<ref id="CR79">
<label>79.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western">
<surname>Jeon</surname>
<given-names>HH</given-names>
</name>
<name name-style="western">
<surname>Yu</surname>
<given-names>Q</given-names>
</name>
<name name-style="western">
<surname>Lu</surname>
<given-names>Y</given-names>
</name>
<name name-style="western">
<surname>Spencer</surname>
<given-names>E</given-names>
</name>
<name name-style="western">
<surname>Lu</surname>
<given-names>C</given-names>
</name>
<name name-style="western">
<surname>Milovanova</surname>
<given-names>T</given-names>
</name>
<etal />
</person-group>
<article-title>FOXO1 regulates VEGFA expression and promotes angiogenesis in healing wounds</article-title>
<source>The Journal of Pathology</source>
<year>2018</year>
<volume>245</volume>
<issue>3</issue>
<fpage>258</fpage>
<lpage>264</lpage>
<pub-id pub-id-type="doi">10.1002/path.5075</pub-id>
<pub-id pub-id-type="pmid">29574902</pub-id>
<pub-id pub-id-type="pmcid">PMC6566901</pub-id>
</element-citation>
</ref>
<ref id="CR80">
<label>80.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western">
<surname>Galili</surname>
<given-names>N</given-names>
</name>
<name name-style="western">
<surname>Davis</surname>
<given-names>RJ</given-names>
</name>
<name name-style="western">
<surname>Fredericks</surname>
<given-names>WJ</given-names>
</name>
<name name-style="western">
<surname>Mukhopadhyay</surname>
<given-names>S</given-names>
</name>
<name name-style="western">
<surname>Rauscher</surname>
<given-names>FJ</given-names>
<suffix>3rd</suffix>
</name>
<name name-style="western">
<surname>Emanuel</surname>
<given-names>BS</given-names>
</name>
<etal />
</person-group>
<article-title>Fusion of a fork head domain gene to PAX3 in the solid tumour alveolar rhabdomyosarcoma</article-title>
<source>Nature Genetics</source>
<year>1993</year>
<volume>5</volume>
<issue>3</issue>
<fpage>230</fpage>
<lpage>235</lpage>
<pub-id pub-id-type="doi">10.1038/ng1193-230</pub-id>
<pub-id pub-id-type="pmid">8275086</pub-id>
</element-citation>
</ref>
<ref id="CR81">
<label>81.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western">
<surname>Davis</surname>
<given-names>RJ</given-names>
</name>
<name name-style="western">
<surname>D’Cruz</surname>
<given-names>CM</given-names>
</name>
<name name-style="western">
<surname>Lovell</surname>
<given-names>MA</given-names>
</name>
<name name-style="western">
<surname>Biegel</surname>
<given-names>JA</given-names>
</name>
<name name-style="western">
<surname>Barr</surname>
<given-names>FG</given-names>
</name>
</person-group>
<article-title>Fusion of PAX7 to FKHR by the variant t(1;13)(p36;q14) translocation in alveolar rhabdomyosarcoma</article-title>
<source>Cancer Research</source>
<year>1994</year>
<volume>54</volume>
<issue>11</issue>
<fpage>2869</fpage>
<lpage>2872</lpage>
<pub-id pub-id-type="pmid">8187070</pub-id>
</element-citation>
</ref>
<ref id="CR82">
<label>82.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western">
<surname>Buckingham</surname>
<given-names>M</given-names>
</name>
<name name-style="western">
<surname>Relaix</surname>
<given-names>F</given-names>
</name>
</person-group>
<article-title>PAX3 and PAX7 as upstream regulators of myogenesis</article-title>
<source>Seminars in Cell &amp; Developmental Biology</source>
<year>2015</year>
<volume>44</volume>
<fpage>115</fpage>
<lpage>125</lpage>
<pub-id pub-id-type="doi">10.1016/j.semcdb.2015.09.017</pub-id>
<pub-id pub-id-type="pmid">26424495</pub-id>
</element-citation>
</ref>
<ref id="CR83">
<label>83.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western">
<surname>Marshall</surname>
<given-names>AD</given-names>
</name>
<name name-style="western">
<surname>Lagutina</surname>
<given-names>I</given-names>
</name>
<name name-style="western">
<surname>Grosveld</surname>
<given-names>GC</given-names>
</name>
</person-group>
<article-title>PAX3-FOXO1 induces cannabinoid receptor 1 to enhance cell invasion and metastasis</article-title>
<source>Cancer Research</source>
<year>2011</year>
<volume>71</volume>
<issue>24</issue>
<fpage>7471</fpage>
<lpage>7480</lpage>
<pub-id pub-id-type="doi">10.1158/0008-5472.CAN-11-0924</pub-id>
<pub-id pub-id-type="pmid">22037868</pub-id>
</element-citation>
</ref>
<ref id="CR84">
<label>84.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western">
<surname>Slany</surname>
<given-names>RK</given-names>
</name>
</person-group>
<article-title>The molecular biology of mixed lineage leukemia</article-title>
<source>Haematologica</source>
<year>2009</year>
<volume>94</volume>
<issue>7</issue>
<fpage>984</fpage>
<lpage>993</lpage>
<pub-id pub-id-type="doi">10.3324/haematol.2008.002436</pub-id>
<pub-id pub-id-type="pmid">19535349</pub-id>
<pub-id pub-id-type="pmcid">PMC2704309</pub-id>
</element-citation>
</ref>
<ref id="CR85">
<label>85.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western">
<surname>Meyer</surname>
<given-names>C</given-names>
</name>
<name name-style="western">
<surname>Burmeister</surname>
<given-names>T</given-names>
</name>
<name name-style="western">
<surname>Groger</surname>
<given-names>D</given-names>
</name>
<name name-style="western">
<surname>Tsaur</surname>
<given-names>G</given-names>
</name>
<name name-style="western">
<surname>Fechina</surname>
<given-names>L</given-names>
</name>
<name name-style="western">
<surname>Renneville</surname>
<given-names>A</given-names>
</name>
<etal />
</person-group>
<article-title>The MLL recombinome of acute leukemias in 2017</article-title>
<source>Leukemia</source>
<year>2018</year>
<volume>32</volume>
<issue>2</issue>
<fpage>273</fpage>
<lpage>284</lpage>
<pub-id pub-id-type="doi">10.1038/leu.2017.213</pub-id>
<pub-id pub-id-type="pmid">28701730</pub-id>
<pub-id pub-id-type="pmcid">PMC5808070</pub-id>
</element-citation>
</ref>
<ref id="CR86">
<label>86.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western">
<surname>Calnan</surname>
<given-names>DR</given-names>
</name>
<name name-style="western">
<surname>Brunet</surname>
<given-names>A</given-names>
</name>
</person-group>
<article-title>The FoxO code</article-title>
<source>Oncogene</source>
<year>2008</year>
<volume>27</volume>
<issue>16</issue>
<fpage>2276</fpage>
<lpage>2288</lpage>
<pub-id pub-id-type="doi">10.1038/onc.2008.21</pub-id>
<pub-id pub-id-type="pmid">18391970</pub-id>
</element-citation>
</ref>
<ref id="CR87">
<label>87.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western">
<surname>Mikse</surname>
<given-names>OR</given-names>
</name>
<name name-style="western">
<surname>Blake</surname>
<given-names>DC</given-names>
<suffix>Jr</suffix>
</name>
<name name-style="western">
<surname>Jones</surname>
<given-names>NR</given-names>
</name>
<name name-style="western">
<surname>Sun</surname>
<given-names>YW</given-names>
</name>
<name name-style="western">
<surname>Amin</surname>
<given-names>S</given-names>
</name>
<name name-style="western">
<surname>Gallagher</surname>
<given-names>CJ</given-names>
</name>
<etal />
</person-group>
<article-title>FOXO3 encodes a carcinogen-activated transcription factor frequently deleted in early-stage lung adenocarcinoma</article-title>
<source>Cancer Research</source>
<year>2010</year>
<volume>70</volume>
<issue>15</issue>
<fpage>6205</fpage>
<lpage>6215</lpage>
<pub-id pub-id-type="doi">10.1158/0008-5472.CAN-09-4008</pub-id>
<pub-id pub-id-type="pmid">20631076</pub-id>
</element-citation>
</ref>
<ref id="CR88">
<label>88.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western">
<surname>Herzog</surname>
<given-names>CR</given-names>
</name>
<name name-style="western">
<surname>Blake</surname>
<given-names>DC</given-names>
<suffix>Jr</suffix>
</name>
<name name-style="western">
<surname>Mikse</surname>
<given-names>OR</given-names>
</name>
<name name-style="western">
<surname>Grigoryeva</surname>
<given-names>LS</given-names>
</name>
<name name-style="western">
<surname>Gundermann</surname>
<given-names>EL</given-names>
</name>
</person-group>
<article-title>FoxO3a gene is a target of deletion in mouse lung adenocarcinoma</article-title>
<source>Oncology Reports</source>
<year>2009</year>
<volume>22</volume>
<issue>4</issue>
<fpage>837</fpage>
<lpage>843</lpage>
<pub-id pub-id-type="doi">10.3892/or_00000507</pub-id>
<pub-id pub-id-type="pmid">19724863</pub-id>
</element-citation>
</ref>
<ref id="CR89">
<label>89.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western">
<surname>Thelander</surname>
<given-names>EF</given-names>
</name>
<name name-style="western">
<surname>Ichimura</surname>
<given-names>K</given-names>
</name>
<name name-style="western">
<surname>Corcoran</surname>
<given-names>M</given-names>
</name>
<name name-style="western">
<surname>Barbany</surname>
<given-names>G</given-names>
</name>
<name name-style="western">
<surname>Nordgren</surname>
<given-names>A</given-names>
</name>
<name name-style="western">
<surname>Heyman</surname>
<given-names>M</given-names>
</name>
<etal />
</person-group>
<article-title>Characterization of 6q deletions in mature B cell lymphomas and childhood acute lymphoblastic leukemia</article-title>
<source>Leukemia &amp; Lymphoma</source>
<year>2008</year>
<volume>49</volume>
<issue>3</issue>
<fpage>477</fpage>
<lpage>487</lpage>
<pub-id pub-id-type="doi">10.1080/10428190701817282</pub-id>
<pub-id pub-id-type="pmid">18297524</pub-id>
</element-citation>
</ref>
<ref id="CR90">
<label>90.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western">
<surname>Magro</surname>
<given-names>G</given-names>
</name>
<name name-style="western">
<surname>Righi</surname>
<given-names>A</given-names>
</name>
<name name-style="western">
<surname>Casorzo</surname>
<given-names>L</given-names>
</name>
<name name-style="western">
<surname>Antonietta</surname>
<given-names>T</given-names>
</name>
<name name-style="western">
<surname>Salvatorelli</surname>
<given-names>L</given-names>
</name>
<name name-style="western">
<surname>Kacerovska</surname>
<given-names>D</given-names>
</name>
<etal />
</person-group>
<article-title>Mammary and vaginal myofibroblastomas are genetically related lesions: fluorescence in situ hybridization analysis shows deletion of 13q14 region</article-title>
<source>Human Pathology</source>
<year>2012</year>
<volume>43</volume>
<issue>11</issue>
<fpage>1887</fpage>
<lpage>1893</lpage>
<pub-id pub-id-type="doi">10.1016/j.humpath.2012.01.015</pub-id>
<pub-id pub-id-type="pmid">22575260</pub-id>
</element-citation>
</ref>
<ref id="CR91">
<label>91.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western">
<surname>Karube</surname>
<given-names>K</given-names>
</name>
<name name-style="western">
<surname>Nakagawa</surname>
<given-names>M</given-names>
</name>
<name name-style="western">
<surname>Tsuzuki</surname>
<given-names>S</given-names>
</name>
<name name-style="western">
<surname>Ko</surname>
<given-names>Y</given-names>
</name>
<name name-style="western">
<surname>Nakamura</surname>
<given-names>S</given-names>
</name>
<name name-style="western">
<surname>Seto</surname>
<given-names>M</given-names>
</name>
</person-group>
<article-title>Identification of Foxo3 and Prdm1 as tumor suppressor gene candidates in Nk cell neoplasms by the combination of genomic and functional analyses</article-title>
<source>Annals of Oncology</source>
<year>2011</year>
<volume>22</volume>
<fpage>100</fpage>
<lpage>101</lpage>
<pub-id pub-id-type="doi">10.1093/annonc/mdr194</pub-id>
<pub-id pub-id-type="pmid">21690554</pub-id>
</element-citation>
</ref>
<ref id="CR92">
<label>92.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western">
<surname>Uehara</surname>
<given-names>K</given-names>
</name>
<name name-style="western">
<surname>Ikehara</surname>
<given-names>F</given-names>
</name>
<name name-style="western">
<surname>Shibuya</surname>
<given-names>R</given-names>
</name>
<name name-style="western">
<surname>Nakazato</surname>
<given-names>I</given-names>
</name>
<name name-style="western">
<surname>Oshiro</surname>
<given-names>M</given-names>
</name>
<name name-style="western">
<surname>Kiyuna</surname>
<given-names>M</given-names>
</name>
<etal />
</person-group>
<article-title>Molecular signature of tumors with monoallelic 13q14 deletion: a case series of spindle cell lipoma and genetically-related tumors demonstrating a link between FOXO1 status and p38 MAPK pathway</article-title>
<source>Pathology Oncology Research</source>
<year>2018</year>
<volume>24</volume>
<issue>4</issue>
<fpage>861</fpage>
<lpage>869</lpage>
<pub-id pub-id-type="doi">10.1007/s12253-017-0303-6</pub-id>
<pub-id pub-id-type="pmid">28887603</pub-id>
<pub-id pub-id-type="pmcid">PMC6132820</pub-id>
</element-citation>
</ref>
<ref id="CR93">
<label>93.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western">
<surname>Lowe</surname>
<given-names>SW</given-names>
</name>
<name name-style="western">
<surname>Cepero</surname>
<given-names>E</given-names>
</name>
<name name-style="western">
<surname>Evan</surname>
<given-names>G</given-names>
</name>
</person-group>
<article-title>Intrinsic tumour suppression</article-title>
<source>Nature</source>
<year>2004</year>
<volume>432</volume>
<issue>7015</issue>
<fpage>307</fpage>
<lpage>315</lpage>
<pub-id pub-id-type="doi">10.1038/nature03098</pub-id>
<pub-id pub-id-type="pmid">15549092</pub-id>
</element-citation>
</ref>
<ref id="CR94">
<label>94.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western">
<surname>Janku</surname>
<given-names>F</given-names>
</name>
<name name-style="western">
<surname>Yap</surname>
<given-names>TA</given-names>
</name>
<name name-style="western">
<surname>Meric-Bernstam</surname>
<given-names>F</given-names>
</name>
</person-group>
<article-title>Targeting the PI3K pathway in cancer: are we making headway?</article-title>
<source>Nature Reviews. Clinical Oncology</source>
<year>2018</year>
<volume>15</volume>
<issue>5</issue>
<fpage>273</fpage>
<lpage>291</lpage>
<pub-id pub-id-type="doi">10.1038/nrclinonc.2018.28</pub-id>
<pub-id pub-id-type="pmid">29508857</pub-id>
</element-citation>
</ref>
<ref id="CR95">
<label>95.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western">
<surname>Chang</surname>
<given-names>L</given-names>
</name>
<name name-style="western">
<surname>Chiang</surname>
<given-names>SH</given-names>
</name>
<name name-style="western">
<surname>Saltiel</surname>
<given-names>AR</given-names>
</name>
</person-group>
<article-title>Insulin signaling and the regulation of glucose transport</article-title>
<source>Molecular Medicine</source>
<year>2004</year>
<volume>10</volume>
<issue>7–12</issue>
<fpage>65</fpage>
<lpage>71</lpage>
<pub-id pub-id-type="doi">10.2119/2005-00029.Saltiel</pub-id>
<pub-id pub-id-type="pmid">16307172</pub-id>
<pub-id pub-id-type="pmcid">PMC1431367</pub-id>
</element-citation>
</ref>
<ref id="CR96">
<label>96.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western">
<surname>Fu</surname>
<given-names>Z</given-names>
</name>
<name name-style="western">
<surname>Gilbert</surname>
<given-names>ER</given-names>
</name>
<name name-style="western">
<surname>Liu</surname>
<given-names>D</given-names>
</name>
</person-group>
<article-title>Regulation of insulin synthesis and secretion and pancreatic Beta-cell dysfunction in diabetes</article-title>
<source>Current Diabetes Reviews</source>
<year>2013</year>
<volume>9</volume>
<issue>1</issue>
<fpage>25</fpage>
<lpage>53</lpage>
<pub-id pub-id-type="doi">10.2174/157339913804143225</pub-id>
<pub-id pub-id-type="pmid">22974359</pub-id>
<pub-id pub-id-type="pmcid">PMC3934755</pub-id>
</element-citation>
</ref>
<ref id="CR97">
<label>97.</label>
<mixed-citation publication-type="other">Sun, S., Sun, Y., Rong, X., &amp; Bai, L. (2019). High glucose promotes breast cancer proliferation and metastasis by impairing angiotensinogen expression. <italic toggle="yes">Bioscience Reports, 39</italic>(6). 10.1042/BSR20190436.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1042/BSR20190436</pub-id>
<pub-id pub-id-type="pmcid">PMC6567675</pub-id>
<pub-id pub-id-type="pmid">31142626</pub-id>
</mixed-citation>
</ref>
<ref id="CR98">
<label>98.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western">
<surname>van der Heide</surname>
<given-names>LP</given-names>
</name>
<name name-style="western">
<surname>Jacobs</surname>
<given-names>FM</given-names>
</name>
<name name-style="western">
<surname>Burbach</surname>
<given-names>JP</given-names>
</name>
<name name-style="western">
<surname>Hoekman</surname>
<given-names>MF</given-names>
</name>
<name name-style="western">
<surname>Smidt</surname>
<given-names>MP</given-names>
</name>
</person-group>
<article-title>FoxO6 transcriptional activity is regulated by Thr26 and Ser184, independent of nucleo-cytoplasmic shuttling</article-title>
<source>The Biochemical Journal</source>
<year>2005</year>
<volume>391</volume>
<issue>Pt 3</issue>
<fpage>623</fpage>
<lpage>629</lpage>
<pub-id pub-id-type="doi">10.1042/BJ20050525</pub-id>
<pub-id pub-id-type="pmid">15987244</pub-id>
<pub-id pub-id-type="pmcid">PMC1276963</pub-id>
</element-citation>
</ref>
<ref id="CR99">
<label>99.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western">
<surname>Obsilova</surname>
<given-names>V</given-names>
</name>
<name name-style="western">
<surname>Vecer</surname>
<given-names>J</given-names>
</name>
<name name-style="western">
<surname>Herman</surname>
<given-names>P</given-names>
</name>
<name name-style="western">
<surname>Pabianova</surname>
<given-names>A</given-names>
</name>
<name name-style="western">
<surname>Sulc</surname>
<given-names>M</given-names>
</name>
<name name-style="western">
<surname>Teisinger</surname>
<given-names>J</given-names>
</name>
<etal />
</person-group>
<article-title>14-3-3 protein interacts with nuclear localization sequence of forkhead transcription factor FoxO4</article-title>
<source>Biochemistry</source>
<year>2005</year>
<volume>44</volume>
<issue>34</issue>
<fpage>11608</fpage>
<lpage>11617</lpage>
<pub-id pub-id-type="doi">10.1021/bi050618r</pub-id>
<pub-id pub-id-type="pmid">16114898</pub-id>
</element-citation>
</ref>
<ref id="CR100">
<label>100.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western">
<surname>Silhan</surname>
<given-names>J</given-names>
</name>
<name name-style="western">
<surname>Vacha</surname>
<given-names>P</given-names>
</name>
<name name-style="western">
<surname>Strnadova</surname>
<given-names>P</given-names>
</name>
<name name-style="western">
<surname>Vecer</surname>
<given-names>J</given-names>
</name>
<name name-style="western">
<surname>Herman</surname>
<given-names>P</given-names>
</name>
<name name-style="western">
<surname>Sulc</surname>
<given-names>M</given-names>
</name>
<etal />
</person-group>
<article-title>14-3-3 protein masks the DNA binding interface of forkhead transcription factor FOXO4</article-title>
<source>The Journal of Biological Chemistry</source>
<year>2009</year>
<volume>284</volume>
<issue>29</issue>
<fpage>19349</fpage>
<lpage>19360</lpage>
<pub-id pub-id-type="doi">10.1074/jbc.M109.002725</pub-id>
<pub-id pub-id-type="pmid">19416966</pub-id>
<pub-id pub-id-type="pmcid">PMC2740560</pub-id>
</element-citation>
</ref>
<ref id="CR101">
<label>101.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western">
<surname>Rena</surname>
<given-names>G</given-names>
</name>
<name name-style="western">
<surname>Prescott</surname>
<given-names>AR</given-names>
</name>
<name name-style="western">
<surname>Guo</surname>
<given-names>S</given-names>
</name>
<name name-style="western">
<surname>Cohen</surname>
<given-names>P</given-names>
</name>
<name name-style="western">
<surname>Unterman</surname>
<given-names>TG</given-names>
</name>
</person-group>
<article-title>Roles of the forkhead in rhabdomyosarcoma (FKHR) phosphorylation sites in regulating 14-3-3 binding, transactivation and nuclear targetting</article-title>
<source>The Biochemical Journal</source>
<year>2001</year>
<volume>354</volume>
<issue>Pt 3</issue>
<fpage>605</fpage>
<lpage>612</lpage>
<pub-id pub-id-type="doi">10.1042/0264-6021:3540605</pub-id>
<pub-id pub-id-type="pmid">11237865</pub-id>
<pub-id pub-id-type="pmcid">PMC1221692</pub-id>
</element-citation>
</ref>
<ref id="CR102">
<label>102.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western">
<surname>Rena</surname>
<given-names>G</given-names>
</name>
<name name-style="western">
<surname>Woods</surname>
<given-names>YL</given-names>
</name>
<name name-style="western">
<surname>Prescott</surname>
<given-names>AR</given-names>
</name>
<name name-style="western">
<surname>Peggie</surname>
<given-names>M</given-names>
</name>
<name name-style="western">
<surname>Unterman</surname>
<given-names>TG</given-names>
</name>
<name name-style="western">
<surname>Williams</surname>
<given-names>MR</given-names>
</name>
<etal />
</person-group>
<article-title>Two novel phosphorylation sites on FKHR that are critical for its nuclear exclusion</article-title>
<source>The EMBO Journal</source>
<year>2002</year>
<volume>21</volume>
<issue>9</issue>
<fpage>2263</fpage>
<lpage>2271</lpage>
<pub-id pub-id-type="doi">10.1093/emboj/21.9.2263</pub-id>
<pub-id pub-id-type="pmid">11980723</pub-id>
<pub-id pub-id-type="pmcid">PMC125977</pub-id>
</element-citation>
</ref>
<ref id="CR103">
<label>103.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western">
<surname>Yan</surname>
<given-names>L</given-names>
</name>
<name name-style="western">
<surname>Lavin</surname>
<given-names>VA</given-names>
</name>
<name name-style="western">
<surname>Moser</surname>
<given-names>LR</given-names>
</name>
<name name-style="western">
<surname>Cui</surname>
<given-names>Q</given-names>
</name>
<name name-style="western">
<surname>Kanies</surname>
<given-names>C</given-names>
</name>
<name name-style="western">
<surname>Yang</surname>
<given-names>E</given-names>
</name>
</person-group>
<article-title>PP2A regulates the pro-apoptotic activity of FOXO1</article-title>
<source>The Journal of Biological Chemistry</source>
<year>2008</year>
<volume>283</volume>
<issue>12</issue>
<fpage>7411</fpage>
<lpage>7420</lpage>
<pub-id pub-id-type="doi">10.1074/jbc.M708083200</pub-id>
<pub-id pub-id-type="pmid">18211894</pub-id>
<pub-id pub-id-type="pmcid">PMC2276329</pub-id>
</element-citation>
</ref>
<ref id="CR104">
<label>104.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western">
<surname>Singh</surname>
<given-names>A</given-names>
</name>
<name name-style="western">
<surname>Ye</surname>
<given-names>M</given-names>
</name>
<name name-style="western">
<surname>Bucur</surname>
<given-names>O</given-names>
</name>
<name name-style="western">
<surname>Zhu</surname>
<given-names>S</given-names>
</name>
<name name-style="western">
<surname>Tanya Santos</surname>
<given-names>M</given-names>
</name>
<name name-style="western">
<surname>Rabinovitz</surname>
<given-names>I</given-names>
</name>
<etal />
</person-group>
<article-title>Protein phosphatase 2A reactivates FOXO3a through a dynamic interplay with 14-3-3 and AKT</article-title>
<source>Molecular Biology of the Cell</source>
<year>2010</year>
<volume>21</volume>
<issue>6</issue>
<fpage>1140</fpage>
<lpage>1152</lpage>
<pub-id pub-id-type="doi">10.1091/mbc.E09-09-0795</pub-id>
<pub-id pub-id-type="pmid">20110348</pub-id>
<pub-id pub-id-type="pmcid">PMC2836964</pub-id>
</element-citation>
</ref>
<ref id="CR105">
<label>105.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western">
<surname>Hornsveld</surname>
<given-names>M</given-names>
</name>
<name name-style="western">
<surname>Dansen</surname>
<given-names>TB</given-names>
</name>
<name name-style="western">
<surname>Derksen</surname>
<given-names>PW</given-names>
</name>
<name name-style="western">
<surname>Burgering</surname>
<given-names>BMT</given-names>
</name>
</person-group>
<article-title>Re-evaluating the role of FOXOs in cancer</article-title>
<source>Seminars in Cancer Biology</source>
<year>2018</year>
<volume>50</volume>
<fpage>90</fpage>
<lpage>100</lpage>
<pub-id pub-id-type="doi">10.1016/j.semcancer.2017.11.017</pub-id>
<pub-id pub-id-type="pmid">29175105</pub-id>
</element-citation>
</ref>
<ref id="CR106">
<label>106.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western">
<surname>Zhang</surname>
<given-names>H</given-names>
</name>
<name name-style="western">
<surname>Pan</surname>
<given-names>Y</given-names>
</name>
<name name-style="western">
<surname>Zheng</surname>
<given-names>L</given-names>
</name>
<name name-style="western">
<surname>Choe</surname>
<given-names>C</given-names>
</name>
<name name-style="western">
<surname>Lindgren</surname>
<given-names>B</given-names>
</name>
<name name-style="western">
<surname>Jensen</surname>
<given-names>ED</given-names>
</name>
<etal />
</person-group>
<article-title>FOXO1 inhibits Runx2 transcriptional activity and prostate cancer cell migration and invasion</article-title>
<source>Cancer Research</source>
<year>2011</year>
<volume>71</volume>
<issue>9</issue>
<fpage>3257</fpage>
<lpage>3267</lpage>
<pub-id pub-id-type="doi">10.1158/0008-5472.CAN-10-2603</pub-id>
<pub-id pub-id-type="pmid">21505104</pub-id>
<pub-id pub-id-type="pmcid">PMC3108023</pub-id>
</element-citation>
</ref>
<ref id="CR107">
<label>107.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western">
<surname>Wang</surname>
<given-names>L</given-names>
</name>
<name name-style="western">
<surname>Brugge</surname>
<given-names>JS</given-names>
</name>
<name name-style="western">
<surname>Janes</surname>
<given-names>KA</given-names>
</name>
</person-group>
<article-title>Intersection of FOXO- and RUNX1-mediated gene expression programs in single breast epithelial cells during morphogenesis and tumor progression</article-title>
<source>Proceedings of the National Academy of Sciences of the United States of America</source>
<year>2011</year>
<volume>108</volume>
<issue>40</issue>
<fpage>E803</fpage>
<lpage>E812</lpage>
<pub-id pub-id-type="doi">10.1073/pnas.1103423108</pub-id>
<pub-id pub-id-type="pmid">21873240</pub-id>
<pub-id pub-id-type="pmcid">PMC3189061</pub-id>
</element-citation>
</ref>
<ref id="CR108">
<label>108.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western">
<surname>Yamamura</surname>
<given-names>Y</given-names>
</name>
<name name-style="western">
<surname>Lee</surname>
<given-names>WL</given-names>
</name>
<name name-style="western">
<surname>Inoue</surname>
<given-names>K</given-names>
</name>
<name name-style="western">
<surname>Ida</surname>
<given-names>H</given-names>
</name>
<name name-style="western">
<surname>Ito</surname>
<given-names>Y</given-names>
</name>
</person-group>
<article-title>RUNX3 cooperates with FoxO3a to induce apoptosis in gastric cancer cells</article-title>
<source>The Journal of Biological Chemistry</source>
<year>2006</year>
<volume>281</volume>
<issue>8</issue>
<fpage>5267</fpage>
<lpage>5276</lpage>
<pub-id pub-id-type="doi">10.1074/jbc.M512151200</pub-id>
<pub-id pub-id-type="pmid">16373335</pub-id>
</element-citation>
</ref>
<ref id="CR109">
<label>109.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western">
<surname>Lee</surname>
<given-names>MJ</given-names>
</name>
<name name-style="western">
<surname>Yu</surname>
<given-names>GR</given-names>
</name>
<name name-style="western">
<surname>Yoo</surname>
<given-names>HJ</given-names>
</name>
<name name-style="western">
<surname>Kim</surname>
<given-names>JH</given-names>
</name>
<name name-style="western">
<surname>Yoon</surname>
<given-names>BI</given-names>
</name>
<name name-style="western">
<surname>Choi</surname>
<given-names>YK</given-names>
</name>
<etal />
</person-group>
<article-title>ANXA8 down-regulation by EGF-FOXO4 signaling is involved in cell scattering and tumor metastasis of cholangiocarcinoma</article-title>
<source>Gastroenterology</source>
<year>2009</year>
<volume>137</volume>
<issue>3</issue>
<fpage>1138</fpage>
<lpage>1150</lpage>
<pub-id pub-id-type="doi">10.1053/j.gastro.2009.04.015</pub-id>
<pub-id pub-id-type="pmid">19376120</pub-id>
</element-citation>
</ref>
<ref id="CR110">
<label>110.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western">
<surname>Xu</surname>
<given-names>K</given-names>
</name>
<name name-style="western">
<surname>Pei</surname>
<given-names>H</given-names>
</name>
<name name-style="western">
<surname>Zhang</surname>
<given-names>Z</given-names>
</name>
<name name-style="western">
<surname>Dong</surname>
<given-names>S</given-names>
</name>
<name name-style="western">
<surname>Fu</surname>
<given-names>RJ</given-names>
</name>
<name name-style="western">
<surname>Wang</surname>
<given-names>WM</given-names>
</name>
<etal />
</person-group>
<article-title>FoxO3a mediates glioma cell invasion by regulating MMP9 expression</article-title>
<source>Oncology Reports</source>
<year>2016</year>
<volume>36</volume>
<issue>5</issue>
<fpage>3044</fpage>
<lpage>3050</lpage>
<pub-id pub-id-type="doi">10.3892/or.2016.5087</pub-id>
<pub-id pub-id-type="pmid">27633065</pub-id>
</element-citation>
</ref>
<ref id="CR111">
<label>111.</label>
<mixed-citation publication-type="other">Rothenberg, S. M., Concannon, K., Cullen, S., Boulay, G., Turke, A. B., Faber, A. C., et al. (2015). Inhibition of mutant EGFR in lung cancer cells triggers SOX2-FOXO6-dependent survival pathways. <italic toggle="yes">Elife, 4</italic>. 10.7554/eLife.06132.<pub-id pub-id-type="doi" assigning-authority="pmc">10.7554/eLife.06132</pub-id>
<pub-id pub-id-type="pmcid">PMC4384750</pub-id>
<pub-id pub-id-type="pmid">25686219</pub-id>
</mixed-citation>
</ref>
<ref id="CR112">
<label>112.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western">
<surname>Wang</surname>
<given-names>Y</given-names>
</name>
<name name-style="western">
<surname>Bibi</surname>
<given-names>M</given-names>
</name>
<name name-style="western">
<surname>Min</surname>
<given-names>P</given-names>
</name>
<name name-style="western">
<surname>Deng</surname>
<given-names>W</given-names>
</name>
<name name-style="western">
<surname>Zhang</surname>
<given-names>Y</given-names>
</name>
<name name-style="western">
<surname>Du</surname>
<given-names>J</given-names>
</name>
</person-group>
<article-title>SOX2 promotes hypoxia-induced breast cancer cell migration by inducing NEDD9 expression and subsequent activation of Rac1/HIF-1alpha signaling</article-title>
<source>Cellular &amp; Molecular Biology Letters</source>
<year>2019</year>
<volume>24</volume>
<fpage>55</fpage>
<pub-id pub-id-type="doi">10.1186/s11658-019-0180-y</pub-id>
<pub-id pub-id-type="pmid">31462898</pub-id>
<pub-id pub-id-type="pmcid">PMC6704701</pub-id>
</element-citation>
</ref>
<ref id="CR113">
<label>113.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western">
<surname>Liou</surname>
<given-names>GY</given-names>
</name>
<name name-style="western">
<surname>Storz</surname>
<given-names>P</given-names>
</name>
</person-group>
<article-title>Reactive oxygen species in cancer</article-title>
<source>Free Radical Research</source>
<year>2010</year>
<volume>44</volume>
<issue>5</issue>
<fpage>479</fpage>
<lpage>496</lpage>
<pub-id pub-id-type="doi">10.3109/10715761003667554</pub-id>
<pub-id pub-id-type="pmid">20370557</pub-id>
<pub-id pub-id-type="pmcid">PMC3880197</pub-id>
</element-citation>
</ref>
<ref id="CR114">
<label>114.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western">
<surname>Zorov</surname>
<given-names>DB</given-names>
</name>
<name name-style="western">
<surname>Juhaszova</surname>
<given-names>M</given-names>
</name>
<name name-style="western">
<surname>Sollott</surname>
<given-names>SJ</given-names>
</name>
</person-group>
<article-title>Mitochondrial reactive oxygen species (ROS) and ROS-induced ROS release</article-title>
<source>Physiological Reviews</source>
<year>2014</year>
<volume>94</volume>
<issue>3</issue>
<fpage>909</fpage>
<lpage>950</lpage>
<pub-id pub-id-type="doi">10.1152/physrev.00026.2013</pub-id>
<pub-id pub-id-type="pmid">24987008</pub-id>
<pub-id pub-id-type="pmcid">PMC4101632</pub-id>
</element-citation>
</ref>
<ref id="CR115">
<label>115.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western">
<surname>Candas</surname>
<given-names>D</given-names>
</name>
<name name-style="western">
<surname>Li</surname>
<given-names>JJ</given-names>
</name>
</person-group>
<article-title>MnSOD in oxidative stress response-potential regulation via mitochondrial protein influx</article-title>
<source>Antioxidants &amp; Redox Signaling</source>
<year>2014</year>
<volume>20</volume>
<issue>10</issue>
<fpage>1599</fpage>
<lpage>1617</lpage>
<pub-id pub-id-type="doi">10.1089/ars.2013.5305</pub-id>
<pub-id pub-id-type="pmid">23581847</pub-id>
<pub-id pub-id-type="pmcid">PMC3942709</pub-id>
</element-citation>
</ref>
<ref id="CR116">
<label>116.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western">
<surname>Kops</surname>
<given-names>GJ</given-names>
</name>
<name name-style="western">
<surname>Dansen</surname>
<given-names>TB</given-names>
</name>
<name name-style="western">
<surname>Polderman</surname>
<given-names>PE</given-names>
</name>
<name name-style="western">
<surname>Saarloos</surname>
<given-names>I</given-names>
</name>
<name name-style="western">
<surname>Wirtz</surname>
<given-names>KW</given-names>
</name>
<name name-style="western">
<surname>Coffer</surname>
<given-names>PJ</given-names>
</name>
<etal />
</person-group>
<article-title>Forkhead transcription factor FOXO3a protects quiescent cells from oxidative stress</article-title>
<source>Nature</source>
<year>2002</year>
<volume>419</volume>
<issue>6904</issue>
<fpage>316</fpage>
<lpage>321</lpage>
<pub-id pub-id-type="doi">10.1038/nature01036</pub-id>
<pub-id pub-id-type="pmid">12239572</pub-id>
</element-citation>
</ref>
<ref id="CR117">
<label>117.</label>
<mixed-citation publication-type="other">Beretta, G. L., Corno, C., Zaffaroni, N., &amp; Perego, P. (2019). Role of FoxO proteins in cellular response to antitumor agents. <italic toggle="yes">Cancers (Basel), 11</italic>(1). 10.3390/cancers11010090.<pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/cancers11010090</pub-id>
<pub-id pub-id-type="pmcid">PMC6356788</pub-id>
<pub-id pub-id-type="pmid">30646603</pub-id>
</mixed-citation>
</ref>
<ref id="CR118">
<label>118.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western">
<surname>Essers</surname>
<given-names>MA</given-names>
</name>
<name name-style="western">
<surname>Weijzen</surname>
<given-names>S</given-names>
</name>
<name name-style="western">
<surname>de Vries-Smits</surname>
<given-names>AM</given-names>
</name>
<name name-style="western">
<surname>Saarloos</surname>
<given-names>I</given-names>
</name>
<name name-style="western">
<surname>de Ruiter</surname>
<given-names>ND</given-names>
</name>
<name name-style="western">
<surname>Bos</surname>
<given-names>JL</given-names>
</name>
<etal />
</person-group>
<article-title>FOXO transcription factor activation by oxidative stress mediated by the small GTPase Ral and JNK</article-title>
<source>The EMBO Journal</source>
<year>2004</year>
<volume>23</volume>
<issue>24</issue>
<fpage>4802</fpage>
<lpage>4812</lpage>
<pub-id pub-id-type="doi">10.1038/sj.emboj.7600476</pub-id>
<pub-id pub-id-type="pmid">15538382</pub-id>
<pub-id pub-id-type="pmcid">PMC535088</pub-id>
</element-citation>
</ref>
<ref id="CR119">
<label>119.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western">
<surname>Huang</surname>
<given-names>H</given-names>
</name>
<name name-style="western">
<surname>Tindall</surname>
<given-names>DJ</given-names>
</name>
</person-group>
<article-title>Dynamic FoxO transcription factors</article-title>
<source>Journal of Cell Science</source>
<year>2007</year>
<volume>120</volume>
<issue>Pt 15</issue>
<fpage>2479</fpage>
<lpage>2487</lpage>
<pub-id pub-id-type="doi">10.1242/jcs.001222</pub-id>
<pub-id pub-id-type="pmid">17646672</pub-id>
</element-citation>
</ref>
<ref id="CR120">
<label>120.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western">
<surname>Tikhanovich</surname>
<given-names>I</given-names>
</name>
<name name-style="western">
<surname>Kuravi</surname>
<given-names>S</given-names>
</name>
<name name-style="western">
<surname>Campbell</surname>
<given-names>RV</given-names>
</name>
<name name-style="western">
<surname>Kharbanda</surname>
<given-names>KK</given-names>
</name>
<name name-style="western">
<surname>Artigues</surname>
<given-names>A</given-names>
</name>
<name name-style="western">
<surname>Villar</surname>
<given-names>MT</given-names>
</name>
<etal />
</person-group>
<article-title>Regulation of FOXO3 by phosphorylation and methylation in hepatitis C virus infection and alcohol exposure</article-title>
<source>Hepatology</source>
<year>2014</year>
<volume>59</volume>
<issue>1</issue>
<fpage>58</fpage>
<lpage>70</lpage>
<pub-id pub-id-type="doi">10.1002/hep.26618</pub-id>
<pub-id pub-id-type="pmid">23857333</pub-id>
<pub-id pub-id-type="pmcid">PMC3844049</pub-id>
</element-citation>
</ref>
<ref id="CR121">
<label>121.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western">
<surname>Valis</surname>
<given-names>K</given-names>
</name>
<name name-style="western">
<surname>Prochazka</surname>
<given-names>L</given-names>
</name>
<name name-style="western">
<surname>Boura</surname>
<given-names>E</given-names>
</name>
<name name-style="western">
<surname>Chladova</surname>
<given-names>J</given-names>
</name>
<name name-style="western">
<surname>Obsil</surname>
<given-names>T</given-names>
</name>
<name name-style="western">
<surname>Rohlena</surname>
<given-names>J</given-names>
</name>
<etal />
</person-group>
<article-title>Hippo/Mst1 stimulates transcription of the proapoptotic mediator NOXA in a FoxO1-dependent manner</article-title>
<source>Cancer Research</source>
<year>2011</year>
<volume>71</volume>
<issue>3</issue>
<fpage>946</fpage>
<lpage>954</lpage>
<pub-id pub-id-type="doi">10.1158/0008-5472.CAN-10-2203</pub-id>
<pub-id pub-id-type="pmid">21245099</pub-id>
</element-citation>
</ref>
<ref id="CR122">
<label>122.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western">
<surname>Zhao</surname>
<given-names>Y</given-names>
</name>
<name name-style="western">
<surname>Wang</surname>
<given-names>Y</given-names>
</name>
<name name-style="western">
<surname>Zhu</surname>
<given-names>WG</given-names>
</name>
</person-group>
<article-title>Applications of post-translational modifications of FoxO family proteins in biological functions</article-title>
<source>Journal of Molecular Cell Biology</source>
<year>2011</year>
<volume>3</volume>
<issue>5</issue>
<fpage>276</fpage>
<lpage>282</lpage>
<pub-id pub-id-type="doi">10.1093/jmcb/mjr013</pub-id>
<pub-id pub-id-type="pmid">21669942</pub-id>
</element-citation>
</ref>
<ref id="CR123">
<label>123.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western">
<surname>Lehtinen</surname>
<given-names>MK</given-names>
</name>
<name name-style="western">
<surname>Yuan</surname>
<given-names>Z</given-names>
</name>
<name name-style="western">
<surname>Boag</surname>
<given-names>PR</given-names>
</name>
<name name-style="western">
<surname>Yang</surname>
<given-names>Y</given-names>
</name>
<name name-style="western">
<surname>Villen</surname>
<given-names>J</given-names>
</name>
<name name-style="western">
<surname>Becker</surname>
<given-names>EB</given-names>
</name>
<etal />
</person-group>
<article-title>A conserved MST-FOXO signaling pathway mediates oxidative-stress responses and extends life span</article-title>
<source>Cell</source>
<year>2006</year>
<volume>125</volume>
<issue>5</issue>
<fpage>987</fpage>
<lpage>1001</lpage>
<pub-id pub-id-type="doi">10.1016/j.cell.2006.03.046</pub-id>
<pub-id pub-id-type="pmid">16751106</pub-id>
</element-citation>
</ref>
<ref id="CR124">
<label>124.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western">
<surname>Park</surname>
<given-names>J</given-names>
</name>
<name name-style="western">
<surname>Choi</surname>
<given-names>Y</given-names>
</name>
<name name-style="western">
<surname>Ko</surname>
<given-names>YS</given-names>
</name>
<name name-style="western">
<surname>Kim</surname>
<given-names>Y</given-names>
</name>
<name name-style="western">
<surname>Pyo</surname>
<given-names>JS</given-names>
</name>
<name name-style="western">
<surname>Jang</surname>
<given-names>BG</given-names>
</name>
<etal />
</person-group>
<article-title>FOXO1 suppression is a determinant of acquired lapatinib-resistance in HER2-positive gastric cancer cells through MET upregulation</article-title>
<source>Cancer Research and Treatment</source>
<year>2018</year>
<volume>50</volume>
<issue>1</issue>
<fpage>239</fpage>
<lpage>254</lpage>
<pub-id pub-id-type="doi">10.4143/crt.2016.580</pub-id>
<pub-id pub-id-type="pmid">28343375</pub-id>
<pub-id pub-id-type="pmcid">PMC5784629</pub-id>
</element-citation>
</ref>
<ref id="CR125">
<label>125.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western">
<surname>Ruiz-Saenz</surname>
<given-names>A</given-names>
</name>
<name name-style="western">
<surname>Dreyer</surname>
<given-names>C</given-names>
</name>
<name name-style="western">
<surname>Campbell</surname>
<given-names>MR</given-names>
</name>
<name name-style="western">
<surname>Steri</surname>
<given-names>V</given-names>
</name>
<name name-style="western">
<surname>Gulizia</surname>
<given-names>N</given-names>
</name>
<name name-style="western">
<surname>Moasser</surname>
<given-names>MM</given-names>
</name>
</person-group>
<article-title>HER2 amplification in tumors activates PI3K/Akt signaling independent of HER3</article-title>
<source>Cancer Research</source>
<year>2018</year>
<volume>78</volume>
<issue>13</issue>
<fpage>3645</fpage>
<lpage>3658</lpage>
<pub-id pub-id-type="doi">10.1158/0008-5472.CAN-18-0430</pub-id>
<pub-id pub-id-type="pmid">29760043</pub-id>
<pub-id pub-id-type="pmcid">PMC6779043</pub-id>
</element-citation>
</ref>
<ref id="CR126">
<label>126.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western">
<surname>McGovern</surname>
<given-names>UB</given-names>
</name>
<name name-style="western">
<surname>Francis</surname>
<given-names>RE</given-names>
</name>
<name name-style="western">
<surname>Peck</surname>
<given-names>B</given-names>
</name>
<name name-style="western">
<surname>Guest</surname>
<given-names>SK</given-names>
</name>
<name name-style="western">
<surname>Wang</surname>
<given-names>J</given-names>
</name>
<name name-style="western">
<surname>Myatt</surname>
<given-names>SS</given-names>
</name>
<etal />
</person-group>
<article-title>Gefitinib (Iressa) represses FOXM1 expression via FOXO3a in breast cancer</article-title>
<source>Molecular Cancer Therapeutics</source>
<year>2009</year>
<volume>8</volume>
<issue>3</issue>
<fpage>582</fpage>
<lpage>591</lpage>
<pub-id pub-id-type="doi">10.1158/1535-7163.MCT-08-0805</pub-id>
<pub-id pub-id-type="pmid">19276163</pub-id>
</element-citation>
</ref>
<ref id="CR127">
<label>127.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western">
<surname>Krol</surname>
<given-names>J</given-names>
</name>
<name name-style="western">
<surname>Francis</surname>
<given-names>RE</given-names>
</name>
<name name-style="western">
<surname>Albergaria</surname>
<given-names>A</given-names>
</name>
<name name-style="western">
<surname>Sunters</surname>
<given-names>A</given-names>
</name>
<name name-style="western">
<surname>Polychronis</surname>
<given-names>A</given-names>
</name>
<name name-style="western">
<surname>Coombes</surname>
<given-names>RC</given-names>
</name>
<etal />
</person-group>
<article-title>The transcription factor FOXO3a is a crucial cellular target of gefitinib (Iressa) in breast cancer cells</article-title>
<source>Molecular Cancer Therapeutics</source>
<year>2007</year>
<volume>6</volume>
<issue>12 Pt 1</issue>
<fpage>3169</fpage>
<lpage>3179</lpage>
<pub-id pub-id-type="doi">10.1158/1535-7163.MCT-07-0507</pub-id>
<pub-id pub-id-type="pmid">18089711</pub-id>
</element-citation>
</ref>
<ref id="CR128">
<label>128.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western">
<surname>Xia</surname>
<given-names>W</given-names>
</name>
<name name-style="western">
<surname>Bacus</surname>
<given-names>S</given-names>
</name>
<name name-style="western">
<surname>Hegde</surname>
<given-names>P</given-names>
</name>
<name name-style="western">
<surname>Husain</surname>
<given-names>I</given-names>
</name>
<name name-style="western">
<surname>Strum</surname>
<given-names>J</given-names>
</name>
<name name-style="western">
<surname>Liu</surname>
<given-names>L</given-names>
</name>
<etal />
</person-group>
<article-title>A model of acquired autoresistance to a potent ErbB2 tyrosine kinase inhibitor and a therapeutic strategy to prevent its onset in breast cancer</article-title>
<source>Proceedings of the National Academy of Sciences of the United States of America</source>
<year>2006</year>
<volume>103</volume>
<issue>20</issue>
<fpage>7795</fpage>
<lpage>7800</lpage>
<pub-id pub-id-type="doi">10.1073/pnas.0602468103</pub-id>
<pub-id pub-id-type="pmid">16682622</pub-id>
<pub-id pub-id-type="pmcid">PMC1472524</pub-id>
</element-citation>
</ref>
<ref id="CR129">
<label>129.</label>
<mixed-citation publication-type="other">Mahmud, Z., Gomes, A. R., Lee, H. J., Aimjongjun, S., Jiramongkol, Y., Yao, S., et al. (2019). EP300 and SIRT1/6 co-regulate lapatinib sensitivity via modulating FOXO3-acetylation and activity in breast cancer. <italic toggle="yes">Cancers (Basel), 11</italic>(8). 10.3390/cancers11081067.<pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/cancers11081067</pub-id>
<pub-id pub-id-type="pmcid">PMC6721388</pub-id>
<pub-id pub-id-type="pmid">31357743</pub-id>
</mixed-citation>
</ref>
<ref id="CR130">
<label>130.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western">
<surname>D’Alessio</surname>
<given-names>A</given-names>
</name>
<name name-style="western">
<surname>De Luca</surname>
<given-names>A</given-names>
</name>
<name name-style="western">
<surname>Maiello</surname>
<given-names>MR</given-names>
</name>
<name name-style="western">
<surname>Lamura</surname>
<given-names>L</given-names>
</name>
<name name-style="western">
<surname>Rachiglio</surname>
<given-names>AM</given-names>
</name>
<name name-style="western">
<surname>Napolitano</surname>
<given-names>M</given-names>
</name>
<etal />
</person-group>
<article-title>Effects of the combined blockade of EGFR and ErbB-2 on signal transduction and regulation of cell cycle regulatory proteins in breast cancer cells</article-title>
<source>Breast Cancer Research and Treatment</source>
<year>2010</year>
<volume>123</volume>
<issue>2</issue>
<fpage>387</fpage>
<lpage>396</lpage>
<pub-id pub-id-type="doi">10.1007/s10549-009-0649-x</pub-id>
<pub-id pub-id-type="pmid">19946741</pub-id>
</element-citation>
</ref>
<ref id="CR131">
<label>131.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western">
<surname>Coombes</surname>
<given-names>RC</given-names>
</name>
<name name-style="western">
<surname>Tat</surname>
<given-names>T</given-names>
</name>
<name name-style="western">
<surname>Miller</surname>
<given-names>ML</given-names>
</name>
<name name-style="western">
<surname>Reise</surname>
<given-names>JA</given-names>
</name>
<name name-style="western">
<surname>Mansi</surname>
<given-names>JL</given-names>
</name>
<name name-style="western">
<surname>Hadjiminas</surname>
<given-names>DJ</given-names>
</name>
<etal />
</person-group>
<article-title>An open-label study of lapatinib in women with HER-2-negative early breast cancer: the lapatinib pre-surgical study (LPS study)</article-title>
<source>Annals of Oncology</source>
<year>2013</year>
<volume>24</volume>
<issue>4</issue>
<fpage>924</fpage>
<lpage>930</lpage>
<pub-id pub-id-type="doi">10.1093/annonc/mds594</pub-id>
<pub-id pub-id-type="pmid">23233650</pub-id>
</element-citation>
</ref>
<ref id="CR132">
<label>132.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western">
<surname>Aimjongjun</surname>
<given-names>S</given-names>
</name>
<name name-style="western">
<surname>Mahmud</surname>
<given-names>Z</given-names>
</name>
<name name-style="western">
<surname>Jiramongkol</surname>
<given-names>Y</given-names>
</name>
<name name-style="western">
<surname>Alasiri</surname>
<given-names>G</given-names>
</name>
<name name-style="western">
<surname>Yao</surname>
<given-names>S</given-names>
</name>
<name name-style="western">
<surname>Yague</surname>
<given-names>E</given-names>
</name>
<etal />
</person-group>
<article-title>Lapatinib sensitivity in nasopharyngeal carcinoma is modulated by SIRT2-mediated FOXO3 deacetylation</article-title>
<source>BMC Cancer</source>
<year>2019</year>
<volume>19</volume>
<issue>1</issue>
<fpage>1106</fpage>
<pub-id pub-id-type="doi">10.1186/s12885-019-6308-7</pub-id>
<pub-id pub-id-type="pmid">31727006</pub-id>
<pub-id pub-id-type="pmcid">PMC6854897</pub-id>
</element-citation>
</ref>
<ref id="CR133">
<label>133.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western">
<surname>Choi</surname>
<given-names>Y</given-names>
</name>
<name name-style="western">
<surname>Ko</surname>
<given-names>YS</given-names>
</name>
<name name-style="western">
<surname>Park</surname>
<given-names>J</given-names>
</name>
<name name-style="western">
<surname>Choi</surname>
<given-names>Y</given-names>
</name>
<name name-style="western">
<surname>Kim</surname>
<given-names>Y</given-names>
</name>
<name name-style="western">
<surname>Pyo</surname>
<given-names>JS</given-names>
</name>
<etal />
</person-group>
<article-title>HER2-induced metastasis is mediated by AKT/JNK/EMT signaling pathway in gastric cancer</article-title>
<source>World Journal of Gastroenterology</source>
<year>2016</year>
<volume>22</volume>
<issue>41</issue>
<fpage>9141</fpage>
<lpage>9153</lpage>
<pub-id pub-id-type="doi">10.3748/wjg.v22.i41.9141</pub-id>
<pub-id pub-id-type="pmid">27895401</pub-id>
<pub-id pub-id-type="pmcid">PMC5107595</pub-id>
</element-citation>
</ref>
<ref id="CR134">
<label>134.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western">
<surname>Asada</surname>
<given-names>S</given-names>
</name>
<name name-style="western">
<surname>Daitoku</surname>
<given-names>H</given-names>
</name>
<name name-style="western">
<surname>Matsuzaki</surname>
<given-names>H</given-names>
</name>
<name name-style="western">
<surname>Saito</surname>
<given-names>T</given-names>
</name>
<name name-style="western">
<surname>Sudo</surname>
<given-names>T</given-names>
</name>
<name name-style="western">
<surname>Mukai</surname>
<given-names>H</given-names>
</name>
<etal />
</person-group>
<article-title>Mitogen-activated protein kinases, Erk and p38, phosphorylate and regulate Foxo1</article-title>
<source>Cellular Signalling</source>
<year>2007</year>
<volume>19</volume>
<issue>3</issue>
<fpage>519</fpage>
<lpage>527</lpage>
<pub-id pub-id-type="doi">10.1016/j.cellsig.2006.08.015</pub-id>
<pub-id pub-id-type="pmid">17113751</pub-id>
</element-citation>
</ref>
<ref id="CR135">
<label>135.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western">
<surname>Torres</surname>
<given-names>M</given-names>
</name>
<name name-style="western">
<surname>Forman</surname>
<given-names>HJ</given-names>
</name>
</person-group>
<article-title>Redox signaling and the MAP kinase pathways</article-title>
<source>Biofactors</source>
<year>2003</year>
<volume>17</volume>
<issue>1–4</issue>
<fpage>287</fpage>
<lpage>296</lpage>
<pub-id pub-id-type="doi">10.1002/biof.5520170128</pub-id>
<pub-id pub-id-type="pmid">12897450</pub-id>
</element-citation>
</ref>
<ref id="CR136">
<label>136.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western">
<surname>Caunt</surname>
<given-names>CJ</given-names>
</name>
<name name-style="western">
<surname>Keyse</surname>
<given-names>SM</given-names>
</name>
</person-group>
<article-title>Dual-specificity MAP kinase phosphatases (MKPs): shaping the outcome of MAP kinase signalling</article-title>
<source>The FEBS Journal</source>
<year>2013</year>
<volume>280</volume>
<issue>2</issue>
<fpage>489</fpage>
<lpage>504</lpage>
<pub-id pub-id-type="doi">10.1111/j.1742-4658.2012.08716.x</pub-id>
<pub-id pub-id-type="pmid">22812510</pub-id>
<pub-id pub-id-type="pmcid">PMC3594966</pub-id>
</element-citation>
</ref>
<ref id="CR137">
<label>137.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western">
<surname>Melhem</surname>
<given-names>A</given-names>
</name>
<name name-style="western">
<surname>Yamada</surname>
<given-names>SD</given-names>
</name>
<name name-style="western">
<surname>Fleming</surname>
<given-names>GF</given-names>
</name>
<name name-style="western">
<surname>Delgado</surname>
<given-names>B</given-names>
</name>
<name name-style="western">
<surname>Brickley</surname>
<given-names>DR</given-names>
</name>
<name name-style="western">
<surname>Wu</surname>
<given-names>W</given-names>
</name>
<etal />
</person-group>
<article-title>Administration of glucocorticoids to ovarian cancer patients is associated with expression of the anti-apoptotic genes SGK1 and MKP1/DUSP1 in ovarian tissues</article-title>
<source>Clinical Cancer Research</source>
<year>2009</year>
<volume>15</volume>
<issue>9</issue>
<fpage>3196</fpage>
<lpage>3204</lpage>
<pub-id pub-id-type="doi">10.1158/1078-0432.CCR-08-2131</pub-id>
<pub-id pub-id-type="pmid">19383827</pub-id>
<pub-id pub-id-type="pmcid">PMC4707040</pub-id>
</element-citation>
</ref>
<ref id="CR138">
<label>138.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western">
<surname>Wu</surname>
<given-names>Z</given-names>
</name>
<name name-style="western">
<surname>Jiao</surname>
<given-names>P</given-names>
</name>
<name name-style="western">
<surname>Huang</surname>
<given-names>X</given-names>
</name>
<name name-style="western">
<surname>Feng</surname>
<given-names>B</given-names>
</name>
<name name-style="western">
<surname>Feng</surname>
<given-names>Y</given-names>
</name>
<name name-style="western">
<surname>Yang</surname>
<given-names>S</given-names>
</name>
<etal />
</person-group>
<article-title>MAPK phosphatase-3 promotes hepatic gluconeogenesis through dephosphorylation of forkhead box O1 in mice</article-title>
<source>The Journal of Clinical Investigation</source>
<year>2010</year>
<volume>120</volume>
<issue>11</issue>
<fpage>3901</fpage>
<lpage>3911</lpage>
<pub-id pub-id-type="doi">10.1172/JCI43250</pub-id>
<pub-id pub-id-type="pmid">20921625</pub-id>
<pub-id pub-id-type="pmcid">PMC2964981</pub-id>
</element-citation>
</ref>
<ref id="CR139">
<label>139.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western">
<surname>Wang</surname>
<given-names>Z</given-names>
</name>
<name name-style="western">
<surname>Dong</surname>
<given-names>C</given-names>
</name>
</person-group>
<article-title>Gluconeogenesis in cancer: function and regulation of PEPCK, FBPase, and G6Pase</article-title>
<source>Trends in Cancer</source>
<year>2019</year>
<volume>5</volume>
<issue>1</issue>
<fpage>30</fpage>
<lpage>45</lpage>
<pub-id pub-id-type="doi">10.1016/j.trecan.2018.11.003</pub-id>
<pub-id pub-id-type="pmid">30616754</pub-id>
</element-citation>
</ref>
<ref id="CR140">
<label>140.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western">
<surname>Buchheit</surname>
<given-names>CL</given-names>
</name>
<name name-style="western">
<surname>Weigel</surname>
<given-names>KJ</given-names>
</name>
<name name-style="western">
<surname>Schafer</surname>
<given-names>ZT</given-names>
</name>
</person-group>
<article-title>Cancer cell survival during detachment from the ECM: multiple barriers to tumour progression</article-title>
<source>Nature Reviews. Cancer</source>
<year>2014</year>
<volume>14</volume>
<issue>9</issue>
<fpage>632</fpage>
<lpage>641</lpage>
<pub-id pub-id-type="doi">10.1038/nrc3789</pub-id>
<pub-id pub-id-type="pmid">25098270</pub-id>
</element-citation>
</ref>
<ref id="CR141">
<label>141.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western">
<surname>Paoli</surname>
<given-names>P</given-names>
</name>
<name name-style="western">
<surname>Giannoni</surname>
<given-names>E</given-names>
</name>
<name name-style="western">
<surname>Chiarugi</surname>
<given-names>P</given-names>
</name>
</person-group>
<article-title>Anoikis molecular pathways and its role in cancer progression</article-title>
<source>Biochimica et Biophysica Acta</source>
<year>2013</year>
<volume>1833</volume>
<issue>12</issue>
<fpage>3481</fpage>
<lpage>3498</lpage>
<pub-id pub-id-type="doi">10.1016/j.bbamcr.2013.06.026</pub-id>
<pub-id pub-id-type="pmid">23830918</pub-id>
</element-citation>
</ref>
<ref id="CR142">
<label>142.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western">
<surname>Hornsveld</surname>
<given-names>M</given-names>
</name>
<name name-style="western">
<surname>Tenhagen</surname>
<given-names>M</given-names>
</name>
<name name-style="western">
<surname>van de Ven</surname>
<given-names>RA</given-names>
</name>
<name name-style="western">
<surname>Smits</surname>
<given-names>AM</given-names>
</name>
<name name-style="western">
<surname>van Triest</surname>
<given-names>MH</given-names>
</name>
<name name-style="western">
<surname>van Amersfoort</surname>
<given-names>M</given-names>
</name>
<etal />
</person-group>
<article-title>Restraining FOXO3-dependent transcriptional BMF activation underpins tumour growth and metastasis of E-cadherin-negative breast cancer</article-title>
<source>Cell Death and Differentiation</source>
<year>2016</year>
<volume>23</volume>
<issue>9</issue>
<fpage>1483</fpage>
<lpage>1492</lpage>
<pub-id pub-id-type="doi">10.1038/cdd.2016.33</pub-id>
<pub-id pub-id-type="pmid">27035620</pub-id>
<pub-id pub-id-type="pmcid">PMC5072425</pub-id>
</element-citation>
</ref>
<ref id="CR143">
<label>143.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western">
<surname>Behren</surname>
<given-names>A</given-names>
</name>
<name name-style="western">
<surname>Muhlen</surname>
<given-names>S</given-names>
</name>
<name name-style="western">
<surname>Acuna Sanhueza</surname>
<given-names>GA</given-names>
</name>
<name name-style="western">
<surname>Schwager</surname>
<given-names>C</given-names>
</name>
<name name-style="western">
<surname>Plinkert</surname>
<given-names>PK</given-names>
</name>
<name name-style="western">
<surname>Huber</surname>
<given-names>PE</given-names>
</name>
<etal />
</person-group>
<article-title>Phenotype-assisted transcriptome analysis identifies FOXM1 downstream from Ras-MKK3-p38 to regulate in vitro cellular invasion</article-title>
<source>Oncogene</source>
<year>2010</year>
<volume>29</volume>
<issue>10</issue>
<fpage>1519</fpage>
<lpage>1530</lpage>
<pub-id pub-id-type="doi">10.1038/onc.2009.436</pub-id>
<pub-id pub-id-type="pmid">20023695</pub-id>
</element-citation>
</ref>
<ref id="CR144">
<label>144.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western">
<surname>Demuth</surname>
<given-names>T</given-names>
</name>
<name name-style="western">
<surname>Reavie</surname>
<given-names>LB</given-names>
</name>
<name name-style="western">
<surname>Rennert</surname>
<given-names>JL</given-names>
</name>
<name name-style="western">
<surname>Nakada</surname>
<given-names>M</given-names>
</name>
<name name-style="western">
<surname>Nakada</surname>
<given-names>S</given-names>
</name>
<name name-style="western">
<surname>Hoelzinger</surname>
<given-names>DB</given-names>
</name>
<etal />
</person-group>
<article-title>MAP-ing glioma invasion: mitogen-activated protein kinase kinase 3 and p38 drive glioma invasion and progression and predict patient survival</article-title>
<source>Molecular Cancer Therapeutics</source>
<year>2007</year>
<volume>6</volume>
<issue>4</issue>
<fpage>1212</fpage>
<lpage>1222</lpage>
<pub-id pub-id-type="doi">10.1158/1535-7163.MCT-06-0711</pub-id>
<pub-id pub-id-type="pmid">17406030</pub-id>
</element-citation>
</ref>
<ref id="CR145">
<label>145.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western">
<surname>Hickson</surname>
<given-names>JA</given-names>
</name>
<name name-style="western">
<surname>Huo</surname>
<given-names>D</given-names>
</name>
<name name-style="western">
<surname>Vander Griend</surname>
<given-names>DJ</given-names>
</name>
<name name-style="western">
<surname>Lin</surname>
<given-names>A</given-names>
</name>
<name name-style="western">
<surname>Rinker-Schaeffer</surname>
<given-names>CW</given-names>
</name>
<name name-style="western">
<surname>Yamada</surname>
<given-names>SD</given-names>
</name>
</person-group>
<article-title>The p38 kinases MKK4 and MKK6 suppress metastatic colonization in human ovarian carcinoma</article-title>
<source>Cancer Research</source>
<year>2006</year>
<volume>66</volume>
<issue>4</issue>
<fpage>2264</fpage>
<lpage>2270</lpage>
<pub-id pub-id-type="doi">10.1158/0008-5472.CAN-05-3676</pub-id>
<pub-id pub-id-type="pmid">16489030</pub-id>
</element-citation>
</ref>
<ref id="CR146">
<label>146.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western">
<surname>Procaccia</surname>
<given-names>S</given-names>
</name>
<name name-style="western">
<surname>Ordan</surname>
<given-names>M</given-names>
</name>
<name name-style="western">
<surname>Cohen</surname>
<given-names>I</given-names>
</name>
<name name-style="western">
<surname>Bendetz-Nezer</surname>
<given-names>S</given-names>
</name>
<name name-style="western">
<surname>Seger</surname>
<given-names>R</given-names>
</name>
</person-group>
<article-title>Direct binding of MEK1 and MEK2 to AKT induces Foxo1 phosphorylation, cellular migration and metastasis</article-title>
<source>Scientific Reports</source>
<year>2017</year>
<volume>7</volume>
<fpage>43078</fpage>
<pub-id pub-id-type="doi">10.1038/srep43078</pub-id>
<pub-id pub-id-type="pmid">28225038</pub-id>
<pub-id pub-id-type="pmcid">PMC5320536</pub-id>
</element-citation>
</ref>
<ref id="CR147">
<label>147.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western">
<surname>Roy</surname>
<given-names>SK</given-names>
</name>
<name name-style="western">
<surname>Srivastava</surname>
<given-names>RK</given-names>
</name>
<name name-style="western">
<surname>Shankar</surname>
<given-names>S</given-names>
</name>
</person-group>
<article-title>Inhibition of PI3K/AKT and MAPK/ERK pathways causes activation of FOXO transcription factor, leading to cell cycle arrest and apoptosis in pancreatic cancer</article-title>
<source>Journal of Molecular Signaling</source>
<year>2010</year>
<volume>5</volume>
<fpage>10</fpage>
<pub-id pub-id-type="doi">10.1186/1750-2187-5-10</pub-id>
<pub-id pub-id-type="pmid">20642839</pub-id>
<pub-id pub-id-type="pmcid">PMC2915986</pub-id>
</element-citation>
</ref>
<ref id="CR148">
<label>148.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western">
<surname>Wang</surname>
<given-names>X</given-names>
</name>
<name name-style="western">
<surname>Chen</surname>
<given-names>WR</given-names>
</name>
<name name-style="western">
<surname>Xing</surname>
<given-names>D</given-names>
</name>
</person-group>
<article-title>A pathway from JNK through decreased ERK and Akt activities for FOXO3a nuclear translocation in response to UV irradiation</article-title>
<source>Journal of Cellular Physiology</source>
<year>2012</year>
<volume>227</volume>
<issue>3</issue>
<fpage>1168</fpage>
<lpage>1178</lpage>
<pub-id pub-id-type="doi">10.1002/jcp.22839</pub-id>
<pub-id pub-id-type="pmid">21604264</pub-id>
</element-citation>
</ref>
<ref id="CR149">
<label>149.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western">
<surname>Shin</surname>
<given-names>S</given-names>
</name>
<name name-style="western">
<surname>Buel</surname>
<given-names>GR</given-names>
</name>
<name name-style="western">
<surname>Nagiec</surname>
<given-names>MJ</given-names>
</name>
<name name-style="western">
<surname>Han</surname>
<given-names>MJ</given-names>
</name>
<name name-style="western">
<surname>Roux</surname>
<given-names>PP</given-names>
</name>
<name name-style="western">
<surname>Blenis</surname>
<given-names>J</given-names>
</name>
<etal />
</person-group>
<article-title>ERK2 regulates epithelial-to-mesenchymal plasticity through DOCK10-dependent Rac1/FoxO1 activation</article-title>
<source>Proceedings of the National Academy of Sciences of the United States of America</source>
<year>2019</year>
<volume>116</volume>
<issue>8</issue>
<fpage>2967</fpage>
<lpage>2976</lpage>
<pub-id pub-id-type="doi">10.1073/pnas.1811923116</pub-id>
<pub-id pub-id-type="pmid">30728292</pub-id>
<pub-id pub-id-type="pmcid">PMC6386703</pub-id>
</element-citation>
</ref>
<ref id="CR150">
<label>150.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western">
<surname>Ho</surname>
<given-names>KK</given-names>
</name>
<name name-style="western">
<surname>McGuire</surname>
<given-names>VA</given-names>
</name>
<name name-style="western">
<surname>Koo</surname>
<given-names>CY</given-names>
</name>
<name name-style="western">
<surname>Muir</surname>
<given-names>KW</given-names>
</name>
<name name-style="western">
<surname>de Olano</surname>
<given-names>N</given-names>
</name>
<name name-style="western">
<surname>Maifoshie</surname>
<given-names>E</given-names>
</name>
<etal />
</person-group>
<article-title>Phosphorylation of FOXO3a on Ser-7 by p38 promotes its nuclear localization in response to doxorubicin</article-title>
<source>The Journal of Biological Chemistry</source>
<year>2012</year>
<volume>287</volume>
<issue>2</issue>
<fpage>1545</fpage>
<lpage>1555</lpage>
<pub-id pub-id-type="doi">10.1074/jbc.M111.284224</pub-id>
<pub-id pub-id-type="pmid">22128155</pub-id>
<pub-id pub-id-type="pmcid">PMC3256863</pub-id>
</element-citation>
</ref>
<ref id="CR151">
<label>151.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western">
<surname>Marzi</surname>
<given-names>L</given-names>
</name>
<name name-style="western">
<surname>Combes</surname>
<given-names>E</given-names>
</name>
<name name-style="western">
<surname>Vie</surname>
<given-names>N</given-names>
</name>
<name name-style="western">
<surname>Ayrolles-Torro</surname>
<given-names>A</given-names>
</name>
<name name-style="western">
<surname>Tosi</surname>
<given-names>D</given-names>
</name>
<name name-style="western">
<surname>Desigaud</surname>
<given-names>D</given-names>
</name>
<etal />
</person-group>
<article-title>FOXO3a and the MAPK p38 are activated by cetuximab to induce cell death and inhibit cell proliferation and their expression predicts cetuximab efficacy in colorectal cancer</article-title>
<source>British Journal of Cancer</source>
<year>2016</year>
<volume>115</volume>
<issue>10</issue>
<fpage>1223</fpage>
<lpage>1233</lpage>
<pub-id pub-id-type="doi">10.1038/bjc.2016.313</pub-id>
<pub-id pub-id-type="pmid">27685445</pub-id>
<pub-id pub-id-type="pmcid">PMC5104890</pub-id>
</element-citation>
</ref>
<ref id="CR152">
<label>152.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western">
<surname>Liu</surname>
<given-names>CY</given-names>
</name>
<name name-style="western">
<surname>Kaufman</surname>
<given-names>RJ</given-names>
</name>
</person-group>
<article-title>The unfolded protein response</article-title>
<source>Journal of Cell Science</source>
<year>2003</year>
<volume>116</volume>
<issue>Pt 10</issue>
<fpage>1861</fpage>
<lpage>1862</lpage>
<pub-id pub-id-type="doi">10.1242/jcs.00408</pub-id>
<pub-id pub-id-type="pmid">12692187</pub-id>
</element-citation>
</ref>
<ref id="CR153">
<label>153.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western">
<surname>Alasiri</surname>
<given-names>G</given-names>
</name>
<name name-style="western">
<surname>Fan</surname>
<given-names>LY</given-names>
</name>
<name name-style="western">
<surname>Zona</surname>
<given-names>S</given-names>
</name>
<name name-style="western">
<surname>Goldsbrough</surname>
<given-names>IG</given-names>
</name>
<name name-style="western">
<surname>Ke</surname>
<given-names>HL</given-names>
</name>
<name name-style="western">
<surname>Auner</surname>
<given-names>HW</given-names>
</name>
<etal />
</person-group>
<article-title>ER stress and cancer: the FOXO forkhead transcription factor link</article-title>
<source>Molecular and Cellular Endocrinology</source>
<year>2018</year>
<volume>462</volume>
<issue>Pt B</issue>
<fpage>67</fpage>
<lpage>81</lpage>
<pub-id pub-id-type="doi">10.1016/j.mce.2017.05.027</pub-id>
<pub-id pub-id-type="pmid">28572047</pub-id>
</element-citation>
</ref>
<ref id="CR154">
<label>154.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western">
<surname>Zhang</surname>
<given-names>W</given-names>
</name>
<name name-style="western">
<surname>Hietakangas</surname>
<given-names>V</given-names>
</name>
<name name-style="western">
<surname>Wee</surname>
<given-names>S</given-names>
</name>
<name name-style="western">
<surname>Lim</surname>
<given-names>SC</given-names>
</name>
<name name-style="western">
<surname>Gunaratne</surname>
<given-names>J</given-names>
</name>
<name name-style="western">
<surname>Cohen</surname>
<given-names>SM</given-names>
</name>
</person-group>
<article-title>ER stress potentiates insulin resistance through PERK-mediated FOXO phosphorylation</article-title>
<source>Genes &amp; Development</source>
<year>2013</year>
<volume>27</volume>
<issue>4</issue>
<fpage>441</fpage>
<lpage>449</lpage>
<pub-id pub-id-type="doi">10.1101/gad.201731.112</pub-id>
<pub-id pub-id-type="pmid">23431056</pub-id>
<pub-id pub-id-type="pmcid">PMC3589560</pub-id>
</element-citation>
</ref>
<ref id="CR155">
<label>155.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western">
<surname>Alasiri</surname>
<given-names>G</given-names>
</name>
<name name-style="western">
<surname>Jiramongkol</surname>
<given-names>Y</given-names>
</name>
<name name-style="western">
<surname>Zona</surname>
<given-names>S</given-names>
</name>
<name name-style="western">
<surname>Fan</surname>
<given-names>LY</given-names>
</name>
<name name-style="western">
<surname>Mahmud</surname>
<given-names>Z</given-names>
</name>
<name name-style="western">
<surname>Gong</surname>
<given-names>G</given-names>
</name>
<etal />
</person-group>
<article-title>Regulation of PERK expression by FOXO3: a vulnerability of drug-resistant cancer cells</article-title>
<source>Oncogene</source>
<year>2019</year>
<volume>38</volume>
<issue>36</issue>
<fpage>6382</fpage>
<lpage>6398</lpage>
<pub-id pub-id-type="doi">10.1038/s41388-019-0890-7</pub-id>
<pub-id pub-id-type="pmid">31312024</pub-id>
<pub-id pub-id-type="pmcid">PMC6756075</pub-id>
</element-citation>
</ref>
<ref id="CR156">
<label>156.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western">
<surname>Huang</surname>
<given-names>H</given-names>
</name>
<name name-style="western">
<surname>Regan</surname>
<given-names>KM</given-names>
</name>
<name name-style="western">
<surname>Wang</surname>
<given-names>F</given-names>
</name>
<name name-style="western">
<surname>Wang</surname>
<given-names>D</given-names>
</name>
<name name-style="western">
<surname>Smith</surname>
<given-names>DI</given-names>
</name>
<name name-style="western">
<surname>van Deursen</surname>
<given-names>JM</given-names>
</name>
<etal />
</person-group>
<article-title>Skp2 inhibits FOXO1 in tumor suppression through ubiquitin-mediated degradation</article-title>
<source>Proceedings of the National Academy of Sciences of the United States of America</source>
<year>2005</year>
<volume>102</volume>
<issue>5</issue>
<fpage>1649</fpage>
<lpage>1654</lpage>
<pub-id pub-id-type="doi">10.1073/pnas.0406789102</pub-id>
<pub-id pub-id-type="pmid">15668399</pub-id>
<pub-id pub-id-type="pmcid">PMC545492</pub-id>
</element-citation>
</ref>
<ref id="CR157">
<label>157.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western">
<surname>Wu</surname>
<given-names>J</given-names>
</name>
<name name-style="western">
<surname>Lee</surname>
<given-names>SW</given-names>
</name>
<name name-style="western">
<surname>Zhang</surname>
<given-names>X</given-names>
</name>
<name name-style="western">
<surname>Han</surname>
<given-names>F</given-names>
</name>
<name name-style="western">
<surname>Kwan</surname>
<given-names>SY</given-names>
</name>
<name name-style="western">
<surname>Yuan</surname>
<given-names>X</given-names>
</name>
<etal />
</person-group>
<article-title>Foxo3a transcription factor is a negative regulator of Skp2 and Skp2 SCF complex</article-title>
<source>Oncogene</source>
<year>2013</year>
<volume>32</volume>
<issue>1</issue>
<fpage>78</fpage>
<lpage>85</lpage>
<pub-id pub-id-type="doi">10.1038/onc.2012.26</pub-id>
<pub-id pub-id-type="pmid">22310285</pub-id>
<pub-id pub-id-type="pmcid">PMC3536937</pub-id>
</element-citation>
</ref>
<ref id="CR158">
<label>158.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western">
<surname>Fu</surname>
<given-names>W</given-names>
</name>
<name name-style="western">
<surname>Ma</surname>
<given-names>Q</given-names>
</name>
<name name-style="western">
<surname>Chen</surname>
<given-names>L</given-names>
</name>
<name name-style="western">
<surname>Li</surname>
<given-names>P</given-names>
</name>
<name name-style="western">
<surname>Zhang</surname>
<given-names>M</given-names>
</name>
<name name-style="western">
<surname>Ramamoorthy</surname>
<given-names>S</given-names>
</name>
<etal />
</person-group>
<article-title>MDM2 acts downstream of p53 as an E3 ligase to promote FOXO ubiquitination and degradation</article-title>
<source>The Journal of Biological Chemistry</source>
<year>2009</year>
<volume>284</volume>
<issue>21</issue>
<fpage>13987</fpage>
<lpage>14000</lpage>
<pub-id pub-id-type="doi">10.1074/jbc.M901758200</pub-id>
<pub-id pub-id-type="pmid">19321440</pub-id>
<pub-id pub-id-type="pmcid">PMC2682847</pub-id>
</element-citation>
</ref>
<ref id="CR159">
<label>159.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western">
<surname>Yang</surname>
<given-names>W</given-names>
</name>
<name name-style="western">
<surname>Dolloff</surname>
<given-names>NG</given-names>
</name>
<name name-style="western">
<surname>El-Deiry</surname>
<given-names>WS</given-names>
</name>
</person-group>
<article-title>ERK and MDM2 prey on FOXO3a</article-title>
<source>Nature Cell Biology</source>
<year>2008</year>
<volume>10</volume>
<issue>2</issue>
<fpage>125</fpage>
<lpage>126</lpage>
<pub-id pub-id-type="doi">10.1038/ncb0208-125</pub-id>
<pub-id pub-id-type="pmid">18246039</pub-id>
</element-citation>
</ref>
<ref id="CR160">
<label>160.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western">
<surname>van der Horst</surname>
<given-names>A</given-names>
</name>
<name name-style="western">
<surname>de Vries-Smits</surname>
<given-names>AM</given-names>
</name>
<name name-style="western">
<surname>Brenkman</surname>
<given-names>AB</given-names>
</name>
<name name-style="western">
<surname>van Triest</surname>
<given-names>MH</given-names>
</name>
<name name-style="western">
<surname>van den Broek</surname>
<given-names>N</given-names>
</name>
<name name-style="western">
<surname>Colland</surname>
<given-names>F</given-names>
</name>
<etal />
</person-group>
<article-title>FOXO4 transcriptional activity is regulated by monoubiquitination and USP7/HAUSP</article-title>
<source>Nature Cell Biology</source>
<year>2006</year>
<volume>8</volume>
<issue>10</issue>
<fpage>1064</fpage>
<lpage>1073</lpage>
<pub-id pub-id-type="doi">10.1038/ncb1469</pub-id>
<pub-id pub-id-type="pmid">16964248</pub-id>
</element-citation>
</ref>
<ref id="CR161">
<label>161.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western">
<surname>Huang</surname>
<given-names>H</given-names>
</name>
<name name-style="western">
<surname>Tindall</surname>
<given-names>DJ</given-names>
</name>
</person-group>
<article-title>Regulation of FOXO protein stability via ubiquitination and proteasome degradation</article-title>
<source>Biochimica et Biophysica Acta</source>
<year>2011</year>
<volume>1813</volume>
<issue>11</issue>
<fpage>1961</fpage>
<lpage>1964</lpage>
<pub-id pub-id-type="doi">10.1016/j.bbamcr.2011.01.007</pub-id>
<pub-id pub-id-type="pmid">21238503</pub-id>
<pub-id pub-id-type="pmcid">PMC3110514</pub-id>
</element-citation>
</ref>
<ref id="CR162">
<label>162.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western">
<surname>Mihaylova</surname>
<given-names>MM</given-names>
</name>
<name name-style="western">
<surname>Shaw</surname>
<given-names>RJ</given-names>
</name>
</person-group>
<article-title>The AMPK signalling pathway coordinates cell growth, autophagy and metabolism</article-title>
<source>Nature Cell Biology</source>
<year>2011</year>
<volume>13</volume>
<issue>9</issue>
<fpage>1016</fpage>
<lpage>1023</lpage>
<pub-id pub-id-type="doi">10.1038/ncb2329</pub-id>
<pub-id pub-id-type="pmid">21892142</pub-id>
<pub-id pub-id-type="pmcid">PMC3249400</pub-id>
</element-citation>
</ref>
<ref id="CR163">
<label>163.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western">
<surname>Yun</surname>
<given-names>H</given-names>
</name>
<name name-style="western">
<surname>Park</surname>
<given-names>S</given-names>
</name>
<name name-style="western">
<surname>Kim</surname>
<given-names>MJ</given-names>
</name>
<name name-style="western">
<surname>Yang</surname>
<given-names>WK</given-names>
</name>
<name name-style="western">
<surname>Im</surname>
<given-names>DU</given-names>
</name>
<name name-style="western">
<surname>Yang</surname>
<given-names>KR</given-names>
</name>
<etal />
</person-group>
<article-title>AMP-activated protein kinase mediates the antioxidant effects of resveratrol through regulation of the transcription factor FoxO1</article-title>
<source>The FEBS Journal</source>
<year>2014</year>
<volume>281</volume>
<issue>19</issue>
<fpage>4421</fpage>
<lpage>4438</lpage>
<pub-id pub-id-type="doi">10.1111/febs.12949</pub-id>
<pub-id pub-id-type="pmid">25065674</pub-id>
</element-citation>
</ref>
<ref id="CR164">
<label>164.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western">
<surname>Saline</surname>
<given-names>M</given-names>
</name>
<name name-style="western">
<surname>Badertscher</surname>
<given-names>L</given-names>
</name>
<name name-style="western">
<surname>Wolter</surname>
<given-names>M</given-names>
</name>
<name name-style="western">
<surname>Lau</surname>
<given-names>R</given-names>
</name>
<name name-style="western">
<surname>Gunnarsson</surname>
<given-names>A</given-names>
</name>
<name name-style="western">
<surname>Jacso</surname>
<given-names>T</given-names>
</name>
<etal />
</person-group>
<article-title>AMPK and AKT protein kinases hierarchically phosphorylate the N-terminus of the FOXO1 transcription factor, modulating interactions with 14-3-3 proteins</article-title>
<source>The Journal of Biological Chemistry</source>
<year>2019</year>
<volume>294</volume>
<issue>35</issue>
<fpage>13106</fpage>
<lpage>13116</lpage>
<pub-id pub-id-type="doi">10.1074/jbc.RA119.008649</pub-id>
<pub-id pub-id-type="pmid">31308176</pub-id>
<pub-id pub-id-type="pmcid">PMC6721940</pub-id>
</element-citation>
</ref>
<ref id="CR165">
<label>165.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western">
<surname>Awad</surname>
<given-names>H</given-names>
</name>
<name name-style="western">
<surname>Nolette</surname>
<given-names>N</given-names>
</name>
<name name-style="western">
<surname>Hinton</surname>
<given-names>M</given-names>
</name>
<name name-style="western">
<surname>Dakshinamurti</surname>
<given-names>S</given-names>
</name>
</person-group>
<article-title>AMPK and FoxO1 regulate catalase expression in hypoxic pulmonary arterial smooth muscle</article-title>
<source>Pediatric Pulmonology</source>
<year>2014</year>
<volume>49</volume>
<issue>9</issue>
<fpage>885</fpage>
<lpage>897</lpage>
<pub-id pub-id-type="doi">10.1002/ppul.22919</pub-id>
<pub-id pub-id-type="pmid">24167160</pub-id>
</element-citation>
</ref>
<ref id="CR166">
<label>166.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western">
<surname>Greer</surname>
<given-names>EL</given-names>
</name>
<name name-style="western">
<surname>Oskoui</surname>
<given-names>PR</given-names>
</name>
<name name-style="western">
<surname>Banko</surname>
<given-names>MR</given-names>
</name>
<name name-style="western">
<surname>Maniar</surname>
<given-names>JM</given-names>
</name>
<name name-style="western">
<surname>Gygi</surname>
<given-names>MP</given-names>
</name>
<name name-style="western">
<surname>Gygi</surname>
<given-names>SP</given-names>
</name>
<etal />
</person-group>
<article-title>The energy sensor AMP-activated protein kinase directly regulates the mammalian FOXO3 transcription factor</article-title>
<source>The Journal of Biological Chemistry</source>
<year>2007</year>
<volume>282</volume>
<issue>41</issue>
<fpage>30107</fpage>
<lpage>30119</lpage>
<pub-id pub-id-type="doi">10.1074/jbc.M705325200</pub-id>
<pub-id pub-id-type="pmid">17711846</pub-id>
</element-citation>
</ref>
<ref id="CR167">
<label>167.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western">
<surname>Nagarajan</surname>
<given-names>A</given-names>
</name>
<name name-style="western">
<surname>Dogra</surname>
<given-names>SK</given-names>
</name>
<name name-style="western">
<surname>Sun</surname>
<given-names>L</given-names>
</name>
<name name-style="western">
<surname>Gandotra</surname>
<given-names>N</given-names>
</name>
<name name-style="western">
<surname>Ho</surname>
<given-names>T</given-names>
</name>
<name name-style="western">
<surname>Cai</surname>
<given-names>G</given-names>
</name>
<etal />
</person-group>
<article-title>Paraoxonase 2 facilitates pancreatic cancer growth and metastasis by stimulating GLUT1-mediated glucose transport</article-title>
<source>Molecular Cell</source>
<year>2017</year>
<volume>67</volume>
<issue>4</issue>
<fpage>685</fpage>
<lpage>701</lpage>
<pub-id pub-id-type="doi">10.1016/j.molcel.2017.07.014</pub-id>
<pub-id pub-id-type="pmid">28803777</pub-id>
<pub-id pub-id-type="pmcid">PMC5567863</pub-id>
</element-citation>
</ref>
<ref id="CR168">
<label>168.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western">
<surname>Hu</surname>
<given-names>MC</given-names>
</name>
<name name-style="western">
<surname>Lee</surname>
<given-names>DF</given-names>
</name>
<name name-style="western">
<surname>Xia</surname>
<given-names>W</given-names>
</name>
<name name-style="western">
<surname>Golfman</surname>
<given-names>LS</given-names>
</name>
<name name-style="western">
<surname>Ou-Yang</surname>
<given-names>F</given-names>
</name>
<name name-style="western">
<surname>Yang</surname>
<given-names>JY</given-names>
</name>
<etal />
</person-group>
<article-title>IkappaB kinase promotes tumorigenesis through inhibition of forkhead FOXO3a</article-title>
<source>Cell</source>
<year>2004</year>
<volume>117</volume>
<issue>2</issue>
<fpage>225</fpage>
<lpage>237</lpage>
<pub-id pub-id-type="doi">10.1016/s0092-8674(04)00302-2</pub-id>
<pub-id pub-id-type="pmid">15084260</pub-id>
</element-citation>
</ref>
<ref id="CR169">
<label>169.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western">
<surname>Mazumdar</surname>
<given-names>A</given-names>
</name>
<name name-style="western">
<surname>Kumar</surname>
<given-names>R</given-names>
</name>
</person-group>
<article-title>Estrogen regulation of Pak1 and FKHR pathways in breast cancer cells</article-title>
<source>FEBS Letters</source>
<year>2003</year>
<volume>535</volume>
<issue>1–3</issue>
<fpage>6</fpage>
<lpage>10</lpage>
<pub-id pub-id-type="doi">10.1016/s0014-5793(02)03846-2</pub-id>
<pub-id pub-id-type="pmid">12560069</pub-id>
</element-citation>
</ref>
<ref id="CR170">
<label>170.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western">
<surname>Kim</surname>
<given-names>S</given-names>
</name>
<name name-style="western">
<surname>Kim</surname>
<given-names>Y</given-names>
</name>
<name name-style="western">
<surname>Lee</surname>
<given-names>J</given-names>
</name>
<name name-style="western">
<surname>Chung</surname>
<given-names>J</given-names>
</name>
</person-group>
<article-title>Regulation of FOXO1 by TAK1-Nemo-like kinase pathway</article-title>
<source>The Journal of Biological Chemistry</source>
<year>2010</year>
<volume>285</volume>
<issue>11</issue>
<fpage>8122</fpage>
<lpage>8129</lpage>
<pub-id pub-id-type="doi">10.1074/jbc.M110.101824</pub-id>
<pub-id pub-id-type="pmid">20061393</pub-id>
<pub-id pub-id-type="pmcid">PMC2832963</pub-id>
</element-citation>
</ref>
<ref id="CR171">
<label>171.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western">
<surname>Becker</surname>
<given-names>W</given-names>
</name>
</person-group>
<article-title>Emerging role of DYRK family protein kinases as regulators of protein stability in cell cycle control</article-title>
<source>Cell Cycle</source>
<year>2012</year>
<volume>11</volume>
<issue>18</issue>
<fpage>3389</fpage>
<lpage>3394</lpage>
<pub-id pub-id-type="doi">10.4161/cc.21404</pub-id>
<pub-id pub-id-type="pmid">22918246</pub-id>
<pub-id pub-id-type="pmcid">PMC3466549</pub-id>
</element-citation>
</ref>
<ref id="CR172">
<label>172.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western">
<surname>Woods</surname>
<given-names>YL</given-names>
</name>
<name name-style="western">
<surname>Rena</surname>
<given-names>G</given-names>
</name>
<name name-style="western">
<surname>Morrice</surname>
<given-names>N</given-names>
</name>
<name name-style="western">
<surname>Barthel</surname>
<given-names>A</given-names>
</name>
<name name-style="western">
<surname>Becker</surname>
<given-names>W</given-names>
</name>
<name name-style="western">
<surname>Guo</surname>
<given-names>S</given-names>
</name>
<etal />
</person-group>
<article-title>The kinase DYRK1A phosphorylates the transcription factor FKHR at Ser329 in vitro, a novel in vivo phosphorylation site</article-title>
<source>The Biochemical Journal</source>
<year>2001</year>
<volume>355</volume>
<issue>Pt 3</issue>
<fpage>597</fpage>
<lpage>607</lpage>
<pub-id pub-id-type="doi">10.1042/bj3550597</pub-id>
<pub-id pub-id-type="pmid">11311120</pub-id>
<pub-id pub-id-type="pmcid">PMC1221773</pub-id>
</element-citation>
</ref>
<ref id="CR173">
<label>173.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western">
<surname>Wu</surname>
<given-names>Y</given-names>
</name>
<name name-style="western">
<surname>Pan</surname>
<given-names>Q</given-names>
</name>
<name name-style="western">
<surname>Yan</surname>
<given-names>H</given-names>
</name>
<name name-style="western">
<surname>Zhang</surname>
<given-names>K</given-names>
</name>
<name name-style="western">
<surname>Guo</surname>
<given-names>X</given-names>
</name>
<name name-style="western">
<surname>Xu</surname>
<given-names>Z</given-names>
</name>
<etal />
</person-group>
<article-title>Novel mechanism of Foxo1 phosphorylation in glucagon signaling in control of glucose homeostasis</article-title>
<source>Diabetes</source>
<year>2018</year>
<volume>67</volume>
<issue>11</issue>
<fpage>2167</fpage>
<lpage>2182</lpage>
<pub-id pub-id-type="doi">10.2337/db18-0674</pub-id>
<pub-id pub-id-type="pmid">30201683</pub-id>
<pub-id pub-id-type="pmcid">PMC6198346</pub-id>
</element-citation>
</ref>
<ref id="CR174">
<label>174.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western">
<surname>Lim</surname>
<given-names>S</given-names>
</name>
<name name-style="western">
<surname>Kaldis</surname>
<given-names>P</given-names>
</name>
</person-group>
<article-title>Cdks, cyclins and CKIs: roles beyond cell cycle regulation</article-title>
<source>Development</source>
<year>2013</year>
<volume>140</volume>
<issue>15</issue>
<fpage>3079</fpage>
<lpage>3093</lpage>
<pub-id pub-id-type="doi">10.1242/dev.091744</pub-id>
<pub-id pub-id-type="pmid">23861057</pub-id>
</element-citation>
</ref>
<ref id="CR175">
<label>175.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western">
<surname>Yuan</surname>
<given-names>Z</given-names>
</name>
<name name-style="western">
<surname>Becker</surname>
<given-names>EB</given-names>
</name>
<name name-style="western">
<surname>Merlo</surname>
<given-names>P</given-names>
</name>
<name name-style="western">
<surname>Yamada</surname>
<given-names>T</given-names>
</name>
<name name-style="western">
<surname>DiBacco</surname>
<given-names>S</given-names>
</name>
<name name-style="western">
<surname>Konishi</surname>
<given-names>Y</given-names>
</name>
<etal />
</person-group>
<article-title>Activation of FOXO1 by Cdk1 in cycling cells and postmitotic neurons</article-title>
<source>Science</source>
<year>2008</year>
<volume>319</volume>
<issue>5870</issue>
<fpage>1665</fpage>
<lpage>1668</lpage>
<pub-id pub-id-type="doi">10.1126/science.1152337</pub-id>
<pub-id pub-id-type="pmid">18356527</pub-id>
</element-citation>
</ref>
<ref id="CR176">
<label>176.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western">
<surname>Liu</surname>
<given-names>P</given-names>
</name>
<name name-style="western">
<surname>Kao</surname>
<given-names>TP</given-names>
</name>
<name name-style="western">
<surname>Huang</surname>
<given-names>H</given-names>
</name>
</person-group>
<article-title>CDK1 promotes cell proliferation and survival via phosphorylation and inhibition of FOXO1 transcription factor</article-title>
<source>Oncogene</source>
<year>2008</year>
<volume>27</volume>
<issue>34</issue>
<fpage>4733</fpage>
<lpage>4744</lpage>
<pub-id pub-id-type="doi">10.1038/onc.2008.104</pub-id>
<pub-id pub-id-type="pmid">18408765</pub-id>
</element-citation>
</ref>
<ref id="CR177">
<label>177.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western">
<surname>Huang</surname>
<given-names>H</given-names>
</name>
<name name-style="western">
<surname>Regan</surname>
<given-names>KM</given-names>
</name>
<name name-style="western">
<surname>Lou</surname>
<given-names>Z</given-names>
</name>
<name name-style="western">
<surname>Chen</surname>
<given-names>J</given-names>
</name>
<name name-style="western">
<surname>Tindall</surname>
<given-names>DJ</given-names>
</name>
</person-group>
<article-title>CDK2-dependent phosphorylation of FOXO1 as an apoptotic response to DNA damage</article-title>
<source>Science</source>
<year>2006</year>
<volume>314</volume>
<issue>5797</issue>
<fpage>294</fpage>
<lpage>297</lpage>
<pub-id pub-id-type="doi">10.1126/science.1130512</pub-id>
<pub-id pub-id-type="pmid">17038621</pub-id>
</element-citation>
</ref>
<ref id="CR178">
<label>178.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western">
<surname>Lu</surname>
<given-names>H</given-names>
</name>
<name name-style="western">
<surname>Liu</surname>
<given-names>P</given-names>
</name>
<name name-style="western">
<surname>Pan</surname>
<given-names>Y</given-names>
</name>
<name name-style="western">
<surname>Huang</surname>
<given-names>H</given-names>
</name>
</person-group>
<article-title>Inhibition of cyclin-dependent kinase phosphorylation of FOXO1 and prostate cancer cell growth by a peptide derived from FOXO1</article-title>
<source>Neoplasia</source>
<year>2011</year>
<volume>13</volume>
<issue>9</issue>
<fpage>854</fpage>
<lpage>863</lpage>
<pub-id pub-id-type="doi">10.1593/neo.11594</pub-id>
<pub-id pub-id-type="pmid">21969818</pub-id>
<pub-id pub-id-type="pmcid">PMC3182277</pub-id>
</element-citation>
</ref>
<ref id="CR179">
<label>179.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western">
<surname>Du</surname>
<given-names>WW</given-names>
</name>
<name name-style="western">
<surname>Yang</surname>
<given-names>W</given-names>
</name>
<name name-style="western">
<surname>Liu</surname>
<given-names>E</given-names>
</name>
<name name-style="western">
<surname>Yang</surname>
<given-names>Z</given-names>
</name>
<name name-style="western">
<surname>Dhaliwal</surname>
<given-names>P</given-names>
</name>
<name name-style="western">
<surname>Yang</surname>
<given-names>BB</given-names>
</name>
</person-group>
<article-title>Foxo3 circular RNA retards cell cycle progression via forming ternary complexes with p21 and CDK2</article-title>
<source>Nucleic Acids Research</source>
<year>2016</year>
<volume>44</volume>
<issue>6</issue>
<fpage>2846</fpage>
<lpage>2858</lpage>
<pub-id pub-id-type="doi">10.1093/nar/gkw027</pub-id>
<pub-id pub-id-type="pmid">26861625</pub-id>
<pub-id pub-id-type="pmcid">PMC4824104</pub-id>
</element-citation>
</ref>
<ref id="CR180">
<label>180.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western">
<surname>Consolaro</surname>
<given-names>F</given-names>
</name>
<name name-style="western">
<surname>Ghaem-Maghami</surname>
<given-names>S</given-names>
</name>
<name name-style="western">
<surname>Bortolozzi</surname>
<given-names>R</given-names>
</name>
<name name-style="western">
<surname>Zona</surname>
<given-names>S</given-names>
</name>
<name name-style="western">
<surname>Khongkow</surname>
<given-names>M</given-names>
</name>
<name name-style="western">
<surname>Basso</surname>
<given-names>G</given-names>
</name>
<etal />
</person-group>
<article-title>FOXO3a and posttranslational modifications mediate glucocorticoid sensitivity in B-ALL</article-title>
<source>Molecular Cancer Research</source>
<year>2015</year>
<volume>13</volume>
<issue>12</issue>
<fpage>1578</fpage>
<lpage>1590</lpage>
<pub-id pub-id-type="doi">10.1158/1541-7786.MCR-15-0127</pub-id>
<pub-id pub-id-type="pmid">26376801</pub-id>
</element-citation>
</ref>
<ref id="CR181">
<label>181.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western">
<surname>Nestal de Moraes</surname>
<given-names>G</given-names>
</name>
<name name-style="western">
<surname>Castro</surname>
<given-names>CP</given-names>
</name>
<name name-style="western">
<surname>Salustiano</surname>
<given-names>EJ</given-names>
</name>
<name name-style="western">
<surname>Dumas</surname>
<given-names>ML</given-names>
</name>
<name name-style="western">
<surname>Costas</surname>
<given-names>F</given-names>
</name>
<name name-style="western">
<surname>Lam</surname>
<given-names>EW</given-names>
</name>
<etal />
</person-group>
<article-title>The pterocarpanquinone LQB-118 induces apoptosis in acute myeloid leukemia cells of distinct molecular subtypes and targets FoxO3a and FoxM1 transcription factors</article-title>
<source>International Journal of Oncology</source>
<year>2014</year>
<volume>45</volume>
<issue>5</issue>
<fpage>1949</fpage>
<lpage>1958</lpage>
<pub-id pub-id-type="doi">10.3892/ijo.2014.2615</pub-id>
<pub-id pub-id-type="pmid">25174716</pub-id>
</element-citation>
</ref>
<ref id="CR182">
<label>182.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western">
<surname>Fernandez de Mattos</surname>
<given-names>S</given-names>
</name>
<name name-style="western">
<surname>Villalonga</surname>
<given-names>P</given-names>
</name>
<name name-style="western">
<surname>Clardy</surname>
<given-names>J</given-names>
</name>
<name name-style="western">
<surname>Lam</surname>
<given-names>EW</given-names>
</name>
</person-group>
<article-title>FOXO3a mediates the cytotoxic effects of cisplatin in colon cancer cells</article-title>
<source>Molecular Cancer Therapeutics</source>
<year>2008</year>
<volume>7</volume>
<issue>10</issue>
<fpage>3237</fpage>
<lpage>3246</lpage>
<pub-id pub-id-type="doi">10.1158/1535-7163.MCT-08-0398</pub-id>
<pub-id pub-id-type="pmid">18852127</pub-id>
<pub-id pub-id-type="pmcid">PMC2748241</pub-id>
</element-citation>
</ref>
<ref id="CR183">
<label>183.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western">
<surname>Sunters</surname>
<given-names>A</given-names>
</name>
<name name-style="western">
<surname>Fernandez de Mattos</surname>
<given-names>S</given-names>
</name>
<name name-style="western">
<surname>Stahl</surname>
<given-names>M</given-names>
</name>
<name name-style="western">
<surname>Brosens</surname>
<given-names>JJ</given-names>
</name>
<name name-style="western">
<surname>Zoumpoulidou</surname>
<given-names>G</given-names>
</name>
<name name-style="western">
<surname>Saunders</surname>
<given-names>CA</given-names>
</name>
<etal />
</person-group>
<article-title>FoxO3a transcriptional regulation of Bim controls apoptosis in paclitaxel-treated breast cancer cell lines</article-title>
<source>The Journal of Biological Chemistry</source>
<year>2003</year>
<volume>278</volume>
<issue>50</issue>
<fpage>49795</fpage>
<lpage>49805</lpage>
<pub-id pub-id-type="doi">10.1074/jbc.M309523200</pub-id>
<pub-id pub-id-type="pmid">14527951</pub-id>
</element-citation>
</ref>
<ref id="CR184">
<label>184.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western">
<surname>Sunters</surname>
<given-names>A</given-names>
</name>
<name name-style="western">
<surname>Madureira</surname>
<given-names>PA</given-names>
</name>
<name name-style="western">
<surname>Pomeranz</surname>
<given-names>KM</given-names>
</name>
<name name-style="western">
<surname>Aubert</surname>
<given-names>M</given-names>
</name>
<name name-style="western">
<surname>Brosens</surname>
<given-names>JJ</given-names>
</name>
<name name-style="western">
<surname>Cook</surname>
<given-names>SJ</given-names>
</name>
<etal />
</person-group>
<article-title>Paclitaxel-induced nuclear translocation of FOXO3a in breast cancer cells is mediated by c-Jun NH2-terminal kinase and Akt</article-title>
<source>Cancer Research</source>
<year>2006</year>
<volume>66</volume>
<issue>1</issue>
<fpage>212</fpage>
<lpage>220</lpage>
<pub-id pub-id-type="doi">10.1158/0008-5472.CAN-05-1997</pub-id>
<pub-id pub-id-type="pmid">16397234</pub-id>
</element-citation>
</ref>
<ref id="CR185">
<label>185.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western">
<surname>Tran</surname>
<given-names>H</given-names>
</name>
<name name-style="western">
<surname>Brunet</surname>
<given-names>A</given-names>
</name>
<name name-style="western">
<surname>Grenier</surname>
<given-names>JM</given-names>
</name>
<name name-style="western">
<surname>Datta</surname>
<given-names>SR</given-names>
</name>
<name name-style="western">
<surname>Fornace</surname>
<given-names>AJ</given-names>
<suffix>Jr</suffix>
</name>
<name name-style="western">
<surname>DiStefano</surname>
<given-names>PS</given-names>
</name>
<etal />
</person-group>
<article-title>DNA repair pathway stimulated by the forkhead transcription factor FOXO3a through the Gadd45 protein</article-title>
<source>Science</source>
<year>2002</year>
<volume>296</volume>
<issue>5567</issue>
<fpage>530</fpage>
<lpage>534</lpage>
<pub-id pub-id-type="doi">10.1126/science.1068712</pub-id>
<pub-id pub-id-type="pmid">11964479</pub-id>
</element-citation>
</ref>
<ref id="CR186">
<label>186.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western">
<surname>Tsai</surname>
<given-names>WB</given-names>
</name>
<name name-style="western">
<surname>Chung</surname>
<given-names>YM</given-names>
</name>
<name name-style="western">
<surname>Takahashi</surname>
<given-names>Y</given-names>
</name>
<name name-style="western">
<surname>Xu</surname>
<given-names>Z</given-names>
</name>
<name name-style="western">
<surname>Hu</surname>
<given-names>MC</given-names>
</name>
</person-group>
<article-title>Functional interaction between FOXO3a and ATM regulates DNA damage response</article-title>
<source>Nature Cell Biology</source>
<year>2008</year>
<volume>10</volume>
<issue>4</issue>
<fpage>460</fpage>
<lpage>467</lpage>
<pub-id pub-id-type="doi">10.1038/ncb1709</pub-id>
<pub-id pub-id-type="pmid">18344987</pub-id>
<pub-id pub-id-type="pmcid">PMC2674111</pub-id>
</element-citation>
</ref>
<ref id="CR187">
<label>187.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western">
<surname>Chen</surname>
<given-names>H</given-names>
</name>
<name name-style="western">
<surname>Tini</surname>
<given-names>M</given-names>
</name>
<name name-style="western">
<surname>Evans</surname>
<given-names>RM</given-names>
</name>
</person-group>
<article-title>HATs on and beyond chromatin</article-title>
<source>Current Opinion in Cell Biology</source>
<year>2001</year>
<volume>13</volume>
<issue>2</issue>
<fpage>218</fpage>
<lpage>224</lpage>
<pub-id pub-id-type="doi">10.1016/s0955-0674(00)00200-3</pub-id>
<pub-id pub-id-type="pmid">11248556</pub-id>
</element-citation>
</ref>
<ref id="CR188">
<label>188.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western">
<surname>Daitoku</surname>
<given-names>H</given-names>
</name>
<name name-style="western">
<surname>Sakamaki</surname>
<given-names>J</given-names>
</name>
<name name-style="western">
<surname>Fukamizu</surname>
<given-names>A</given-names>
</name>
</person-group>
<article-title>Regulation of FoxO transcription factors by acetylation and protein-protein interactions</article-title>
<source>Biochimica et Biophysica Acta</source>
<year>2011</year>
<volume>1813</volume>
<issue>11</issue>
<fpage>1954</fpage>
<lpage>1960</lpage>
<pub-id pub-id-type="doi">10.1016/j.bbamcr.2011.03.001</pub-id>
<pub-id pub-id-type="pmid">21396404</pub-id>
</element-citation>
</ref>
<ref id="CR189">
<label>189.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western">
<surname>Matsuzaki</surname>
<given-names>H</given-names>
</name>
<name name-style="western">
<surname>Daitoku</surname>
<given-names>H</given-names>
</name>
<name name-style="western">
<surname>Hatta</surname>
<given-names>M</given-names>
</name>
<name name-style="western">
<surname>Aoyama</surname>
<given-names>H</given-names>
</name>
<name name-style="western">
<surname>Yoshimochi</surname>
<given-names>K</given-names>
</name>
<name name-style="western">
<surname>Fukamizu</surname>
<given-names>A</given-names>
</name>
</person-group>
<article-title>Acetylation of Foxo1 alters its DNA-binding ability and sensitivity to phosphorylation</article-title>
<source>Proceedings of the National Academy of Sciences of the United States of America</source>
<year>2005</year>
<volume>102</volume>
<issue>32</issue>
<fpage>11278</fpage>
<lpage>11283</lpage>
<pub-id pub-id-type="doi">10.1073/pnas.0502738102</pub-id>
<pub-id pub-id-type="pmid">16076959</pub-id>
<pub-id pub-id-type="pmcid">PMC1183558</pub-id>
</element-citation>
</ref>
<ref id="CR190">
<label>190.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western">
<surname>Xie</surname>
<given-names>Q</given-names>
</name>
<name name-style="western">
<surname>Chen</surname>
<given-names>J</given-names>
</name>
<name name-style="western">
<surname>Yuan</surname>
<given-names>Z</given-names>
</name>
</person-group>
<article-title>Post-translational regulation of FOXO</article-title>
<source>Acta Biochimica et Biophysica Sinica Shanghai</source>
<year>2012</year>
<volume>44</volume>
<issue>11</issue>
<fpage>897</fpage>
<lpage>901</lpage>
<pub-id pub-id-type="doi">10.1093/abbs/gms067</pub-id>
<pub-id pub-id-type="pmid">22935512</pub-id>
</element-citation>
</ref>
<ref id="CR191">
<label>191.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western">
<surname>Tsai</surname>
<given-names>KL</given-names>
</name>
<name name-style="western">
<surname>Sun</surname>
<given-names>YJ</given-names>
</name>
<name name-style="western">
<surname>Huang</surname>
<given-names>CY</given-names>
</name>
<name name-style="western">
<surname>Yang</surname>
<given-names>JY</given-names>
</name>
<name name-style="western">
<surname>Hung</surname>
<given-names>MC</given-names>
</name>
<name name-style="western">
<surname>Hsiao</surname>
<given-names>CD</given-names>
</name>
</person-group>
<article-title>Crystal structure of the human FOXO3a-DBD/DNA complex suggests the effects of post-translational modification</article-title>
<source>Nucleic Acids Research</source>
<year>2007</year>
<volume>35</volume>
<issue>20</issue>
<fpage>6984</fpage>
<lpage>6994</lpage>
<pub-id pub-id-type="doi">10.1093/nar/gkm703</pub-id>
<pub-id pub-id-type="pmid">17940099</pub-id>
<pub-id pub-id-type="pmcid">PMC2175300</pub-id>
</element-citation>
</ref>
<ref id="CR192">
<label>192.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western">
<surname>Perrot</surname>
<given-names>V</given-names>
</name>
<name name-style="western">
<surname>Rechler</surname>
<given-names>MM</given-names>
</name>
</person-group>
<article-title>The coactivator p300 directly acetylates the forkhead transcription factor Foxo1 and stimulates Foxo1-induced transcription</article-title>
<source>Molecular Endocrinology</source>
<year>2005</year>
<volume>19</volume>
<issue>9</issue>
<fpage>2283</fpage>
<lpage>2298</lpage>
<pub-id pub-id-type="doi">10.1210/me.2004-0292</pub-id>
<pub-id pub-id-type="pmid">15890677</pub-id>
</element-citation>
</ref>
<ref id="CR193">
<label>193.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western">
<surname>Hatta</surname>
<given-names>M</given-names>
</name>
<name name-style="western">
<surname>Liu</surname>
<given-names>F</given-names>
</name>
<name name-style="western">
<surname>Cirillo</surname>
<given-names>LA</given-names>
</name>
</person-group>
<article-title>Acetylation curtails nucleosome binding, not stable nucleosome remodeling, by FoxO1</article-title>
<source>Biochemical and Biophysical Research Communications</source>
<year>2009</year>
<volume>379</volume>
<issue>4</issue>
<fpage>1005</fpage>
<lpage>1008</lpage>
<pub-id pub-id-type="doi">10.1016/j.bbrc.2009.01.014</pub-id>
<pub-id pub-id-type="pmid">19146829</pub-id>
</element-citation>
</ref>
<ref id="CR194">
<label>194.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western">
<surname>Nakagawa</surname>
<given-names>T</given-names>
</name>
<name name-style="western">
<surname>Guarente</surname>
<given-names>L</given-names>
</name>
</person-group>
<article-title>Sirtuins at a glance</article-title>
<source>Journal of Cell Science</source>
<year>2011</year>
<volume>124</volume>
<issue>Pt 6</issue>
<fpage>833</fpage>
<lpage>838</lpage>
<pub-id pub-id-type="doi">10.1242/jcs.081067</pub-id>
<pub-id pub-id-type="pmid">21378304</pub-id>
<pub-id pub-id-type="pmcid">PMC3048886</pub-id>
</element-citation>
</ref>
<ref id="CR195">
<label>195.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western">
<surname>Wang</surname>
<given-names>F</given-names>
</name>
<name name-style="western">
<surname>Nguyen</surname>
<given-names>M</given-names>
</name>
<name name-style="western">
<surname>Qin</surname>
<given-names>FX</given-names>
</name>
<name name-style="western">
<surname>Tong</surname>
<given-names>Q</given-names>
</name>
</person-group>
<article-title>SIRT2 deacetylates FOXO3a in response to oxidative stress and caloric restriction</article-title>
<source>Aging Cell</source>
<year>2007</year>
<volume>6</volume>
<issue>4</issue>
<fpage>505</fpage>
<lpage>514</lpage>
<pub-id pub-id-type="doi">10.1111/j.1474-9726.2007.00304.x</pub-id>
<pub-id pub-id-type="pmid">17521387</pub-id>
</element-citation>
</ref>
<ref id="CR196">
<label>196.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western">
<surname>Wang</surname>
<given-names>F</given-names>
</name>
<name name-style="western">
<surname>Chan</surname>
<given-names>CH</given-names>
</name>
<name name-style="western">
<surname>Chen</surname>
<given-names>K</given-names>
</name>
<name name-style="western">
<surname>Guan</surname>
<given-names>X</given-names>
</name>
<name name-style="western">
<surname>Lin</surname>
<given-names>HK</given-names>
</name>
<name name-style="western">
<surname>Tong</surname>
<given-names>Q</given-names>
</name>
</person-group>
<article-title>Deacetylation of FOXO3 by SIRT1 or SIRT2 leads to Skp2-mediated FOXO3 ubiquitination and degradation</article-title>
<source>Oncogene</source>
<year>2012</year>
<volume>31</volume>
<issue>12</issue>
<fpage>1546</fpage>
<lpage>1557</lpage>
<pub-id pub-id-type="doi">10.1038/onc.2011.347</pub-id>
<pub-id pub-id-type="pmid">21841822</pub-id>
</element-citation>
</ref>
<ref id="CR197">
<label>197.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western">
<surname>Peck</surname>
<given-names>B</given-names>
</name>
<name name-style="western">
<surname>Chen</surname>
<given-names>CY</given-names>
</name>
<name name-style="western">
<surname>Ho</surname>
<given-names>KK</given-names>
</name>
<name name-style="western">
<surname>Di Fruscia</surname>
<given-names>P</given-names>
</name>
<name name-style="western">
<surname>Myatt</surname>
<given-names>SS</given-names>
</name>
<name name-style="western">
<surname>Coombes</surname>
<given-names>RC</given-names>
</name>
<etal />
</person-group>
<article-title>SIRT inhibitors induce cell death and p53 acetylation through targeting both SIRT1 and SIRT2</article-title>
<source>Molecular Cancer Therapeutics</source>
<year>2010</year>
<volume>9</volume>
<issue>4</issue>
<fpage>844</fpage>
<lpage>855</lpage>
<pub-id pub-id-type="doi">10.1158/1535-7163.MCT-09-0971</pub-id>
<pub-id pub-id-type="pmid">20371709</pub-id>
</element-citation>
</ref>
<ref id="CR198">
<label>198.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western">
<surname>Kitamura</surname>
<given-names>YI</given-names>
</name>
<name name-style="western">
<surname>Kitamura</surname>
<given-names>T</given-names>
</name>
<name name-style="western">
<surname>Kruse</surname>
<given-names>JP</given-names>
</name>
<name name-style="western">
<surname>Raum</surname>
<given-names>JC</given-names>
</name>
<name name-style="western">
<surname>Stein</surname>
<given-names>R</given-names>
</name>
<name name-style="western">
<surname>Gu</surname>
<given-names>W</given-names>
</name>
<etal />
</person-group>
<article-title>FoxO1 protects against pancreatic beta cell failure through NeuroD and MafA induction</article-title>
<source>Cell Metabolism</source>
<year>2005</year>
<volume>2</volume>
<issue>3</issue>
<fpage>153</fpage>
<lpage>163</lpage>
<pub-id pub-id-type="doi">10.1016/j.cmet.2005.08.004</pub-id>
<pub-id pub-id-type="pmid">16154098</pub-id>
</element-citation>
</ref>
<ref id="CR199">
<label>199.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western">
<surname>Sachini</surname>
<given-names>N</given-names>
</name>
<name name-style="western">
<surname>Arampatzi</surname>
<given-names>P</given-names>
</name>
<name name-style="western">
<surname>Klonizakis</surname>
<given-names>A</given-names>
</name>
<name name-style="western">
<surname>Nikolaou</surname>
<given-names>C</given-names>
</name>
<name name-style="western">
<surname>Makatounakis</surname>
<given-names>T</given-names>
</name>
<name name-style="western">
<surname>Lam</surname>
<given-names>EW</given-names>
</name>
<etal />
</person-group>
<article-title>Promyelocytic leukemia protein (PML) controls breast cancer cell proliferation by modulating forkhead transcription factors</article-title>
<source>Molecular Oncology</source>
<year>2019</year>
<volume>13</volume>
<issue>6</issue>
<fpage>1369</fpage>
<lpage>1387</lpage>
<pub-id pub-id-type="doi">10.1002/1878-0261.12486</pub-id>
<pub-id pub-id-type="pmid">30927552</pub-id>
<pub-id pub-id-type="pmcid">PMC6547613</pub-id>
</element-citation>
</ref>
<ref id="CR200">
<label>200.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western">
<surname>Khongkow</surname>
<given-names>M</given-names>
</name>
<name name-style="western">
<surname>Olmos</surname>
<given-names>Y</given-names>
</name>
<name name-style="western">
<surname>Gong</surname>
<given-names>C</given-names>
</name>
<name name-style="western">
<surname>Gomes</surname>
<given-names>AR</given-names>
</name>
<name name-style="western">
<surname>Monteiro</surname>
<given-names>LJ</given-names>
</name>
<name name-style="western">
<surname>Yague</surname>
<given-names>E</given-names>
</name>
<etal />
</person-group>
<article-title>SIRT6 modulates paclitaxel and epirubicin resistance and survival in breast cancer</article-title>
<source>Carcinogenesis</source>
<year>2013</year>
<volume>34</volume>
<issue>7</issue>
<fpage>1476</fpage>
<lpage>1486</lpage>
<pub-id pub-id-type="doi">10.1093/carcin/bgt098</pub-id>
<pub-id pub-id-type="pmid">23514751</pub-id>
</element-citation>
</ref>
<ref id="CR201">
<label>201.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western">
<surname>Chuang</surname>
<given-names>PY</given-names>
</name>
<name name-style="western">
<surname>Dai</surname>
<given-names>Y</given-names>
</name>
<name name-style="western">
<surname>Liu</surname>
<given-names>R</given-names>
</name>
<name name-style="western">
<surname>He</surname>
<given-names>H</given-names>
</name>
<name name-style="western">
<surname>Kretzler</surname>
<given-names>M</given-names>
</name>
<name name-style="western">
<surname>Jim</surname>
<given-names>B</given-names>
</name>
<etal />
</person-group>
<article-title>Alteration of forkhead box O (foxo4) acetylation mediates apoptosis of podocytes in diabetes mellitus</article-title>
<source>PLoS One</source>
<year>2011</year>
<volume>6</volume>
<issue>8</issue>
<fpage>e23566</fpage>
<pub-id pub-id-type="doi">10.1371/journal.pone.0023566</pub-id>
<pub-id pub-id-type="pmid">21858169</pub-id>
<pub-id pub-id-type="pmcid">PMC3157434</pub-id>
</element-citation>
</ref>
<ref id="CR202">
<label>202.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western">
<surname>Papa</surname>
<given-names>L</given-names>
</name>
<name name-style="western">
<surname>Germain</surname>
<given-names>D</given-names>
</name>
</person-group>
<article-title>SirT3 regulates the mitochondrial unfolded protein response</article-title>
<source>Molecular and Cellular Biology</source>
<year>2014</year>
<volume>34</volume>
<issue>4</issue>
<fpage>699</fpage>
<lpage>710</lpage>
<pub-id pub-id-type="doi">10.1128/MCB.01337-13</pub-id>
<pub-id pub-id-type="pmid">24324009</pub-id>
<pub-id pub-id-type="pmcid">PMC3911493</pub-id>
</element-citation>
</ref>
<ref id="CR203">
<label>203.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western">
<surname>Kenny</surname>
<given-names>TC</given-names>
</name>
<name name-style="western">
<surname>Hart</surname>
<given-names>P</given-names>
</name>
<name name-style="western">
<surname>Ragazzi</surname>
<given-names>M</given-names>
</name>
<name name-style="western">
<surname>Sersinghe</surname>
<given-names>M</given-names>
</name>
<name name-style="western">
<surname>Chipuk</surname>
<given-names>J</given-names>
</name>
<name name-style="western">
<surname>Sagar</surname>
<given-names>MAK</given-names>
</name>
<etal />
</person-group>
<article-title>Selected mitochondrial DNA landscapes activate the SIRT3 axis of the UPR(mt) to promote metastasis</article-title>
<source>Oncogene</source>
<year>2017</year>
<volume>36</volume>
<issue>31</issue>
<fpage>4393</fpage>
<lpage>4404</lpage>
<pub-id pub-id-type="doi">10.1038/onc.2017.52</pub-id>
<pub-id pub-id-type="pmid">28368421</pub-id>
<pub-id pub-id-type="pmcid">PMC5542861</pub-id>
</element-citation>
</ref>
<ref id="CR204">
<label>204.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western">
<surname>Pramanik</surname>
<given-names>KC</given-names>
</name>
<name name-style="western">
<surname>Fofaria</surname>
<given-names>NM</given-names>
</name>
<name name-style="western">
<surname>Gupta</surname>
<given-names>P</given-names>
</name>
<name name-style="western">
<surname>Srivastava</surname>
<given-names>SK</given-names>
</name>
</person-group>
<article-title>CBP-mediated FOXO-1 acetylation inhibits pancreatic tumor growth by targeting SirT</article-title>
<source>Molecular Cancer Therapeutics</source>
<year>2014</year>
<volume>13</volume>
<issue>3</issue>
<fpage>687</fpage>
<lpage>698</lpage>
<pub-id pub-id-type="doi">10.1158/1535-7163.MCT-13-0863</pub-id>
<pub-id pub-id-type="pmid">24419059</pub-id>
<pub-id pub-id-type="pmcid">PMC3954235</pub-id>
</element-citation>
</ref>
<ref id="CR205">
<label>205.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western">
<surname>Olmos</surname>
<given-names>Y</given-names>
</name>
<name name-style="western">
<surname>Brosens</surname>
<given-names>JJ</given-names>
</name>
<name name-style="western">
<surname>Lam</surname>
<given-names>EW</given-names>
</name>
</person-group>
<article-title>Interplay between SIRT proteins and tumour suppressor transcription factors in chemotherapeutic resistance of cancer</article-title>
<source>Drug Resistance Updates</source>
<year>2011</year>
<volume>14</volume>
<issue>1</issue>
<fpage>35</fpage>
<lpage>44</lpage>
<pub-id pub-id-type="doi">10.1016/j.drup.2010.12.001</pub-id>
<pub-id pub-id-type="pmid">21195657</pub-id>
</element-citation>
</ref>
<ref id="CR206">
<label>206.</label>
<mixed-citation publication-type="other">Di Fruscia, P., Ho, K. K., Laohasinnarong, S., Khongkow, M., Kroll, S. H., Islam, S. A., et al. (2012). The discovery of novel 10,11-dihydro-5H-dibenz[b,f]azepine SIRT2 inhibitors. <italic toggle="yes">Medchemcomm</italic> (3), doi:10.1039/C2MD00290F.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1039/C2MD00290F</pub-id>
<pub-id pub-id-type="pmcid">PMC3856871</pub-id>
<pub-id pub-id-type="pmid">24340169</pub-id>
</mixed-citation>
</ref>
<ref id="CR207">
<label>207.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western">
<surname>Jin</surname>
<given-names>B</given-names>
</name>
<name name-style="western">
<surname>Li</surname>
<given-names>Y</given-names>
</name>
<name name-style="western">
<surname>Robertson</surname>
<given-names>KD</given-names>
</name>
</person-group>
<article-title>DNA methylation: superior or subordinate in the epigenetic hierarchy?</article-title>
<source>Genes &amp; Cancer</source>
<year>2011</year>
<volume>2</volume>
<issue>6</issue>
<fpage>607</fpage>
<lpage>617</lpage>
<pub-id pub-id-type="doi">10.1177/1947601910393957</pub-id>
<pub-id pub-id-type="pmid">21941617</pub-id>
<pub-id pub-id-type="pmcid">PMC3174260</pub-id>
</element-citation>
</ref>
<ref id="CR208">
<label>208.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western">
<surname>Yamagata</surname>
<given-names>K</given-names>
</name>
<name name-style="western">
<surname>Daitoku</surname>
<given-names>H</given-names>
</name>
<name name-style="western">
<surname>Takahashi</surname>
<given-names>Y</given-names>
</name>
<name name-style="western">
<surname>Namiki</surname>
<given-names>K</given-names>
</name>
<name name-style="western">
<surname>Hisatake</surname>
<given-names>K</given-names>
</name>
<name name-style="western">
<surname>Kako</surname>
<given-names>K</given-names>
</name>
<etal />
</person-group>
<article-title>Arginine methylation of FOXO transcription factors inhibits their phosphorylation by Akt</article-title>
<source>Molecular Cell</source>
<year>2008</year>
<volume>32</volume>
<issue>2</issue>
<fpage>221</fpage>
<lpage>231</lpage>
<pub-id pub-id-type="doi">10.1016/j.molcel.2008.09.013</pub-id>
<pub-id pub-id-type="pmid">18951090</pub-id>
</element-citation>
</ref>
<ref id="CR209">
<label>209.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western">
<surname>Xie</surname>
<given-names>Q</given-names>
</name>
<name name-style="western">
<surname>Hao</surname>
<given-names>Y</given-names>
</name>
<name name-style="western">
<surname>Tao</surname>
<given-names>L</given-names>
</name>
<name name-style="western">
<surname>Peng</surname>
<given-names>S</given-names>
</name>
<name name-style="western">
<surname>Rao</surname>
<given-names>C</given-names>
</name>
<name name-style="western">
<surname>Chen</surname>
<given-names>H</given-names>
</name>
<etal />
</person-group>
<article-title>Lysine methylation of FOXO3 regulates oxidative stress-induced neuronal cell death</article-title>
<source>EMBO Reports</source>
<year>2012</year>
<volume>13</volume>
<issue>4</issue>
<fpage>371</fpage>
<lpage>377</lpage>
<pub-id pub-id-type="doi">10.1038/embor.2012.25</pub-id>
<pub-id pub-id-type="pmid">22402663</pub-id>
<pub-id pub-id-type="pmcid">PMC3321157</pub-id>
</element-citation>
</ref>
<ref id="CR210">
<label>210.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western">
<surname>Han</surname>
<given-names>D</given-names>
</name>
<name name-style="western">
<surname>Huang</surname>
<given-names>M</given-names>
</name>
<name name-style="western">
<surname>Wang</surname>
<given-names>T</given-names>
</name>
<name name-style="western">
<surname>Li</surname>
<given-names>Z</given-names>
</name>
<name name-style="western">
<surname>Chen</surname>
<given-names>Y</given-names>
</name>
<name name-style="western">
<surname>Liu</surname>
<given-names>C</given-names>
</name>
<etal />
</person-group>
<article-title>Lysine methylation of transcription factors in cancer</article-title>
<source>Cell Death &amp; Disease</source>
<year>2019</year>
<volume>10</volume>
<issue>4</issue>
<fpage>290</fpage>
<pub-id pub-id-type="doi">10.1038/s41419-019-1524-2</pub-id>
<pub-id pub-id-type="pmid">30926778</pub-id>
<pub-id pub-id-type="pmcid">PMC6441099</pub-id>
</element-citation>
</ref>
<ref id="CR211">
<label>211.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western">
<surname>Buuh</surname>
<given-names>ZY</given-names>
</name>
<name name-style="western">
<surname>Lyu</surname>
<given-names>Z</given-names>
</name>
<name name-style="western">
<surname>Wang</surname>
<given-names>RE</given-names>
</name>
</person-group>
<article-title>Interrogating the roles of post-translational modifications of non-histone proteins</article-title>
<source>Journal of Medicinal Chemistry</source>
<year>2018</year>
<volume>61</volume>
<issue>8</issue>
<fpage>3239</fpage>
<lpage>3252</lpage>
<pub-id pub-id-type="doi">10.1021/acs.jmedchem.6b01817</pub-id>
<pub-id pub-id-type="pmid">28505447</pub-id>
</element-citation>
</ref>
<ref id="CR212">
<label>212.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western">
<surname>Jia</surname>
<given-names>X</given-names>
</name>
<name name-style="western">
<surname>Li</surname>
<given-names>C</given-names>
</name>
<name name-style="western">
<surname>Li</surname>
<given-names>L</given-names>
</name>
<name name-style="western">
<surname>Liu</surname>
<given-names>X</given-names>
</name>
<name name-style="western">
<surname>Zhou</surname>
<given-names>L</given-names>
</name>
<name name-style="western">
<surname>Zhang</surname>
<given-names>W</given-names>
</name>
<etal />
</person-group>
<article-title>Neddylation inactivation facilitates FOXO3a nuclear export to suppress estrogen receptor transcription and improve fulvestrant sensitivity</article-title>
<source>Clinical Cancer Research</source>
<year>2019</year>
<volume>25</volume>
<issue>12</issue>
<fpage>3658</fpage>
<lpage>3672</lpage>
<pub-id pub-id-type="doi">10.1158/1078-0432.CCR-18-2434</pub-id>
<pub-id pub-id-type="pmid">30833270</pub-id>
</element-citation>
</ref>
<ref id="CR213">
<label>213.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western">
<surname>Shao</surname>
<given-names>J</given-names>
</name>
<name name-style="western">
<surname>Sheng</surname>
<given-names>H</given-names>
</name>
<name name-style="western">
<surname>DuBois</surname>
<given-names>RN</given-names>
</name>
</person-group>
<article-title>Peroxisome proliferator-activated receptors modulate K-Ras-mediated transformation of intestinal epithelial cells</article-title>
<source>Cancer Research</source>
<year>2002</year>
<volume>62</volume>
<issue>11</issue>
<fpage>3282</fpage>
<lpage>3288</lpage>
<pub-id pub-id-type="pmid">12036946</pub-id>
</element-citation>
</ref>
<ref id="CR214">
<label>214.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western">
<surname>Tachibana</surname>
<given-names>K</given-names>
</name>
<name name-style="western">
<surname>Yamasaki</surname>
<given-names>D</given-names>
</name>
<name name-style="western">
<surname>Ishimoto</surname>
<given-names>K</given-names>
</name>
<name name-style="western">
<surname>Doi</surname>
<given-names>T</given-names>
</name>
</person-group>
<article-title>The role of PPARs in cancer</article-title>
<source>PPAR Research</source>
<year>2008</year>
<volume>2008</volume>
<fpage>102737</fpage>
<pub-id pub-id-type="doi">10.1155/2008/102737</pub-id>
<pub-id pub-id-type="pmid">18584037</pub-id>
<pub-id pub-id-type="pmcid">PMC2435221</pub-id>
</element-citation>
</ref>
<ref id="CR215">
<label>215.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western">
<surname>Qu</surname>
<given-names>S</given-names>
</name>
<name name-style="western">
<surname>Su</surname>
<given-names>D</given-names>
</name>
<name name-style="western">
<surname>Altomonte</surname>
<given-names>J</given-names>
</name>
<name name-style="western">
<surname>Kamagate</surname>
<given-names>A</given-names>
</name>
<name name-style="western">
<surname>He</surname>
<given-names>J</given-names>
</name>
<name name-style="western">
<surname>Perdomo</surname>
<given-names>G</given-names>
</name>
<etal />
</person-group>
<article-title>PPAR{alpha} mediates the hypolipidemic action of fibrates by antagonizing FoxO1</article-title>
<source>American Journal of Physiology. Endocrinology and Metabolism</source>
<year>2007</year>
<volume>292</volume>
<issue>2</issue>
<fpage>E421</fpage>
<lpage>E434</lpage>
<pub-id pub-id-type="doi">10.1152/ajpendo.00157.2006</pub-id>
<pub-id pub-id-type="pmid">16985262</pub-id>
<pub-id pub-id-type="pmcid">PMC2665003</pub-id>
</element-citation>
</ref>
<ref id="CR216">
<label>216.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western">
<surname>Lee</surname>
<given-names>SJ</given-names>
</name>
<name name-style="western">
<surname>Mahankali</surname>
<given-names>M</given-names>
</name>
<name name-style="western">
<surname>Bitar</surname>
<given-names>A</given-names>
</name>
<name name-style="western">
<surname>Zou</surname>
<given-names>H</given-names>
</name>
<name name-style="western">
<surname>Chao</surname>
<given-names>E</given-names>
</name>
<name name-style="western">
<surname>Nguyen</surname>
<given-names>H</given-names>
</name>
<etal />
</person-group>
<article-title>A novel role for RARalpha agonists as apolipoprotein CIII inhibitors identified from high throughput screening</article-title>
<source>Scientific Reports</source>
<year>2017</year>
<volume>7</volume>
<issue>1</issue>
<fpage>5824</fpage>
<pub-id pub-id-type="doi">10.1038/s41598-017-05163-w</pub-id>
<pub-id pub-id-type="pmid">28724938</pub-id>
<pub-id pub-id-type="pmcid">PMC5517646</pub-id>
</element-citation>
</ref>
<ref id="CR217">
<label>217.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western">
<surname>Shi</surname>
<given-names>J</given-names>
</name>
<name name-style="western">
<surname>Yang</surname>
<given-names>H</given-names>
</name>
<name name-style="western">
<surname>Duan</surname>
<given-names>X</given-names>
</name>
<name name-style="western">
<surname>Li</surname>
<given-names>L</given-names>
</name>
<name name-style="western">
<surname>Sun</surname>
<given-names>L</given-names>
</name>
<name name-style="western">
<surname>Li</surname>
<given-names>Q</given-names>
</name>
<etal />
</person-group>
<article-title>Apolipoproteins as differentiating and predictive markers for assessing clinical outcomes in patients with small cell lung cancer</article-title>
<source>Yonsei Medical Journal</source>
<year>2016</year>
<volume>57</volume>
<issue>3</issue>
<fpage>549</fpage>
<lpage>556</lpage>
<pub-id pub-id-type="doi">10.3349/ymj.2016.57.3.549</pub-id>
<pub-id pub-id-type="pmid">26996551</pub-id>
<pub-id pub-id-type="pmcid">PMC4800341</pub-id>
</element-citation>
</ref>
<ref id="CR218">
<label>218.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western">
<surname>Luo</surname>
<given-names>X</given-names>
</name>
<name name-style="western">
<surname>Zhao</surname>
<given-names>X</given-names>
</name>
<name name-style="western">
<surname>Cheng</surname>
<given-names>C</given-names>
</name>
<name name-style="western">
<surname>Li</surname>
<given-names>N</given-names>
</name>
<name name-style="western">
<surname>Liu</surname>
<given-names>Y</given-names>
</name>
<name name-style="western">
<surname>Cao</surname>
<given-names>Y</given-names>
</name>
</person-group>
<article-title>The implications of signaling lipids in cancer metastasis</article-title>
<source>Experimental &amp; Molecular Medicine</source>
<year>2018</year>
<volume>50</volume>
<issue>9</issue>
<fpage>127</fpage>
<pub-id pub-id-type="doi">10.1038/s12276-018-0150-x</pub-id>
<pub-id pub-id-type="pmid">30242145</pub-id>
<pub-id pub-id-type="pmcid">PMC6154999</pub-id>
</element-citation>
</ref>
<ref id="CR219">
<label>219.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western">
<surname>Luo</surname>
<given-names>X</given-names>
</name>
<name name-style="western">
<surname>Cheng</surname>
<given-names>C</given-names>
</name>
<name name-style="western">
<surname>Tan</surname>
<given-names>Z</given-names>
</name>
<name name-style="western">
<surname>Li</surname>
<given-names>N</given-names>
</name>
<name name-style="western">
<surname>Tang</surname>
<given-names>M</given-names>
</name>
<name name-style="western">
<surname>Yang</surname>
<given-names>L</given-names>
</name>
<etal />
</person-group>
<article-title>Emerging roles of lipid metabolism in cancer metastasis</article-title>
<source>Molecular Cancer</source>
<year>2017</year>
<volume>16</volume>
<issue>1</issue>
<fpage>76</fpage>
<pub-id pub-id-type="doi">10.1186/s12943-017-0646-3</pub-id>
<pub-id pub-id-type="pmid">28399876</pub-id>
<pub-id pub-id-type="pmcid">PMC5387196</pub-id>
</element-citation>
</ref>
<ref id="CR220">
<label>220.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western">
<surname>Davey</surname>
<given-names>RA</given-names>
</name>
<name name-style="western">
<surname>Grossmann</surname>
<given-names>M</given-names>
</name>
</person-group>
<article-title>Androgen receptor structure, function and biology: from bench to bedside</article-title>
<source>Clinical Biochemist Reviews</source>
<year>2016</year>
<volume>37</volume>
<issue>1</issue>
<fpage>3</fpage>
<lpage>15</lpage>
<pub-id pub-id-type="pmcid">PMC4810760</pub-id>
<pub-id pub-id-type="pmid">27057074</pub-id>
</element-citation>
</ref>
<ref id="CR221">
<label>221.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western">
<surname>Lin</surname>
<given-names>CY</given-names>
</name>
<name name-style="western">
<surname>Jan</surname>
<given-names>YJ</given-names>
</name>
<name name-style="western">
<surname>Kuo</surname>
<given-names>LK</given-names>
</name>
<name name-style="western">
<surname>Wang</surname>
<given-names>BJ</given-names>
</name>
<name name-style="western">
<surname>Huo</surname>
<given-names>C</given-names>
</name>
<name name-style="western">
<surname>Jiang</surname>
<given-names>SS</given-names>
</name>
<etal />
</person-group>
<article-title>Elevation of androgen receptor promotes prostate cancer metastasis by induction of epithelial-mesenchymal transition and reduction of KAT5</article-title>
<source>Cancer Science</source>
<year>2018</year>
<volume>109</volume>
<issue>11</issue>
<fpage>3564</fpage>
<lpage>3574</lpage>
<pub-id pub-id-type="doi">10.1111/cas.13776</pub-id>
<pub-id pub-id-type="pmid">30142696</pub-id>
<pub-id pub-id-type="pmcid">PMC6215884</pub-id>
</element-citation>
</ref>
<ref id="CR222">
<label>222.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western">
<surname>Huang</surname>
<given-names>Q</given-names>
</name>
<name name-style="western">
<surname>Sun</surname>
<given-names>Y</given-names>
</name>
<name name-style="western">
<surname>Ma</surname>
<given-names>X</given-names>
</name>
<name name-style="western">
<surname>Gao</surname>
<given-names>Y</given-names>
</name>
<name name-style="western">
<surname>Li</surname>
<given-names>X</given-names>
</name>
<name name-style="western">
<surname>Niu</surname>
<given-names>Y</given-names>
</name>
<etal />
</person-group>
<article-title>Androgen receptor increases hematogenous metastasis yet decreases lymphatic metastasis of renal cell carcinoma</article-title>
<source>Nature Communications</source>
<year>2017</year>
<volume>8</volume>
<issue>1</issue>
<fpage>918</fpage>
<pub-id pub-id-type="doi">10.1038/s41467-017-00701-6</pub-id>
<pub-id pub-id-type="pmid">29030639</pub-id>
<pub-id pub-id-type="pmcid">PMC5640635</pub-id>
</element-citation>
</ref>
<ref id="CR223">
<label>223.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western">
<surname>Li</surname>
<given-names>P</given-names>
</name>
<name name-style="western">
<surname>Lee</surname>
<given-names>H</given-names>
</name>
<name name-style="western">
<surname>Guo</surname>
<given-names>S</given-names>
</name>
<name name-style="western">
<surname>Unterman</surname>
<given-names>TG</given-names>
</name>
<name name-style="western">
<surname>Jenster</surname>
<given-names>G</given-names>
</name>
<name name-style="western">
<surname>Bai</surname>
<given-names>W</given-names>
</name>
</person-group>
<article-title>AKT-independent protection of prostate cancer cells from apoptosis mediated through complex formation between the androgen receptor and FKHR</article-title>
<source>Molecular and Cellular Biology</source>
<year>2003</year>
<volume>23</volume>
<issue>1</issue>
<fpage>104</fpage>
<lpage>118</lpage>
<pub-id pub-id-type="doi">10.1128/mcb.23.1.104-118.2003</pub-id>
<pub-id pub-id-type="pmid">12482965</pub-id>
<pub-id pub-id-type="pmcid">PMC140652</pub-id>
</element-citation>
</ref>
<ref id="CR224">
<label>224.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western">
<surname>Deroo</surname>
<given-names>BJ</given-names>
</name>
<name name-style="western">
<surname>Korach</surname>
<given-names>KS</given-names>
</name>
</person-group>
<article-title>Estrogen receptors and human disease</article-title>
<source>The Journal of Clinical Investigation</source>
<year>2006</year>
<volume>116</volume>
<issue>3</issue>
<fpage>561</fpage>
<lpage>570</lpage>
<pub-id pub-id-type="doi">10.1172/JCI27987</pub-id>
<pub-id pub-id-type="pmid">16511588</pub-id>
<pub-id pub-id-type="pmcid">PMC2373424</pub-id>
</element-citation>
</ref>
<ref id="CR225">
<label>225.</label>
<mixed-citation publication-type="other">Lei, J. T., Gou, X., Seker, S., &amp; Ellis, M. J. (2019). ESR1 alterations and metastasis in estrogen receptor positive breast cancer. <italic toggle="yes">Journal of Cancer Metastasis and Treatment, 5</italic>. 10.20517/2394-4722.2019.12.<pub-id pub-id-type="doi" assigning-authority="pmc">10.20517/2394-4722.2019.12</pub-id>
<pub-id pub-id-type="pmcid">PMC6519472</pub-id>
<pub-id pub-id-type="pmid">31106278</pub-id>
</mixed-citation>
</ref>
<ref id="CR226">
<label>226.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western">
<surname>Schuur</surname>
<given-names>ER</given-names>
</name>
<name name-style="western">
<surname>Loktev</surname>
<given-names>AV</given-names>
</name>
<name name-style="western">
<surname>Sharma</surname>
<given-names>M</given-names>
</name>
<name name-style="western">
<surname>Sun</surname>
<given-names>Z</given-names>
</name>
<name name-style="western">
<surname>Roth</surname>
<given-names>RA</given-names>
</name>
<name name-style="western">
<surname>Weigel</surname>
<given-names>RJ</given-names>
</name>
</person-group>
<article-title>Ligand-dependent interaction of estrogen receptor-alpha with members of the forkhead transcription factor family</article-title>
<source>The Journal of Biological Chemistry</source>
<year>2001</year>
<volume>276</volume>
<issue>36</issue>
<fpage>33554</fpage>
<lpage>33560</lpage>
<pub-id pub-id-type="doi">10.1074/jbc.M105555200</pub-id>
<pub-id pub-id-type="pmid">11435445</pub-id>
</element-citation>
</ref>
<ref id="CR227">
<label>227.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western">
<surname>Ray Chaudhuri</surname>
<given-names>A</given-names>
</name>
<name name-style="western">
<surname>Nussenzweig</surname>
<given-names>A</given-names>
</name>
</person-group>
<article-title>The multifaceted roles of PARP1 in DNA repair and chromatin remodelling</article-title>
<source>Nature Reviews. Molecular Cell Biology</source>
<year>2017</year>
<volume>18</volume>
<issue>10</issue>
<fpage>610</fpage>
<lpage>621</lpage>
<pub-id pub-id-type="doi">10.1038/nrm.2017.53</pub-id>
<pub-id pub-id-type="pmid">28676700</pub-id>
<pub-id pub-id-type="pmcid">PMC6591728</pub-id>
</element-citation>
</ref>
<ref id="CR228">
<label>228.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western">
<surname>Kim</surname>
<given-names>MY</given-names>
</name>
<name name-style="western">
<surname>Zhang</surname>
<given-names>T</given-names>
</name>
<name name-style="western">
<surname>Kraus</surname>
<given-names>WL</given-names>
</name>
</person-group>
<article-title>Poly(ADP-ribosyl)ation by PARP-1: ‘PAR-laying’ NAD+ into a nuclear signal</article-title>
<source>Genes &amp; Development</source>
<year>2005</year>
<volume>19</volume>
<issue>17</issue>
<fpage>1951</fpage>
<lpage>1967</lpage>
<pub-id pub-id-type="doi">10.1101/gad.1331805</pub-id>
<pub-id pub-id-type="pmid">16140981</pub-id>
</element-citation>
</ref>
<ref id="CR229">
<label>229.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western">
<surname>Rodriguez</surname>
<given-names>MI</given-names>
</name>
<name name-style="western">
<surname>Peralta-Leal</surname>
<given-names>A</given-names>
</name>
<name name-style="western">
<surname>O’Valle</surname>
<given-names>F</given-names>
</name>
<name name-style="western">
<surname>Rodriguez-Vargas</surname>
<given-names>JM</given-names>
</name>
<name name-style="western">
<surname>Gonzalez-Flores</surname>
<given-names>A</given-names>
</name>
<name name-style="western">
<surname>Majuelos-Melguizo</surname>
<given-names>J</given-names>
</name>
<etal />
</person-group>
<article-title>PARP-1 regulates metastatic melanoma through modulation of vimentin-induced malignant transformation</article-title>
<source>PLoS Genetics</source>
<year>2013</year>
<volume>9</volume>
<issue>6</issue>
<fpage>e1003531</fpage>
<pub-id pub-id-type="doi">10.1371/journal.pgen.1003531</pub-id>
<pub-id pub-id-type="pmid">23785295</pub-id>
<pub-id pub-id-type="pmcid">PMC3681683</pub-id>
</element-citation>
</ref>
<ref id="CR230">
<label>230.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western">
<surname>Lai</surname>
<given-names>Y</given-names>
</name>
<name name-style="western">
<surname>Kong</surname>
<given-names>Z</given-names>
</name>
<name name-style="western">
<surname>Zeng</surname>
<given-names>T</given-names>
</name>
<name name-style="western">
<surname>Xu</surname>
<given-names>S</given-names>
</name>
<name name-style="western">
<surname>Duan</surname>
<given-names>X</given-names>
</name>
<name name-style="western">
<surname>Li</surname>
<given-names>S</given-names>
</name>
<etal />
</person-group>
<article-title>PARP1-siRNA suppresses human prostate cancer cell growth and progression</article-title>
<source>Oncology Reports</source>
<year>2018</year>
<volume>39</volume>
<issue>4</issue>
<fpage>1901</fpage>
<lpage>1909</lpage>
<pub-id pub-id-type="doi">10.3892/or.2018.6238</pub-id>
<pub-id pub-id-type="pmid">29393407</pub-id>
</element-citation>
</ref>
<ref id="CR231">
<label>231.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western">
<surname>Choi</surname>
<given-names>EB</given-names>
</name>
<name name-style="western">
<surname>Yang</surname>
<given-names>AY</given-names>
</name>
<name name-style="western">
<surname>Kim</surname>
<given-names>SC</given-names>
</name>
<name name-style="western">
<surname>Lee</surname>
<given-names>J</given-names>
</name>
<name name-style="western">
<surname>Choi</surname>
<given-names>JK</given-names>
</name>
<name name-style="western">
<surname>Choi</surname>
<given-names>C</given-names>
</name>
<etal />
</person-group>
<article-title>PARP1 enhances lung adenocarcinoma metastasis by novel mechanisms independent of DNA repair</article-title>
<source>Oncogene</source>
<year>2016</year>
<volume>35</volume>
<issue>35</issue>
<fpage>4569</fpage>
<lpage>4579</lpage>
<pub-id pub-id-type="doi">10.1038/onc.2016.3</pub-id>
<pub-id pub-id-type="pmid">26898760</pub-id>
</element-citation>
</ref>
<ref id="CR232">
<label>232.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western">
<surname>Sakamaki</surname>
<given-names>J</given-names>
</name>
<name name-style="western">
<surname>Daitoku</surname>
<given-names>H</given-names>
</name>
<name name-style="western">
<surname>Yoshimochi</surname>
<given-names>K</given-names>
</name>
<name name-style="western">
<surname>Miwa</surname>
<given-names>M</given-names>
</name>
<name name-style="western">
<surname>Fukamizu</surname>
<given-names>A</given-names>
</name>
</person-group>
<article-title>Regulation of FOXO1-mediated transcription and cell proliferation by PARP-1</article-title>
<source>Biochemical and Biophysical Research Communications</source>
<year>2009</year>
<volume>382</volume>
<issue>3</issue>
<fpage>497</fpage>
<lpage>502</lpage>
<pub-id pub-id-type="doi">10.1016/j.bbrc.2009.03.022</pub-id>
<pub-id pub-id-type="pmid">19281796</pub-id>
</element-citation>
</ref>
<ref id="CR233">
<label>233.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western">
<surname>Puigserver</surname>
<given-names>P</given-names>
</name>
<name name-style="western">
<surname>Rhee</surname>
<given-names>J</given-names>
</name>
<name name-style="western">
<surname>Donovan</surname>
<given-names>J</given-names>
</name>
<name name-style="western">
<surname>Walkey</surname>
<given-names>CJ</given-names>
</name>
<name name-style="western">
<surname>Yoon</surname>
<given-names>JC</given-names>
</name>
<name name-style="western">
<surname>Oriente</surname>
<given-names>F</given-names>
</name>
<etal />
</person-group>
<article-title>Insulin-regulated hepatic gluconeogenesis through FOXO1-PGC-1alpha interaction</article-title>
<source>Nature</source>
<year>2003</year>
<volume>423</volume>
<issue>6939</issue>
<fpage>550</fpage>
<lpage>555</lpage>
<pub-id pub-id-type="doi">10.1038/nature01667</pub-id>
<pub-id pub-id-type="pmid">12754525</pub-id>
</element-citation>
</ref>
<ref id="CR234">
<label>234.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western">
<surname>Schilling</surname>
<given-names>MM</given-names>
</name>
<name name-style="western">
<surname>Oeser</surname>
<given-names>JK</given-names>
</name>
<name name-style="western">
<surname>Boustead</surname>
<given-names>JN</given-names>
</name>
<name name-style="western">
<surname>Flemming</surname>
<given-names>BP</given-names>
</name>
<name name-style="western">
<surname>O’Brien</surname>
<given-names>RM</given-names>
</name>
</person-group>
<article-title>Gluconeogenesis: re-evaluating the FOXO1-PGC-1alpha connection</article-title>
<source>Nature</source>
<year>2006</year>
<volume>443</volume>
<issue>7111</issue>
<fpage>E10</fpage>
<lpage>E11</lpage>
<pub-id pub-id-type="doi">10.1038/nature05288</pub-id>
<pub-id pub-id-type="pmid">17024043</pub-id>
</element-citation>
</ref>
<ref id="CR235">
<label>235.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western">
<surname>Daitoku</surname>
<given-names>H</given-names>
</name>
<name name-style="western">
<surname>Yamagata</surname>
<given-names>K</given-names>
</name>
<name name-style="western">
<surname>Matsuzaki</surname>
<given-names>H</given-names>
</name>
<name name-style="western">
<surname>Hatta</surname>
<given-names>M</given-names>
</name>
<name name-style="western">
<surname>Fukamizu</surname>
<given-names>A</given-names>
</name>
</person-group>
<article-title>Regulation of PGC-1 promoter activity by protein kinase B and the forkhead transcription factor FKHR</article-title>
<source>Diabetes</source>
<year>2003</year>
<volume>52</volume>
<issue>3</issue>
<fpage>642</fpage>
<lpage>649</lpage>
<pub-id pub-id-type="doi">10.2337/diabetes.52.3.642</pub-id>
<pub-id pub-id-type="pmid">12606503</pub-id>
</element-citation>
</ref>
<ref id="CR236">
<label>236.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western">
<surname>Sekine</surname>
<given-names>K</given-names>
</name>
<name name-style="western">
<surname>Chen</surname>
<given-names>YR</given-names>
</name>
<name name-style="western">
<surname>Kojima</surname>
<given-names>N</given-names>
</name>
<name name-style="western">
<surname>Ogata</surname>
<given-names>K</given-names>
</name>
<name name-style="western">
<surname>Fukamizu</surname>
<given-names>A</given-names>
</name>
<name name-style="western">
<surname>Miyajima</surname>
<given-names>A</given-names>
</name>
</person-group>
<article-title>Foxo1 links insulin signaling to C/EBPalpha and regulates gluconeogenesis during liver development</article-title>
<source>The EMBO Journal</source>
<year>2007</year>
<volume>26</volume>
<issue>15</issue>
<fpage>3607</fpage>
<lpage>3615</lpage>
<pub-id pub-id-type="doi">10.1038/sj.emboj.7601784</pub-id>
<pub-id pub-id-type="pmid">17627282</pub-id>
<pub-id pub-id-type="pmcid">PMC1949016</pub-id>
</element-citation>
</ref>
<ref id="CR237">
<label>237.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western">
<surname>Montal</surname>
<given-names>ED</given-names>
</name>
<name name-style="western">
<surname>Dewi</surname>
<given-names>R</given-names>
</name>
<name name-style="western">
<surname>Bhalla</surname>
<given-names>K</given-names>
</name>
<name name-style="western">
<surname>Ou</surname>
<given-names>L</given-names>
</name>
<name name-style="western">
<surname>Hwang</surname>
<given-names>BJ</given-names>
</name>
<name name-style="western">
<surname>Ropell</surname>
<given-names>AE</given-names>
</name>
<etal />
</person-group>
<article-title>PEPCK coordinates the regulation of central carbon metabolism to promote cancer cell growth</article-title>
<source>Molecular Cell</source>
<year>2015</year>
<volume>60</volume>
<issue>4</issue>
<fpage>571</fpage>
<lpage>583</lpage>
<pub-id pub-id-type="doi">10.1016/j.molcel.2015.09.025</pub-id>
<pub-id pub-id-type="pmid">26481663</pub-id>
<pub-id pub-id-type="pmcid">PMC4656111</pub-id>
</element-citation>
</ref>
<ref id="CR238">
<label>238.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western">
<surname>Vincent</surname>
<given-names>EE</given-names>
</name>
<name name-style="western">
<surname>Sergushichev</surname>
<given-names>A</given-names>
</name>
<name name-style="western">
<surname>Griss</surname>
<given-names>T</given-names>
</name>
<name name-style="western">
<surname>Gingras</surname>
<given-names>MC</given-names>
</name>
<name name-style="western">
<surname>Samborska</surname>
<given-names>B</given-names>
</name>
<name name-style="western">
<surname>Ntimbane</surname>
<given-names>T</given-names>
</name>
<etal />
</person-group>
<article-title>Mitochondrial phosphoenolpyruvate carboxykinase regulates metabolic adaptation and enables glucose-independent tumor growth</article-title>
<source>Molecular Cell</source>
<year>2015</year>
<volume>60</volume>
<issue>2</issue>
<fpage>195</fpage>
<lpage>207</lpage>
<pub-id pub-id-type="doi">10.1016/j.molcel.2015.08.013</pub-id>
<pub-id pub-id-type="pmid">26474064</pub-id>
</element-citation>
</ref>
<ref id="CR239">
<label>239.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western">
<surname>Chen</surname>
<given-names>J</given-names>
</name>
<name name-style="western">
<surname>Lee</surname>
<given-names>HJ</given-names>
</name>
<name name-style="western">
<surname>Wu</surname>
<given-names>X</given-names>
</name>
<name name-style="western">
<surname>Huo</surname>
<given-names>L</given-names>
</name>
<name name-style="western">
<surname>Kim</surname>
<given-names>SJ</given-names>
</name>
<name name-style="western">
<surname>Xu</surname>
<given-names>L</given-names>
</name>
<etal />
</person-group>
<article-title>Gain of glucose-independent growth upon metastasis of breast cancer cells to the brain</article-title>
<source>Cancer Research</source>
<year>2015</year>
<volume>75</volume>
<issue>3</issue>
<fpage>554</fpage>
<lpage>565</lpage>
<pub-id pub-id-type="doi">10.1158/0008-5472.CAN-14-2268</pub-id>
<pub-id pub-id-type="pmid">25511375</pub-id>
<pub-id pub-id-type="pmcid">PMC4315743</pub-id>
</element-citation>
</ref>
<ref id="CR240">
<label>240.</label>
<mixed-citation publication-type="other">Nepal, M., Che, R., Ma, C., Zhang, J., &amp; Fei, P. (2017). FANCD2 and DNA damage. <italic toggle="yes">International Journal of Molecular Sciences, 18</italic>(8). 10.3390/ijms18081804.<pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/ijms18081804</pub-id>
<pub-id pub-id-type="pmcid">PMC5578191</pub-id>
<pub-id pub-id-type="pmid">28825622</pub-id>
</mixed-citation>
</ref>
<ref id="CR241">
<label>241.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western">
<surname>Li</surname>
<given-names>J</given-names>
</name>
<name name-style="western">
<surname>Du</surname>
<given-names>W</given-names>
</name>
<name name-style="western">
<surname>Maynard</surname>
<given-names>S</given-names>
</name>
<name name-style="western">
<surname>Andreassen</surname>
<given-names>PR</given-names>
</name>
<name name-style="western">
<surname>Pang</surname>
<given-names>Q</given-names>
</name>
</person-group>
<article-title>Oxidative stress-specific interaction between FANCD2 and FOXO3a</article-title>
<source>Blood</source>
<year>2010</year>
<volume>115</volume>
<issue>8</issue>
<fpage>1545</fpage>
<lpage>1548</lpage>
<pub-id pub-id-type="doi">10.1182/blood-2009-07-234385</pub-id>
<pub-id pub-id-type="pmid">20040763</pub-id>
<pub-id pub-id-type="pmcid">PMC2830760</pub-id>
</element-citation>
</ref>
<ref id="CR242">
<label>242.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western">
<surname>Ozawa</surname>
<given-names>H</given-names>
</name>
<name name-style="western">
<surname>Iwatsuki</surname>
<given-names>M</given-names>
</name>
<name name-style="western">
<surname>Mimori</surname>
<given-names>K</given-names>
</name>
<name name-style="western">
<surname>Sato</surname>
<given-names>T</given-names>
</name>
<name name-style="western">
<surname>Johansson</surname>
<given-names>F</given-names>
</name>
<name name-style="western">
<surname>Toh</surname>
<given-names>H</given-names>
</name>
<etal />
</person-group>
<article-title>FANCD2 mRNA overexpression is a bona fide indicator of lymph node metastasis in human colorectal cancer</article-title>
<source>Annals of Surgical Oncology</source>
<year>2010</year>
<volume>17</volume>
<issue>9</issue>
<fpage>2341</fpage>
<lpage>2348</lpage>
<pub-id pub-id-type="doi">10.1245/s10434-010-1002-7</pub-id>
<pub-id pub-id-type="pmid">20339950</pub-id>
</element-citation>
</ref>
<ref id="CR243">
<label>243.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western">
<surname>Feng</surname>
<given-names>L</given-names>
</name>
<name name-style="western">
<surname>Jin</surname>
<given-names>F</given-names>
</name>
</person-group>
<article-title>Expression and prognostic significance of Fanconi anemia group D2 protein and breast cancer type 1 susceptibility protein in familial and sporadic breast cancer</article-title>
<source>Oncology Letters</source>
<year>2019</year>
<volume>17</volume>
<issue>4</issue>
<fpage>3687</fpage>
<lpage>3700</lpage>
<pub-id pub-id-type="doi">10.3892/ol.2019.10046</pub-id>
<pub-id pub-id-type="pmid">30881493</pub-id>
<pub-id pub-id-type="pmcid">PMC6403512</pub-id>
</element-citation>
</ref>
<ref id="CR244">
<label>244.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western">
<surname>Sosa</surname>
<given-names>V</given-names>
</name>
<name name-style="western">
<surname>Moline</surname>
<given-names>T</given-names>
</name>
<name name-style="western">
<surname>Somoza</surname>
<given-names>R</given-names>
</name>
<name name-style="western">
<surname>Paciucci</surname>
<given-names>R</given-names>
</name>
<name name-style="western">
<surname>Kondoh</surname>
<given-names>H</given-names>
</name>
<name name-style="western">
<surname>Me</surname>
<given-names>LL</given-names>
</name>
</person-group>
<article-title>Oxidative stress and cancer: an overview</article-title>
<source>Ageing Research Reviews</source>
<year>2013</year>
<volume>12</volume>
<issue>1</issue>
<fpage>376</fpage>
<lpage>390</lpage>
<pub-id pub-id-type="doi">10.1016/j.arr.2012.10.004</pub-id>
<pub-id pub-id-type="pmid">23123177</pub-id>
</element-citation>
</ref>
<ref id="CR245">
<label>245.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western">
<surname>Myatt</surname>
<given-names>SS</given-names>
</name>
<name name-style="western">
<surname>Brosens</surname>
<given-names>JJ</given-names>
</name>
<name name-style="western">
<surname>Lam</surname>
<given-names>EW</given-names>
</name>
</person-group>
<article-title>Sense and sensitivity: FOXO and ROS in cancer development and treatment</article-title>
<source>Antioxidants &amp; Redox Signaling</source>
<year>2011</year>
<volume>14</volume>
<issue>4</issue>
<fpage>675</fpage>
<lpage>687</lpage>
<pub-id pub-id-type="doi">10.1089/ars.2010.3383</pub-id>
<pub-id pub-id-type="pmid">20649462</pub-id>
</element-citation>
</ref>
<ref id="CR246">
<label>246.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western">
<surname>Chen</surname>
<given-names>H</given-names>
</name>
<name name-style="western">
<surname>Liu</surname>
<given-names>H</given-names>
</name>
<name name-style="western">
<surname>Qing</surname>
<given-names>G</given-names>
</name>
</person-group>
<article-title>Targeting oncogenic Myc as a strategy for cancer treatment</article-title>
<source>Signal Transduction and Targeted Therapy</source>
<year>2018</year>
<volume>3</volume>
<fpage>5</fpage>
<pub-id pub-id-type="doi">10.1038/s41392-018-0008-7</pub-id>
<pub-id pub-id-type="pmid">29527331</pub-id>
<pub-id pub-id-type="pmcid">PMC5837124</pub-id>
</element-citation>
</ref>
<ref id="CR247">
<label>247.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western">
<surname>Chandramohan</surname>
<given-names>V</given-names>
</name>
<name name-style="western">
<surname>Jeay</surname>
<given-names>S</given-names>
</name>
<name name-style="western">
<surname>Pianetti</surname>
<given-names>S</given-names>
</name>
<name name-style="western">
<surname>Sonenshein</surname>
<given-names>GE</given-names>
</name>
</person-group>
<article-title>Reciprocal control of forkhead box O 3a and c-Myc via the phosphatidylinositol 3-kinase pathway coordinately regulates p27Kip1 levels</article-title>
<source>Journal of Immunology</source>
<year>2004</year>
<volume>172</volume>
<issue>9</issue>
<fpage>5522</fpage>
<lpage>5527</lpage>
<pub-id pub-id-type="doi">10.4049/jimmunol.172.9.5522</pub-id>
<pub-id pub-id-type="pmid">15100294</pub-id>
</element-citation>
</ref>
<ref id="CR248">
<label>248.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western">
<surname>Lloyd</surname>
<given-names>RV</given-names>
</name>
<name name-style="western">
<surname>Erickson</surname>
<given-names>LA</given-names>
</name>
<name name-style="western">
<surname>Jin</surname>
<given-names>L</given-names>
</name>
<name name-style="western">
<surname>Kulig</surname>
<given-names>E</given-names>
</name>
<name name-style="western">
<surname>Qian</surname>
<given-names>X</given-names>
</name>
<name name-style="western">
<surname>Cheville</surname>
<given-names>JC</given-names>
</name>
<etal />
</person-group>
<article-title>p27kip1: a multifunctional cyclin-dependent kinase inhibitor with prognostic significance in human cancers</article-title>
<source>The American Journal of Pathology</source>
<year>1999</year>
<volume>154</volume>
<issue>2</issue>
<fpage>313</fpage>
<lpage>323</lpage>
<pub-id pub-id-type="doi">10.1016/S0002-9440(10)65277-7</pub-id>
<pub-id pub-id-type="pmid">10027389</pub-id>
<pub-id pub-id-type="pmcid">PMC1850003</pub-id>
</element-citation>
</ref>
<ref id="CR249">
<label>249.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western">
<surname>Zhao</surname>
<given-names>Y</given-names>
</name>
<name name-style="western">
<surname>Tindall</surname>
<given-names>DJ</given-names>
</name>
<name name-style="western">
<surname>Huang</surname>
<given-names>H</given-names>
</name>
</person-group>
<article-title>Modulation of androgen receptor by FOXA1 and FOXO1 factors in prostate cancer</article-title>
<source>International Journal of Biological Sciences</source>
<year>2014</year>
<volume>10</volume>
<issue>6</issue>
<fpage>614</fpage>
<lpage>619</lpage>
<pub-id pub-id-type="doi">10.7150/ijbs.8389</pub-id>
<pub-id pub-id-type="pmid">24948874</pub-id>
<pub-id pub-id-type="pmcid">PMC4062954</pub-id>
</element-citation>
</ref>
<ref id="CR250">
<label>250.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western">
<surname>Miska</surname>
<given-names>EA</given-names>
</name>
</person-group>
<article-title>How microRNAs control cell division, differentiation and death</article-title>
<source>Current Opinion in Genetics &amp; Development</source>
<year>2005</year>
<volume>15</volume>
<issue>5</issue>
<fpage>563</fpage>
<lpage>568</lpage>
<pub-id pub-id-type="doi">10.1016/j.gde.2005.08.005</pub-id>
<pub-id pub-id-type="pmid">16099643</pub-id>
</element-citation>
</ref>
<ref id="CR251">
<label>251.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western">
<surname>Vandenboom Ii</surname>
<given-names>TG</given-names>
</name>
<name name-style="western">
<surname>Li</surname>
<given-names>Y</given-names>
</name>
<name name-style="western">
<surname>Philip</surname>
<given-names>PA</given-names>
</name>
<name name-style="western">
<surname>Sarkar</surname>
<given-names>FH</given-names>
</name>
</person-group>
<article-title>MicroRNA and cancer: tiny molecules with major implications</article-title>
<source>Current Genomics</source>
<year>2008</year>
<volume>9</volume>
<issue>2</issue>
<fpage>97</fpage>
<lpage>109</lpage>
<pub-id pub-id-type="doi">10.2174/138920208784139555</pub-id>
<pub-id pub-id-type="pmid">19440450</pub-id>
<pub-id pub-id-type="pmcid">PMC2674802</pub-id>
</element-citation>
</ref>
<ref id="CR252">
<label>252.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western">
<surname>Li</surname>
<given-names>F</given-names>
</name>
<name name-style="western">
<surname>Liu</surname>
<given-names>B</given-names>
</name>
<name name-style="western">
<surname>Gao</surname>
<given-names>Y</given-names>
</name>
<name name-style="western">
<surname>Liu</surname>
<given-names>Y</given-names>
</name>
<name name-style="western">
<surname>Xu</surname>
<given-names>Y</given-names>
</name>
<name name-style="western">
<surname>Tong</surname>
<given-names>W</given-names>
</name>
<etal />
</person-group>
<article-title>Upregulation of microRNA-107 induces proliferation in human gastric cancer cells by targeting the transcription factor FOXO1</article-title>
<source>FEBS Letters</source>
<year>2014</year>
<volume>588</volume>
<issue>4</issue>
<fpage>538</fpage>
<lpage>544</lpage>
<pub-id pub-id-type="doi">10.1016/j.febslet.2013.12.009</pub-id>
<pub-id pub-id-type="pmid">24374340</pub-id>
</element-citation>
</ref>
<ref id="CR253">
<label>253.</label>
<mixed-citation publication-type="other">Li, W., Zhang, J., Chen, T., Yin, P., Yang, J., &amp; Cao, Y. (2015). miR-132 upregulation promotes gastric cancer cell growth through suppression of FoxO1 translation. <italic toggle="yes">Tumour Biology</italic>. 10.1007/s13277-015-3924-y.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s13277-015-3924-y</pub-id>
<pub-id pub-id-type="pmid">26298723</pub-id>
</mixed-citation>
</ref>
<ref id="CR254">
<label>254.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western">
<surname>Yang</surname>
<given-names>XW</given-names>
</name>
<name name-style="western">
<surname>Shen</surname>
<given-names>GZ</given-names>
</name>
<name name-style="western">
<surname>Cao</surname>
<given-names>LQ</given-names>
</name>
<name name-style="western">
<surname>Jiang</surname>
<given-names>XF</given-names>
</name>
<name name-style="western">
<surname>Peng</surname>
<given-names>HP</given-names>
</name>
<name name-style="western">
<surname>Shen</surname>
<given-names>G</given-names>
</name>
<etal />
</person-group>
<article-title>MicroRNA-1269 promotes proliferation in human hepatocellular carcinoma via downregulation of FOXO1</article-title>
<source>BMC Cancer</source>
<year>2014</year>
<volume>14</volume>
<fpage>909</fpage>
<pub-id pub-id-type="doi">10.1186/1471-2407-14-909</pub-id>
<pub-id pub-id-type="pmid">25472505</pub-id>
<pub-id pub-id-type="pmcid">PMC4265494</pub-id>
</element-citation>
</ref>
<ref id="CR255">
<label>255.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western">
<surname>Wu</surname>
<given-names>L</given-names>
</name>
<name name-style="western">
<surname>Li</surname>
<given-names>H</given-names>
</name>
<name name-style="western">
<surname>Jia</surname>
<given-names>CY</given-names>
</name>
<name name-style="western">
<surname>Cheng</surname>
<given-names>W</given-names>
</name>
<name name-style="western">
<surname>Yu</surname>
<given-names>M</given-names>
</name>
<name name-style="western">
<surname>Peng</surname>
<given-names>M</given-names>
</name>
<etal />
</person-group>
<article-title>MicroRNA-223 regulates FOXO1 expression and cell proliferation</article-title>
<source>FEBS Letters</source>
<year>2012</year>
<volume>586</volume>
<issue>7</issue>
<fpage>1038</fpage>
<lpage>1043</lpage>
<pub-id pub-id-type="doi">10.1016/j.febslet.2012.02.050</pub-id>
<pub-id pub-id-type="pmid">22569260</pub-id>
</element-citation>
</ref>
<ref id="CR256">
<label>256.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western">
<surname>Song</surname>
<given-names>W</given-names>
</name>
<name name-style="western">
<surname>Li</surname>
<given-names>Q</given-names>
</name>
<name name-style="western">
<surname>Wang</surname>
<given-names>L</given-names>
</name>
<name name-style="western">
<surname>Wang</surname>
<given-names>L</given-names>
</name>
</person-group>
<article-title>Modulation of FoxO1 expression by miR-21 to promote growth of pancreatic ductal adenocarcinoma</article-title>
<source>Cellular Physiology and Biochemistry</source>
<year>2015</year>
<volume>35</volume>
<issue>1</issue>
<fpage>184</fpage>
<lpage>190</lpage>
<pub-id pub-id-type="doi">10.1159/000369686</pub-id>
<pub-id pub-id-type="pmid">25591761</pub-id>
</element-citation>
</ref>
<ref id="CR257">
<label>257.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western">
<surname>Song</surname>
<given-names>W</given-names>
</name>
<name name-style="western">
<surname>Wang</surname>
<given-names>L</given-names>
</name>
<name name-style="western">
<surname>Wang</surname>
<given-names>L</given-names>
</name>
<name name-style="western">
<surname>Li</surname>
<given-names>Q</given-names>
</name>
</person-group>
<article-title>Interplay of miR-21 and FoxO1 modulates growth of pancreatic ductal adenocarcinoma</article-title>
<source>Tumour Biology</source>
<year>2015</year>
<volume>36</volume>
<issue>6</issue>
<fpage>4741</fpage>
<lpage>4745</lpage>
<pub-id pub-id-type="doi">10.1007/s13277-015-3123-x</pub-id>
<pub-id pub-id-type="pmid">25623117</pub-id>
</element-citation>
</ref>
<ref id="CR258">
<label>258.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western">
<surname>Liu</surname>
<given-names>ZL</given-names>
</name>
<name name-style="western">
<surname>Wang</surname>
<given-names>H</given-names>
</name>
<name name-style="western">
<surname>Liu</surname>
<given-names>J</given-names>
</name>
<name name-style="western">
<surname>Wang</surname>
<given-names>ZX</given-names>
</name>
</person-group>
<article-title>MicroRNA-21 (miR-21) expression promotes growth, metastasis, and chemo- or radioresistance in non-small cell lung cancer cells by targeting PTEN</article-title>
<source>Molecular and Cellular Biochemistry</source>
<year>2013</year>
<volume>372</volume>
<issue>1–2</issue>
<fpage>35</fpage>
<lpage>45</lpage>
<pub-id pub-id-type="doi">10.1007/s11010-012-1443-3</pub-id>
<pub-id pub-id-type="pmid">22956424</pub-id>
</element-citation>
</ref>
<ref id="CR259">
<label>259.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western">
<surname>Li</surname>
<given-names>C</given-names>
</name>
<name name-style="western">
<surname>Zhang</surname>
<given-names>K</given-names>
</name>
<name name-style="western">
<surname>Chen</surname>
<given-names>J</given-names>
</name>
<name name-style="western">
<surname>Chen</surname>
<given-names>L</given-names>
</name>
<name name-style="western">
<surname>Wang</surname>
<given-names>R</given-names>
</name>
<name name-style="western">
<surname>Chu</surname>
<given-names>X</given-names>
</name>
</person-group>
<article-title>MicroRNAs as regulators and mediators of forkhead box transcription factors function in human cancers</article-title>
<source>Oncotarget</source>
<year>2017</year>
<volume>8</volume>
<issue>7</issue>
<fpage>12433</fpage>
<lpage>12450</lpage>
<pub-id pub-id-type="doi">10.18632/oncotarget.14015</pub-id>
<pub-id pub-id-type="pmid">27999212</pub-id>
<pub-id pub-id-type="pmcid">PMC5355356</pub-id>
</element-citation>
</ref>
<ref id="CR260">
<label>260.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western">
<surname>Leung</surname>
<given-names>WK</given-names>
</name>
<name name-style="western">
<surname>He</surname>
<given-names>M</given-names>
</name>
<name name-style="western">
<surname>Chan</surname>
<given-names>AW</given-names>
</name>
<name name-style="western">
<surname>Law</surname>
<given-names>PT</given-names>
</name>
<name name-style="western">
<surname>Wong</surname>
<given-names>N</given-names>
</name>
</person-group>
<article-title>Wnt/beta-catenin activates MiR-183/96/182 expression in hepatocellular carcinoma that promotes cell invasion</article-title>
<source>Cancer Letters</source>
<year>2015</year>
<volume>362</volume>
<issue>1</issue>
<fpage>97</fpage>
<lpage>105</lpage>
<pub-id pub-id-type="doi">10.1016/j.canlet.2015.03.023</pub-id>
<pub-id pub-id-type="pmid">25813403</pub-id>
</element-citation>
</ref>
<ref id="CR261">
<label>261.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western">
<surname>Ren</surname>
<given-names>JW</given-names>
</name>
<name name-style="western">
<surname>Li</surname>
<given-names>ZJ</given-names>
</name>
<name name-style="western">
<surname>Tu</surname>
<given-names>C</given-names>
</name>
</person-group>
<article-title>MiR-135 post-transcriptionally regulates FOXO1 expression and promotes cell proliferation in human malignant melanoma cells</article-title>
<source>International Journal of Clinical and Experimental Pathology</source>
<year>2015</year>
<volume>8</volume>
<issue>6</issue>
<fpage>6356</fpage>
<lpage>6366</lpage>
<pub-id pub-id-type="pmid">26261511</pub-id>
<pub-id pub-id-type="pmcid">PMC4525845</pub-id>
</element-citation>
</ref>
<ref id="CR262">
<label>262.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western">
<surname>Yao</surname>
<given-names>GD</given-names>
</name>
<name name-style="western">
<surname>Zhang</surname>
<given-names>YF</given-names>
</name>
<name name-style="western">
<surname>Chen</surname>
<given-names>P</given-names>
</name>
<name name-style="western">
<surname>Ren</surname>
<given-names>XB</given-names>
</name>
</person-group>
<article-title>MicroRNA-544 promotes colorectal cancer progression by targeting forkhead box O1</article-title>
<source>Oncology Letters</source>
<year>2018</year>
<volume>15</volume>
<issue>1</issue>
<fpage>991</fpage>
<lpage>997</lpage>
<pub-id pub-id-type="doi">10.3892/ol.2017.7381</pub-id>
<pub-id pub-id-type="pmid">29422969</pub-id>
<pub-id pub-id-type="pmcid">PMC5772941</pub-id>
</element-citation>
</ref>
<ref id="CR263">
<label>263.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western">
<surname>Myatt</surname>
<given-names>SS</given-names>
</name>
<name name-style="western">
<surname>Wang</surname>
<given-names>J</given-names>
</name>
<name name-style="western">
<surname>Monteiro</surname>
<given-names>LJ</given-names>
</name>
<name name-style="western">
<surname>Christian</surname>
<given-names>M</given-names>
</name>
<name name-style="western">
<surname>Ho</surname>
<given-names>KK</given-names>
</name>
<name name-style="western">
<surname>Fusi</surname>
<given-names>L</given-names>
</name>
<etal />
</person-group>
<article-title>Definition of microRNAs that repress expression of the tumor suppressor gene FOXO1 in endometrial cancer</article-title>
<source>Cancer Research</source>
<year>2010</year>
<volume>70</volume>
<issue>1</issue>
<fpage>367</fpage>
<lpage>377</lpage>
<pub-id pub-id-type="doi">10.1158/0008-5472.CAN-09-1891</pub-id>
<pub-id pub-id-type="pmid">20028871</pub-id>
<pub-id pub-id-type="pmcid">PMC2880714</pub-id>
</element-citation>
</ref>
<ref id="CR264">
<label>264.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western">
<surname>Li</surname>
<given-names>W</given-names>
</name>
<name name-style="western">
<surname>Yi</surname>
<given-names>J</given-names>
</name>
<name name-style="western">
<surname>Zheng</surname>
<given-names>X</given-names>
</name>
<name name-style="western">
<surname>Liu</surname>
<given-names>S</given-names>
</name>
<name name-style="western">
<surname>Fu</surname>
<given-names>W</given-names>
</name>
<name name-style="western">
<surname>Ren</surname>
<given-names>L</given-names>
</name>
<etal />
</person-group>
<article-title>miR-29c plays a suppressive role in breast cancer by targeting the TIMP3/STAT1/FOXO1 pathway</article-title>
<source>Clinical Epigenetics</source>
<year>2018</year>
<volume>10</volume>
<fpage>64</fpage>
<pub-id pub-id-type="doi">10.1186/s13148-018-0495-y</pub-id>
<pub-id pub-id-type="pmid">29796115</pub-id>
<pub-id pub-id-type="pmcid">PMC5956756</pub-id>
</element-citation>
</ref>
<ref id="CR265">
<label>265.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western">
<surname>Pei</surname>
<given-names>H</given-names>
</name>
<name name-style="western">
<surname>Jin</surname>
<given-names>Z</given-names>
</name>
<name name-style="western">
<surname>Chen</surname>
<given-names>S</given-names>
</name>
<name name-style="western">
<surname>Sun</surname>
<given-names>X</given-names>
</name>
<name name-style="western">
<surname>Yu</surname>
<given-names>J</given-names>
</name>
<name name-style="western">
<surname>Guo</surname>
<given-names>W</given-names>
</name>
</person-group>
<article-title>MiR-135b promotes proliferation and invasion of osteosarcoma cells via targeting FOXO1</article-title>
<source>Molecular and Cellular Biochemistry</source>
<year>2015</year>
<volume>400</volume>
<issue>1–2</issue>
<fpage>245</fpage>
<lpage>252</lpage>
<pub-id pub-id-type="doi">10.1007/s11010-014-2281-2</pub-id>
<pub-id pub-id-type="pmid">25416447</pub-id>
</element-citation>
</ref>
<ref id="CR266">
<label>266.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western">
<surname>Xia</surname>
<given-names>J</given-names>
</name>
<name name-style="western">
<surname>Wu</surname>
<given-names>Z</given-names>
</name>
<name name-style="western">
<surname>Yu</surname>
<given-names>C</given-names>
</name>
<name name-style="western">
<surname>He</surname>
<given-names>W</given-names>
</name>
<name name-style="western">
<surname>Zheng</surname>
<given-names>H</given-names>
</name>
<name name-style="western">
<surname>He</surname>
<given-names>Y</given-names>
</name>
<etal />
</person-group>
<article-title>miR-124 inhibits cell proliferation in gastric cancer through down-regulation of SPHK1</article-title>
<source>The Journal of Pathology</source>
<year>2012</year>
<volume>227</volume>
<issue>4</issue>
<fpage>470</fpage>
<lpage>480</lpage>
<pub-id pub-id-type="doi">10.1002/path.4030</pub-id>
<pub-id pub-id-type="pmid">22450659</pub-id>
</element-citation>
</ref>
<ref id="CR267">
<label>267.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western">
<surname>Wang</surname>
<given-names>Y</given-names>
</name>
<name name-style="western">
<surname>Hu</surname>
<given-names>C</given-names>
</name>
<name name-style="western">
<surname>Cheng</surname>
<given-names>J</given-names>
</name>
<name name-style="western">
<surname>Chen</surname>
<given-names>B</given-names>
</name>
<name name-style="western">
<surname>Ke</surname>
<given-names>Q</given-names>
</name>
<name name-style="western">
<surname>Lv</surname>
<given-names>Z</given-names>
</name>
<etal />
</person-group>
<article-title>MicroRNA-145 suppresses hepatocellular carcinoma by targeting IRS1 and its downstream Akt signaling</article-title>
<source>Biochemical and Biophysical Research Communications</source>
<year>2014</year>
<volume>446</volume>
<issue>4</issue>
<fpage>1255</fpage>
<lpage>1260</lpage>
<pub-id pub-id-type="doi">10.1016/j.bbrc.2014.03.107</pub-id>
<pub-id pub-id-type="pmid">24690171</pub-id>
</element-citation>
</ref>
<ref id="CR268">
<label>268.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western">
<surname>Gao</surname>
<given-names>F</given-names>
</name>
<name name-style="western">
<surname>Wang</surname>
<given-names>W</given-names>
</name>
</person-group>
<article-title>MicroRNA-96 promotes the proliferation of colorectal cancer cells and targets tumor protein p53 inducible nuclear protein 1, forkhead box protein O1 (FOXO1) and FOXO3a</article-title>
<source>Molecular Medicine Reports</source>
<year>2015</year>
<volume>11</volume>
<issue>2</issue>
<fpage>1200</fpage>
<lpage>1206</lpage>
<pub-id pub-id-type="doi">10.3892/mmr.2014.2854</pub-id>
<pub-id pub-id-type="pmid">25369914</pub-id>
</element-citation>
</ref>
<ref id="CR269">
<label>269.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western">
<surname>Wallis</surname>
<given-names>CJ</given-names>
</name>
<name name-style="western">
<surname>Gordanpour</surname>
<given-names>A</given-names>
</name>
<name name-style="western">
<surname>Bendavid</surname>
<given-names>JS</given-names>
</name>
<name name-style="western">
<surname>Sugar</surname>
<given-names>L</given-names>
</name>
<name name-style="western">
<surname>Nam</surname>
<given-names>RK</given-names>
</name>
<name name-style="western">
<surname>Seth</surname>
<given-names>A</given-names>
</name>
</person-group>
<article-title>MiR-182 is associated with growth, migration and invasion in prostate cancer via suppression of FOXO1</article-title>
<source>Journal of Cancer</source>
<year>2015</year>
<volume>6</volume>
<issue>12</issue>
<fpage>1295</fpage>
<lpage>1305</lpage>
<pub-id pub-id-type="doi">10.7150/jca.13176</pub-id>
<pub-id pub-id-type="pmid">26640590</pub-id>
<pub-id pub-id-type="pmcid">PMC4643086</pub-id>
</element-citation>
</ref>
<ref id="CR270">
<label>270.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western">
<surname>Segura</surname>
<given-names>MF</given-names>
</name>
<name name-style="western">
<surname>Hanniford</surname>
<given-names>D</given-names>
</name>
<name name-style="western">
<surname>Menendez</surname>
<given-names>S</given-names>
</name>
<name name-style="western">
<surname>Reavie</surname>
<given-names>L</given-names>
</name>
<name name-style="western">
<surname>Zou</surname>
<given-names>X</given-names>
</name>
<name name-style="western">
<surname>Alvarez-Diaz</surname>
<given-names>S</given-names>
</name>
<etal />
</person-group>
<article-title>Aberrant miR-182 expression promotes melanoma metastasis by repressing FOXO3 and microphthalmia-associated transcription factor</article-title>
<source>Proceedings of the National Academy of Sciences of the United States of America</source>
<year>2009</year>
<volume>106</volume>
<issue>6</issue>
<fpage>1814</fpage>
<lpage>1819</lpage>
<pub-id pub-id-type="doi">10.1073/pnas.0808263106</pub-id>
<pub-id pub-id-type="pmid">19188590</pub-id>
<pub-id pub-id-type="pmcid">PMC2634798</pub-id>
</element-citation>
</ref>
<ref id="CR271">
<label>271.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western">
<surname>Xu</surname>
<given-names>X</given-names>
</name>
<name name-style="western">
<surname>Ayub</surname>
<given-names>B</given-names>
</name>
<name name-style="western">
<surname>Liu</surname>
<given-names>Z</given-names>
</name>
<name name-style="western">
<surname>Serna</surname>
<given-names>VA</given-names>
</name>
<name name-style="western">
<surname>Qiang</surname>
<given-names>W</given-names>
</name>
<name name-style="western">
<surname>Liu</surname>
<given-names>Y</given-names>
</name>
<etal />
</person-group>
<article-title>Anti-miR182 reduces ovarian cancer burden, invasion, and metastasis: an in vivo study in orthotopic xenografts of nude mice</article-title>
<source>Molecular Cancer Therapeutics</source>
<year>2014</year>
<volume>13</volume>
<issue>7</issue>
<fpage>1729</fpage>
<lpage>1739</lpage>
<pub-id pub-id-type="doi">10.1158/1535-7163.MCT-13-0982</pub-id>
<pub-id pub-id-type="pmid">24825857</pub-id>
<pub-id pub-id-type="pmcid">PMC4096544</pub-id>
</element-citation>
</ref>
<ref id="CR272">
<label>272.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western">
<surname>Liu</surname>
<given-names>Y</given-names>
</name>
<name name-style="western">
<surname>Ao</surname>
<given-names>X</given-names>
</name>
<name name-style="western">
<surname>Ding</surname>
<given-names>W</given-names>
</name>
<name name-style="western">
<surname>Ponnusamy</surname>
<given-names>M</given-names>
</name>
<name name-style="western">
<surname>Wu</surname>
<given-names>W</given-names>
</name>
<name name-style="western">
<surname>Hao</surname>
<given-names>X</given-names>
</name>
<etal />
</person-group>
<article-title>Critical role of FOXO3a in carcinogenesis</article-title>
<source>Molecular Cancer</source>
<year>2018</year>
<volume>17</volume>
<issue>1</issue>
<fpage>104</fpage>
<pub-id pub-id-type="doi">10.1186/s12943-018-0856-3</pub-id>
<pub-id pub-id-type="pmid">30045773</pub-id>
<pub-id pub-id-type="pmcid">PMC6060507</pub-id>
</element-citation>
</ref>
<ref id="CR273">
<label>273.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western">
<surname>Wong</surname>
<given-names>HK</given-names>
</name>
<name name-style="western">
<surname>Veremeyko</surname>
<given-names>T</given-names>
</name>
<name name-style="western">
<surname>Patel</surname>
<given-names>N</given-names>
</name>
<name name-style="western">
<surname>Lemere</surname>
<given-names>CA</given-names>
</name>
<name name-style="western">
<surname>Walsh</surname>
<given-names>DM</given-names>
</name>
<name name-style="western">
<surname>Esau</surname>
<given-names>C</given-names>
</name>
<etal />
</person-group>
<article-title>De-repression of FOXO3a death axis by microRNA-132 and -212 causes neuronal apoptosis in Alzheimer’s disease</article-title>
<source>Human Molecular Genetics</source>
<year>2013</year>
<volume>22</volume>
<issue>15</issue>
<fpage>3077</fpage>
<lpage>3092</lpage>
<pub-id pub-id-type="doi">10.1093/hmg/ddt164</pub-id>
<pub-id pub-id-type="pmid">23585551</pub-id>
</element-citation>
</ref>
<ref id="CR274">
<label>274.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western">
<surname>Fu</surname>
<given-names>Q</given-names>
</name>
<name name-style="western">
<surname>Du</surname>
<given-names>Y</given-names>
</name>
<name name-style="western">
<surname>Yang</surname>
<given-names>C</given-names>
</name>
<name name-style="western">
<surname>Zhang</surname>
<given-names>D</given-names>
</name>
<name name-style="western">
<surname>Zhang</surname>
<given-names>N</given-names>
</name>
<name name-style="western">
<surname>Liu</surname>
<given-names>X</given-names>
</name>
<etal />
</person-group>
<article-title>An oncogenic role of miR-592 in tumorigenesis of human colorectal cancer by targeting forkhead box O3A (FoxO3A)</article-title>
<source>Expert Opinion on Therapeutic Targets</source>
<year>2016</year>
<volume>20</volume>
<issue>7</issue>
<fpage>771</fpage>
<lpage>782</lpage>
<pub-id pub-id-type="doi">10.1080/14728222.2016.1181753</pub-id>
<pub-id pub-id-type="pmid">27167185</pub-id>
</element-citation>
</ref>
<ref id="CR275">
<label>275.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western">
<surname>Qiu</surname>
<given-names>X</given-names>
</name>
<name name-style="western">
<surname>Dou</surname>
<given-names>Y</given-names>
</name>
</person-group>
<article-title>miR-1307 promotes the proliferation of prostate cancer by targeting FOXO3A</article-title>
<source>Biomedicine &amp; Pharmacotherapy</source>
<year>2017</year>
<volume>88</volume>
<fpage>430</fpage>
<lpage>435</lpage>
<pub-id pub-id-type="doi">10.1016/j.biopha.2016.11.120</pub-id>
<pub-id pub-id-type="pmid">28122308</pub-id>
</element-citation>
</ref>
<ref id="CR276">
<label>276.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western">
<surname>Liu</surname>
<given-names>X</given-names>
</name>
<name name-style="western">
<surname>Zhang</surname>
<given-names>Z</given-names>
</name>
<name name-style="western">
<surname>Sun</surname>
<given-names>L</given-names>
</name>
<name name-style="western">
<surname>Chai</surname>
<given-names>N</given-names>
</name>
<name name-style="western">
<surname>Tang</surname>
<given-names>S</given-names>
</name>
<name name-style="western">
<surname>Jin</surname>
<given-names>J</given-names>
</name>
<etal />
</person-group>
<article-title>MicroRNA-499-5p promotes cellular invasion and tumor metastasis in colorectal cancer by targeting FOXO4 and PDCD4</article-title>
<source>Carcinogenesis</source>
<year>2011</year>
<volume>32</volume>
<issue>12</issue>
<fpage>1798</fpage>
<lpage>1805</lpage>
<pub-id pub-id-type="doi">10.1093/carcin/bgr213</pub-id>
<pub-id pub-id-type="pmid">21934092</pub-id>
</element-citation>
</ref>
<ref id="CR277">
<label>277.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western">
<surname>Wang</surname>
<given-names>GJ</given-names>
</name>
<name name-style="western">
<surname>Liu</surname>
<given-names>GH</given-names>
</name>
<name name-style="western">
<surname>Ye</surname>
<given-names>YW</given-names>
</name>
<name name-style="western">
<surname>Fu</surname>
<given-names>Y</given-names>
</name>
<name name-style="western">
<surname>Zhang</surname>
<given-names>XF</given-names>
</name>
</person-group>
<article-title>The role of microRNA-1274a in the tumorigenesis of gastric cancer: accelerating cancer cell proliferation and migration via directly targeting FOXO4</article-title>
<source>Biochemical and Biophysical Research Communications</source>
<year>2015</year>
<volume>459</volume>
<issue>4</issue>
<fpage>629</fpage>
<lpage>635</lpage>
<pub-id pub-id-type="doi">10.1016/j.bbrc.2015.02.160</pub-id>
<pub-id pub-id-type="pmid">25753202</pub-id>
</element-citation>
</ref>
<ref id="CR278">
<label>278.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western">
<surname>Li</surname>
<given-names>J</given-names>
</name>
<name name-style="western">
<surname>Hu</surname>
<given-names>L</given-names>
</name>
<name name-style="western">
<surname>Tian</surname>
<given-names>C</given-names>
</name>
<name name-style="western">
<surname>Lu</surname>
<given-names>F</given-names>
</name>
<name name-style="western">
<surname>Wu</surname>
<given-names>J</given-names>
</name>
<name name-style="western">
<surname>Liu</surname>
<given-names>L</given-names>
</name>
</person-group>
<article-title>microRNA-150 promotes cervical cancer cell growth and survival by targeting FOXO4</article-title>
<source>BMC Molecular Biology</source>
<year>2015</year>
<volume>16</volume>
<fpage>24</fpage>
<pub-id pub-id-type="doi">10.1186/s12867-015-0052-6</pub-id>
<pub-id pub-id-type="pmid">26715362</pub-id>
<pub-id pub-id-type="pmcid">PMC4696189</pub-id>
</element-citation>
</ref>
<ref id="CR279">
<label>279.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western">
<surname>Li</surname>
<given-names>H</given-names>
</name>
<name name-style="western">
<surname>Ouyang</surname>
<given-names>R</given-names>
</name>
<name name-style="western">
<surname>Wang</surname>
<given-names>Z</given-names>
</name>
<name name-style="western">
<surname>Zhou</surname>
<given-names>W</given-names>
</name>
<name name-style="western">
<surname>Chen</surname>
<given-names>H</given-names>
</name>
<name name-style="western">
<surname>Jiang</surname>
<given-names>Y</given-names>
</name>
<etal />
</person-group>
<article-title>MiR-150 promotes cellular metastasis in non-small cell lung cancer by targeting FOXO4</article-title>
<source>Scientific Reports</source>
<year>2016</year>
<volume>6</volume>
<fpage>39001</fpage>
<pub-id pub-id-type="doi">10.1038/srep39001</pub-id>
<pub-id pub-id-type="pmid">27976702</pub-id>
<pub-id pub-id-type="pmcid">PMC5157020</pub-id>
</element-citation>
</ref>
<ref id="CR280">
<label>280.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western">
<surname>Zheng</surname>
<given-names>F</given-names>
</name>
<name name-style="western">
<surname>Tang</surname>
<given-names>Q</given-names>
</name>
<name name-style="western">
<surname>Zheng</surname>
<given-names>XH</given-names>
</name>
<name name-style="western">
<surname>Wu</surname>
<given-names>J</given-names>
</name>
<name name-style="western">
<surname>Huang</surname>
<given-names>H</given-names>
</name>
<name name-style="western">
<surname>Zhang</surname>
<given-names>H</given-names>
</name>
<etal />
</person-group>
<article-title>Inactivation of Stat3 and crosstalk of miRNA155-5p and FOXO3a contribute to the induction of IGFBP1 expression by beta-elemene in human lung cancer</article-title>
<source>Experimental &amp; Molecular Medicine</source>
<year>2018</year>
<volume>50</volume>
<issue>9</issue>
<fpage>121</fpage>
<pub-id pub-id-type="doi">10.1038/s12276-018-0146-6</pub-id>
<pub-id pub-id-type="pmid">30209296</pub-id>
<pub-id pub-id-type="pmcid">PMC6135838</pub-id>
</element-citation>
</ref>
<ref id="CR281">
<label>281.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western">
<surname>Zhang</surname>
<given-names>Y</given-names>
</name>
<name name-style="western">
<surname>Zhao</surname>
<given-names>H</given-names>
</name>
<name name-style="western">
<surname>Zhang</surname>
<given-names>L</given-names>
</name>
</person-group>
<article-title>Identification of the tumorsuppressive function of circular RNA FOXO3 in nonsmall cell lung cancer through sponging miR155</article-title>
<source>Molecular Medicine Reports</source>
<year>2018</year>
<volume>17</volume>
<issue>6</issue>
<fpage>7692</fpage>
<lpage>7700</lpage>
<pub-id pub-id-type="doi">10.3892/mmr.2018.8830</pub-id>
<pub-id pub-id-type="pmid">29620202</pub-id>
<pub-id pub-id-type="pmcid">PMC5983971</pub-id>
</element-citation>
</ref>
<ref id="CR282">
<label>282.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western">
<surname>Yang</surname>
<given-names>W</given-names>
</name>
<name name-style="western">
<surname>Du</surname>
<given-names>WW</given-names>
</name>
<name name-style="western">
<surname>Li</surname>
<given-names>X</given-names>
</name>
<name name-style="western">
<surname>Yee</surname>
<given-names>AJ</given-names>
</name>
<name name-style="western">
<surname>Yang</surname>
<given-names>BB</given-names>
</name>
</person-group>
<article-title>Foxo3 activity promoted by non-coding effects of circular RNA and Foxo3 pseudogene in the inhibition of tumor growth and angiogenesis</article-title>
<source>Oncogene</source>
<year>2016</year>
<volume>35</volume>
<issue>30</issue>
<fpage>3919</fpage>
<lpage>3931</lpage>
<pub-id pub-id-type="doi">10.1038/onc.2015.460</pub-id>
<pub-id pub-id-type="pmid">26657152</pub-id>
</element-citation>
</ref>
<ref id="CR283">
<label>283.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western">
<surname>Cheng</surname>
<given-names>CW</given-names>
</name>
<name name-style="western">
<surname>Chen</surname>
<given-names>PM</given-names>
</name>
<name name-style="western">
<surname>Hsieh</surname>
<given-names>YH</given-names>
</name>
<name name-style="western">
<surname>Weng</surname>
<given-names>CC</given-names>
</name>
<name name-style="western">
<surname>Chang</surname>
<given-names>CW</given-names>
</name>
<name name-style="western">
<surname>Yao</surname>
<given-names>CC</given-names>
</name>
<etal />
</person-group>
<article-title>Foxo3a-mediated overexpression of microRNA-622 suppresses tumor metastasis by repressing hypoxia-inducible factor-1alpha in ERK-responsive lung cancer</article-title>
<source>Oncotarget</source>
<year>2015</year>
<volume>6</volume>
<issue>42</issue>
<fpage>44222</fpage>
<lpage>44238</lpage>
<pub-id pub-id-type="doi">10.18632/oncotarget.5826</pub-id>
<pub-id pub-id-type="pmid">26528854</pub-id>
<pub-id pub-id-type="pmcid">PMC4792553</pub-id>
</element-citation>
</ref>
<ref id="CR284">
<label>284.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western">
<surname>Liu</surname>
<given-names>H</given-names>
</name>
<name name-style="western">
<surname>Yin</surname>
<given-names>J</given-names>
</name>
<name name-style="western">
<surname>Wang</surname>
<given-names>H</given-names>
</name>
<name name-style="western">
<surname>Jiang</surname>
<given-names>G</given-names>
</name>
<name name-style="western">
<surname>Deng</surname>
<given-names>M</given-names>
</name>
<name name-style="western">
<surname>Zhang</surname>
<given-names>G</given-names>
</name>
<etal />
</person-group>
<article-title>FOXO3a modulates WNT/beta-catenin signaling and suppresses epithelial-to-mesenchymal transition in prostate cancer cells</article-title>
<source>Cellular Signalling</source>
<year>2015</year>
<volume>27</volume>
<issue>3</issue>
<fpage>510</fpage>
<lpage>518</lpage>
<pub-id pub-id-type="doi">10.1016/j.cellsig.2015.01.001</pub-id>
<pub-id pub-id-type="pmid">25578861</pub-id>
</element-citation>
</ref>
<ref id="CR285">
<label>285.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western">
<surname>Cai</surname>
<given-names>J</given-names>
</name>
<name name-style="western">
<surname>Fang</surname>
<given-names>L</given-names>
</name>
<name name-style="western">
<surname>Huang</surname>
<given-names>Y</given-names>
</name>
<name name-style="western">
<surname>Li</surname>
<given-names>R</given-names>
</name>
<name name-style="western">
<surname>Yuan</surname>
<given-names>J</given-names>
</name>
<name name-style="western">
<surname>Yang</surname>
<given-names>Y</given-names>
</name>
<etal />
</person-group>
<article-title>miR-205 targets PTEN and PHLPP2 to augment AKT signaling and drive malignant phenotypes in non-small cell lung cancer</article-title>
<source>Cancer Research</source>
<year>2013</year>
<volume>73</volume>
<issue>17</issue>
<fpage>5402</fpage>
<lpage>5415</lpage>
<pub-id pub-id-type="doi">10.1158/0008-5472.CAN-13-0297</pub-id>
<pub-id pub-id-type="pmid">23856247</pub-id>
</element-citation>
</ref>
<ref id="CR286">
<label>286.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western">
<surname>Hannenhalli</surname>
<given-names>S</given-names>
</name>
<name name-style="western">
<surname>Kaestner</surname>
<given-names>KH</given-names>
</name>
</person-group>
<article-title>The evolution of Fox genes and their role in development and disease</article-title>
<source>Nature Reviews. Genetics</source>
<year>2009</year>
<volume>10</volume>
<issue>4</issue>
<fpage>233</fpage>
<lpage>240</lpage>
<pub-id pub-id-type="doi">10.1038/nrg2523</pub-id>
<pub-id pub-id-type="pmid">19274050</pub-id>
<pub-id pub-id-type="pmcid">PMC2733165</pub-id>
</element-citation>
</ref>
<ref id="CR287">
<label>287.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western">
<surname>Kalin</surname>
<given-names>TV</given-names>
</name>
<name name-style="western">
<surname>Ustiyan</surname>
<given-names>V</given-names>
</name>
<name name-style="western">
<surname>Kalinichenko</surname>
<given-names>VV</given-names>
</name>
</person-group>
<article-title>Multiple faces of FoxM1 transcription factor: lessons from transgenic mouse models</article-title>
<source>Cell Cycle</source>
<year>2011</year>
<volume>10</volume>
<issue>3</issue>
<fpage>396</fpage>
<lpage>405</lpage>
<pub-id pub-id-type="doi">10.4161/cc.10.3.14709</pub-id>
<pub-id pub-id-type="pmid">21270518</pub-id>
<pub-id pub-id-type="pmcid">PMC3115014</pub-id>
</element-citation>
</ref>
<ref id="CR288">
<label>288.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western">
<surname>Raychaudhuri</surname>
<given-names>P</given-names>
</name>
<name name-style="western">
<surname>Park</surname>
<given-names>HJ</given-names>
</name>
</person-group>
<article-title>FoxM1: a master regulator of tumor metastasis</article-title>
<source>Cancer Research</source>
<year>2011</year>
<volume>71</volume>
<issue>13</issue>
<fpage>4329</fpage>
<lpage>4333</lpage>
<pub-id pub-id-type="doi">10.1158/0008-5472.CAN-11-0640</pub-id>
<pub-id pub-id-type="pmid">21712406</pub-id>
<pub-id pub-id-type="pmcid">PMC3129416</pub-id>
</element-citation>
</ref>
<ref id="CR289">
<label>289.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western">
<surname>Bella</surname>
<given-names>L</given-names>
</name>
<name name-style="western">
<surname>Zona</surname>
<given-names>S</given-names>
</name>
<name name-style="western">
<surname>Nestal de Moraes</surname>
<given-names>G</given-names>
</name>
<name name-style="western">
<surname>Lam</surname>
<given-names>EW</given-names>
</name>
</person-group>
<article-title>FOXM1: a key oncofoetal transcription factor in health and disease</article-title>
<source>Seminars in Cancer Biology</source>
<year>2014</year>
<volume>29</volume>
<fpage>32</fpage>
<lpage>39</lpage>
<pub-id pub-id-type="doi">10.1016/j.semcancer.2014.07.008</pub-id>
<pub-id pub-id-type="pmid">25068996</pub-id>
</element-citation>
</ref>
<ref id="CR290">
<label>290.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western">
<surname>Zona</surname>
<given-names>S</given-names>
</name>
<name name-style="western">
<surname>Bella</surname>
<given-names>L</given-names>
</name>
<name name-style="western">
<surname>Burton</surname>
<given-names>MJ</given-names>
</name>
<name name-style="western">
<surname>Nestal de Moraes</surname>
<given-names>G</given-names>
</name>
<name name-style="western">
<surname>Lam</surname>
<given-names>EW</given-names>
</name>
</person-group>
<article-title>FOXM1: an emerging master regulator of DNA damage response and genotoxic agent resistance</article-title>
<source>Biochimica et Biophysica Acta</source>
<year>2014</year>
<volume>1839</volume>
<issue>11</issue>
<fpage>1316</fpage>
<lpage>1322</lpage>
<pub-id pub-id-type="doi">10.1016/j.bbagrm.2014.09.016</pub-id>
<pub-id pub-id-type="pmid">25287128</pub-id>
<pub-id pub-id-type="pmcid">PMC4316173</pub-id>
</element-citation>
</ref>
<ref id="CR291">
<label>291.</label>
<mixed-citation publication-type="other">Liu, H., Song, Y., Qiu, H., Liu, Y., Luo, K., Yi, Y., et al. (2019). Downregulation of FOXO3a by DNMT1 promotes breast cancer stem cell properties and tumorigenesis. <italic toggle="yes">Cell Death and Differentiation</italic>. 10.1038/s41418-019-0389-3.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41418-019-0389-3</pub-id>
<pub-id pub-id-type="pmcid">PMC7206060</pub-id>
<pub-id pub-id-type="pmid">31296961</pub-id>
</mixed-citation>
</ref>
<ref id="CR292">
<label>292.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western">
<surname>Yu</surname>
<given-names>C</given-names>
</name>
<name name-style="western">
<surname>Chen</surname>
<given-names>L</given-names>
</name>
<name name-style="western">
<surname>Yie</surname>
<given-names>L</given-names>
</name>
<name name-style="western">
<surname>Wei</surname>
<given-names>L</given-names>
</name>
<name name-style="western">
<surname>Wen</surname>
<given-names>T</given-names>
</name>
<name name-style="western">
<surname>Liu</surname>
<given-names>Y</given-names>
</name>
<etal />
</person-group>
<article-title>Targeting FoxM1 inhibits proliferation, invasion and migration of nasopharyngeal carcinoma through the epithelialto-mesenchymal transition pathway</article-title>
<source>Oncology Reports</source>
<year>2015</year>
<volume>33</volume>
<issue>5</issue>
<fpage>2402</fpage>
<lpage>2410</lpage>
<pub-id pub-id-type="doi">10.3892/or.2015.3834</pub-id>
<pub-id pub-id-type="pmid">25738652</pub-id>
</element-citation>
</ref>
<ref id="CR293">
<label>293.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western">
<surname>Yang</surname>
<given-names>N</given-names>
</name>
<name name-style="western">
<surname>Wang</surname>
<given-names>C</given-names>
</name>
<name name-style="western">
<surname>Wang</surname>
<given-names>Z</given-names>
</name>
<name name-style="western">
<surname>Zona</surname>
<given-names>S</given-names>
</name>
<name name-style="western">
<surname>Lin</surname>
<given-names>SX</given-names>
</name>
<name name-style="western">
<surname>Wang</surname>
<given-names>X</given-names>
</name>
<etal />
</person-group>
<article-title>FOXM1 recruits nuclear Aurora kinase A to participate in a positive feedback loop essential for the self-renewal of breast cancer stem cells</article-title>
<source>Oncogene</source>
<year>2017</year>
<volume>36</volume>
<issue>24</issue>
<fpage>3428</fpage>
<lpage>3440</lpage>
<pub-id pub-id-type="doi">10.1038/onc.2016.490</pub-id>
<pub-id pub-id-type="pmid">28114286</pub-id>
<pub-id pub-id-type="pmcid">PMC5485180</pub-id>
</element-citation>
</ref>
<ref id="CR294">
<label>294.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western">
<surname>Lee</surname>
<given-names>SY</given-names>
</name>
<name name-style="western">
<surname>Lee</surname>
<given-names>GR</given-names>
</name>
<name name-style="western">
<surname>Woo</surname>
<given-names>DH</given-names>
</name>
<name name-style="western">
<surname>Park</surname>
<given-names>NH</given-names>
</name>
<name name-style="western">
<surname>Cha</surname>
<given-names>HJ</given-names>
</name>
<name name-style="western">
<surname>Moon</surname>
<given-names>YH</given-names>
</name>
<etal />
</person-group>
<article-title>Depletion of Aurora A leads to upregulation of FoxO1 to induce cell cycle arrest in hepatocellular carcinoma cells</article-title>
<source>Cell Cycle</source>
<year>2013</year>
<volume>12</volume>
<issue>1</issue>
<fpage>67</fpage>
<lpage>75</lpage>
<pub-id pub-id-type="doi">10.4161/cc.22962</pub-id>
<pub-id pub-id-type="pmid">23255113</pub-id>
<pub-id pub-id-type="pmcid">PMC3570518</pub-id>
</element-citation>
</ref>
<ref id="CR295">
<label>295.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western">
<surname>Yang</surname>
<given-names>H</given-names>
</name>
<name name-style="western">
<surname>Wen</surname>
<given-names>L</given-names>
</name>
<name name-style="western">
<surname>Wen</surname>
<given-names>M</given-names>
</name>
<name name-style="western">
<surname>Liu</surname>
<given-names>T</given-names>
</name>
<name name-style="western">
<surname>Zhao</surname>
<given-names>L</given-names>
</name>
<name name-style="western">
<surname>Wu</surname>
<given-names>B</given-names>
</name>
<etal />
</person-group>
<article-title>FoxM1 promotes epithelial-mesenchymal transition, invasion, and migration of tongue squamous cell carcinoma cells through a c-Met/AKT-dependent positive feedback loop</article-title>
<source>Anti-Cancer Drugs</source>
<year>2018</year>
<volume>29</volume>
<issue>3</issue>
<fpage>216</fpage>
<lpage>226</lpage>
<pub-id pub-id-type="doi">10.1097/CAD.0000000000000585</pub-id>
<pub-id pub-id-type="pmid">29360662</pub-id>
<pub-id pub-id-type="pmcid">PMC5821477</pub-id>
</element-citation>
</ref>
<ref id="CR296">
<label>296.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western">
<surname>Xia</surname>
<given-names>L</given-names>
</name>
<name name-style="western">
<surname>Huang</surname>
<given-names>W</given-names>
</name>
<name name-style="western">
<surname>Tian</surname>
<given-names>D</given-names>
</name>
<name name-style="western">
<surname>Zhu</surname>
<given-names>H</given-names>
</name>
<name name-style="western">
<surname>Qi</surname>
<given-names>X</given-names>
</name>
<name name-style="western">
<surname>Chen</surname>
<given-names>Z</given-names>
</name>
<etal />
</person-group>
<article-title>Overexpression of forkhead box C1 promotes tumor metastasis and indicates poor prognosis in hepatocellular carcinoma</article-title>
<source>Hepatology</source>
<year>2013</year>
<volume>57</volume>
<issue>2</issue>
<fpage>610</fpage>
<lpage>624</lpage>
<pub-id pub-id-type="doi">10.1002/hep.26029</pub-id>
<pub-id pub-id-type="pmid">22911555</pub-id>
</element-citation>
</ref>
<ref id="CR297">
<label>297.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western">
<surname>Berry</surname>
<given-names>FB</given-names>
</name>
<name name-style="western">
<surname>Skarie</surname>
<given-names>JM</given-names>
</name>
<name name-style="western">
<surname>Mirzayans</surname>
<given-names>F</given-names>
</name>
<name name-style="western">
<surname>Fortin</surname>
<given-names>Y</given-names>
</name>
<name name-style="western">
<surname>Hudson</surname>
<given-names>TJ</given-names>
</name>
<name name-style="western">
<surname>Raymond</surname>
<given-names>V</given-names>
</name>
<etal />
</person-group>
<article-title>FOXC1 is required for cell viability and resistance to oxidative stress in the eye through the transcriptional regulation of FOXO1A</article-title>
<source>Human Molecular Genetics</source>
<year>2008</year>
<volume>17</volume>
<issue>4</issue>
<fpage>490</fpage>
<lpage>505</lpage>
<pub-id pub-id-type="doi">10.1093/hmg/ddm326</pub-id>
<pub-id pub-id-type="pmid">17993506</pub-id>
</element-citation>
</ref>
<ref id="CR298">
<label>298.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western">
<surname>Liu</surname>
<given-names>J</given-names>
</name>
<name name-style="western">
<surname>Zhang</surname>
<given-names>Z</given-names>
</name>
<name name-style="western">
<surname>Li</surname>
<given-names>X</given-names>
</name>
<name name-style="western">
<surname>Chen</surname>
<given-names>J</given-names>
</name>
<name name-style="western">
<surname>Wang</surname>
<given-names>G</given-names>
</name>
<name name-style="western">
<surname>Tian</surname>
<given-names>Z</given-names>
</name>
<etal />
</person-group>
<article-title>Forkhead box C1 promotes colorectal cancer metastasis through transactivating ITGA7 and FGFR4 expression</article-title>
<source>Oncogene</source>
<year>2018</year>
<volume>37</volume>
<issue>41</issue>
<fpage>5477</fpage>
<lpage>5491</lpage>
<pub-id pub-id-type="doi">10.1038/s41388-018-0355-4</pub-id>
<pub-id pub-id-type="pmid">29884889</pub-id>
</element-citation>
</ref>
<ref id="CR299">
<label>299.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western">
<surname>Sizemore</surname>
<given-names>ST</given-names>
</name>
<name name-style="western">
<surname>Keri</surname>
<given-names>RA</given-names>
</name>
</person-group>
<article-title>The forkhead box transcription factor FOXC1 promotes breast cancer invasion by inducing matrix metalloprotease 7 (MMP7) expression</article-title>
<source>The Journal of Biological Chemistry</source>
<year>2012</year>
<volume>287</volume>
<issue>29</issue>
<fpage>24631</fpage>
<lpage>24640</lpage>
<pub-id pub-id-type="doi">10.1074/jbc.M112.375865</pub-id>
<pub-id pub-id-type="pmid">22645147</pub-id>
<pub-id pub-id-type="pmcid">PMC3397891</pub-id>
</element-citation>
</ref>
<ref id="CR300">
<label>300.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western">
<surname>Ou-Yang</surname>
<given-names>L</given-names>
</name>
<name name-style="western">
<surname>Xiao</surname>
<given-names>SJ</given-names>
</name>
<name name-style="western">
<surname>Liu</surname>
<given-names>P</given-names>
</name>
<name name-style="western">
<surname>Yi</surname>
<given-names>SJ</given-names>
</name>
<name name-style="western">
<surname>Zhang</surname>
<given-names>XL</given-names>
</name>
<name name-style="western">
<surname>Ou-Yang</surname>
<given-names>S</given-names>
</name>
<etal />
</person-group>
<article-title>Forkhead box C1 induces epithelialmesenchymal transition and is a potential therapeutic target in nasopharyngeal carcinoma</article-title>
<source>Molecular Medicine Reports</source>
<year>2015</year>
<volume>12</volume>
<issue>6</issue>
<fpage>8003</fpage>
<lpage>8009</lpage>
<pub-id pub-id-type="doi">10.3892/mmr.2015.4427</pub-id>
<pub-id pub-id-type="pmid">26461269</pub-id>
<pub-id pub-id-type="pmcid">PMC4758279</pub-id>
</element-citation>
</ref>
<ref id="CR301">
<label>301.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western">
<surname>Xu</surname>
<given-names>ZY</given-names>
</name>
<name name-style="western">
<surname>Ding</surname>
<given-names>SM</given-names>
</name>
<name name-style="western">
<surname>Zhou</surname>
<given-names>L</given-names>
</name>
<name name-style="western">
<surname>Xie</surname>
<given-names>HY</given-names>
</name>
<name name-style="western">
<surname>Chen</surname>
<given-names>KJ</given-names>
</name>
<name name-style="western">
<surname>Zhang</surname>
<given-names>W</given-names>
</name>
<etal />
</person-group>
<article-title>FOXC1 contributes to microvascular invasion in primary hepatocellular carcinoma via regulating epithelial-mesenchymal transition</article-title>
<source>International Journal of Biological Sciences</source>
<year>2012</year>
<volume>8</volume>
<issue>8</issue>
<fpage>1130</fpage>
<lpage>1141</lpage>
<pub-id pub-id-type="doi">10.7150/ijbs.4769</pub-id>
<pub-id pub-id-type="pmid">22991501</pub-id>
<pub-id pub-id-type="pmcid">PMC3445051</pub-id>
</element-citation>
</ref>
<ref id="CR302">
<label>302.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western">
<surname>Wang</surname>
<given-names>J</given-names>
</name>
<name name-style="western">
<surname>Li</surname>
<given-names>L</given-names>
</name>
<name name-style="western">
<surname>Liu</surname>
<given-names>S</given-names>
</name>
<name name-style="western">
<surname>Zhao</surname>
<given-names>Y</given-names>
</name>
<name name-style="western">
<surname>Wang</surname>
<given-names>L</given-names>
</name>
<name name-style="western">
<surname>Du</surname>
<given-names>G</given-names>
</name>
</person-group>
<article-title>FOXC1 promotes melanoma by activating MST1R/PI3K/AKT</article-title>
<source>Oncotarget</source>
<year>2016</year>
<volume>7</volume>
<issue>51)</issue>
<fpage>84375</fpage>
<lpage>84387</lpage>
<pub-id pub-id-type="doi">10.18632/oncotarget.11224</pub-id>
<pub-id pub-id-type="pmid">27533251</pub-id>
<pub-id pub-id-type="pmcid">PMC5356666</pub-id>
</element-citation>
</ref>
<ref id="CR303">
<label>303.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western">
<surname>Gozo</surname>
<given-names>MC</given-names>
</name>
<name name-style="western">
<surname>Jia</surname>
<given-names>D</given-names>
</name>
<name name-style="western">
<surname>Aspuria</surname>
<given-names>PJ</given-names>
</name>
<name name-style="western">
<surname>Cheon</surname>
<given-names>DJ</given-names>
</name>
<name name-style="western">
<surname>Miura</surname>
<given-names>N</given-names>
</name>
<name name-style="western">
<surname>Walts</surname>
<given-names>AE</given-names>
</name>
<etal />
</person-group>
<article-title>FOXC2 augments tumor propagation and metastasis in osteosarcoma</article-title>
<source>Oncotarget</source>
<year>2016</year>
<volume>7</volume>
<issue>42</issue>
<fpage>68792</fpage>
<lpage>68802</lpage>
<pub-id pub-id-type="doi">10.18632/oncotarget.11990</pub-id>
<pub-id pub-id-type="pmid">27634875</pub-id>
<pub-id pub-id-type="pmcid">PMC5356590</pub-id>
</element-citation>
</ref>
<ref id="CR304">
<label>304.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western">
<surname>Cui</surname>
<given-names>YM</given-names>
</name>
<name name-style="western">
<surname>Jiao</surname>
<given-names>HL</given-names>
</name>
<name name-style="western">
<surname>Ye</surname>
<given-names>YP</given-names>
</name>
<name name-style="western">
<surname>Chen</surname>
<given-names>CM</given-names>
</name>
<name name-style="western">
<surname>Wang</surname>
<given-names>JX</given-names>
</name>
<name name-style="western">
<surname>Tang</surname>
<given-names>N</given-names>
</name>
<etal />
</person-group>
<article-title>FOXC2 promotes colorectal cancer metastasis by directly targeting MET</article-title>
<source>Oncogene</source>
<year>2015</year>
<volume>34</volume>
<issue>33</issue>
<fpage>4379</fpage>
<lpage>4390</lpage>
<pub-id pub-id-type="doi">10.1038/onc.2014.368</pub-id>
<pub-id pub-id-type="pmid">25381815</pub-id>
</element-citation>
</ref>
<ref id="CR305">
<label>305.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western">
<surname>Hollier</surname>
<given-names>BG</given-names>
</name>
<name name-style="western">
<surname>Tinnirello</surname>
<given-names>AA</given-names>
</name>
<name name-style="western">
<surname>Werden</surname>
<given-names>SJ</given-names>
</name>
<name name-style="western">
<surname>Evans</surname>
<given-names>KW</given-names>
</name>
<name name-style="western">
<surname>Taube</surname>
<given-names>JH</given-names>
</name>
<name name-style="western">
<surname>Sarkar</surname>
<given-names>TR</given-names>
</name>
<etal />
</person-group>
<article-title>FOXC2 expression links epithelial-mesenchymal transition and stem cell properties in breast cancer</article-title>
<source>Cancer Research</source>
<year>2013</year>
<volume>73</volume>
<issue>6</issue>
<fpage>1981</fpage>
<lpage>1992</lpage>
<pub-id pub-id-type="doi">10.1158/0008-5472.CAN-12-2962</pub-id>
<pub-id pub-id-type="pmid">23378344</pub-id>
<pub-id pub-id-type="pmcid">PMC3602160</pub-id>
</element-citation>
</ref>
<ref id="CR306">
<label>306.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western">
<surname>Mani</surname>
<given-names>SA</given-names>
</name>
<name name-style="western">
<surname>Yang</surname>
<given-names>J</given-names>
</name>
<name name-style="western">
<surname>Brooks</surname>
<given-names>M</given-names>
</name>
<name name-style="western">
<surname>Schwaninger</surname>
<given-names>G</given-names>
</name>
<name name-style="western">
<surname>Zhou</surname>
<given-names>A</given-names>
</name>
<name name-style="western">
<surname>Miura</surname>
<given-names>N</given-names>
</name>
<etal />
</person-group>
<article-title>Mesenchyme forkhead 1 (FOXC2) plays a key role in metastasis and is associated with aggressive basal-like breast cancers</article-title>
<source>Proceedings of the National Academy of Sciences of the United States of America</source>
<year>2007</year>
<volume>104</volume>
<issue>24</issue>
<fpage>10069</fpage>
<lpage>10074</lpage>
<pub-id pub-id-type="doi">10.1073/pnas.0703900104</pub-id>
<pub-id pub-id-type="pmid">17537911</pub-id>
<pub-id pub-id-type="pmcid">PMC1891217</pub-id>
</element-citation>
</ref>
<ref id="CR307">
<label>307.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western">
<surname>Cui</surname>
<given-names>YM</given-names>
</name>
<name name-style="western">
<surname>Jiang</surname>
<given-names>D</given-names>
</name>
<name name-style="western">
<surname>Zhang</surname>
<given-names>SH</given-names>
</name>
<name name-style="western">
<surname>Wu</surname>
<given-names>P</given-names>
</name>
<name name-style="western">
<surname>Ye</surname>
<given-names>YP</given-names>
</name>
<name name-style="western">
<surname>Chen</surname>
<given-names>CM</given-names>
</name>
<etal />
</person-group>
<article-title>FOXC2 promotes colorectal cancer proliferation through inhibition of FOXO3a and activation of MAPK and AKT signaling pathways</article-title>
<source>Cancer Letters</source>
<year>2014</year>
<volume>353</volume>
<issue>1</issue>
<fpage>87</fpage>
<lpage>94</lpage>
<pub-id pub-id-type="doi">10.1016/j.canlet.2014.07.008</pub-id>
<pub-id pub-id-type="pmid">25069037</pub-id>
</element-citation>
</ref>
<ref id="CR308">
<label>308.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western">
<surname>Chatterjee</surname>
<given-names>S</given-names>
</name>
<name name-style="western">
<surname>Behnam Azad</surname>
<given-names>B</given-names>
</name>
<name name-style="western">
<surname>Nimmagadda</surname>
<given-names>S</given-names>
</name>
</person-group>
<article-title>The intricate role of CXCR4 in cancer</article-title>
<source>Advances in Cancer Research</source>
<year>2014</year>
<volume>124</volume>
<fpage>31</fpage>
<lpage>82</lpage>
<pub-id pub-id-type="doi">10.1016/B978-0-12-411638-2.00002-1</pub-id>
<pub-id pub-id-type="pmid">25287686</pub-id>
<pub-id pub-id-type="pmcid">PMC4322894</pub-id>
</element-citation>
</ref>
<ref id="CR309">
<label>309.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western">
<surname>Malin</surname>
<given-names>D</given-names>
</name>
<name name-style="western">
<surname>Kim</surname>
<given-names>IM</given-names>
</name>
<name name-style="western">
<surname>Boetticher</surname>
<given-names>E</given-names>
</name>
<name name-style="western">
<surname>Kalin</surname>
<given-names>TV</given-names>
</name>
<name name-style="western">
<surname>Ramakrishna</surname>
<given-names>S</given-names>
</name>
<name name-style="western">
<surname>Meliton</surname>
<given-names>L</given-names>
</name>
<etal />
</person-group>
<article-title>Forkhead box F1 is essential for migration of mesenchymal cells and directly induces integrin-beta3 expression</article-title>
<source>Molecular and Cellular Biology</source>
<year>2007</year>
<volume>27</volume>
<issue>7</issue>
<fpage>2486</fpage>
<lpage>2498</lpage>
<pub-id pub-id-type="doi">10.1128/MCB.01736-06</pub-id>
<pub-id pub-id-type="pmid">17261592</pub-id>
<pub-id pub-id-type="pmcid">PMC1899898</pub-id>
</element-citation>
</ref>
<ref id="CR310">
<label>310.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western">
<surname>Nilsson</surname>
<given-names>G</given-names>
</name>
<name name-style="western">
<surname>Kannius-Janson</surname>
<given-names>M</given-names>
</name>
</person-group>
<article-title>Forkhead box F1 promotes breast cancer cell migration by upregulating lysyl oxidase and suppressing Smad2/3 signaling</article-title>
<source>BMC Cancer</source>
<year>2016</year>
<volume>16</volume>
<fpage>142</fpage>
<pub-id pub-id-type="doi">10.1186/s12885-016-2196-2</pub-id>
<pub-id pub-id-type="pmid">26908052</pub-id>
<pub-id pub-id-type="pmcid">PMC4763409</pub-id>
</element-citation>
</ref>
<ref id="CR311">
<label>311.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western">
<surname>Kun-Peng</surname>
<given-names>Z</given-names>
</name>
<name name-style="western">
<surname>Chun-Lin</surname>
<given-names>Z</given-names>
</name>
<name name-style="western">
<surname>Xiao-Long</surname>
<given-names>M</given-names>
</name>
</person-group>
<article-title>Antisense lncRNA FOXF1-AS1 promotes migration and invasion of osteosarcoma cells through the FOXF1/MMP-2/-9 pathway</article-title>
<source>International Journal of Biological Sciences</source>
<year>2017</year>
<volume>13</volume>
<issue>9</issue>
<fpage>1180</fpage>
<lpage>1191</lpage>
<pub-id pub-id-type="doi">10.7150/ijbs.21722</pub-id>
<pub-id pub-id-type="pmid">29104509</pub-id>
<pub-id pub-id-type="pmcid">PMC5666333</pub-id>
</element-citation>
</ref>
<ref id="CR312">
<label>312.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western">
<surname>Tamura</surname>
<given-names>M</given-names>
</name>
<name name-style="western">
<surname>Sasaki</surname>
<given-names>Y</given-names>
</name>
<name name-style="western">
<surname>Koyama</surname>
<given-names>R</given-names>
</name>
<name name-style="western">
<surname>Takeda</surname>
<given-names>K</given-names>
</name>
<name name-style="western">
<surname>Idogawa</surname>
<given-names>M</given-names>
</name>
<name name-style="western">
<surname>Tokino</surname>
<given-names>T</given-names>
</name>
</person-group>
<article-title>Forkhead transcription factor FOXF1 is a novel target gene of the p53 family and regulates cancer cell migration and invasiveness</article-title>
<source>Oncogene</source>
<year>2014</year>
<volume>33</volume>
<issue>40</issue>
<fpage>4837</fpage>
<lpage>4846</lpage>
<pub-id pub-id-type="doi">10.1038/onc.2013.427</pub-id>
<pub-id pub-id-type="pmid">24186199</pub-id>
</element-citation>
</ref>
<ref id="CR313">
<label>313.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western">
<surname>Wang</surname>
<given-names>S</given-names>
</name>
<name name-style="western">
<surname>Xiao</surname>
<given-names>Z</given-names>
</name>
<name name-style="western">
<surname>Hong</surname>
<given-names>Z</given-names>
</name>
<name name-style="western">
<surname>Jiao</surname>
<given-names>H</given-names>
</name>
<name name-style="western">
<surname>Zhu</surname>
<given-names>S</given-names>
</name>
<name name-style="western">
<surname>Zhao</surname>
<given-names>Y</given-names>
</name>
<etal />
</person-group>
<article-title>FOXF1 promotes angiogenesis and accelerates bevacizumab resistance in colorectal cancer by transcriptionally activating VEGFA</article-title>
<source>Cancer Letters</source>
<year>2018</year>
<volume>439</volume>
<fpage>78</fpage>
<lpage>90</lpage>
<pub-id pub-id-type="doi">10.1016/j.canlet.2018.09.026</pub-id>
<pub-id pub-id-type="pmid">30253191</pub-id>
</element-citation>
</ref>
<ref id="CR314">
<label>314.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western">
<surname>Wang</surname>
<given-names>S</given-names>
</name>
<name name-style="western">
<surname>Yan</surname>
<given-names>S</given-names>
</name>
<name name-style="western">
<surname>Zhu</surname>
<given-names>S</given-names>
</name>
<name name-style="western">
<surname>Zhao</surname>
<given-names>Y</given-names>
</name>
<name name-style="western">
<surname>Yan</surname>
<given-names>J</given-names>
</name>
<name name-style="western">
<surname>Xiao</surname>
<given-names>Z</given-names>
</name>
<etal />
</person-group>
<article-title>FOXF1 induces epithelial-mesenchymal transition in colorectal cancer metastasis by transcriptionally activating SNAI1</article-title>
<source>Neoplasia</source>
<year>2018</year>
<volume>20</volume>
<issue>10</issue>
<fpage>996</fpage>
<lpage>1007</lpage>
<pub-id pub-id-type="doi">10.1016/j.neo.2018.08.004</pub-id>
<pub-id pub-id-type="pmid">30189360</pub-id>
<pub-id pub-id-type="pmcid">PMC6134153</pub-id>
</element-citation>
</ref>
<ref id="CR315">
<label>315.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western">
<surname>Saito</surname>
<given-names>RA</given-names>
</name>
<name name-style="western">
<surname>Micke</surname>
<given-names>P</given-names>
</name>
<name name-style="western">
<surname>Paulsson</surname>
<given-names>J</given-names>
</name>
<name name-style="western">
<surname>Augsten</surname>
<given-names>M</given-names>
</name>
<name name-style="western">
<surname>Pena</surname>
<given-names>C</given-names>
</name>
<name name-style="western">
<surname>Jonsson</surname>
<given-names>P</given-names>
</name>
<etal />
</person-group>
<article-title>Forkhead box F1 regulates tumor-promoting properties of cancer-associated fibroblasts in lung cancer</article-title>
<source>Cancer Research</source>
<year>2010</year>
<volume>70</volume>
<issue>7</issue>
<fpage>2644</fpage>
<lpage>2654</lpage>
<pub-id pub-id-type="doi">10.1158/0008-5472.CAN-09-3644</pub-id>
<pub-id pub-id-type="pmid">20233876</pub-id>
</element-citation>
</ref>
<ref id="CR316">
<label>316.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western">
<surname>Sato</surname>
<given-names>Y</given-names>
</name>
<name name-style="western">
<surname>Baba</surname>
<given-names>T</given-names>
</name>
<name name-style="western">
<surname>Zubair</surname>
<given-names>M</given-names>
</name>
<name name-style="western">
<surname>Miyabayashi</surname>
<given-names>K</given-names>
</name>
<name name-style="western">
<surname>Toyama</surname>
<given-names>Y</given-names>
</name>
<name name-style="western">
<surname>Maekawa</surname>
<given-names>M</given-names>
</name>
<etal />
</person-group>
<article-title>Importance of forkhead transcription factor Fkhl18 for development of testicular vasculature</article-title>
<source>Molecular Reproduction and Development</source>
<year>2008</year>
<volume>75</volume>
<issue>9</issue>
<fpage>1361</fpage>
<lpage>1371</lpage>
<pub-id pub-id-type="doi">10.1002/mrd.20888</pub-id>
<pub-id pub-id-type="pmid">18288644</pub-id>
</element-citation>
</ref>
<ref id="CR317">
<label>317.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western">
<surname>Lu</surname>
<given-names>Q</given-names>
</name>
<name name-style="western">
<surname>Ma</surname>
<given-names>X</given-names>
</name>
<name name-style="western">
<surname>Li</surname>
<given-names>Y</given-names>
</name>
<name name-style="western">
<surname>Song</surname>
<given-names>W</given-names>
</name>
<name name-style="western">
<surname>Zhang</surname>
<given-names>L</given-names>
</name>
<name name-style="western">
<surname>Shu</surname>
<given-names>Y</given-names>
</name>
<etal />
</person-group>
<article-title>Overexpression of FOXS1 in gastric cancer cell lines inhibits proliferation, metastasis, and epithelial-mesenchymal transition of tumor through downregulating wnt/beta-catenin pathway</article-title>
<source>Journal of Cellular Biochemistry</source>
<year>2019</year>
<volume>120</volume>
<issue>3</issue>
<fpage>2897</fpage>
<lpage>2907</lpage>
<pub-id pub-id-type="doi">10.1002/jcb.26821</pub-id>
<pub-id pub-id-type="pmid">30500980</pub-id>
</element-citation>
</ref>
<ref id="CR318">
<label>318.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western">
<surname>Sun</surname>
<given-names>R</given-names>
</name>
<name name-style="western">
<surname>Meng</surname>
<given-names>X</given-names>
</name>
<name name-style="western">
<surname>Wang</surname>
<given-names>W</given-names>
</name>
<name name-style="western">
<surname>Liu</surname>
<given-names>B</given-names>
</name>
<name name-style="western">
<surname>Lv</surname>
<given-names>X</given-names>
</name>
<name name-style="western">
<surname>Yuan</surname>
<given-names>J</given-names>
</name>
<etal />
</person-group>
<article-title>Five genes may predict metastasis in non-small cell lung cancer using bioinformatics analysis</article-title>
<source>Oncology Letters</source>
<year>2019</year>
<volume>18</volume>
<issue>2</issue>
<fpage>1723</fpage>
<lpage>1732</lpage>
<pub-id pub-id-type="doi">10.3892/ol.2019.10498</pub-id>
<pub-id pub-id-type="pmid">31423239</pub-id>
<pub-id pub-id-type="pmcid">PMC6607402</pub-id>
</element-citation>
</ref>
<ref id="CR319">
<label>319.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western">
<surname>Vezzali</surname>
<given-names>R</given-names>
</name>
<name name-style="western">
<surname>Weise</surname>
<given-names>SC</given-names>
</name>
<name name-style="western">
<surname>Hellbach</surname>
<given-names>N</given-names>
</name>
<name name-style="western">
<surname>Machado</surname>
<given-names>V</given-names>
</name>
<name name-style="western">
<surname>Heidrich</surname>
<given-names>S</given-names>
</name>
<name name-style="western">
<surname>Vogel</surname>
<given-names>T</given-names>
</name>
</person-group>
<article-title>The FOXG1/FOXO/SMAD network balances proliferation and differentiation of cortical progenitors and activates Kcnh3 expression in mature neurons</article-title>
<source>Oncotarget</source>
<year>2016</year>
<volume>7</volume>
<issue>25</issue>
<fpage>37436</fpage>
<lpage>37455</lpage>
<pub-id pub-id-type="doi">10.18632/oncotarget.9545</pub-id>
<pub-id pub-id-type="pmid">27224923</pub-id>
<pub-id pub-id-type="pmcid">PMC5122323</pub-id>
</element-citation>
</ref>
<ref id="CR320">
<label>320.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western">
<surname>Seoane</surname>
<given-names>J</given-names>
</name>
<name name-style="western">
<surname>Le</surname>
<given-names>HV</given-names>
</name>
<name name-style="western">
<surname>Shen</surname>
<given-names>L</given-names>
</name>
<name name-style="western">
<surname>Anderson</surname>
<given-names>SA</given-names>
</name>
<name name-style="western">
<surname>Massague</surname>
<given-names>J</given-names>
</name>
</person-group>
<article-title>Integration of Smad and forkhead pathways in the control of neuroepithelial and glioblastoma cell proliferation</article-title>
<source>Cell</source>
<year>2004</year>
<volume>117</volume>
<issue>2</issue>
<fpage>211</fpage>
<lpage>223</lpage>
<pub-id pub-id-type="doi">10.1016/s0092-8674(04)00298-3</pub-id>
<pub-id pub-id-type="pmid">15084259</pub-id>
</element-citation>
</ref>
<ref id="CR321">
<label>321.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western">
<surname>Zeng</surname>
<given-names>F</given-names>
</name>
<name name-style="western">
<surname>Xue</surname>
<given-names>M</given-names>
</name>
<name name-style="western">
<surname>Xiao</surname>
<given-names>T</given-names>
</name>
<name name-style="western">
<surname>Li</surname>
<given-names>Y</given-names>
</name>
<name name-style="western">
<surname>Xiao</surname>
<given-names>S</given-names>
</name>
<name name-style="western">
<surname>Jiang</surname>
<given-names>B</given-names>
</name>
<etal />
</person-group>
<article-title>MiR-200b promotes the cell proliferation and metastasis of cervical cancer by inhibiting FOXG1</article-title>
<source>Biomedicine &amp; Pharmacotherapy</source>
<year>2016</year>
<volume>79</volume>
<fpage>294</fpage>
<lpage>301</lpage>
<pub-id pub-id-type="doi">10.1016/j.biopha.2016.02.033</pub-id>
<pub-id pub-id-type="pmid">27044840</pub-id>
</element-citation>
</ref>
<ref id="CR322">
<label>322.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western">
<surname>Zhang</surname>
<given-names>J</given-names>
</name>
<name name-style="western">
<surname>Yang</surname>
<given-names>Y</given-names>
</name>
<name name-style="western">
<surname>Yang</surname>
<given-names>T</given-names>
</name>
<name name-style="western">
<surname>Yuan</surname>
<given-names>S</given-names>
</name>
<name name-style="western">
<surname>Wang</surname>
<given-names>R</given-names>
</name>
<name name-style="western">
<surname>Pan</surname>
<given-names>Z</given-names>
</name>
<etal />
</person-group>
<article-title>Double-negative feedback loop between microRNA-422a and forkhead box (FOX)G1/Q1/E1 regulates hepatocellular carcinoma tumor growth and metastasis</article-title>
<source>Hepatology</source>
<year>2015</year>
<volume>61</volume>
<issue>2</issue>
<fpage>561</fpage>
<lpage>573</lpage>
<pub-id pub-id-type="doi">10.1002/hep.27491</pub-id>
<pub-id pub-id-type="pmid">25251503</pub-id>
</element-citation>
</ref>
<ref id="CR323">
<label>323.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western">
<surname>Nestal de Moraes</surname>
<given-names>G</given-names>
</name>
<name name-style="western">
<surname>Khongkow</surname>
<given-names>P</given-names>
</name>
<name name-style="western">
<surname>Gong</surname>
<given-names>C</given-names>
</name>
<name name-style="western">
<surname>Yao</surname>
<given-names>S</given-names>
</name>
<name name-style="western">
<surname>Gomes</surname>
<given-names>AR</given-names>
</name>
<name name-style="western">
<surname>Ji</surname>
<given-names>Z</given-names>
</name>
<etal />
</person-group>
<article-title>Forkhead box K2 modulates epirubicin and paclitaxel sensitivity through FOXO3a in breast cancer</article-title>
<source>Oncogenesis</source>
<year>2015</year>
<volume>4</volume>
<fpage>e167</fpage>
<pub-id pub-id-type="doi">10.1038/oncsis.2015.26</pub-id>
<pub-id pub-id-type="pmid">26344694</pub-id>
<pub-id pub-id-type="pmcid">PMC4767938</pub-id>
</element-citation>
</ref>
<ref id="CR324">
<label>324.</label>
<mixed-citation publication-type="other">Nestal de Moraes, G., Carneiro, L. D. T., Maia, R. C., Lam, E. W., &amp; Sharrocks, A. D. (2019). FOXK2 transcription factor and its emerging roles in cancer. <italic toggle="yes">Cancers (Basel), 11</italic>(3). 10.3390/cancers11030393.<pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/cancers11030393</pub-id>
<pub-id pub-id-type="pmcid">PMC6468357</pub-id>
<pub-id pub-id-type="pmid">30897782</pub-id>
</mixed-citation>
</ref>
<ref id="CR325">
<label>325.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western">
<surname>Zhang</surname>
<given-names>H</given-names>
</name>
<name name-style="western">
<surname>Meng</surname>
<given-names>F</given-names>
</name>
<name name-style="western">
<surname>Liu</surname>
<given-names>G</given-names>
</name>
<name name-style="western">
<surname>Zhang</surname>
<given-names>B</given-names>
</name>
<name name-style="western">
<surname>Zhu</surname>
<given-names>J</given-names>
</name>
<name name-style="western">
<surname>Wu</surname>
<given-names>F</given-names>
</name>
<etal />
</person-group>
<article-title>Forkhead transcription factor foxq1 promotes epithelial-mesenchymal transition and breast cancer metastasis</article-title>
<source>Cancer Research</source>
<year>2011</year>
<volume>71</volume>
<issue>4</issue>
<fpage>1292</fpage>
<lpage>1301</lpage>
<pub-id pub-id-type="doi">10.1158/0008-5472.CAN-10-2825</pub-id>
<pub-id pub-id-type="pmid">21285253</pub-id>
<pub-id pub-id-type="pmcid">PMC3906209</pub-id>
</element-citation>
</ref>
<ref id="CR326">
<label>326.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western">
<surname>Zhang</surname>
<given-names>J</given-names>
</name>
<name name-style="western">
<surname>Liu</surname>
<given-names>Y</given-names>
</name>
<name name-style="western">
<surname>Zhang</surname>
<given-names>J</given-names>
</name>
<name name-style="western">
<surname>Cui</surname>
<given-names>X</given-names>
</name>
<name name-style="western">
<surname>Li</surname>
<given-names>G</given-names>
</name>
<name name-style="western">
<surname>Wang</surname>
<given-names>J</given-names>
</name>
<etal />
</person-group>
<article-title>FOXQ1 promotes gastric cancer metastasis through upregulation of Snail</article-title>
<source>Oncology Reports</source>
<year>2016</year>
<volume>35</volume>
<issue>6</issue>
<fpage>3607</fpage>
<lpage>3613</lpage>
<pub-id pub-id-type="doi">10.3892/or.2016.4736</pub-id>
<pub-id pub-id-type="pmid">27109028</pub-id>
</element-citation>
</ref>
<ref id="CR327">
<label>327.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western">
<surname>Zhu</surname>
<given-names>Z</given-names>
</name>
<name name-style="western">
<surname>Zhu</surname>
<given-names>Z</given-names>
</name>
<name name-style="western">
<surname>Pang</surname>
<given-names>Z</given-names>
</name>
<name name-style="western">
<surname>Xing</surname>
<given-names>Y</given-names>
</name>
<name name-style="western">
<surname>Wan</surname>
<given-names>F</given-names>
</name>
<name name-style="western">
<surname>Lan</surname>
<given-names>D</given-names>
</name>
<etal />
</person-group>
<article-title>Short hairpin RNA targeting FOXQ1 inhibits invasion and metastasis via the reversal of epithelial-mesenchymal transition in bladder cancer</article-title>
<source>International Journal of Oncology</source>
<year>2013</year>
<volume>42</volume>
<issue>4</issue>
<fpage>1271</fpage>
<lpage>1278</lpage>
<pub-id pub-id-type="doi">10.3892/ijo.2013.1807</pub-id>
<pub-id pub-id-type="pmid">23403865</pub-id>
</element-citation>
</ref>
<ref id="CR328">
<label>328.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western">
<surname>Fan</surname>
<given-names>DM</given-names>
</name>
<name name-style="western">
<surname>Feng</surname>
<given-names>XS</given-names>
</name>
<name name-style="western">
<surname>Qi</surname>
<given-names>PW</given-names>
</name>
<name name-style="western">
<surname>Chen</surname>
<given-names>YW</given-names>
</name>
</person-group>
<article-title>Forkhead factor FOXQ1 promotes TGF-beta1 expression and induces epithelial-mesenchymal transition</article-title>
<source>Molecular and Cellular Biochemistry</source>
<year>2014</year>
<volume>397</volume>
<issue>1–2</issue>
<fpage>179</fpage>
<lpage>186</lpage>
<pub-id pub-id-type="doi">10.1007/s11010-014-2185-1</pub-id>
<pub-id pub-id-type="pmid">25287361</pub-id>
</element-citation>
</ref>
<ref id="CR329">
<label>329.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western">
<surname>Xia</surname>
<given-names>L</given-names>
</name>
<name name-style="western">
<surname>Huang</surname>
<given-names>W</given-names>
</name>
<name name-style="western">
<surname>Tian</surname>
<given-names>D</given-names>
</name>
<name name-style="western">
<surname>Zhang</surname>
<given-names>L</given-names>
</name>
<name name-style="western">
<surname>Qi</surname>
<given-names>X</given-names>
</name>
<name name-style="western">
<surname>Chen</surname>
<given-names>Z</given-names>
</name>
<etal />
</person-group>
<article-title>Forkhead box Q1 promotes hepatocellular carcinoma metastasis by transactivating ZEB2 and VersicanV1 expression</article-title>
<source>Hepatology</source>
<year>2014</year>
<volume>59</volume>
<issue>3</issue>
<fpage>958</fpage>
<lpage>973</lpage>
<pub-id pub-id-type="doi">10.1002/hep.26735</pub-id>
<pub-id pub-id-type="pmid">24005989</pub-id>
</element-citation>
</ref>
<ref id="CR330">
<label>330.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western">
<surname>Pei</surname>
<given-names>Y</given-names>
</name>
<name name-style="western">
<surname>Wang</surname>
<given-names>P</given-names>
</name>
<name name-style="western">
<surname>Liu</surname>
<given-names>H</given-names>
</name>
<name name-style="western">
<surname>He</surname>
<given-names>F</given-names>
</name>
<name name-style="western">
<surname>Ming</surname>
<given-names>L</given-names>
</name>
</person-group>
<article-title>FOXQ1 promotes esophageal cancer proliferation and metastasis by negatively modulating CDH1</article-title>
<source>Biomedicine &amp; Pharmacotherapy</source>
<year>2015</year>
<volume>74</volume>
<fpage>89</fpage>
<lpage>94</lpage>
<pub-id pub-id-type="doi">10.1016/j.biopha.2015.07.010</pub-id>
<pub-id pub-id-type="pmid">26349968</pub-id>
</element-citation>
</ref>
<ref id="CR331">
<label>331.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western">
<surname>Abba</surname>
<given-names>M</given-names>
</name>
<name name-style="western">
<surname>Patil</surname>
<given-names>N</given-names>
</name>
<name name-style="western">
<surname>Rasheed</surname>
<given-names>K</given-names>
</name>
<name name-style="western">
<surname>Nelson</surname>
<given-names>LD</given-names>
</name>
<name name-style="western">
<surname>Mudduluru</surname>
<given-names>G</given-names>
</name>
<name name-style="western">
<surname>Leupold</surname>
<given-names>JH</given-names>
</name>
<etal />
</person-group>
<article-title>Unraveling the role of FOXQ1 in colorectal cancer metastasis</article-title>
<source>Molecular Cancer Research</source>
<year>2013</year>
<volume>11</volume>
<issue>9</issue>
<fpage>1017</fpage>
<lpage>1028</lpage>
<pub-id pub-id-type="doi">10.1158/1541-7786.MCR-13-0024</pub-id>
<pub-id pub-id-type="pmid">23723077</pub-id>
</element-citation>
</ref>
<ref id="CR332">
<label>332.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western">
<surname>Wang</surname>
<given-names>QS</given-names>
</name>
<name name-style="western">
<surname>Kong</surname>
<given-names>PZ</given-names>
</name>
<name name-style="western">
<surname>Li</surname>
<given-names>XQ</given-names>
</name>
<name name-style="western">
<surname>Yang</surname>
<given-names>F</given-names>
</name>
<name name-style="western">
<surname>Feng</surname>
<given-names>YM</given-names>
</name>
</person-group>
<article-title>FOXF2 deficiency promotes epithelial-mesenchymal transition and metastasis of basal-like breast cancer</article-title>
<source>Breast Cancer Research</source>
<year>2015</year>
<volume>17</volume>
<fpage>30</fpage>
<pub-id pub-id-type="doi">10.1186/s13058-015-0531-1</pub-id>
<pub-id pub-id-type="pmid">25848863</pub-id>
<pub-id pub-id-type="pmcid">PMC4361145</pub-id>
</element-citation>
</ref>
<ref id="CR333">
<label>333.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western">
<surname>Dou</surname>
<given-names>C</given-names>
</name>
<name name-style="western">
<surname>Jin</surname>
<given-names>X</given-names>
</name>
<name name-style="western">
<surname>Sun</surname>
<given-names>L</given-names>
</name>
<name name-style="western">
<surname>Zhang</surname>
<given-names>B</given-names>
</name>
<name name-style="western">
<surname>Han</surname>
<given-names>M</given-names>
</name>
<name name-style="western">
<surname>Li</surname>
<given-names>T</given-names>
</name>
</person-group>
<article-title>FOXF2 deficiency promotes hepatocellular carcinoma metastasis by inducing mesenchymal-epithelial transition</article-title>
<source>Cancer Biomarkers</source>
<year>2017</year>
<volume>19</volume>
<issue>4</issue>
<fpage>447</fpage>
<lpage>454</lpage>
<pub-id pub-id-type="doi">10.3233/CBM-170139</pub-id>
<pub-id pub-id-type="pmid">28582850</pub-id>
</element-citation>
</ref>
<ref id="CR334">
<label>334.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western">
<surname>Cai</surname>
<given-names>J</given-names>
</name>
<name name-style="western">
<surname>Tian</surname>
<given-names>AX</given-names>
</name>
<name name-style="western">
<surname>Wang</surname>
<given-names>QS</given-names>
</name>
<name name-style="western">
<surname>Kong</surname>
<given-names>PZ</given-names>
</name>
<name name-style="western">
<surname>Du</surname>
<given-names>X</given-names>
</name>
<name name-style="western">
<surname>Li</surname>
<given-names>XQ</given-names>
</name>
<etal />
</person-group>
<article-title>FOXF2 suppresses the FOXC2-mediated epithelial-mesenchymal transition and multidrug resistance of basal-like breast cancer</article-title>
<source>Cancer Letters</source>
<year>2015</year>
<volume>367</volume>
<issue>2</issue>
<fpage>129</fpage>
<lpage>137</lpage>
<pub-id pub-id-type="doi">10.1016/j.canlet.2015.07.001</pub-id>
<pub-id pub-id-type="pmid">26210254</pub-id>
</element-citation>
</ref>
<ref id="CR335">
<label>335.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western">
<surname>Chakrabarty</surname>
<given-names>A</given-names>
</name>
<name name-style="western">
<surname>Bhola</surname>
<given-names>NE</given-names>
</name>
<name name-style="western">
<surname>Sutton</surname>
<given-names>C</given-names>
</name>
<name name-style="western">
<surname>Ghosh</surname>
<given-names>R</given-names>
</name>
<name name-style="western">
<surname>Kuba</surname>
<given-names>MG</given-names>
</name>
<name name-style="western">
<surname>Dave</surname>
<given-names>B</given-names>
</name>
<etal />
</person-group>
<article-title>Trastuzumab-resistant cells rely on a HER2-PI3K-FoxO-survivin axis and are sensitive to PI3K inhibitors</article-title>
<source>Cancer Research</source>
<year>2013</year>
<volume>73</volume>
<issue>3</issue>
<fpage>1190</fpage>
<lpage>1200</lpage>
<pub-id pub-id-type="doi">10.1158/0008-5472.CAN-12-2440</pub-id>
<pub-id pub-id-type="pmid">23204226</pub-id>
<pub-id pub-id-type="pmcid">PMC3563941</pub-id>
</element-citation>
</ref>
<ref id="CR336">
<label>336.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western">
<surname>Ho</surname>
<given-names>JA</given-names>
</name>
<name name-style="western">
<surname>Fan</surname>
<given-names>NC</given-names>
</name>
<name name-style="western">
<surname>Jou</surname>
<given-names>AF</given-names>
</name>
<name name-style="western">
<surname>Wu</surname>
<given-names>LC</given-names>
</name>
<name name-style="western">
<surname>Sun</surname>
<given-names>TP</given-names>
</name>
</person-group>
<article-title>Monitoring the subcellular localization of doxorubicin in CHO-K1 using MEKC-LIF: liposomal carrier for enhanced drug delivery</article-title>
<source>Talanta</source>
<year>2012</year>
<volume>99</volume>
<fpage>683</fpage>
<lpage>688</lpage>
<pub-id pub-id-type="doi">10.1016/j.talanta.2012.06.077</pub-id>
<pub-id pub-id-type="pmid">22967611</pub-id>
</element-citation>
</ref>
<ref id="CR337">
<label>337.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western">
<surname>Wang</surname>
<given-names>K</given-names>
</name>
<name name-style="western">
<surname>Li</surname>
<given-names>PF</given-names>
</name>
</person-group>
<article-title>Foxo3a regulates apoptosis by negatively targeting miR-21</article-title>
<source>The Journal of Biological Chemistry</source>
<year>2010</year>
<volume>285</volume>
<issue>22</issue>
<fpage>16958</fpage>
<lpage>16966</lpage>
<pub-id pub-id-type="doi">10.1074/jbc.M109.093005</pub-id>
<pub-id pub-id-type="pmid">20371612</pub-id>
<pub-id pub-id-type="pmcid">PMC2878079</pub-id>
</element-citation>
</ref>
<ref id="CR338">
<label>338.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western">
<surname>Cox</surname>
<given-names>J</given-names>
</name>
<name name-style="western">
<surname>Vittal</surname>
<given-names>A</given-names>
</name>
<name name-style="western">
<surname>O’Neil</surname>
<given-names>M</given-names>
</name>
<name name-style="western">
<surname>Li</surname>
<given-names>ZA</given-names>
</name>
<name name-style="western">
<surname>Kuravi</surname>
<given-names>S</given-names>
</name>
<name name-style="western">
<surname>Bridges</surname>
<given-names>B</given-names>
</name>
<etal />
</person-group>
<article-title>Nuclear to cytoplasmic translocation of FOXO3 determines the sensitivity of human hepatocellular carcinoma to doxorubicin</article-title>
<source>Hepatology</source>
<year>2014</year>
<volume>60</volume>
<fpage>880a–880a</fpage>
</element-citation>
</ref>
<ref id="CR339">
<label>339.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western">
<surname>Brunet</surname>
<given-names>A</given-names>
</name>
<name name-style="western">
<surname>Sweeney</surname>
<given-names>LB</given-names>
</name>
<name name-style="western">
<surname>Sturgill</surname>
<given-names>JF</given-names>
</name>
<name name-style="western">
<surname>Chua</surname>
<given-names>KF</given-names>
</name>
<name name-style="western">
<surname>Greer</surname>
<given-names>PL</given-names>
</name>
<name name-style="western">
<surname>Lin</surname>
<given-names>Y</given-names>
</name>
<etal />
</person-group>
<article-title>Stress-dependent regulation of FOXO transcription factors by the SIRT1 deacetylase</article-title>
<source>Science</source>
<year>2004</year>
<volume>303</volume>
<issue>5666</issue>
<fpage>2011</fpage>
<lpage>2015</lpage>
<pub-id pub-id-type="doi">10.1126/science.1094637</pub-id>
<pub-id pub-id-type="pmid">14976264</pub-id>
</element-citation>
</ref>
<ref id="CR340">
<label>340.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western">
<surname>Shiota</surname>
<given-names>M</given-names>
</name>
<name name-style="western">
<surname>Yokomizo</surname>
<given-names>A</given-names>
</name>
<name name-style="western">
<surname>Kashiwagi</surname>
<given-names>E</given-names>
</name>
<name name-style="western">
<surname>Tada</surname>
<given-names>Y</given-names>
</name>
<name name-style="western">
<surname>Inokuchi</surname>
<given-names>J</given-names>
</name>
<name name-style="western">
<surname>Tatsugami</surname>
<given-names>K</given-names>
</name>
<etal />
</person-group>
<article-title>Foxo3a expression and acetylation regulate cancer cell growth and sensitivity to cisplatin</article-title>
<source>Cancer Science</source>
<year>2010</year>
<volume>101</volume>
<issue>5</issue>
<fpage>1177</fpage>
<lpage>1185</lpage>
<pub-id pub-id-type="doi">10.1111/j.1349-7006.2010.01503.x</pub-id>
<pub-id pub-id-type="pmid">20210796</pub-id>
<pub-id pub-id-type="pmcid">PMC11159407</pub-id>
</element-citation>
</ref>
<ref id="CR341">
<label>341.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western">
<surname>Wang</surname>
<given-names>TH</given-names>
</name>
<name name-style="western">
<surname>Popp</surname>
<given-names>DM</given-names>
</name>
<name name-style="western">
<surname>Wang</surname>
<given-names>HS</given-names>
</name>
<name name-style="western">
<surname>Saitoh</surname>
<given-names>M</given-names>
</name>
<name name-style="western">
<surname>Mural</surname>
<given-names>JG</given-names>
</name>
<name name-style="western">
<surname>Henley</surname>
<given-names>DC</given-names>
</name>
<etal />
</person-group>
<article-title>Microtubule dysfunction induced by paclitaxel initiates apoptosis through both c-Jun N-terminal kinase (JNK)-dependent and -independent pathways in ovarian cancer cells</article-title>
<source>Journal of Biological Chemistry</source>
<year>1999</year>
<volume>274</volume>
<issue>12</issue>
<fpage>8208</fpage>
<lpage>8216</lpage>
<pub-id pub-id-type="doi">10.1074/jbc.274.12.8208</pub-id>
<pub-id pub-id-type="pmid">10075725</pub-id>
</element-citation>
</ref>
<ref id="CR342">
<label>342.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western">
<surname>Khongkow</surname>
<given-names>P</given-names>
</name>
<name name-style="western">
<surname>Gomes</surname>
<given-names>AR</given-names>
</name>
<name name-style="western">
<surname>Gong</surname>
<given-names>C</given-names>
</name>
<name name-style="western">
<surname>Man</surname>
<given-names>EP</given-names>
</name>
<name name-style="western">
<surname>Tsang</surname>
<given-names>JW</given-names>
</name>
<name name-style="western">
<surname>Zhao</surname>
<given-names>F</given-names>
</name>
<etal />
</person-group>
<article-title>Paclitaxel targets FOXM1 to regulate KIF20A in mitotic catastrophe and breast cancer paclitaxel resistance</article-title>
<source>Oncogene</source>
<year>2016</year>
<volume>35</volume>
<issue>8</issue>
<fpage>990</fpage>
<lpage>1002</lpage>
<pub-id pub-id-type="doi">10.1038/onc.2015.152</pub-id>
<pub-id pub-id-type="pmid">25961928</pub-id>
<pub-id pub-id-type="pmcid">PMC4538879</pub-id>
</element-citation>
</ref>
<ref id="CR343">
<label>343.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western">
<surname>Lee</surname>
<given-names>LF</given-names>
</name>
<name name-style="western">
<surname>Li</surname>
<given-names>GX</given-names>
</name>
<name name-style="western">
<surname>Templeton</surname>
<given-names>DJ</given-names>
</name>
<name name-style="western">
<surname>Ting</surname>
<given-names>JPY</given-names>
</name>
</person-group>
<article-title>Paclitaxel (Taxol)-induced gene expression and cell death are both mediated by the activation of c-jun NH2-terminal kinase (JNK/SAPK)</article-title>
<source>Journal of Biological Chemistry</source>
<year>1998</year>
<volume>273</volume>
<issue>43</issue>
<fpage>28253</fpage>
<lpage>28260</lpage>
<pub-id pub-id-type="doi">10.1074/jbc.273.43.28253</pub-id>
<pub-id pub-id-type="pmid">9774447</pub-id>
</element-citation>
</ref>
<ref id="CR344">
<label>344.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western">
<surname>Liu</surname>
<given-names>H</given-names>
</name>
<name name-style="western">
<surname>Li</surname>
<given-names>Q</given-names>
</name>
<name name-style="western">
<surname>Cheng</surname>
<given-names>X</given-names>
</name>
<name name-style="western">
<surname>Wang</surname>
<given-names>H</given-names>
</name>
<name name-style="western">
<surname>Wang</surname>
<given-names>G</given-names>
</name>
<name name-style="western">
<surname>Hao</surname>
<given-names>H</given-names>
</name>
</person-group>
<article-title>UDP-glucuronosyltransferase 1A determinates intracellular accumulation and anti-cancer effect of beta-lapachone in human colon cancer cells</article-title>
<source>PLoS One</source>
<year>2015</year>
<volume>10</volume>
<issue>2</issue>
<fpage>e0117051</fpage>
<pub-id pub-id-type="doi">10.1371/journal.pone.0117051</pub-id>
<pub-id pub-id-type="pmid">25692465</pub-id>
<pub-id pub-id-type="pmcid">PMC4333567</pub-id>
</element-citation>
</ref>
<ref id="CR345">
<label>345.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western">
<surname>Li</surname>
<given-names>Y</given-names>
</name>
<name name-style="western">
<surname>Yu</surname>
<given-names>J</given-names>
</name>
<name name-style="western">
<surname>Du</surname>
<given-names>D</given-names>
</name>
<name name-style="western">
<surname>Fu</surname>
<given-names>S</given-names>
</name>
<name name-style="western">
<surname>Chen</surname>
<given-names>Y</given-names>
</name>
<name name-style="western">
<surname>Yu</surname>
<given-names>F</given-names>
</name>
<etal />
</person-group>
<article-title>Involvement of post-transcriptional regulation of FOXO1 by HuR in 5-FU-induced apoptosis in breast cancer cells</article-title>
<source>Oncology Letters</source>
<year>2013</year>
<volume>6</volume>
<issue>1</issue>
<fpage>156</fpage>
<lpage>160</lpage>
<pub-id pub-id-type="doi">10.3892/ol.2013.1352</pub-id>
<pub-id pub-id-type="pmid">23946796</pub-id>
<pub-id pub-id-type="pmcid">PMC3742653</pub-id>
</element-citation>
</ref>
<ref id="CR346">
<label>346.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western">
<surname>Shi</surname>
<given-names>F</given-names>
</name>
<name name-style="western">
<surname>Li</surname>
<given-names>T</given-names>
</name>
<name name-style="western">
<surname>Liu</surname>
<given-names>Z</given-names>
</name>
<name name-style="western">
<surname>Qu</surname>
<given-names>K</given-names>
</name>
<name name-style="western">
<surname>Shi</surname>
<given-names>C</given-names>
</name>
<name name-style="western">
<surname>Li</surname>
<given-names>Y</given-names>
</name>
<etal />
</person-group>
<article-title>FOXO1: Another avenue for treating digestive malignancy?</article-title>
<source>Seminars in Cancer Biology</source>
<year>2018</year>
<volume>50</volume>
<fpage>124</fpage>
<lpage>131</lpage>
<pub-id pub-id-type="doi">10.1016/j.semcancer.2017.09.009</pub-id>
<pub-id pub-id-type="pmid">28965871</pub-id>
<pub-id pub-id-type="pmcid">PMC5874167</pub-id>
</element-citation>
</ref>
<ref id="CR347">
<label>347.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western">
<surname>Boreddy</surname>
<given-names>SR</given-names>
</name>
<name name-style="western">
<surname>Pramanik</surname>
<given-names>KC</given-names>
</name>
<name name-style="western">
<surname>Srivastava</surname>
<given-names>SK</given-names>
</name>
</person-group>
<article-title>Pancreatic tumor suppression by benzyl isothiocyanate is associated with inhibition of PI3K/AKT/FOXO pathway</article-title>
<source>Clinical Cancer Research</source>
<year>2011</year>
<volume>17</volume>
<issue>7</issue>
<fpage>1784</fpage>
<lpage>1795</lpage>
<pub-id pub-id-type="doi">10.1158/1078-0432.CCR-10-1891</pub-id>
<pub-id pub-id-type="pmid">21350002</pub-id>
<pub-id pub-id-type="pmcid">PMC3076680</pub-id>
</element-citation>
</ref>
<ref id="CR348">
<label>348.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western">
<surname>Tolba</surname>
<given-names>MF</given-names>
</name>
<name name-style="western">
<surname>Abdel-Rahman</surname>
<given-names>SZ</given-names>
</name>
</person-group>
<article-title>Pterostilbine, an active component of blueberries, sensitizes colon cancer cells to 5-fluorouracil cytotoxicity</article-title>
<source>Scientific Reports</source>
<year>2015</year>
<volume>5</volume>
<fpage>15239</fpage>
<pub-id pub-id-type="doi">10.1038/srep15239</pub-id>
<pub-id pub-id-type="pmid">26472352</pub-id>
<pub-id pub-id-type="pmcid">PMC4608003</pub-id>
</element-citation>
</ref>
<ref id="CR349">
<label>349.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western">
<surname>Yamaguchi</surname>
<given-names>F</given-names>
</name>
<name name-style="western">
<surname>Hirata</surname>
<given-names>Y</given-names>
</name>
<name name-style="western">
<surname>Akram</surname>
<given-names>H</given-names>
</name>
<name name-style="western">
<surname>Kamitori</surname>
<given-names>K</given-names>
</name>
<name name-style="western">
<surname>Dong</surname>
<given-names>Y</given-names>
</name>
<name name-style="western">
<surname>Sui</surname>
<given-names>L</given-names>
</name>
<etal />
</person-group>
<article-title>FOXO/TXNIP pathway is involved in the suppression of hepatocellular carcinoma growth by glutamate antagonist MK-801</article-title>
<source>BMC Cancer</source>
<year>2013</year>
<volume>13</volume>
<fpage>468</fpage>
<pub-id pub-id-type="doi">10.1186/1471-2407-13-468</pub-id>
<pub-id pub-id-type="pmid">35715788</pub-id>
<pub-id pub-id-type="pmcid">PMC9204986</pub-id>
</element-citation>
</ref>
<ref id="CR350">
<label>350.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western">
<surname>Jiang</surname>
<given-names>J</given-names>
</name>
<name name-style="western">
<surname>Chen</surname>
<given-names>Y</given-names>
</name>
<name name-style="western">
<surname>Dong</surname>
<given-names>T</given-names>
</name>
<name name-style="western">
<surname>Yue</surname>
<given-names>M</given-names>
</name>
<name name-style="western">
<surname>Zhang</surname>
<given-names>Y</given-names>
</name>
<name name-style="western">
<surname>An</surname>
<given-names>T</given-names>
</name>
<etal />
</person-group>
<article-title>Polydatin inhibits hepatocellular carcinoma via the AKT/STAT3-FOXO1 signaling pathway</article-title>
<source>Oncology Letters</source>
<year>2019</year>
<volume>17</volume>
<issue>5</issue>
<fpage>4505</fpage>
<lpage>4513</lpage>
<pub-id pub-id-type="doi">10.3892/ol.2019.10123</pub-id>
<pub-id pub-id-type="pmid">30944640</pub-id>
<pub-id pub-id-type="pmcid">PMC6444395</pub-id>
</element-citation>
</ref>
<ref id="CR351">
<label>351.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western">
<surname>Jiang</surname>
<given-names>G</given-names>
</name>
<name name-style="western">
<surname>Wu</surname>
<given-names>AD</given-names>
</name>
<name name-style="western">
<surname>Huang</surname>
<given-names>C</given-names>
</name>
<name name-style="western">
<surname>Gu</surname>
<given-names>J</given-names>
</name>
<name name-style="western">
<surname>Zhang</surname>
<given-names>L</given-names>
</name>
<name name-style="western">
<surname>Huang</surname>
<given-names>H</given-names>
</name>
<etal />
</person-group>
<article-title>Isorhapontigenin (ISO) inhibits invasive bladder cancer formation in vivo and human bladder cancer invasion in vitro by targeting STAT1/FOXO1 axis</article-title>
<source>Cancer Prevention Research (Philadelphia, Pa.)</source>
<year>2016</year>
<volume>9</volume>
<issue>7</issue>
<fpage>567</fpage>
<lpage>580</lpage>
<pub-id pub-id-type="doi">10.1158/1940-6207.CAPR-15-0338</pub-id>
<pub-id pub-id-type="pmcid">PMC4930725</pub-id>
<pub-id pub-id-type="pmid">27080594</pub-id>
</element-citation>
</ref>
<ref id="CR352">
<label>352.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western">
<surname>Belguise</surname>
<given-names>K</given-names>
</name>
<name name-style="western">
<surname>Guo</surname>
<given-names>S</given-names>
</name>
<name name-style="western">
<surname>Sonenshein</surname>
<given-names>GE</given-names>
</name>
</person-group>
<article-title>Activation of FOXO3a by the green tea polyphenol epigallocatechin-3-gallate induces estrogen receptor alpha expression reversing invasive phenotype of breast cancer cells</article-title>
<source>Cancer Research</source>
<year>2007</year>
<volume>67</volume>
<issue>12</issue>
<fpage>5763</fpage>
<lpage>5770</lpage>
<pub-id pub-id-type="doi">10.1158/0008-5472.CAN-06-4327</pub-id>
<pub-id pub-id-type="pmid">17575143</pub-id>
</element-citation>
</ref>
<ref id="CR353">
<label>353.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western">
<surname>Li</surname>
<given-names>X</given-names>
</name>
<name name-style="western">
<surname>Wu</surname>
<given-names>Q</given-names>
</name>
<name name-style="western">
<surname>Xie</surname>
<given-names>Y</given-names>
</name>
<name name-style="western">
<surname>Ding</surname>
<given-names>Y</given-names>
</name>
<name name-style="western">
<surname>Du</surname>
<given-names>WW</given-names>
</name>
<name name-style="western">
<surname>Sdiri</surname>
<given-names>M</given-names>
</name>
<etal />
</person-group>
<article-title>Ergosterol purified from medicinal mushroom Amauroderma rude inhibits cancer growth in vitro and in vivo by up-regulating multiple tumor suppressors</article-title>
<source>Oncotarget</source>
<year>2015</year>
<volume>6</volume>
<issue>19</issue>
<fpage>17832</fpage>
<lpage>17846</lpage>
<pub-id pub-id-type="doi">10.18632/oncotarget.4026</pub-id>
<pub-id pub-id-type="pmid">26098777</pub-id>
<pub-id pub-id-type="pmcid">PMC4627349</pub-id>
</element-citation>
</ref>
</ref-list>
</back>
</article>
</pmc-articleset>